<PAGE> 1
FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act
of 1934
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 1996
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 For the transition period from ____________ to
_________________
Commission File No. 1-11538
-------
HEALTHSOURCE, INC.
------------------------------------------------------------
(Exact name or registrant as specified in its charter)
New Hampshire 02-0387748
- ---------------------------------- --------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
2 College Park Drive, Hooksett, NH 03106
- ---------------------------------- --------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (603) 268-7000
--------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
At May 3, 1996, 63,677,691 shares of $.10 par value common stock of the
Registrant were outstanding.
1
<PAGE> 2
HEALTHSOURCE, INC.
INDEX
Page Number
-----------
Part I. Financial Information.
- -----------------------------
Item 1. Financial Statements
--------------------
Condensed Consolidated Balance Sheets as of
March 31, 1996 and December 31, 1995 3
Condensed Consolidated Statements of Operations
for the Three Month Periods ended
March 31, 1996 and 1995 4
Condensed Consolidated Statements of Cash Flows
for the Three Month Periods ended
March 31, 1996 and 1995 5
Notes to Condensed Consolidated Financial Statements 6 - 8
Independent Accountants' Report 9
Item 2. Management's Discussion and Analysis of
---------------------------------------
Financial Condition and Results of Operations 10 - 15
---------------------------------------------
Part II. Other Information.
- ---------------------------
Item 1. Legal Proceedings
-----------------
Not Applicable
Item 2. Changes in Securities
---------------------
Not Applicable
Item 3. Defaults Upon Senior Securities
-------------------------------
Not Applicable
Item 4. Submission of Matters to a Vote of
----------------------------------
Security Holders
----------------
Not Applicable
Item 5. Other Information 16 - 17
-----------------
Item 6. Exhibits and Reports on Form 8-K 18
--------------------------------
Signatures 19
2
<PAGE> 3
HEALTHSOURCE, INC. AND SUBSIDIARIES
- -----------------------------------
<TABLE>
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF MARCH 31, 1996 AND DECEMBER 31, 1995
- ----------------------------------------------------------------------------------------
<CAPTION>
March 31, December 31,
1996 1995
--------- ------------
(Unaudited)
ASSETS (in thousands)
- ------
<S> <C> <C>
Current assets:
Cash and cash equivalents ...................... $132,153 $121,467
Marketable securities .......................... 27,429 34,301
Premiums and administrative
fees receivable .............................. 115,204 117,871
Restricted investments ......................... 119,594 123,871
Other current assets ........................... 39,639 29,986
-------- --------
Total current assets ..................... 434,019 427,496
Long-term assets:
Long-term marketable securities ................ 116,028 68,357
Property and leasehold improvements, net ....... 114,747 103,611
Restricted investments ......................... 8,844 8,099
Intangible assets, net ......................... 299,568 254,886
Other assets ................................... 17,030 10,590
-------- --------
TOTAL .................................... $990,236 $873,039
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
- ------------------------------------
Current liabilities:
Medical claims payable ......................... $180,864 $152,649
Accounts payable and accrued expenses .......... 95,800 85,678
Estimated liability under retrospective
refund agreements ............................ 30,043 35,623
Deferred revenue ............................... 12,371 7,489
Other current liabilities ...................... 6,620 1,587
-------- --------
Total current liabilities .................. 325,698 283,026
Long-term liabilities:
Revolving note payable ......................... 10,000 95,000
Convertible subordinated notes ................. 247,250 -
Other liabilities .............................. 6,237 6,931
-------- --------
Total liabilities ........................ 589,185 384,957
-------- --------
Shareholders' equity:
Preferred stock ................................ - 100,000
Common stock ................................... 6,368 6,358
Additional paid-in capital ..................... 222,551 221,048
Retained earnings .............................. 173,981 159,547
Unrealized gain (loss)on marketable
securities .................................... (1,849) 1,129
-------- --------
Shareholders' equity ........................ 401,051 488,082
-------- --------
TOTAL ....................................... $990,236 $873,039
======== ========
</TABLE>
See notes to condensed consolidated financial statements
3
<PAGE> 4
HEALTHSOURCE, INC. AND SUBSIDIARIES
- -----------------------------------
<TABLE>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTH PERIODS ENDED MARCH 31, 1996 AND 1995
<CAPTION>
- --------------------------------------------------------------------------------------------
Three Months Ended
March 31,
--------------------------
1996 1995
--------- ---------
(unaudited) (unaudited)
(in thousands,
except per share data)
<S> <C> <C>
Revenue:
HMO medical premiums .................................. $290,755 $188,312
Other insured medical premiums ......................... 68,112 3,711
Administrative and managed care fees ................... 60,225 16,084
-------- --------
Total operating revenue ............................ 419,092 208,107
-------- --------
Expenses:
Cost of HMO medical premiums ........................... 227,855 146,322
Cost of other insured medical premiums ................. 57,706 2,760
Selling, general and administrative:
HMO and other fully insured services ................. 56,963 28,844
Administrative and managed care services ............. 47,963 12,792
-------- --------
Total selling, general and administrative ......... 104,926 41,636
-------- --------
Depreciation and amortization .......................... 8,709 3,332
-------- --------
Total operating expenses ........................... 399,196 194,050
-------- --------
Operating income ................................... 19,896 14,057
Interest income ........................................... 6,461 3,660
Interest expense .......................................... (2,373) -
-------- --------
Interest income, net .............................. 4,088 3,660
-------- --------
Income before provision for income taxes .................. 23,984 17,717
Provision for income taxes ................................ (8,422) (5,946)
-------- --------
Net income ............................................... $ 15,562 $ 11,771
======== ========
Preferred stock dividend .................................. (1,128) --
-------- --------
Net income available to common shareholders ............... $ 14,434 $ 11,771
======== ========
Net income per share: ..................................... $0.22 $ 0.18
Weighted average number of common and common
equivalent shares outstanding: .......................... 65,953 64,062
</TABLE>
See notes to condensed consolidated financial statements
4
<PAGE> 5
HEALTHSOURCE, INC. AND SUBSIDIARIES
- -----------------------------------
<TABLE>
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTH PERIODS ENDED MARCH 31, 1996 AND 1995
<CAPTION>
- ------------------------------------------------------------------------------------
Three Months Ended
March 31,
-------------------------
1996 1995
---------- ----------
(unaudited) (unaudited)
(in thousands)
<S> <C> <C>
Cash flows from operating activities:
Net income ...................................... $ 15,562 $11,771
Adjustments to reconcile net income
to net cash provided by operating activities:
Depreciation and amortization ............... 8,709 3,332
Changes in assets and liabilities,
net of effects of acquisition:
Premiums and administrative fees .............. 5,345 (4,059)
Other current assets .......................... (8,904) (2,694)
Medical claims payable ........................ 6,346 11,883
Accounts payable and other current liabilities 8,161 1,541
Deferred revenue .............................. 4,359 4,685
--------- -------
Net cash provided by operating activities ... 39,578 26,459
--------- -------
Cash flows from investing activities:
Investment in affiliates/intangible
assets, net of cash acquired .................. (46,879) (1,785)
(Increase) decrease in marketable securities .... (26,631) 14,030
Additions to property and leasehold improvements (13,715) (7,939)
Increase in other assets
and restricted investments .................... (2,908) (2,225)
--------- -------
Net cash provided by (used in)
Investing activities .................... (90,133) 2,081
--------- -------
Cash flows from financing activities:
Issuance of convertible subordinated notes ...... 247,250 --
Redemption of preferred stock ................... (100,000) --
Preferred stock dividends ....................... (1,128) --
Net repayment of revolving note payable ......... (85,000) --
Issuance of common stock ........................ 813 760
Repayment of other liabilities .................. (694) (10)
--------- -------
Net cash provided by financing activities . 61,241 750
--------- -------
Increase in cash and cash equivalents ................ 10,686 29,290
Cash and cash equivalents, beginning of period ....... 121,467 67,193
--------- -------
Cash and cash equivalents, end of period ............. $ 132,153 $96,483
========= =======
Supplemental disclosure of cash flow information:
Income taxes paid ............................... $ 2,312 $ 1,560
Interest paid ................................... 1,856 --
</TABLE>
See notes to condensed consolidated financial statements
5
<PAGE> 6
HEALTHSOURCE, INC. AND SUBSIDIARIES
- -----------------------------------
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
- ---------------------------------------------------------------
1. BASIS OF PRESENTATION
The unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Rule 10 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all normal recurring
adjustments considered necessary for a fair presentation have been
included.
The results of operations for the three month period ended March 31, 1996
are not necessarily indicative of the results of operations to be expected
for the full year.
2. SUMMARY OF SIGNIFICANT INCOME STATEMENT POLICIES
Revenue - HMO medical premium revenue and other insured medical premiums
are recognized in the month in which members are entitled to receive health
care services and are reported net of retrospective refunds. Medical
premiums collected in advance are recorded as deferred revenue.
Administrative and managed care fees are recognized in the period that
claims processing and other managed care services are provided to
self-funded clients. Revenue from management service agreements is
recognized in the period the Company performs the services.
Cost of HMO Medical Premiums - Cost of HMO medical premiums includes the
costs of all medical services delivered to enrolled members of the
Company's majority-owned HMOs and for whom the entities have recorded HMO
medical premium revenue during the reporting period. These costs include
payments for specific medical services and for capitation. The costs of
specific medical services include those paid to physicians, hospitals, and
other health care providers on a fee-for-service basis. These costs include
claims paid, claims in process and pending, estimates of unreported claims,
estimates of contractual adjustments pursuant to hospital and other
provider contracts, and estimates of charges at the balance sheet date for
which the Company will be responsible. The costs of capitation (fixed
monthly payments per member) include payments to certain physicians,
hospitals, laboratories, pharmaceutical and mental health care providers.
Adjustments to prior period estimates are reflected in the current period
and are not significant.
Cost of Other Insured Medical Premiums - Cost of other insured medical
premiums includes the costs of all medical services delivered to enrolled
members of the Company's non-HMO medical plans for whom the entities have
recorded medical premium revenue during the reporting period. These costs
include claims paid, claims in process and claims pending, and estimates of
unreported claims and charges at the balance sheet date for which the
Company will be responsible. Adjustments to prior period estimates are
reflected in the current period and are not significant.
Selling, General and Administrative ("SG&A") Expense - HMO and
fully-insured SG&A expense includes the costs recognized by the Company and
its majority-owned entities: (1) to market and administer the delivery of
medical services for which the Company is at risk; and (2) to develop and
administer its management services agreements. Administrative and managed
care fees SG&A includes the costs recognized by the Company and its
majority-owned entities to market and administer the delivery of medical
services for self-insured clients. Corporate SG&A is included within HMO
and other fully-insured SG&A expense.
6
<PAGE> 7
Impairment of Long-Lived Assets - The Company adopted Statement of
Financial Accounting Standards No.121, "Accounting for the Impairment of
Long-Lived Assets and for Long-Lived Assets to Be Disposed Of'("SFAS121")
in the period ended March 31, 1996. SFAS 121 establishes accounting
standards for the impairment of long-lived assets, certain identifiable
intangibles, and goodwill related to those assets. There was no effect of
adoption of SFAS 121 on the financial statements.
Stock-Based Compensation - Statement of Financial Accounting Standards No.
123, "Accounting for Stock-Based Compensation" ("SFAS 123") became
effective in 1996. As permitted by SFAS 123, the Company has elected to
continue to account for stock-based compensation to employees under APB
Opinion No. 25 and to provide the SFAS 123 required disclosures in its 1996
annual financial statements.
Reclassifications - Certain prior year amounts have been reclassified to
conform with the current year presentation. Other insured medical premiums,
cost of other insured medical premiums and a significant portion of
administrative and managed care fees SG&A relate primarily to the Provident
Transaction. See Note 3.
3. ACQUISITIONS
1996 Acquisition - Effective February 1, 1996, the Company acquired
substantially all of the HMO assets of Central Massachusetts Health Care,
Inc. (now called "Healthsource CMHC" ("HSCMHC")) for approximately $46.5
million in cash, subject to post closing purchase price adjustments.
1995 Acquisition - Effective May 1, 1995, the Company acquired the group
health, HMO and third party administration business of Provident Life and
Accident Insurance Company of America, Inc. (the "Provident Transaction")
for $231 million in cash and securities. The cash payment was $131 million
and the Company issued to Provident non-convertible Class A cumulative
preferred stock with a face value of $100 million (See Note 4).
<TABLE>
The following unaudited pro forma consolidated statement of operations
assumes the Provident and HSCMHC acquisitions occurred on January 1, of
each year (in thousands, except per share data):
<CAPTION>
Three Months Ended
March 31,
-----------------------
1996 1995
-------- --------
<S> <C> <C>
Revenue $429,515 $349,304
Operating income 18,599 13,691
Net income 14,715 11,679
Net income per share $0.21 $0.16
</TABLE>
4. CONVERTIBLE SUBORDINATED NOTES
On March 8, 1996, the Company completed the sale (through a private
offering to institutional investors) of $247 million principal amount of 5%
Convertible Subordinated Notes due 2003. The proceeds of the sale were used
to redeem the outstanding $100 million preferred stock and to repay a
portion of the amount owed under the revolving note payable.
5. INCOME TAXES
The Company provides for income taxes based upon an estimate of its annual
effective tax rate. The estimated effective tax rates for the three months
ended March 31, 1996 and 1995 were 35.1% and 33.6%, respectively.
7
<PAGE> 8
6. COMMITMENTS AND CONTINGENCIES
In January 1996, the Company announced that it had signed a definitive
agreement to purchase substantially all of the operating assets of PACC HMO
and PACC Health Plans for a price of approximately $80 million in cash,
subject to certain adjustments. The definitive agreement is subject to
regulatory and other approvals.
In April 1996, the Company announced that it had signed a letter of intent
to pay an aggregate cash consideration of $27 million to acquire Health
Direct, Inc. and to enter into a ten-year globally capitated provider
agreement with the seller's hospital system. The letter of intent is
non-binding and subject to due diligence, negotiation of a definitive
agreement and the receipt of regulatory and other approvals. There is no
assurance that a definitive agreement will be reached or that such
approvals will be obtained.
8
<PAGE> 9
INDEPENDENT ACCOUNTANTS' REPORT
To the Board of Directors
and Shareholders of
Healthsource, Inc.
Hooksett, New Hampshire
We have reviewed the accompanying condensed consolidated balance sheet of
Healthsource, Inc. and subsidiaries as of March 31, 1996 and the related
condensed consolidated statements of operations and cash flows for the three
month periods ended March 31, 1996 and 1995. These financial statements are the
responsibility of the Company's management.
We conducted our review in accordance with standards established by the American
Institute of Certified Public Accountants. A review of interim financial
information consists principally of applying analytical procedures to financial
data and of making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with generally accepted auditing standards, the objective of which is the
expression of an opinion regarding the financial statements taken as a whole.
Accordingly, we do not express such an opinion.
Based on our review, we are not aware of any material modifications that should
be made to such condensed consolidated financial statements for them to be in
conformity with generally accepted accounting principles.
We have previously audited, in accordance with generally accepted auditing
standards, the consolidated balance sheet of Healthsource, Inc. and subsidiaries
as of December 31, 1995 and the related consolidated statements of operations,
shareholders' equity, and cash flows for the year then ended (not presented
herein); and in our report dated February 16, 1996, we expressed an unqualified
opinion on those consolidated financial statements. In our opinion, the
information set forth in the accompanying condensed consolidated balance sheet
as of December 31, 1995 is fairly stated, in all material respects, in relation
to the consolidated balance sheet from which it has been derived.
Boston, Massachusetts Deloitte & Touche LLP
May 10, 1996
9
<PAGE> 10
HEALTHSOURCE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
GENERAL
- -------
The Company has experienced substantial growth in both revenues and
profitability since its formation in New Hampshire in 1985. Revenue growth has
been accomplished through increasing membership and medical premiums per member
and administrative and managed care fees from self-insured employers and through
acquisitions. The Company has made acquisitions of health maintenance
organization ("HMO") companies resulting in wholly-owned subsidiaries in South
Carolina, Tennessee, Maine, Indiana, North Carolina, Syracuse, New York and
Massachusetts. The Company has formed strategic alliances with hospitals to
operate HMOs in Arkansas, Georgia, north central Texas, and southwestern Ohio
and has formed start-up HMOs in Connecticut and Louisville, Kentucky. It also
formed a strategic alliance with Chubb Life Insurance Company to operate an HMO
("ChubbHealth") in the metropolitan New York City and northern New Jersey areas.
Effective May 1, 1995, the Company acquired the group health, third-party
administration and HMO business ("the Provident Transaction") from Provident
Life and Accident Insurance Company of America, Inc. for $231 million in cash
and preferred stock. To conduct the acquired businesses, the Company organized
and capitalized Healthsource Provident Insurance Company to assume the insured
business and Healthsource Provident Administrators, Inc. to administer the
self-insured business.
The Company has experienced a decline in average premium yield during the first
quarter of 1996 of 6.5% as compared to the same period in 1995.
<TABLE>
First quarter 1996 and 1995 average premium yields including and excluding
South Carolina (where there is a significant amount of low option business with
appropriately lower premiums) were as follows:
<CAPTION>
Region 3-31-96 3-31-95 % change
- ------ ------- ------- --------
<S> <C> <C> <C>
North.......................... $137.93 $143.00 (3.5)%
South with South Carolina...... 117.37 126.00 (6.8)%
South without South Carolina... 123.58 129.99 (4.9)%
Total with South Carolina...... 125.22 133.94 (6.5)%
Total without South Carolina... 130.56 137.24 (4.9)%
</TABLE>
The Company expects this premium pricing environment to continue during 1996 and
possibly beyond. As a result of this premium pricing environment, the Company's
medical loss ratio and ultimately its profitability will depend on its ability
to control health care costs. Since the Company commits to provide its services
to members at agreed upon prices for one year, unexpected cost increases during
this period cannot be passed on to employers or to members. The Company believes
its continued profitability in the first quarter of 1996 can be attributed
primarily to increases in membership, increased revenue from administrative and
managed care services, its cost control efforts, and the effect of the Provident
Transaction and the acquisition of Central Massachusetts Health Care, Inc. (now
called "Healthsource CMHC" or "HSCMHC") in February 1996.
10
<PAGE> 11
<TABLE>
The following table shows membership for the Company's affiliated health plans
as of March 31, 1996 and 1995:
<CAPTION>
3/31/96 3/31/95
------- -------
<S> <C> <C>
HMOs1
Northern Region:
New Hampshire 127,100 96,400
Massachusetts 81,100 -
Indiana 69,000 43,100
Maine 66,800 56,600
New York City 32,500 28,400
New York (Syracuse) 21,900 23,700
Kentucky 12,400 -
New Jersey 8,300 -
Ohio 800 -
--------- ---------
Sub-total 419,900 248,200
--------- ---------
Southern Region:
North Carolina 175,400 117,300
South Carolina 150,200 77,100
Tennessee 68,500 34,300
Arkansas 34,300 17,600
Georgia 10,800 5,400
Texas 5,300 -
--------- ---------
Sub-total 444,500 251,700
--------- ---------
Total HMO 864,400 499,900
--------- ---------
MANAGED INDEMNITY (INSURED)2 64,600 7,900
--------- ---------
SELF AND PARTIALLY INSURED MEDICAL PRODUCTS
- -------------------------------------------
Point of Service 210,900 173,200
Workers' Compensation 122,000 107,700
Other Managed Care/Administration3 2,187,600 307,200
--------- ---------
Total Self-Insured 2,520,500 588,100
------------------ --------- ---------
TOTAL ADMINISTERED MEDICAL 3,449,500 1,095,900
- -------------------------- --------- ---------
DENTAL PRODUCTS 4
Fully Insured 314,100 -
Self Insured 2,170,800 -
--------- ---------
TOTAL ADMINISTERED DENTAL 2,484,900 -
- ------------------------- --------- ---------
<FN>
1 Includes membership for HMOs owned, co-owned, and/or managed by the
Company. Managed indemnity lives previously reported in the Company's HMO
membership are now reported separately as managed indemnity lives. At March
31, 1996 and 1995, these lives were 6,700 and 7,900, respectively.
2 Includes managed indemnity business from the Provident acquisition of
approximately 57,900 at March 31, 1996.
3 Includes self-insured business from the Provident acquisition of
approximately 1,951,000 lives at March 31, 1996. Included in these totals
are approximately 251,000 members at March 31, 1996 which were covered by
minimum premium and experience rated refundable premium products where the
Company shares risk with the employers and where the Company receives an
insurance premium. Many of these employer accounts have managed care
benefit designs.
4 Obtained through the Provident acquisition.
</TABLE>
11
<PAGE> 12
<TABLE>
The following table shows certain income statement data expressed as a
percentage of total operating revenue for the three months ended March 31, 1996
and 1995:
<CAPTION>
Three Months Ended
March 31,
--------------------
(unaudited)
1996 1995
----- -----
<S> <C> <C>
Revenue:
HMO medical premiums 69.4% 90.5%
Other insured medical premiums 16.3 1.8
Administrative and managed
care fees 14.3 7.7
----- -----
Total operating revenue 100.0 100.0
----- -----
Expenses:
Cost of HMO medical premiums 54.4 70.3
Cost of other insured
medical premiums 13.8 1.3
Selling, general and administrative:
HMO and fully-insured 13.6 13.9
Admin. and managed care fees 11.4 6.1
----- -----
Total selling, general and admin. 25.0 20.0
----- -----
Depreciation and amortization 2.0 1.6
----- -----
Total operating expenses 95.2 93.2
Operating income 4.8 6.8
Interest income 1.5 1.7
Interest expense (.6) -
----- -----
Interest and other income, net 0.9 1.7
Income before provision for income taxes 5.7 8.5
Provision for income taxes (2.0) (2.9)
----- -----
Net income 3.7% 5.6%
===== =====
</TABLE>
Three Months Ended March 31, 1996 Compared to Three Months Ended March 31, 1995
- -------------------------------------------------------------------------------
Revenue increased 101% to $419 million from $208 million. This increase was
primarily the result of a 54% increase in HMO medical premium revenue to $291
million from $188 million. The change in HMO medical premium revenue was
attributable to: (1) the combined effect of a 48% increase in average membership
and a 6.5% decrease in average medical premium yield to $125 per member per
month ("pmpm") from $135 pmpm at Healthsource New Hampshire, Healthsource
Tennessee, Healthsource Indiana, Healthsource South Carolina, Healthsource
Maine, Healthsource North Carolina, Healthsource Arkansas, Healthsource Savannah
and Healthsource New York(collectively "Existing Plans");(2) a $21 million
increase due to the acquisition of Healthsource CMHC ("HSCMHC"); and (3) the
commencement of operations of Healthsource North Texas ("HSNTX"), Healthsource
Kentucky ("HSKY") and Healthsource Ohio ("HSOH").
In addition, there was a significant increase in revenue resulting from an
increase in other insured medical premiums to $68 million from $4 million due to
the Provident Transaction. The acquired business consists of fully-insured
managed indemnity products and minimum premium and experience rated refundable
premium products with large employer groups.
The remaining revenue increase was due to a 274% increase in administrative and
managed care fees to $60 million from $16 million which resulted from the
Provident Transaction and the growth of the Company's self-funded,
Point-of-Service (POS) business in various states.
Cost of HMO medical premiums ("health care costs") increased 56% to $228 million
from $146 million. This increase was due to the combined effect of the 48%
increase in average membership with a 5.5% decrease in the average cost of
12
<PAGE> 13
medical premiums to $98 pmpm from $104 pmpm at Existing Plans, the acquisition
of HSCMHC and the commencement of operations of HSNTX, HSKY, and HSOH. This 5.5%
decrease in costs resulted from lower physician, inpatient and outpatient
hospital costs offset by increases in pharmaceutical costs.
The cost of HMO medical premiums as a percent of HMO medical premiums (the
"medical loss ratio" or "MLR") increased to 78.4% from 77.7% because the 6.5%
decrease in average medical premium yield was more than the 5.5% decrease in
average cost of medical premiums at Existing Plans, combined with HSKY, HSNTX,
and HSOH which in the aggregate had higher MLRs than the Existing Plans. The
Company expects the premium pricing environment to exert downward pressure on
average medical premium yield during 1996 and possibly beyond. The Company's MLR
may increase if the Company is unable to keep the cost of medical premiums in
line with premium yields.
The cost of other insured medical premiums increased to $58 million from $3
million as a result of the acquisition of Provident's fully-insured managed
indemnity products and minimum premium and experience rated refundable premium
products.
Total selling, general and administrative (SG&A) expenses increased to $105
million from $42 million due to acquisitions and the development of existing
operations and new businesses. As a percent of total operating revenue, SG&A
expenses increased to 25% from 20% as a result of the self-funded business
acquired in the Provident Transaction which has inherently higher levels of SG&A
expense.
SG&A expenses related to HMO, fully-insured medical business and corporate
administration increased 97% to $57 million from $29 million. This increase
resulted primarily from the SG&A expense associated with the insured portion of
the Provident business, the membership increases at existing HMOs, the
commencement of operations at HSKY, HSNTX and HSOH, development expenses at
start-up HMOs and other business development activities. SG&A expenses related
to administration and managed care fees increased 275% to $48 million from $13
million due to the SG&A expense associated with the self-insured portion of the
Provident business and increases in the Company's administrative service
businesses such as self-insured POS.
Depreciation and amortization expense increased 161% to $9 million from $3
million primarily due to the amortization expense associated with the Provident
Transaction, the acquisition of HSCMHC and depreciation associated with
increased capital purchases.
Interest income increased 76% to $6.4 million from $3.6 million. This increase
resulted primarily from the increase in cash, cash equivalents and marketable
securities associated with the Provident Transaction and the Company's continued
increases in cash available from operations. The Company incurred interest
expense of $2.3 million in 1996 as a result of borrowings associated with the
Provident and HSCMHC acquisitions.
The Company's effective tax rate increased to 35.1% from 33.6% due to the
decline of non-taxable interest income as a percentage of total interest income
and as a percentage of total operating income.
Liquidity and Capital Resources
- -------------------------------
At March 31, 1996, cash, cash equivalents and marketable securities totaled
approximately $276 million, of which $244 million was held by regulated
operating companies and was largely restricted to use in those companies.
During the first quarter of 1996, the Company generated $39 million from
operations and invested approximately $14 million in property and equipment. The
acquisition of HSCMHC resulted in a net cash expenditure of $47 million which
was funded from borrowings under the Chase Facility described below.
13
<PAGE> 14
On March 8, 1996, the Company completed the sale (through a private offering to
institutional investors) of $247 million principal amount of 5% Convertible
Subordinated Notes ("the Notes") due 2003. The Notes are convertible into Common
Stock of the company at a price of $46.965 per share. The Company used the net
proceeds of the offering to redeem the $100 million face amount of the Company's
outstanding 6.25% Class A Cumulative Preferred Stock. The balance of the net
proceeds of the offering was used to repay a portion of the outstanding
principal balance under the Company's $300 million unsecured revolving credit
agreement with Chase Manhattan Bank N.A. as agent ("Chase Facility").
The Chase Facility is committed through March 15, 2000. At March 31, 1996, the
Company had $10 million outstanding. Based on current financial ratios, the
Company has the ability to borrow a total of $240 million under the Chase
Facility.
The principal and interest on the Notes is by their terms subordinated in right
of payment to principal and interest on substantially all existing and future
debt (including debt under the Chase Facility) incurred by the Company ("Senior
Debt"). As of March 31, 1996, the Company has approximately $10 million of
Senior Debt outstanding. As of such date, the Company's subsidiaries had
aggregate liabilities of approximately $306 million, to which the Notes are also
structurally subordinated.
The Company has signed a definitive agreement to purchase substantially all of
the operating assets of PACC HMO and PACC Health Plans for approximately $80
million in cash subject to significant adjustments. Additionally, the Company
announced that it had signed a letter of intent to pay an aggregate cash
consideration of $27 million to acquire Health Direct, Inc. and to enter into a
ten-year globally capitated provider agreement with the seller's hospital
system. The letter of intent is non-binding and subject to due diligence,
negotiation of a definitive agreement, and the receipt of other regulatory
approvals. The Company intends to fund the PACC and Health Direct transactions
from borrowings under the Chase Facility or other financial resources.
Although the Company has no other present commitments for significant capital
expenditures, the Company's 1996 budget reflects capital expenditures in excess
of $40 million. The Company believes that its existing cash balances and cash
flow generated by its wholly-owned plans coupled with the proceeds of the sale
of the Notes and the amounts available for borrowing under the Chase Facility
are adequate to fund its existing operations on a short-term and long-term
basis.
Effects of Inflation
- --------------------
Until recent years, medical premiums and the cost of medical premiums generally
rose at a rate higher than that for consumer goods as a whole. Since 1994,
however, these inflation trends have reversed and medical premiums and costs of
medical premiums have declined significantly as competition has increased and
consumers have demanded premium decreases. The Company experienced decreases of
6.5% in average medical premium yield and 5.5% in the average cost of medical
premiums during the first quarter of 1996 over the same period in 1995. The
Company expects that this competitive trend will continue for the remainder of
1996 and possibly beyond. There is no assurance that the Company's cost of
medical premiums will continue to decline.
The Company attempts to mitigate increases in the cost of medical premiums
through some or all of the following activities: (1) securing global capitation
arrangements with major hospital providers and improving its contracting
methodologies with other providers to achieve lower costs and to promote
risk-sharing; (2) reviewing and, as necessary, modifying benefit designs so as
to discourage inappropriate levels of consumer-driven utilization; (3) using
various utilization review techniques and technologies to mitigate inappropriate
use of healthcare resources by providers; and (4) communicating with the
Company's primary care physicians about the impact of clinically inappropriate
utilization of healthcare resources.
14
<PAGE> 15
Risks associated with any forward looking statements contained in Management's
Discussion and Analysis of Financial Condition and Results of Operations are
discussed in Item 5, Other Information.
15
<PAGE> 16
PART II - OTHER INFORMATION
Items 1, 2, 3, & 4. Not Applicable.
--------------
Item 5. Other Information
-----------------
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995
The statements contained in the Management's Discussion and Analysis of
Financial Condition and Results of Operations and those contained in the
Company's Annual Report on Form 10-K concerning future profitability, premium
pricing levels, future levels of medical-loss ratios, the Company's ability to
control healthcare and SG&A costs and all other statements that are not
historical facts are forward looking statements. Because such statements involve
risks and uncertainties, the following factors, among others, could affect the
Company's actual results and could cause actual future results to differ
materially from those expressed in any forward looking statements either made
herein or previously or subsequently made by or on behalf of Healthsource:
CONTROL AND PREDICTABILITY OF HEALTH CARE COSTS. The Company's profitability
depends in large part on predicting and maintaining effective control of the
healthcare costs of its HMOs. The future profitability of the Company's HMOs is
dependent upon controlling future healthcare costs in part through appropriate
benefit design, utilization control and negotiation of favorable provider
contracts, including global capitation arrangements with major hospitals which
effectively link healthcare costs for assigned members to the premiums received
for such members. The Company may be unable to predict accurately or to control
health care costs because of many factors, including the inherent
unpredictability of rates of utilization of services in any given period and the
volatility of such use particularly in quarterly periods; major epidemics;
undetected increases in costs of units of services (in some cases implemented by
providers without prior notice); changes in risk profile of a rapidly increasing
membership due to pre-existing medical conditions, revised demographics and
other factors; and increased utilization driven by changes in physician practice
patterns and new techniques (i.e., use of bone marrow transplants for an
increasing number of diagnostic categories). There can be no assurance that the
Company will be successful in predicting or mitigating the effect of any of
these factors.
COMPETITION AND PREMIUM PRICING. The managed healthcare industry is highly
competitive at both the local HMO level and in the regional and national
employer markets. The principal competitive factors affecting the Company's
products are premium rates and fees, plan design and flexibility, and
physician/hospital network and reputation. The Company competes in all of its
markets with Blue Cross plans, indemnity insurers, HMOs, TPAs, PPOs and other
managed care companies. The Company also faces competition in many of its
markets from hospitals and other provider groups who have organized their own
networks to contract directly with employer groups.
The cost of providing benefits is in many instances the controlling factor in
obtaining and retaining employer groups, and in certain markets some competitors
are underpricing the Company's products. In many historically under-penetrated
markets such as the Carolinas, many new HMOs have been recently licensed which
is reflected in premium pressure for new and renewal business. As a result of
this competition, the Company experienced a 6.5% decline in average premium
yield per member during the first quarter of 1996. The Company expects that
competition for all business (and related premium pressure) may become even more
intense during the remainder of 1996 and beyond and that, as a result, the
Company may not be able to secure adequate premium pricing.
ACCOUNTING; MIS AND NETWORK DISRUPTION ISSUES. Reserves for incurred but not
reported claims ("IBNR") are a large component of the Company's medical claims
payable reserve and are based upon an estimation of future claims using
traditional actuarial techniques heavily influenced by historical claims
16
<PAGE> 17
experience; rapid growth and changing risk profiles could render the Company's
IBNR estimates inaccurate and there can be no assurance as to the ultimate
accuracy of such estimates or that subsequent adjustments will not cause
fluctuations in the Company's operating results. The ability to predict IBNR,
control costs in general and to manage increasingly complicated global
capitation arrangements depends upon the use of sophisticated customized MIS
systems; there can be no assurance that such systems can be developed quickly
enough to effectively manage the increasing complexity of the Company's
contractual arrangements nor that facility or equipment problems will not
disrupt the Company's ability to effectively provide such MIS support. With the
increasing complexity of contractual arrangements comes the potential for
disagreements with major hospital providers over the reimbursement under such
contracts, which disagreements (if not resolved) could disrupt relations with
affiliated physician providers and could potentially affect the perception of
the Company's plans in the affected markets.
ACQUISITIONS AND NEW PRODUCTS. A significant part of the Company's business
strategy is to diversify into new geographic markets through acquisitions or
start-up plans and to develop new products. Identifying and pursuing acquisition
opportunities, integrating acquired businesses and managing growth requires a
significant amount of management time and skill. The Company may be unable to
(i) negotiate acceptable terms with suitable acquisition candidates or ensure
that, if negotiated, such acquisitions will be either approved by all relevant
regulatory authorities or concluded, (ii) assimilate such acquired companies
free from hidden risks undetected at the time of closing or (iii) manage future
growth effectively. Until start-up HMOs reach a critical mass of membership,
they generally produce operating losses (despite capitated provider contracts)
and failure to generate sufficient membership in start-up markets could
adversely affect operating results. The Company is expanding its product
offerings, most notably by developing and seeking a license for Medicare risk
products in most of its markets. The Company will expend approximately $5
million in 1996 in developing such Medicare products which will still require a
substantial marketing program before the Company generates revenues from such
products in any market; the failure to achieve Medicare membership quickly in
various markets may further impact operating results as such development
expenses are relatively fixed. There can be no assurance that the Company will
successfully mitigate any of the foregoing risks.
IMPACT OF HEALTHCARE REFORM. Many federal and state proposals have been made in
the past to reform the healthcare system. The Company anticipates that federal
and state legislatures will continue to assess alternative healthcare systems
and payment methodologies as well as mandated coverages, capitation limits,
underwriting constraints and other measures that could affect the Company's
business. The Company is unable to predict which, if any, of these healthcare
reform proposals may be adopted. While the Company does not believe it would be
materially adversely impacted by most of the proposed reforms, certain proposals
could have such an impact; for example the imposition of a single-payor system
in any state could potentially eliminate the Company's business in that state.
See "Business - Governmental Regulation" in the Company's Form 10-K.
GOVERNMENTAL REGULATION. The Company's HMOs, insurance companies and certain of
its other subsidiaries are licensed by and subject to periodic examination and
extensive regulation by the states in which they operate and by the federal
government. Such state and federal statutes and regulations are subject to
change and such changes could adversely impact the Company's operations in the
future. There can be no assurance that the Company will be able to obtain any
regulatory approvals required to enter new markets or to offer new products. See
"Business - Governmental Regulation" in the Company's Form 10-K.
VOLATILITY OF THE COMPANY'S STOCK. The market price for the Company's stock may
be affected by investor perception of the Company, by general economic and
market conditions, by fluctuations in quarterly earnings, by general trends in
the healthcare market, and by regulatory developments especially at the federal
level; accordingly, the market price of the Company's stock may be volatile.
17
<PAGE> 18
Item 6. Exhibits and Reports on Form 8-K
--------------------------------
(a) Exhibits
4. Instruments defining the rights of security holders,
including indentures
4.1 Indenture dated as of March 6, 1996 between
Healthsource, Inc. and The Bank of New York, as trustee
4.2 Note Resale Registration Rights Agreement dated as of
March 6, 1996 among Healthsource, Inc. and the
purchasers named therein
10. Material Contracts
10.1 Purchase Agreement dated March 1, 1996 among
Healthsource, Inc. And Bear, Stearns & Co., as
representative of the Initial Purchasers named therein
11. Statement re: Computation of Net Income Per Share
15. Letter regarding unaudited interim financial information
15.1 Letter dated May 10, 1996 by Deloitte & Touche LLP
regarding unaudited interim financial information. See
page 9.
27. Financial Data Schedule
(b) Reports on Form 8-K
The following reports on Form 8-K were filed with the Securities and
Exchange Commission during the quarter ended March 31, 1996 and
subsequently:
(i) On January 26, 1996, the Company filed a Form 8-K reporting
the signing of a definitive agreement on January 23, 1996
with PACC HMO and PACC Health Plans, affiliated Oregon
nonprofit managed care companies, to purchase substantially
all of the operating assets of those entities for an
estimated net purchase price of $80 million in cash.
(ii) On February 23, 1996, the Company filed a Form 8-K reporting
the closing on February 9, 1996 of its previously-announced
agreement to acquire the operating assets of Central
Massachusetts Health Care, Inc., a Worcester, Massachusetts
nonprofit HMO, for $46.5 million in cash, subject to certain
post-closing adjustments.
(iii) On February 28, 1996, the Company filed a Form 8-K
announcing its intention to conduct a private offering of
$215 million principal amount of convertible subordinated
notes, with other terms to be agreed upon.
(iv) On March 21, 1996, the Company filed a Form 8-K reporting
the completion on March 8, 1996 of its private offering of
$247,250,000 principal amount of 5% Convertible Subordinated
Notes Due 2003.
(v) On April 18, 1996, the Company filed a Form 8-K reporting
the signing of a non-binding letter of intent to pay an
aggregate consideration of $27 million to acquire Health
Direct, Inc., a Des Plaines, Illinois HMO, and enter into a
long-term globally capitated provider agreement with the
seller's hospital system.
18
<PAGE> 19
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
HEALTHSOURCE, INC.
Dated: May 10, 1996 By
/S/ Norman C. Payson
--------------------------------
Norman C. Payson, M.D.
President and
Chief Executive Officer
By
/S/ Thomas M. Congoran
--------------------------------
Thomas M. Congoran
Chief Financial Officer/Principal
Accounting Officer
19
<PAGE> 20
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
HEALTHSOURCE, INC.
Dated: May 10, 1996 By
-----------------------------
Norman C. Payson, M.D.
President and
Chief Executive Officer
By
------------------------------
Thomas M. Congoran
Chief Financial Officer/Principal
Accounting Officer
19
<PAGE> 1
Exhibit 4.1
================================================================================
HEALTHSOURCE, INC.
Issuer
AND
THE BANK OF NEW YORK
Trustee
INDENTURE
Dated as of March 6, 1996
5% Convertible Subordinated Notes Due 2003
================================================================================
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
ARTICLE I
DEFINITIONS
Section 1.1 Definitions ............................................. 2
ARTICLE II
ISSUE, DESCRIPTION, EXECUTION, REGISTRATION
AND EXCHANGE OF NOTES
Section 2.1 Designation, Amount and Issue
of Notes ................................................ 8
Section 2.2 Form of Notes ........................................... 8
Section 2.3 Date and Denomination of Notes;
Payments of Interest .................................... 10
Section 2.4 Execution of Notes ...................................... 11
Section 2.5 Exchange and Registration of
Transfer of Notes; Restrictions
on Transfer; Depositary ................................. 12
Section 2.6 Mutilated, Destroyed, Lost or
Stolen Notes ............................................ 23
Section 2.7 Temporary Notes ......................................... 24
Section 2.8 Cancellation of Notes Paid, Etc. ........................ 25
ARTICLE III
REDEMPTION OF NOTES
Section 3.1 Redemption Prices ....................................... 25
Section 3.2 Notice of Redemption;
Selection of Notes ...................................... 26
Section 3.3 Payment of Notes Called for
Redemption .............................................. 28
Section 3.4 Conversion Arrangement on Call
for Redemption .......................................... 28
Section 3.5 Purchase of Notes Upon a Change
of Control .............................................. 29
ARTICLE IV
PARTICULAR COVENANTS OF THE COMPANY
Section 4.1 Payment of Principal, Premium
and Interest ............................................ 30
Section 4.2 Maintenance of Office or Agency ......................... 31
</TABLE>
i
<PAGE> 3
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
Section 4.3 Appointments to Fill Vacancies in
Trustee's Office ........................................ 31
Section 4.4 Provisions as to Paying Agent ........................... 31
Section 4.5 Corporate Existence ..................................... 33
Section 4.6 Rule 144A Information Requirement ....................... 33
Section 4.7 Stay, Extension and Usury Laws .......................... 33
Section 4.8 Compliance Statement; Notice of
Defaults ................................................ 33
ARTICLE V
NOTEHOLDERS' LISTS AND REPORTS BY
THE COMPANY
Section 5.1 Noteholders' Lists ...................................... 34
Section 5.2 Reports by Company ...................................... 34
ARTICLE VI
DEFAULTS AND REMEDIES
Section 6.1 Events of Default ....................................... 35
Section 6.2 Payments of Notes on Default; Suit
Therefor ................................................ 37
Section 6.3 Application of Monies Collected by
Trustee ................................................. 39
Section 6.4 Proceedings by Noteholder ............................... 40
Section 6.5 Proceedings by Trustee .................................. 41
Section 6.6 Remedies Cumulative and Continuing ...................... 41
Section 6.7 Direction of Proceedings and Waiver
of Defaults by Majority of
Noteholders ............................................. 41
Section 6.8 Notice of Defaults ...................................... 42
Section 6.9 Undertaking to Pay Costs ................................ 42
ARTICLE VII
CONCERNING THE TRUSTEE
Section 7.1 Duties and Responsibilities
of Trustee .............................................. 43
Section 7.2 Reports by Trustee to Holders ........................... 44
Section 7.3 Reliance on Documents, Opinions, Etc. ................... 44
Section 7.4 No Responsibility for Recitals, Etc. .................... 46
Section 7.5 Trustee, Paying Agents, Conversion
Agents or Registrar May Own Notes ....................... 46
Section 7.6 Monies to Be Held in Trust .............................. 46
Section 7.7 Compensation and Expenses of Trustee .................... 46
Section 7.8 Officers' Certificate as Evidence ....................... 47
Section 7.9 Conflicting Interests of Trustee ........................ 47
</TABLE>
ii
<PAGE> 4
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
Section 7.10 Eligibility of Trustee .................................. 47
Section 7.11 Resignation or Removal of Trustee ....................... 48
Section 7.12 Acceptance by Successor Trustee ......................... 49
Section 7.13 Successor, by Merger, Etc ............................... 50
Section 7.14 Limitation on Rights of Trustee
as Creditor ............................................. 50
ARTICLE VIII
CONCERNING THE NOTEHOLDERS
Section 8.1 Action by Noteholders ................................... 50
Section 8.2 Proof of Execution by Noteholders ....................... 51
Section 8.3 Who Are Deemed Absolute Owners .......................... 51
Section 8.4 Company-Owned Notes Disregarded ......................... 52
Section 8.5 Revocation of Consents, Future
Holders Bound ........................................... 52
ARTICLE IX
NOTEHOLDERS MEETINGS
Section 9.1 Purposes for Which Meetings May be
Called .................................................. 53
Section 9.2 Manner of Calling Meetings; Record Date ................. 53
Section 9.3 Call of Meeting by Company or
Noteholders ............................................. 53
Section 9.4 Who May Attend and Vote at Meetings ..................... 54
Section 9.5 Manner of Voting at Meetings and
Record to be Kept ....................................... 54
Section 9.6 Exercise of Rights of Trustee and
Noteholders Not To Be Hindered or
Delayed ................................................. 55
ARTICLE X
SUPPLEMENTAL INDENTURES
Section 10.1 Supplemental Indentures Without
Consent of Noteholders .................................. 55
Section 10.2 Supplemental Indentures With
Consent of Noteholders .................................. 57
Section 10.3 Effect of Supplemental Indentures ....................... 57
Section 10.4 Notation on Notes ....................................... 58
Section 10.5 Evidence of Compliance of Supplemental
Indenture to Be Furnished Trustee ....................... 58
</TABLE>
iii
<PAGE> 5
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
ARTICLE XI
CONSOLIDATION, MERGER, SALE, CONVEYANCE,
TRANSFER AND LEASE
Section 11.1 Company May Consolidate, Etc. on
Certain Terms ........................................... 58
Section 11.2 Successor Company To Be Substituted ..................... 59
Section 11.3 Opinion of Counsel To Be Given
to Trustee .............................................. 59
ARTICLE XII
SATISFACTION AND DISCHARGE OF INDENTURE;
UNCLAIMED MONEYS
Section 12.1 Legal Defeasance and Covenant
Defeasance of the Notes ................................. 60
Section 12.2 Termination of Obligations upon
Cancellation of the Notes ............................... 62
Section 12.3 Survival of Certain Obligations ......................... 63
Section 12.4 Acknowledgment of Discharge by Trustee .................. 63
Section 12.5 Application of Trust Assets ............................. 63
Section 12.6 Repayment to the Company; Unclaimed
Money ................................................... 64
Section 12.7 Reinstatement ........................................... 64
ARTICLE XIII
IMMUNITY OF INCORPORATORS, STOCKHOLDERS,
OFFICERS AND DIRECTORS
Section 13.1 Indenture and Notes Solely Corporate
Obligations ............................................. 65
ARTICLE XIV
CONVERSION OF NOTES
Section 14.1 Right to Convert ........................................ 65
Section 14.2 Exercise of Conversion Privilege;
Issuance of Common Stock on
Conversion; No Adjustment for
Interest or Dividends ................................... 66
Section 14.3 Cash Payments in Lieu of Fractional
Shares .................................................. 68
Section 14.4 Conversion Price ........................................ 68
Section 14.5 Adjustment of Conversion Price .......................... 68
Section 14.6 Effect of Reclassification,
Consolidation, Merger or Sale ........................... 78
</TABLE>
iv
<PAGE> 6
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
Section 14.7 Taxes on Shares Issued .................................. 79
Section 14.8 Reservation of Shares; Shares to Be
Fully Paid; Listing of Common Stock ..................... 80
Section 14.9 Responsibility of Trustee ............................... 80
Section 14.10 Notice to Holders Prior to Certain
Actions ................................................. 81
ARTICLE XV
SUBORDINATION
Section 15.1 Agreement to Subordinate ................................ 82
Section 15.2 Certain Definitions ..................................... 82
Section 15.3 Liquidation; Dissolution; Bankruptcy .................... 83
Section 15.4 Default on Senior Indebtedness .......................... 83
Section 15.5 When Distribution Must Be Paid Over ..................... 84
Section 15.6 Notice by Company ....................................... 85
Section 15.7 Subrogation ............................................. 85
Section 15.8 Relative Rights ......................................... 85
Section 15.9 Subordination May Not Be Impaired by
Company ................................................. 86
Section 15.10 Distribution or Notice to
Representative .......................................... 86
Section 15.11 Rights of Trustee and Paying Agent ...................... 86
Section 15.12 Authorization to Effect Subordination ................... 87
Section 15.13 Conversions Not Deemed Payment .......................... 87
Section 15.14 Amendments .............................................. 88
ARTICLE XVI
MISCELLANEOUS PROVISIONS
Section 16.1 Pooling of Interests .................................... 88
Section 16.2 Provisions Binding on Company's
Successors .............................................. 88
Section 16.3 Official Acts by Successor Company ...................... 88
Section 16.4 Addresses for Notices, Etc. ............................. 88
Section 16.5 Communications by Holders with Other
Holders ................................................. 89
Section 16.6 Governing Law ........................................... 89
Section 16.7 Evidence of Compliance with Conditions
Precedent; Certificates to Trustee ...................... 89
Section 16.8 Legal Holidays .......................................... 90
Section 16.9 No Security Interest Created ............................ 90
Section 16.10 Trust Indenture Act ..................................... 90
Section 16.11 Trust Indenture Act Controls ............................ 90
Section 16.12 Benefits of Indenture ................................... 90
Section 16.13 Table of Contents, Headings Etc. ........................ 90
Section 16.14 Authenticating Agent .................................... 90
Section 16.15 Execution in Counterparts ............................... 91
</TABLE>
v
<PAGE> 7
INDENTURE dated as of March 6, 1996 between HEALTHSOURCE, INC.,
a New Hampshire corporation (hereinafter sometimes called the "Company," as more
fully set forth in Section 1.1), and THE BANK OF NEW YORK, a New York banking
corporation (hereinafter sometimes called the "Trustee," as more fully set forth
in Section 1.1).
W I T N E S S E T H:
WHEREAS, for its lawful corporate purposes, the Company has
duly authorized the issuance of its 5% Convertible Subordinated Notes Due 2003
(hereinafter sometimes called the "Notes"), in an aggregate principal amount not
to exceed $247,250,000 and, to provide the terms and conditions upon which the
Notes are to be authenticated, issued and delivered, the Company has duly
authorized the execution and delivery of this Indenture; and
WHEREAS, the Notes, the certificate of authentication to be
borne by the Notes, a form of assignment, a form of option to require repurchase
by the Company upon a Change of Control (as hereinafter defined), a form of
conversion notice and a certificate of transfer to be borne by the Notes are to
be substantially in the forms hereinafter provided for; and
WHEREAS, all acts and things necessary to make the Notes, when
executed by the Company and authenticated and delivered by the Trustee or a duly
authorized authenticating agent, as in this Indenture provided, the valid,
binding and legal obligations of the Company, and to constitute these presents a
valid agreement according to its terms, have been done and performed, and the
execution of this Indenture and the issuance hereunder of the Notes have in all
respects been duly authorized.
NOW, THEREFORE, THIS INDENTURE WITNESSETH:
That in order to declare the terms and conditions upon which
the Notes are, and are to be, authenticated, issued and delivered, and in
consideration of the premises and of the purchase and acceptance of the Notes by
the holders thereof, the Company covenants and agrees with the Trustee for the
equal and proportionate benefit of the respective holders from time to time of
the Notes (except as otherwise provided below) as follows:
<PAGE> 8
ARTICLE I
DEFINITIONS
Section 1.1 Definitions. The terms defined in this Section 1.1
(except as herein otherwise expressly provided or unless the context otherwise
requires) for all purposes of this Indenture and of any indenture supplemental
hereto shall have the respective meanings specified in this Section 1.1. All
other terms used in this Indenture that are defined in the Trust Indenture Act
(as hereinafter defined) or that are by reference defined in the Securities Act
(as hereinafter defined), except as herein otherwise expressly provided or
unless the context otherwise requires, shall have the meanings assigned to such
terms in said Trust Indenture Act and in said Securities Act as in force at the
date of the execution of this Indenture. The words "herein," "hereof,"
"hereunder" and words of similar import refer to this Indenture as a whole and
not to any particular Article, Section or other Subdivision. The terms defined
in this Article include the plural as well as the singular.
Accredited Investor: The term "Accredited Investor" shall have
the meaning specified in Rule 501(a) under the Securities Act.
Acquisition Price: The term "Acquisition Price" shall
mean the weighted average price paid by the person or group in acquiring the
Voting Stock.
Affiliate: An "Affiliate" of any specified person shall mean an
"affiliate" as defined in Rule 144(a) as promulgated under the Securities Act.
Board of Directors: The term "Board of Directors" shall mean
the Board of Directors of the Company or a committee of such Board of Directors
duly authorized to act for it hereunder.
Board Resolution: The term "Board Resolution" shall mean a copy
of a resolution certified by the Secretary or an Assistant Secretary of the
Company to have been duly adopted by the Board of Directors, or a duly
authorized committee thereof (to the extent permitted by applicable law), and to
be in full force and effect on the date of such certification, and delivered to
the Trustee.
Business Day: The term "Business Day" shall mean a day, other
than a Saturday, a Sunday or a day on which the banking institutions in the
State of New York are authorized or obligated by law or executive order to close
or a day that is declared a national or New York state holiday.
2
<PAGE> 9
Cedel: The term "Cedel" shall mean Cedel Bank societe anonyme.
Change of Control: The term "Change of Control" shall mean an
event or series of events pursuant to which (i) any "person" or "group" (as such
terms are used in Sections 13(d) and 14(d) of the Exchange Act) acquires
"beneficial ownership" (as determined in accordance with Rule 13d-3 under the
Exchange Act), directly or indirectly, of more than 50% of the total Voting
Stock of the Company at an Acquisition Price less than the Conversion Price then
in effect with respect to the Notes and (ii) holders of the Common Stock receive
consideration that is not all or substantially all common stock that is (or upon
consummation of or immediately following such event or events shall be) listed
on a United States national securities exchange or approved for quotation on the
NASDAQ National Market or any similar United States system of automated
dissemination of quotations of securities' prices; provided, however, that any
such person or group shall not be deemed to be the beneficial owner of, or to
beneficially own, any Voting Stock tendered into a tender offer until such
tendered Voting Stock is accepted for purchase under the tender offer.
Closing Date: The term "Closing Date" shall mean March 6, 1996.
Commission: The term "Commission" shall mean the Securities and
Exchange Commission.
Common Stock: The term "Common Stock" shall mean any stock of
any class of the Company that does not have a preference in respect of dividends
or of amounts payable in the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company and that is not subject to redemption
by the Company. Subject to the provisions of Section 14.6, however, shares
issuable on conversion of Notes shall include only shares of the class
designated as common stock of the Company at the date of this Indenture or
shares of any class or classes resulting from any reclassification or
reclassifications thereof and that do not have a preference in respect of
dividends or of amounts payable in the event of any voluntary or involuntary
liquidation, dissolution or winding up of the Company and that are not subject
to redemption by the Company; provided that if at any time there shall be more
than one such resulting class, the shares of each such class then so issuable
shall be substantially in the proportion that the total number of shares of such
class resulting from all such reclassification bears to the total number of
shares of all such classes resulting from all such reclassifications.
3
<PAGE> 10
Company: The term "Company" shall mean Healthsource, Inc., a
New Hampshire corporation, and subject to the provisions of Article XI, shall
include its successors and assigns.
Conversion Price: The term "Conversion Price" shall have the
meaning specified in Section 14.4.
Corporate Trust Office of the Trustee: The term "Corporate
Trust Office of the Trustee," or other similar term, shall mean the office of
the Trustee at which at any particular time its corporate trust business shall
be principally administered, which office is, at the date as of which this
Indenture is dated, located at 101 Barclay Street, Floor 21 West, New York, New
York 10286, Attention: Corporate Trust Trustee Administration.
Custodian: The term "Custodian" shall mean The Bank of New
York, as custodian with respect to the Notes in global form, or any successor
entity thereto.
default: The term "default" shall mean any event that is, or
after notice or passage of time, or both, would be, an Event of Default.
definitive Notes; in definitive form: The term "definitive
Notes" shall have the meaning specified in Section 2.2, any reference to Notes
"in definitive form" shall mean definitive Notes and any reference to Securities
"in definitive form" shall mean definitive Notes or Common Stock as the context
requires.
Depositary: The term "Depositary" shall mean, with respect to
the Notes issuable or issued in whole or in part in global form, the person
specified in Section 2.5(d) as the Depositary with respect to the Notes, until a
successor shall have been appointed and become such pursuant to the applicable
provisions of this Indenture, and thereafter, "Depositary" shall mean or include
such successor.
DWAC: The term "DWAC" shall mean Deposit and Withdrawal at
Custodian Service.
Euroclear: The term "Euroclear" shall mean Morgan Guaranty
Trust Company of New York, Brussels office, as operator of the Euroclear System.
Event of Default: The term "Event of Default" shall mean any
event specified in Section 6.1(a), (b), (c), (d) or (e).
Exchange Act: The term "Exchange Act" shall mean the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.
4
<PAGE> 11
global Note: The term "global Note" shall mean any and all
notes in global form.
Indenture: The term "Indenture" shall mean this instrument as
originally executed or, if amended or supplemented as herein provided, as so
amended or supplemented.
Note or Notes: The terms "Note" or "Notes" shall mean any Note
or Notes, as the case may be, authenticated and delivered under this Indenture.
Noteholder; holder: The terms "Noteholder" or "holder" as
applied to any Note, or other similar terms (but excluding the term "beneficial
holder"), shall mean any person in whose name at the time a particular Note is
registered on the Note registrar's books.
Note register: The term "Note register" shall have the meaning
specified in Section 2.5(a).
Officers' Certificate: The term "Officers' Certificate," when
used with respect to the Company, shall mean a certificate signed by the
President, the Chief Executive Officer, the Chief Operating Officer, the Chief
Financial Officer, any Treasurer, the Secretary or any Assistant Secretary of
the Company, that is delivered to the Trustee. Each such certificate shall
include the statements provided for in Section 16.7 if and to the extent
required by the provisions of such Section.
Opinion of Counsel: The term "Opinion of Counsel" shall mean an
opinion in writing signed by legal counsel, who may be an employee of or counsel
to the Company or other counsel acceptable to the Trustee, that is delivered to
the Trustee. Each such opinion shall include the statements provided for in
Section 16.7 if and to the extent required by the provisions of such Section.
outstanding: The term "outstanding," when used with reference
to Notes, shall, subject to the provisions of Section 8.4, mean, as of any
particular time, all Notes authenticated and delivered by the Trustee under this
Indenture, except
(a) Notes theretofore canceled by the Trustee or delivered to
the Trustee for cancellation;
(b) Notes, or portions thereof, for which monies in the
necessary amount shall have been deposited in trust with the Trustee
for payment or redemption; provided that if such Notes are to be
redeemed prior to the maturity thereof, notice of such redemption shall
have been given as in Article III provided, or provi-
5
<PAGE> 12
sion satisfactory to the Trustee shall have been made for giving such
notice;
(c) Notes paid pursuant to Section 2.6 hereof or Notes in lieu
of or in substitution for which other Notes shall have been
authenticated and delivered pursuant to the terms of Section 2.6 unless
proof satisfactory to the Trustee is presented that any such Notes are
held by bona fide holders in due course; and
(d) Notes converted into Common Stock pursuant to Article XIV
and Notes not deemed outstanding pursuant to Section 3.2.
person: The term "person" shall mean a corporation, an
association, a partnership, an individual, a joint venture, a joint stock
company, a trust, an unincorporated organization or a government or an agency or
a political subdivision thereof.
PORTAL Market: The term "PORTAL Market" shall mean the Private
Offerings, Resales and Trading through Automated Linkages Market operated by the
National Association of Securities Dealers, Inc. or any successor thereto.
Predecessor Note: The term "Predecessor Note" of any
particular Note shall mean every previous Note evidencing all or a portion of
the same debt as that evidenced by such particular Note; and, for the purposes
of this definition, any Note authenticated and delivered under Section 2.6 in
lieu of a lost, destroyed or stolen Note shall be deemed to evidence the same
debt as the lost, destroyed or stolen Note.
QIB: The term "QIB" shall mean a "qualified institutional
buyer" as defined in Rule 144A.
Regulation S: The term "Regulation S" shall mean Regulation S
under the Securities Act and any successor regulation thereto.
Regulation S Global Note: The term "Regulation S Global Note"
shall have the meaning specified in Section 2.2.
Responsible Officer: The term "Responsible Officer," when used
with respect to the Trustee, shall mean an officer of the Trustee assigned and
duly authorized by the Trustee to administer its corporate trust matters.
Restricted Global Note: The term "Restricted Global Note" shall
have the meaning specified in Section 2.2.
Restricted Period: The term "Restricted Period" shall have the
meaning specified in Section 2.2.
6
<PAGE> 13
Restricted Securities: The term "Restricted Securities" shall
have the meaning specified in Section 2.5(d).
Rule 144A: The term "Rule 144A" shall mean Rule 144A as
promulgated under the Securities Act.
Securities Act: The term "Securities Act" shall mean the
Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder.
subsidiary: The term "subsidiary" of any specified person shall
mean (i) a corporation a majority of whose capital stock with voting power under
ordinary circumstances, to elect directors is at the time directly or indirectly
owned by such person or (ii) any other person (other than a corporation) in
which such person or such person and a subsidiary or subsidiaries of such person
or a subsidiary or subsidiaries of such person directly or indirectly, at the
date of determination thereof, has at least majority ownership.
Successor Company: The term "Successor Company" shall have the
meaning specified in Section 11.1.
Trust Indenture Act: The term "Trust Indenture Act" shall mean
the Trust Indenture Act of 1939, as amended, as it was in force at the date of
execution of this Indenture, except as provided in Sections 10.3 and 14.6;
provided that in the event said Trust Indenture Act of 1939 is amended after the
date hereof, the term "Trust Indenture Act" shall mean, to the extent required
by such amendment, said Trust Indenture Act of 1939 as so amended.
Trustee: The term "Trustee" shall mean The Bank of New York,
its successors and any corporation resulting from or surviving any consolidation
or merger to which it or its successors may be a party and any successor trustee
at the time serving as successor trustee hereunder.
U.S. Government Obligations: The term "U.S. Government
Obligations" shall mean securities that are (i) direct obligations of the United
States of America for the payment of which its full faith and credit is pledged
or (ii) obligations of a person controlled or supervised by, and acting as an
agency or instrumentality of, the United States of America the timely payment of
which is unconditionally guaranteed as a full faith and credit obligation by the
United States of America, which, in either case, are not callable or redeemable
at the option of the issuer thereof, and shall also include a depository receipt
issued by a bank (as defined in Section 3(a)(2) of the Securities Act) as
custodian with respect to any such U.S. Government Obligation or a specific
payment of principal or interest on any such U.S. Government Obligation held by
such custodian for the
7
<PAGE> 14
account of the holder of such depository receipt; provided that (except as
required by law) such custodian is not authorized to make any deduction from the
amount payable to the holder of such depository receipt from any amount received
by such custodian in respect of the U.S. Government Obligation or the specific
payment of principal of or interest on the U.S. Government Obligation evidenced
by such depository receipt.
Voting Stock: The term "Voting Stock" shall mean stock of the
class or classes pursuant to which the holders thereof have the general voting
power under ordinary circumstances to elect at least a majority of the board of
directors, managers or trustees of a corporation (irrespective of whether or not
at the time stock of any other class or classes shall have or might have voting
power by reason of the happening of any contingency).
The definitions of certain other terms are as specified in
Sections 2.3, 2.5, 3.5, 12.1, 14.5, 14.6, 15.2 and 15.4.
ARTICLE II
ISSUE, DESCRIPTION, EXECUTION, REGISTRATION
AND EXCHANGE OF NOTES
Section 2.1 Designation, Amount and Issue of Notes. The Notes
shall be designated as "5% Convertible Subordinated Notes Due 2003." Notes not
to exceed the aggregate principal amount of $247,250,000 upon the execution of
this Indenture, or from time to time thereafter, may be executed by the Company
and delivered to the Trustee for authentication, and the Trustee shall thereupon
authenticate and make available for delivery said Notes upon the written order
of the Company, signed by its (a) Chief Executive Officer, President, Chief
Operating Officer or Chief Financial Officer, and (b) any Treasurer or Secretary
or any Assistant Secretary, without any further action by the Company hereunder.
Section 2.2 Form of Notes. The Notes in definitive form
("definitive Notes") shall be substantially in the form of Exhibit A hereto,
with the legends in substantially the form indicated in Exhibit A hereto and
such other legends as may be applicable thereto, which definitive Notes shall be
registered in the name of the holders thereof, duly executed by the Company and
authenticated by the Trustee or the authenticating agent as provided herein.
Unless issued in definitive form, Notes initially offered and
sold in reliance on Rule 144A shall be issued in the form of one or more
permanent global Notes (the "Restricted Global Note"), substantially in the form
of Exhibit B hereto, with the legends in substantially the form set forth in
Exhibit B
8
<PAGE> 15
hereto and such other legends as may be applicable thereto, which Restricted
Global Note shall be deposited on behalf of the holders of the Notes represented
thereby with the Trustee, as custodian for the Depositary, and registered in the
name of a nominee of the Depositary, duly executed by the Company and
authenticated by the Trustee or the authenticating agent as provided herein.
Notes offered and sold outside the United States in reliance on
Regulation S may be evidenced in the form of one or more permanent global Notes
(the "Regulation S Global Note"), substantially in the form of Exhibit C hereto,
with the legends in substantially the form set forth in Exhibit C hereto and
such other legends as may be applicable thereto, which Regulation S Global Note
shall be deposited on behalf of the holders of the Notes represented thereby
with the Trustee, as custodian for the Depositary, and registered in the name of
a nominee of the Depositary, duly executed by the Company and authenticated by
the Trustee or an authenticating agent as provided herein, for credit to the
accounts of the respective depositaries for Euroclear and Cedel (or such other
accounts as they may direct). Prior to or on the 40th day after the later of the
commencement of the offering of the Notes and the Closing Date (the "Restricted
Period"), beneficial interests in the Regulation S Global Note may only be held
through Morgan Guaranty Trust Company of New York, Brussels office, as operator
of Euroclear or Cedel or another agent member of Euroclear and Cedel acting for
and on behalf of them, unless delivery is made through the Restricted Global
Note in accordance with the certification requirements hereof. During the
Restricted Period, interests in the Regulation S Global Note may be exchanged
for interests in the Restricted Global Note or for definitive Notes only in
accordance with the certification requirements described in Section 2.5 below.
Any of the Notes may have such letters, numbers or other marks
of identification and such notations, legends and endorsements as the officers
executing the same may approve (execution thereof to be conclusive evidence of
such approval) and as are not inconsistent with the provisions of this
Indenture, or as may be required to comply with any law or with any rule or
regulation made pursuant thereto or with any rule or regulation of any stock
exchange on which the Notes may be listed, or to conform to usage.
Any global Note shall represent such of the outstanding Notes
as shall be specified therein and shall provide that it shall represent the
aggregate amount of outstanding Notes from time to time endorsed thereon and
that the aggregate amount of outstanding Notes represented thereby may from time
to time be increased or reduced to reflect transfers or exchanges permitted
hereby. Any endorsement of a global Note to reflect the amount
9
<PAGE> 16
of any increase or decrease in the amount of outstanding Notes represented
thereby shall be made by the Trustee or the Custodian, at the direction of the
Trustee, in such manner and upon instructions given by the holder of such Notes
in accordance with the Indenture. Payment of principal of and interest and
premium, if any, on any global Note shall be made to the holder of such Note.
The terms and provisions contained in the forms of Notes
attached as Exhibits A, B and C hereto shall constitute, and are hereby
expressly made, a part of this Indenture and to the extent applicable, the
Company and the Trustee, by their execution and delivery of this Indenture,
expressly agree to such terms and provisions and to be bound thereby.
Section 2.3 Date and Denomination of Notes; Payments of
Interest. The Notes shall be issuable in registered form without coupons in
denominations of $1,000 principal amount and integral multiples thereof. Every
Note shall be dated the date of its authentication, shall bear interest from
March 6, 1996 and shall be payable semiannually on each March 1 and September 1,
commencing September 1, 1996, as specified on the faces of the forms of Notes,
attached as Exhibits A, B and C hereto.
The person in whose name any Note (or its Predecessor Note) is
registered at the close of business on any record date with respect to any
interest payment date (including any Note that is converted after the record
date and on or before the interest payment date) shall be entitled to receive
the interest payable on such interest payment date notwithstanding the
cancellation of such Note upon any transfer, exchange or conversion subsequent
to the record date and prior to such interest payment date. Interest may, at the
option of the Company, be paid by check mailed to the address of such person as
it appears on the Note register; provided that, with respect to any holder of
Notes with an aggregate principal amount equal to or in excess of $5,000,000, at
the request (such request to include appropriate wire instructions) of such
holder in writing to the Trustee on or before the record date preceding any
interest payment date, interest on such holder's Notes shall be paid by wire
transfer in immediately available funds. The term "record date" with respect to
any interest payment date shall mean the February 15 or August 15 preceding said
March 1 or September 1.
Interest on the Notes shall be computed on the basis of a
360-day year composed of twelve 30-day months.
Any interest on any Note that is payable, but is not punctually
paid or duly provided for, on any said March 1 or September 1 (herein called
"Defaulted Interest") shall forthwith cease to be payable to the Noteholder on
the relevant record date by virtue of his having been such Noteholder; and such
Defaulted
10
<PAGE> 17
Interest shall be paid by the Company, at its election in each case, as provided
in clause (1) or (2) below:
(1) The Company may elect to make payment of any Defaulted
Interest to the persons in whose names the Notes (or their respective
Predecessor Notes) are registered at the close of business on a special
record date for the payment of such Defaulted Interest, which shall be
fixed in the following manner. The Company shall notify the Trustee in
writing of the amount of Defaulted Interest to be paid on each Note and
the date of the payment (which shall be not less than 25 days after the
receipt by the Trustee of such notice, unless the Trustee shall consent
to an earlier date), and at the same time, the Company shall deposit
with the Trustee an amount of money equal to the aggregate amount to be
paid in respect of such Defaulted Interest or shall make arrangements
satisfactory to the Trustee for such deposit prior to the date of the
proposed payment, such money when deposited to be held in trust for the
benefit of the persons entitled to such Defaulted Interest as in this
clause provided. Thereupon, the Trustee shall fix a special record date
for the payment of such Defaulted Interest, which shall be not more
than 15 days and not less than 10 days prior to the date of the payment
and not less than 10 days after the receipt by the Trustee of the
notice of the proposed payment. The Trustee shall promptly notify the
Company of such special record date and, in the name and at the expense
of the Company, shall cause notice of the payment of such Defaulted
Interest and the special record date therefor to be mailed, first-class
postage prepaid, to each Noteholder at his address as it appears in the
Note register, not less than 10 days prior to such special record date.
Notice of the proposed payment of such Defaulted Interest and the
special record date therefor having been so mailed, such Defaulted
Interest shall be paid to the persons in whose names the Notes (or
their respective Predecessor Notes) were registered at the close of
business on such special record date and shall no longer be payable
pursuant to the following clause (2).
(2) The Company may make payment of any Defaulted Interest in
any other lawful manner not inconsistent with the requirements of any
securities exchange on which the Notes may be listed, and upon such
notice as may be required by such exchange, if, after notice given by
the Company to the Trustee of the proposed payment pursuant to this
clause, such manner of payment shall be deemed practicable by the
Trustee.
Section 2.4 Execution of Notes. The Notes shall be
signed in the name and on behalf of the Company by the signature of its Chief
Executive Officer, President, Chief Operating
11
<PAGE> 18
Officer or Chief Financial Officer and attested by the signature of its
Treasurer, Secretary or any of its Assistant Secretaries (any of which
signatures may be printed, engraved or otherwise reproduced thereon, by
facsimile or otherwise). Only such Notes as shall bear thereon a certificate of
authentication substantially in the form set forth on forms of Notes attached as
Exhibits A, B and C hereto, manually executed by the Trustee (or an
authenticating agent appointed by the Trustee as provided by Section 16.14),
shall be entitled to the benefits of this Indenture or be valid or obligatory
for any purpose. Such certificate by the Trustee (or such an authenticating
agent) upon any Note executed by the Company shall be conclusive evidence that
the Note so authenticated has been duly authenticated and delivered hereunder
and that the holder is entitled to the benefits of this Indenture.
In case any officer of the Company who shall have signed any of
the Notes shall cease to be such officer before the Notes so signed shall have
been authenticated and delivered by the Trustee, or disposed of by the Company,
such Notes nevertheless may be authenticated and delivered or disposed of as
though the person who signed such Notes had not ceased to be such officer of the
Company; and any Note may be signed on behalf of the Company by such persons as,
at the actual date of the execution of such Note, shall be the proper officers
of the Company, although at the date of the execution of this Indenture any such
person was not such an officer.
Section 2.5 Exchange and Registration of Transfer of Notes;
Restrictions on Transfer; Depositary.
(a) The Company shall cause to be kept at the Corporate Trust
Office of the Trustee a register (the register maintained in such office and in
any other office or agency of the Company designated pursuant to Section 4.2
being herein sometimes collectively referred to as the "Note register") in
which, subject to such reasonable regulations as it may prescribe, the Company
shall provide for the registration of Notes and of transfers of Notes. Such Note
register shall be in written form or in any form capable of being converted into
written form within a reasonable period of time. The Trustee is hereby appointed
"Note registrar" for the purpose of registering Notes and transfers of Notes as
herein provided. The Company may appoint one or more co-registrars.
Upon surrender for registration of transfer of any Note to the
Note registrar or any co-registrar and satisfaction of the requirements for such
transfer set forth in this Section 2.5, the Company shall execute, and the
Trustee shall authenticate and make available for delivery, in the name of the
designated transferee or transferees, one or more new Notes of any authorized
denominations and of a like aggregate principal amount and
12
<PAGE> 19
bearing such restrictive legends as may be required by Section 2.5(d).
Notes may be exchanged for other Notes of any authorized
denominations and of a like aggregate principal amount, upon surrender of the
Notes to be exchanged at any such office or agency. Whenever any Notes are so
surrendered for exchange, the Company shall execute, and the Trustee shall
authenticate and make available for delivery, the Notes that the Noteholder
making the exchange is entitled to receive.
All Notes presented or surrendered for registration of transfer
or for exchange shall (if so required by the Company, the Trustee, the Note
registrar or any co-registrar) be duly endorsed, or be accompanied by a written
instrument of transfer in form satisfactory to the Company, and the Note shall
be duly executed by the Noteholder thereof or his attorney duly authorized in
writing.
No service charge shall be charged to the Noteholder for any
exchange or registration of transfer of Notes, but the Company may require
payment of a sum sufficient to cover any tax, assessments or other governmental
charges that may be imposed in connection therewith.
None of the Company, the Trustee, the Note registrar or any
co-registrar shall be required to exchange or register a transfer of (a) any
Notes for a period of 15 days next preceding the mailing of a notice of
redemption or (b) any Notes called for redemption or, if a portion of any Note
is selected or called for redemption, such portion thereof selected or called
for redemption or (c) any Notes surrendered for conversion or, if a portion of
any Note is surrendered for conversion, such portion thereof surrendered for
conversion or (d) any Notes surrendered for redemption pursuant to Section 3.5
or, if a portion of any Note is surrendered for redemption pursuant to Section
3.5, such portion thereof surrendered for redemption pursuant to Section 3.5.
All Notes issued upon any transfer or exchange of Notes shall
be the valid obligations of the Company, evidencing the same debt and entitled
to the same benefits under this Indenture as the Notes surrendered upon such
registration of transfer or exchange.
(b) So long as the Notes are eligible for book-entry settlement
with the Depositary, or unless otherwise required by law, all Notes to be traded
on the PORTAL Market shall be represented by the Restricted Global Note
registered in the name of the Depositary or the nominee of the Depositary. The
transfer and exchange of beneficial interests in any global Note that does not
involve the issuance of a definitive Note or the transfer of
13
<PAGE> 20
interests to another global Note shall be effected through the Depositary (but
not the Trustee or the Custodian) in accordance with this Indenture (including
the restrictions on transfer set forth herein) and the procedures of the
Depositary therefor. Neither the Trustee nor the Custodian (in such respective
capacities) shall have any responsibility for the transfer and exchange of
beneficial interests in such global Note that does not involve the issuance of a
definitive Note or the transfer of interests to another global Note.
At any time at the request of the beneficial holder of an
interest in a global Note, such beneficial holder shall be entitled to obtain a
definitive Note upon written request to the Trustee and the Custodian in
accordance with the standing instructions and procedures existing between the
Depositary and the Custodian for the issuance thereof. Upon receipt of any such
request, the Trustee or the Custodian, at the direction of the Trustee, shall
cause, in accordance with the standing instructions and procedures existing
between the Depositary and the Custodian, the aggregate principal amount of the
global Note to be reduced and, following such reduction, the Company shall
execute and the Trustee shall authenticate and make available for delivery to
such beneficial holder (or its nominee) a Note or Notes in the appropriate
aggregate principal amount in the name of such beneficial holder (or its
nominee) and bearing such restrictive legends as may be required by this
Indenture.
Any transfer of a beneficial interest in a global Note that
cannot be effected through book-entry settlement must be effected by the
delivery to the transferee (or its nominee) of a definitive Note or Notes
registered in the name of the transferee (or its nominee) on the books
maintained by the Trustee. With respect to any such transfer, the Trustee or the
Custodian, at the direction of the Trustee, shall cause, in accordance with the
standing instructions and procedures existing between the Depositary and the
Custodian, the aggregate principal amount of the global Note to be reduced and,
following such reduction, the Company shall execute and the Trustee shall
authenticate and make available for delivery to the transferee (or such
transferee's nominee, as the case may be), a definitive Note or Notes in the
appropriate aggregate principal amount in the name of such transferee (or its
nominee) and bearing such restrictive legends as may be required by this
Indenture. As a condition to such transfer, if such transfer is made to an
Accredited Investor, the Trustee or the Custodian, at the direction of the
Trustee, shall request such representations and agreements relating to the
restrictions on transfer of such Note or Notes from such transferee (or such
transferee's nominee) substantially in the form as set forth in Exhibit D hereto
and as the Trustee (or the Custodian) may otherwise reasonably require.
14
<PAGE> 21
Any transfer of a definitive Note or Notes must be effected by
the delivery to the transferee (or its nominee) of a definitive Note or Notes
registered in the name of the transferee (or its nominee) on the books
maintained by the Trustee. With respect to any such transfer, the Company shall
execute and the Trustee shall authenticate and make available for delivery to
the transferee (or such transferee's nominee, as the case may be), a definitive
Note or Notes in the appropriate aggregate principal amount in the name of such
transferee (or its nominee) and bearing such restrictive legends as may be
required by this Indenture. As a condition to such transfer, if such transfer is
made to an Accredited Investor, the Trustee or the Custodian, at the direction
of the Trustee, shall request such representations and agreements relating to
the restrictions on transfer of such Note or Notes from such transferee (or such
transferee's nominee) substantially in the form as set forth in Exhibit D hereto
and as the Trustee (or the Custodian) shall otherwise reasonably require.
(c) So long as the Notes are eligible for book-entry
settlement, or unless otherwise required by law, upon any transfer of a
definitive Note to a QIB in accordance with Rule 144A, unless otherwise
requested by the transferor, and upon receipt of the definitive Note or Notes
being so transferred, together with a certificate in the form of Exhibit E
hereto from the transferor that the transferor reasonably believes the
transferee is a QIB and is obtaining such beneficial interest in a transaction
meeting the requirements of Rule 144A and any applicable securities laws of any
state of the United States or any other jurisdiction (or other evidence
satisfactory to the Trustee), the Trustee shall make or direct the Custodian to
make, an endorsement on the Restricted Global Note to reflect an increase in the
aggregate principal amount of the Notes represented by the Restricted Global
Note, the Trustee shall cancel such definitive Note or Notes and cause, or
direct the Custodian to cause, in accordance with the standing instructions and
procedures existing between the Depositary and the Custodian, the aggregate
principal amount of Notes represented by the Restricted Global Note to be
increased accordingly.
So long as the Notes are eligible for book-entry settlement, or
unless otherwise required by law, upon any transfer of a definitive Note in
accordance with Regulation S, if requested by the transferor, and upon receipt
of the definitive Note or Notes being so transferred, together with a
certificate in the form of Exhibit F hereto from the transferor that the
transfer was made in accordance with Rule 903 or 904 of Regulation S under the
Securities Act (or other evidence satisfactory to the Trustee), the Trustee
shall make or direct the Custodian to make, an endorsement on the Regulation S
Global Note to reflect an increase in the aggregate principal amount of the
Notes represented by the Regulation S Global Note, the Trustee
15
<PAGE> 22
shall cancel such definitive Note or Notes and cause, or direct the Custodian to
cause, in accordance with the standing instructions and procedures existing
between the Depositary and the Custodian, the aggregate principal amount of
Notes represented by the Regulation S Global Note to be increased accordingly.
If a holder of a beneficial interest in the Restricted Global
Note wishes at any time to exchange its interest in the Restricted Global Note
for an interest in the Regulation S Global Note, or to transfer its interest in
the Restricted Global Note to a person who wishes to take delivery thereof in
the form of an interest in the Regulation S Global Note, such holder may,
subject to the rules and procedures of the Depositary and to the requirements
set forth in the following sentence, exchange or cause the exchange or transfer
or cause the transfer of such interest for an equivalent beneficial interest in
the Regulation S Global Note. Upon receipt by the Trustee, as transfer agent, of
(1) instructions given in accordance with the Depositary's procedures from or on
behalf of a holder of a beneficial interest in the Restricted Global Note,
directing the Trustee (via DWAC), as transfer agent, to credit or cause to be
credited a beneficial interest in the Regulation S Global Note in an amount
equal to the beneficial interest in the Restricted Global Note to be exchanged
or transferred, (2) a written order given in accordance with the Depositary's
procedures containing information regarding the Euroclear or Cedel account to be
credited with such increase and the name of such account, and (3) a certificate
in the form of Exhibit G given by the holder of such beneficial interest stating
that the exchange or transfer of such interest has been made pursuant to and in
accordance with Rule 903 or Rule 904 of Regulation S under the Securities Act
(or other evidence satisfactory to the Trustee), the Trustee, as transfer agent,
shall promptly deliver appropriate instructions to the Depositary (via DWAC),
its nominee, or the custodian for the Depositary, as the case may be, to reduce
or reflect on its records a reduction of the Restricted Global Note by the
aggregate principal amount of the beneficial interest in such Restricted Global
Note to be so exchanged or transferred from the relevant participant, and the
Trustee, as transfer agent, shall promptly deliver appropriate instructions (via
DWAC) to the Depositary, its nominee, or the custodian for the Depositary, as
the case may be, concurrently with such reduction, to increase or reflect on its
records an increase of the principal amount of such Regulation S Global Note by
the aggregate principal amount of the beneficial interest in such Restricted
Global Note to be so exchanged or transferred, and to credit or cause to be
credited to the account of the person specified in such instructions (who shall
be Morgan Guaranty Trust Company of New York, Brussels office, as operator of
Euroclear or Cedel or another agent member of Euroclear or Cedel, or both, as
the case may be, acting for and on behalf of them) a beneficial interest in such
Regulation S Global Note
16
<PAGE> 23
equal to the reduction in the principal amount of such Restricted Global Note.
If a holder of a beneficial interest in the Regulation S Global
Note wishes at any time to exchange its interest in the Regulation S Global Note
for an interest in the Restricted Global Note, or to transfer its interest in
the Regulation S Global Note to a person who wishes to take delivery thereof in
the form of an interest in the Restricted Global Note, such holder may, subject
to the rules and procedures of Euroclear or Cedel and the Depositary, as the
case may be, and to the requirements set forth in the following sentence,
exchange or cause the exchange or transfer or cause the transfer of such
interest for an equivalent beneficial interest in such Restricted Global Note.
Upon receipt by the Trustee, as transfer agent, of (l) instructions given in
accordance with the procedures of Euroclear or Cedel and the Depositary, as the
case may be, from or on behalf of a beneficial owner of an interest in the
Regulation S Global Note directing the Trustee, as transfer agent, to credit or
cause to be credited a beneficial interest in the Restricted Global Note in an
amount equal to the beneficial interest in the Regulation S Global Note to be
exchanged or transferred, (2) a written order given in accordance with the
procedures of Euroclear or Cedel and the Depositary, as the case may be,
containing information regarding the account with the Depositary to be credited
with such increase and the name of such account, and (3) prior to the expiration
of the Restricted Period, a certificate in the form of Exhibit H given by the
holder of such beneficial interest and stating that the person transferring such
interest in such Regulation S Global Note reasonably believes that the person
acquiring such interest in the Restricted Global Note is a QIB and is obtaining
such beneficial interest in a transaction meeting the requirements of Rule 144A
and any applicable securities laws of any state of the United States or any
other jurisdiction (or other evidence satisfactory to the Trustee), the Trustee,
as transfer agent, shall promptly deliver (via DWAC) appropriate instructions to
the Depositary, its nominee, or the custodian for the Depositary, as the case
may be, to reduce or reflect on its records a reduction of the Regulation S
Global Note by the aggregate principal amount of the beneficial interest in such
Regulation S Global Note to be exchanged or transferred, and the Trustee, as
transfer agent, shall promptly deliver (via DWAC) appropriate instructions to
the Depositary, its nominee, or the custodian for the Depositary, as the case
may be, concurrently with such reduction, to increase or reflect on its records
an increase of the principal amount of the Restricted Global Note by the
aggregate principal amount of the beneficial interest in the Regulation S Global
Note to be so exchanged or transferred, and to credit or cause to be credited to
the account of the person specified in such instructions a beneficial interest
in the Restricted Global Note equal to the reduction in the principal amount of
the Regulation S Global Note. After the expiration of the Restricted Period, the
certif-
17
<PAGE> 24
ication requirement set forth in clause (3) of the second sentence of this
paragraph shall no longer apply to such exchanges and transfers.
If a holder of a definitive Note wishes at any time to
exchange its Note for a beneficial interest in any global Note (or vice versa),
or to transfer its definitive Note to a person who wishes to take delivery
thereof in the form of a beneficial interest in a global Note (or vice versa),
such Notes and beneficial interests may be exchanged or transferred for one
another only in accordance with such procedures as are substantially consistent
with the provisions of the two preceding paragraphs (including the certification
requirements intended to ensure that such exchanges or transfers comply with
Rule 144, Rule 144A or Regulation S, as the case may be) and as may be from time
to time adopted by the Company and the Trustee.
Any beneficial interest in one of the global Notes that is
transferred to a person who takes delivery in the form of an interest in the
other global Note shall, upon transfer, cease to be an interest in such global
Note and become an interest in the other global Note and, accordingly, shall
thereafter be subject to all transfer restrictions and other procedures
applicable to beneficial interests in such other global Note for as long as it
remains such an interest.
Any global Note may be endorsed with or have incorporated in
the text thereof such legends or recitals or changes not inconsistent with the
provisions of this Indenture as may be required by the Custodian, the Depositary
or by the National Association of Securities Dealers, Inc. in order for the
Notes to be tradeable on the PORTAL Market or as may be required for the Notes
to be tradeable on any market developed for trading of securities pursuant to
Rule 144A or required to comply with any applicable law or any regulation
thereunder or with Regulation S or with the rules and regulations of any
securities exchange upon which the Notes may be listed or traded or to conform
with any usage with respect thereto, or to indicate any special limitations or
restrictions to which any particular Notes are subject.
(d) Every Note that bears or is required under this Section
2.5(d) to bear the legend set forth in this Section 2.5(d) (together with any
Common Stock issued upon conversion of the Notes and required to bear the legend
set forth in Section 2.5(e), collectively, the "Restricted Securities") shall be
subject to the restrictions on transfer set forth in this Section 2.5(d), unless
such restrictions on transfer shall have been waived by the written consent of
the Company or removed in accordance with the provisions of Section 2.5(f), and
the holder of each such Restricted Security, by such holder's acceptance
thereof, agrees to be bound by such restrictions on transfer. As used in this
Section 2.5(d), the term "transfer" encompasses any
18
<PAGE> 25
sale, pledge, transfer or other disposition of any Restricted Security.
Until three years after the later of the original issuance
date of any Note and the last date on which the Company or an Affiliate of the
Company was the owner of such Note, any certificate evidencing such Note (and
all securities issued in exchange therefor or substitution thereof, other than
Common Stock, if any, issued upon conversion thereof, which shall bear the
legend set forth in Section 2.5(e), if applicable) shall bear a legend in
substantially the following form, unless otherwise agreed by the Company (with
notice thereof to the Trustee):
THE NOTE EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED
STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS
SET FORTH IN THE FOLLOWING SENTENCE. BY ACQUISITION HEREOF, THE HOLDER
(1) REPRESENTS THAT (A) IT IS A "QUALIFIED INSTITUTIONAL BUYER" (AS
DEFINED IN RULE 144A UNDER THE SECURITIES ACT) OR (B) IT IS AN
INSTITUTIONAL "ACCREDITED INVESTOR" (AS DEFINED IN RULE 501(A)(1), (2),
(3) OR (7) UNDER THE SECURITIES ACT) ("INSTITUTIONAL ACCREDITED
INVESTOR") OR (C) IT IS NOT A U.S. PERSON AND IS ACQUIRING THE NOTE
EVIDENCED HEREBY IN AN OFFSHORE TRANSACTION; (2) AGREES THAT IT WILL
NOT PRIOR TO THE DATE THAT IS THREE YEARS AFTER THE LATER OF THE
ORIGINAL ISSUANCE OF THE NOTE EVIDENCED HEREBY AND THE LAST DATE ON
WHICH HEALTHSOURCE, INC. (THE "COMPANY") OR ANY "AFFILIATE" (AS DEFINED
IN RULE 144 UNDER THE SECURITIES ACT) OF THE COMPANY WAS THE OWNER OF
THE NOTE (THE "RESTRICTION TERMINATION DATE") RESELL OR OTHERWISE
TRANSFER THE NOTE EVIDENCED HEREBY OR THE COMMON STOCK ISSUABLE UPON
CONVERSION OF SUCH NOTE EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY
THEREOF, (B) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE
144A UNDER THE SECURITIES ACT, (C) TO AN INSTITUTIONAL ACCREDITED
INVESTOR THAT, PRIOR TO SUCH TRANSFER, FURNISHES TO THE BANK OF NEW
YORK, AS TRUSTEE, A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS
AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THE NOTE
EVIDENCED HEREBY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM SUCH
TRUSTEE), (D) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904
UNDER THE SECURITIES ACT, (E) PURSUANT TO THE EXEMPTION FROM
REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF
AVAILABLE) OR (F) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BEEN
DECLARED EFFECTIVE UNDER THE SECURITIES ACT; AND (3) AGREES THAT IT
WILL DELIVER TO EACH PERSON TO WHOM THE NOTE EVIDENCED HEREBY IS
TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN
CONNECTION WITH ANY TRANSFER OF THE NOTE EVIDENCED HEREBY BEFORE THE
RESTRICTION TERMINATION DATE, THE HOLDER MUST CHECK THE APPROPRIATE BOX
SET FORTH ON THE REVERSE HEREOF RELATING TO
19
<PAGE> 26
THE MANNER OF SUCH TRANSFER AND SUBMIT THIS CERTIFICATE TO THE BANK OF
NEW YORK, AS TRUSTEE. IF THE PROPOSED TRANSFER IS PURSUANT TO CLAUSE
(C), (D) OR (E) ABOVE, THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH
TO THE BANK OF NEW YORK, AS TRUSTEE, SUCH CERTIFICATIONS, LEGAL
OPINIONS OR OTHER INFORMATION AS THE COMPANY MAY REASONABLY REQUIRE TO
CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT. THIS LEGEND WILL BE REMOVED UPON THE RESTRICTION
TERMINATION DATE. AS USED HEREIN, THE TERMS "OFFSHORE TRANSACTION,"
"UNITED STATES" AND "U.S. PERSON" HAVE THE MEANINGS GIVEN TO THEM BY
REGULATION S UNDER THE SECURITIES ACT.
Any Note (or security issued in exchange or substitution
therefor) as to which such restrictions on transfer shall have expired in
accordance with their terms may, upon satisfaction of the requirements of
Section 2.5(f) and surrender of such Note for exchange to the Note registrar in
accordance with the provisions of this Section 2.5, be exchanged for a new Note
or Notes, of like tenor and aggregate principal amount, which shall not bear the
restrictive legend required by this Section 2.5(d).
Notwithstanding any other provisions of this Indenture (other
than the provisions set forth in this Section 2.5(d)), a global Note may not be
transferred as a whole except by the Depositary to a nominee of the Depositary
or by a nominee of the Depositary to the Depositary or another nominee of the
Depositary or by the Depositary or any such nominee to a successor Depositary or
a nominee of such successor Depositary.
The Depositary shall be a clearing agency registered under the
Exchange Act. The Company initially appoints The Depository Trust Company to act
as Depositary with respect to the global Notes. Initially, the global Notes
shall be issued to the Depositary, registered in the name of Cede & Co., as the
nominee of the Depositary, and deposited with the Trustee as Custodian for Cede
& Co.
If at any time the Depositary for the global Notes notifies
the Company that it is unwilling or unable to continue as Depositary for such
Notes, the Company may appoint a successor Depositary with respect to such
Notes. If a successor Depositary for the Notes is not appointed by the Company
within 90 days after the Company receives such notice, the Company shall
execute, and the Trustee, upon receipt of an Officers' Certificate for the
authentication and delivery of Notes, shall authenticate and make available for
delivery, Notes in definitive form, in an aggregate principal amount equal to
the principal amount of the global Notes in exchange for such global Notes.
20
<PAGE> 27
Definitive Notes issued in exchange for all or a part of a
global Note pursuant to this Section 2.5(d) shall be registered in such names
and in such authorized denominations as the Depositary, pursuant to instructions
from its direct or indirect participants or otherwise, shall instruct the
Trustee. Upon execution and authentication, the Trustee shall make available for
delivery such definitive Notes to the persons in whose names such definitive
Notes are so registered.
At such time as all interests in global Notes have been
redeemed, converted, repurchased or canceled, such global Notes shall be, upon
receipt thereof, canceled by the Trustee in accordance with standing procedures
and instructions existing between the Depositary and the Custodian. At any time
prior to such cancellation, if any interest in a global Note is exchanged for
definitive Notes, redeemed, converted, canceled or transferred to a transferee
who receives definitive Notes therefor or any definitive Note is exchanged or
transferred for part of a global Note, the principal amount of such global Note
shall, in accordance with the standing procedures and instructions existing
between the Depositary and the Custodian, be reduced or increased, as the case
may be, and an endorsement shall be made on such global Note by the Trustee or
the Custodian, at the direction of the Trustee, to reflect such reduction or
increase.
The Company and the Trustee may for all purposes, including
the making of payments due on the Notes, deal with the Depositary as the
authorized representative of the Noteholders for the purposes of exercising the
rights of Noteholders hereunder. The rights of the owner of any beneficial
interest in a global Note shall be limited to those established by law and
agreements between such owners and depository participants or Euroclear and
Cedel; provided that no such agreement shall give any rights to any person
against the Company or the Trustee without the written consent of the parties so
affected. Multiple requests and directions from and votes of, the Depositary as
holder of notes in book entry form with respect to any particular matter shall
not be deemed inconsistent to the extent they do not represent an amount of
notes in excess of those held in the name of the Depositary or its nominee.
(e) Until three years after the later of the original issuance
date of any Note (other than any Note represented by the Regulation S Global
Note) and the last date on which the Company or an Affiliate of the Company was
the owner of such Note, any stock certificate representing Common Stock issued
upon conversion of such Note shall bear a legend in substantially the following
form, unless otherwise agreed by the Company (with written notice thereof to the
Trustee and any transfer agent for the Common Stock):
21
<PAGE> 28
THE COMMON STOCK EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE
U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY
STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED
STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS
SET FORTH IN THE FOLLOWING SENTENCE. THE HOLDER HEREOF AGREES THAT
PRIOR TO THE DATE THAT IS THREE YEARS AFTER THE LATER OF THE ORIGINAL
ISSUANCE OF THE NOTE UPON THE CONVERSION OF WHICH THE COMMON STOCK
EVIDENCED HEREBY WAS ISSUED AND THE LAST DATE ON WHICH HEALTHSOURCE,
INC. (THE "COMPANY") OR ANY "AFFILIATE" (AS DEFINED IN RULE 144 OF THE
SECURITIES ACT) OF THE COMPANY WAS THE OWNER OF THE NOTE UPON THE
CONVERSION OF WHICH THE COMMON STOCK EVIDENCED HEREBY WAS ISSUED OR THE
COMMON STOCK EVIDENCED HEREBY (THE "RESTRICTION TERMINATION DATE"), (1)
IT WILL NOT RESELL OR OTHERWISE TRANSFER THE COMMON STOCK EVIDENCED
HEREBY EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) TO A
"QUALIFIED INSTITUTIONAL BUYER" (AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT) IN COMPLIANCE WITH RULE 144A, (C) TO AN INSTITUTIONAL
"ACCREDITED INVESTOR" (AS DEFINED IN RULE 501(A)(1), (2), (3) OR (7)
UNDER THE SECURITIES ACT) THAT PRIOR TO SUCH TRANSFER, FURNISHES TO THE
BANK OF NEW YORK, AS TRANSFER AGENT, A SIGNED LETTER CONTAINING CERTAIN
REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER
OF THE COMMON STOCK EVIDENCED HEREBY (THE FORM OF WHICH LETTER CAN BE
OBTAINED FROM SUCH TRANSFER AGENT), (D) OUTSIDE THE UNITED STATES IN
COMPLIANCE WITH RULE 904 UNDER THE SECURITIES ACT, (E) PURSUANT TO THE
EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES
ACT (IF AVAILABLE) OR (F) PURSUANT TO A REGISTRATION STATEMENT WHICH
HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES ACT; (2) PRIOR TO ANY
SUCH TRANSFER PURSUANT TO CLAUSE (C), (D) OR (E) ABOVE, IT WILL FURNISH
TO THE BANK OF NEW YORK, AS TRANSFER AGENT, SUCH CERTIFICATIONS, LEGAL
OPINIONS OR OTHER INFORMATION AS THE COMPANY MAY REASONABLY REQUIRE TO
CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM,
OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT; AND (3) IT WILL DELIVER TO EACH PERSON TO WHOM THE
COMMON STOCK EVIDENCED HEREBY IS TRANSFERRED A NOTICE SUBSTANTIALLY TO
THE EFFECT OF THIS LEGEND. THIS LEGEND WILL BE REMOVED UPON THE
RESTRICTION TERMINATION DATE. AS USED HEREIN, THE TERMS "UNITED STATES"
AND "U.S. PERSON" HAVE THE MEANINGS GIVEN TO THEM BY REGULATION S UNDER
THE SECURITIES ACT.
Any such Common Stock as to which such restrictions on
transfer shall have expired in accordance with their terms may, upon
satisfaction of the requirements of Section 2.5(f) and surrender of the
certificates representing such shares of Common Stock for exchange in accordance
with the procedures of the transfer agent for the Common Stock, be exchanged for
a new certificate or certificates for a like aggregate number of shares
22
<PAGE> 29
of Common Stock, which shall not bear the restrictive legend required by this
Section 2.5(e).
(f) Upon any sale or transfer of any Restricted Security
(including any interest in a global Note) (i) that is effected pursuant to an
effective registration statement under the Securities Act, (ii) in the case of
the Common Stock only, that is effected pursuant to Rule 144 as promulgated
under the Securities Act as determined by counsel to the Company or the Trustee
or (iii) in connection with which the Trustee (or transfer agent for the Common
Stock, in the case of shares of Common Stock) receives certificates and other
information (including an Opinion of Counsel, if requested) reasonably
acceptable to the Company and the Trustee (or such transfer agent, as the case
may be) to the effect that such security shall no longer be subject to the
resale restrictions under federal and state securities laws, then (A) in the
case of a Restricted Security in definitive form, the Note registrar or
co-registrar (or transfer agent, in the case of Common Stock) shall permit the
holder thereof to exchange such Restricted Security for a security that does not
bear the legends set forth in Section 2.5(d) or 2.5(e), as applicable, and shall
rescind any such restrictions on transfer and (B) in the case of Restricted
Securities represented by a global Note, such Note shall no longer be subject to
the restrictions contained in the legend set forth in Section 2.5(d) (but still
subject to the other provisions hereof). In addition, any Note (or security
issued in exchange or substitution therefor) or shares of Common Stock issued
upon conversion of any Note, in either case, as to which the restrictions on
transfer described in the legends set forth in Section 2.5(d) and 2.5(e),
respectively, have expired by their terms, may, upon surrender thereof (in
accordance with the terms of this Indenture in the case of Notes) together with
such certifications and other information (including an Opinion of Counsel
having substantial experience in practice under the Securities Act and otherwise
reasonably acceptable to the Company, addressed to the Company and the Trustee
and in a form acceptable to the Company, to the effect that the transfer of such
Restricted Security has been made in compliance with Rule 144 or such successor
provision) acceptable to the Company and the Trustee (or transfer agent, as the
case may be) as either of them may reasonably require, be exchanged for a new
Note or Notes of like tenor and aggregate principal amount (in the case of
Notes), or a new certificate or certificates for a like aggregate number of
shares of Common Stock (in the case of Common Stock), or a new certificate or
other instrument of like tenor and amount (in the case of securities issued in
exchange or substitution for Notes), which shall not bear the restrictive
legends set forth in Sections 2.5(d) and 2.5(e).
(g) Each holder of a Note agrees to indemnify the Company and
the Trustee against any liability that may result
23
<PAGE> 30
from the transfer, exchange or assignment of such holder's Note in violation of
any provision of this Indenture and/or applicable U.S. federal or state
securities law.
Section 2.6 Mutilated, Destroyed, Lost or Stolen Notes. In
case any Note shall become mutilated or be destroyed, lost or stolen, the
Company in its discretion may execute, and upon its request, the Trustee or an
authenticating agent appointed by the Trustee shall authenticate and make
available for delivery a new Note bearing a number not contemporaneously
outstanding in exchange and substitution for the mutilated Note or in lieu of
and in substitution for the Note so destroyed, lost or stolen. The Company may
charge such applicant for the expenses of the Company in replacing a Note. In
every case the applicant for a substituted Note shall furnish to the Company, to
the Trustee and, if applicable, to such authenticating agent such security or
indemnity as may be required by them to save each of them harmless from any
loss, liability, cost or expense caused by or connected with such substitution,
and in every case of destruction, loss or theft, the applicant shall also
furnish to the Company, to the Trustee and, if applicable, to such
authenticating agent evidence to their satisfaction of the destruction, loss or
theft of such Note and of the ownership thereof.
The Trustee or such authenticating agent may authenticate any
such substituted Note and deliver the same upon the receipt of such security or
indemnity as the Trustee, the Company and, if applicable, such authenticating
agent may require. Upon the issuance of any substituted Note, the Company may
require the payment of a sum sufficient to cover any tax or other governmental
charge that may be imposed in relation thereto and any other expenses connected
therewith. In case any Note that has matured or is about to mature or has been
called for redemption or is about to be converted into Common Stock shall become
mutilated or be destroyed, lost or stolen, the Company may, instead of issuing a
substitute Note, pay or authorize the payment of or convert or authorize the
conversion of the same (without surrender thereof, except in the case of a
mutilated Note), as the case may be, if the applicant for such payment or
conversion shall furnish to the Company, to the Trustee and, if applicable, to
such authenticating agent such security or indemnity as may be required by them
to save each of them harmless from any loss, liability, cost or expense caused
by or connected with such substitution, and in case of destruction, loss or
theft, evidence satisfactory to the Company, the Trustee and, if applicable, any
paying agent or conversion agent of the destruction, loss or theft of such Note
and of the ownership thereof.
Every substitute Note issued pursuant to the provisions of
this Section 2.6 in lieu of any Note that is destroyed, lost or stolen shall
constitute an additional contractual obligation of the Company, whether or not
the destroyed, lost or stolen Note
24
<PAGE> 31
shall be enforceable by anyone, and shall be entitled to all the benefits of
(but shall be subject to all the limitations set forth in) this Indenture
equally and proportionately with any and all other Notes duly issued hereunder.
To the extent permitted by law, all Notes shall be held and owned upon the
express condition that the foregoing provisions are exclusive with respect to
the replacement or payment or conversion of mutilated, destroyed, lost or stolen
Notes and shall preclude any and all other rights or remedies notwithstanding
any law or statute existing or hereafter enacted to the contrary with respect to
the replacement or payment or conversion of negotiable instruments or other
securities without their surrender.
Section 2.7 Temporary Notes. Pending the preparation of
definitive Notes, the Company may execute and the Trustee or an authenticating
agent appointed by the Trustee shall, upon written request of the Company,
authenticate and make available for delivery temporary Notes (printed or
lithographed). Temporary Notes shall be issuable in any authorized denomination
and shall be substantially in the form of the definitive Notes but with such
omissions, insertions and variations as may be appropriate for temporary Notes,
all as may be determined by the Company. Every such temporary Note shall be
executed by the Company and authenticated by the Trustee or such authenticating
agent upon the same conditions and in substantially the same manner, and with
the same effect, as the definitive Notes. Without unreasonable delay the Company
shall execute and deliver to the Trustee or such authenticating agent definitive
Notes (other than in the case of Notes in global form) and thereupon any or all
temporary Notes (other than any such global Note) may be surrendered in exchange
therefor, at each office or agency maintained by the Company pursuant to Section
4.2 and the Trustee or such authenticating agent shall authenticate and make
available for delivery in exchange for such temporary Notes an equal aggregate
principal amount of definitive Notes. Such exchange shall be made by the Company
at its own expense and without any charge therefor. Until so exchanged, the
temporary Notes shall in all respects be entitled to the same benefits and
subject to the same limitations under this Indenture as definitive Notes
authenticated and delivered hereunder.
Section 2.8 Cancellation of Notes Paid, Etc. All Notes
surrendered for the purpose of payment, redemption, conversion, exchange or
registration of transfer shall, if surrendered to the Company or any paying
agent or any Note registrar or any conversion agent, be surrendered to the
Trustee and promptly canceled by it or, if surrendered to the Trustee, shall be
promptly canceled by it and no Notes shall be issued in lieu thereof except as
expressly permitted by any of the provisions of this Indenture. The Trustee
shall return canceled Notes to the Company. If the Company shall acquire any of
the Notes, such acquisition shall not operate as a redemption or satisfaction of
25
<PAGE> 32
the indebtedness represented by such Notes unless and until the same are
delivered to the Trustee for cancellation.
Section 2.9 CUSIP Numbers. The Company in issuing the Notes
may use "CUSIP" numbers (if then generally in use), and, if so, the Trustee
shall use "CUSIP" numbers in notices of redemption as a convenience to holders;
provided that any such notice may state that no representation is made as to the
correctness of such numbers either as printed on the Notes or as contained in
any notice of a redemption and that reliance may be placed only on the other
identification numbers printed on the Notes, and any such redemption shall not
be affected by any defect in or omission of such numbers. The Company will
promptly notify the Trustee of any change in the CUSIP numbers.
ARTICLE III
REDEMPTION OF NOTES
Section 3.1 Redemption Prices. The Notes are not redeemable at
the option of the Company prior to March 1, 1999. At any time on or after that
date, the Notes may be redeemed at the Company's option, upon notice as set
forth in Section 3.2, in whole at any time or in part from time to time, at the
optional redemption prices set forth in the forms of Note attached as Exhibits
A, B and C, together with accrued interest to the date fixed for redemption.
Section 3.2 Notice of Redemption; Selection of Notes. In case
the Company shall desire to exercise the right to redeem all or, as the case may
be, any part of the Notes pursuant to Section 3.1, it shall fix a date for
redemption and, in the case of any redemption pursuant to Section 3.1, it or, at
its request accompanied by the proposed form of notice of redemption (which must
be received by the Trustee at least ten days prior to the date the Trustee is
requested to give notice as described below, unless a shorter period is agreed
to by the Trustee), the Trustee in the name of and at the expense of the
Company, shall publish a notice in the Wall Street Journal and mail or cause to
be mailed a notice of such redemption at least 30 and not more than 60 days
prior to the date fixed for redemption to the holders of Notes so to be redeemed
as a whole or in part at their last addresses as the same appear on the Note
register, provided that if the Company shall give such notice, it shall also
give such notice, and notice of the Notes to be redeemed, to the Trustee. Such
mailing shall be by first class mail. The notice, if mailed in the manner herein
provided, shall be conclusively presumed to have been duly given, whether or not
the holder receives such notice. In any case, failure to give such notice by
mail or any defect in the notice to the holder of any Note designated for
26
<PAGE> 33
redemption as a whole or in part shall not affect the validity of the
proceedings for the redemption of any other Note.
Each such notice of redemption shall identify the Notes to be
redeemed (including CUSIP numbers), specify the aggregate principal amount of
Notes to be redeemed, the date fixed for redemption, the redemption price at
which Notes are to be redeemed, the place or places of payment, that payment
will be made upon presentation and surrender of such Notes, that interest
accrued to the date fixed for redemption shall be paid as specified in said
notice and that on and after said date, interest thereon or on the portion
thereof to be redeemed shall cease to accrue. Such notice shall also state the
current Conversion Price and the date on which the right to convert such Notes
or portions thereof into Common Stock shall expire. If fewer than all the Notes
are to be redeemed, the notice of redemption shall identify the Notes to be
redeemed. In case any Note is to be redeemed in part only, the notice of
redemption shall state the portion of the principal amount thereof to be
redeemed and shall state that on and after the date fixed for redemption, upon
surrender of such Note, a new Note or Notes in principal amount equal to the
unredeemed portion thereof shall be issued.
On or prior to the Business Day prior to the redemption date
specified in the notice of redemption given as provided in this Section 3.2, the
Company shall deposit with the Trustee or with one or more paying agents (or, if
the Company is acting as its own paying agent, set aside, segregate and hold in
trust as provided in Section 4.4) an amount of money sufficient to redeem on the
redemption date all the Notes so called for redemption (other than those
theretofore surrendered for conversion into Common Stock) at the appropriate
redemption price, together with accrued interest to the date fixed for
redemption. If any Note called for redemption is converted pursuant hereto, any
money deposited with the Trustee or any paying agent or so segregated and held
in trust for the redemption of such Note shall be paid to the Company upon its
request or, if then held by the Company, shall be discharged from such trust. If
fewer than all the Notes are to be redeemed, the Company shall give the Trustee
written notice in the form of an Officers' Certificate not fewer than 45 days
(or such shorter period of time as may be acceptable to the Trustee) prior to
the redemption date as to the aggregate principal amount of Notes to be
redeemed.
If fewer than all the Notes are to be redeemed, the Trustee
shall select the Notes or portions thereof to be redeemed (in principal amounts
of $1,000 or integral multiples thereof), by lot or, in its discretion, on a pro
rata basis. If any Note selected for partial redemption is converted in part
after such selection, the converted portion of such Note shall be deemed (so far
as may be) to be the portion to be selected for redemption. The Notes (or
portions thereof) so selected shall be deemed duly
27
<PAGE> 34
selected for redemption for all purposes hereof, notwithstanding that any such
Note is converted as a whole or in part before the mailing of the notice of
redemption.
Upon any redemption of less than all Notes, the Company and
the Trustee may treat as outstanding any Notes surrendered for conversion during
the period of 15 days next preceding the mailing of a notice of redemption and
need not treat as outstanding any Note authenticated and delivered during such
period in exchange for the unconverted portion of any Note converted in part
during such period.
Section 3.3 Payment of Notes Called for Redemption. If notice
of redemption has been given as above provided, the Notes or portion of Notes
with respect to which such notice has been given shall, unless converted into
Common Stock pursuant to the terms hereof, become due and payable on the date
and at the place or places stated in such notice at the applicable redemption
price, together with interest thereon accrued to the date fixed for redemption,
and on and after said date (unless the Company shall default in the payment of
such Notes at the redemption price, together with interest thereon accrued to
said date), interest on the Notes or portion of Notes so called for redemption
shall cease to accrue, and such Notes shall cease after the close of business on
the Business Day next preceding the date fixed for redemption to be convertible
into Common Stock and, except as provided in Sections 7.6 and 12.4, to be
entitled to any benefit or security under this Indenture, and the holders
thereof shall have no right in respect of such Notes except the right to receive
the redemption price thereof and unpaid interest thereon to the date fixed for
redemption. On presentation and surrender of such Notes at a place of payment in
said notice specified, the said Notes or the specified portions thereof shall be
paid and redeemed by the Company at the applicable redemption price, together
with interest accrued thereon to the date fixed for redemption; provided that
any semi-annual payment of interest becoming due on the date fixed for
redemption shall be payable to the holders of such Notes registered as such on
the relevant record date subject to the terms and provisions of Section 2.3
hereof.
Upon presentation of any Note redeemed in part only, the
Company shall execute and the Trustee shall authenticate and make available for
delivery to the holder thereof, at the expense of the Company, a new Note or
Notes, of authorized denominations, in principal amount equal to the unredeemed
portion of the Notes so presented.
Notwithstanding the foregoing, the Trustee shall not redeem
any Notes or mail any notice of optional redemption during the continuance of a
default in payment of interest or premium on the Notes or of any Event of
Default of which, in the case of any
28
<PAGE> 35
Event of Default other than under Section 6.1(a) or (b), a Responsible Officer
of the Trustee has actual knowledge. If any Note called for redemption shall not
be so paid upon surrender thereof for redemption, the principal and premium, if
any, shall, until paid or duly provided for, bear interest from the date fixed
for redemption at the rate borne by the Note and such Note shall remain
convertible into Common Stock until the principal and premium, if any, shall
have been paid or duly provided for.
Section 3.4 Conversion Arrangement on Call for Redemption. In
connection with any redemption of Notes, the Company may arrange for the
purchase and conversion of any Notes by an agreement with one or more investment
bankers or other purchasers to purchase such Notes by paying to the Trustee in
trust for the Noteholders, on or prior to the Business Day prior to the date
fixed for redemption, an amount not less than the applicable redemption price,
together with interest accrued to the date fixed for redemption, of such Notes.
Notwithstanding anything to the contrary contained in this Article III, the
obligation of the Company to pay the redemption price of such Notes, together
with interest accrued to the date fixed for redemption, shall be deemed to be
satisfied and discharged to the extent such amount is so paid by such
purchasers. If such an agreement is entered into, a copy of which shall be filed
with the Trustee prior to the date fixed for redemption, any Notes not duly
surrendered for conversion by the holders thereof may, at the option of the
Company, be deemed, to the fullest extent permitted by law, acquired by such
purchasers from such holders and (notwithstanding anything to the contrary
contained in Article XIV) surrendered by such purchasers for conversion, all as
of the time immediately prior to the close of business on the date fixed for
redemption (and the right to convert any such Notes shall be deemed to have been
extended through such time), subject to payment of the above amount as
aforesaid. At the direction of the Company, the Trustee shall hold and dispose
of any such amount paid to it in the same manner as it would monies deposited
with it by the Company for the redemption of Notes. Without the Trustee's prior
written consent, no arrangement between the Company and such purchasers for the
purchase and conversion of any Notes shall increase or otherwise affect any of
the powers, duties, responsibilities or obligations of the Trustee as set forth
in this Indenture, and the Company agrees to indemnify the Trustee from, and
hold it harmless against, any loss, liability or expense arising out of or in
connection with any such arrangement for the purchase and conversion of any
Notes between the Company and such purchasers including the costs and expenses
incurred by the Trustee in the defense of any claim or liability arising out of
or in connection with the exercise or performance of any of its powers, duties,
responsibilities or obligations under this Indenture.
29
<PAGE> 36
Section 3.5 Purchase of Notes Upon a Change of Control.
(a) If a Change of Control shall occur at any time, then each
holder of Notes shall have the right to require that the Company repurchase such
holder's Notes in whole or in part in integral multiples of $1,000 at a purchase
price (the "Change of Control Purchase Price") in cash in an amount equal to
101% of the principal amount of such Notes, plus accrued and unpaid interest
thereon, if any, to the purchase date (the "Change of Control Purchase Date")
pursuant to the offer described below (the "Change of Control Offer") and in
accordance with the other procedures set forth in this Indenture.
(b) Within 30 days following any Change of Control, the
Company shall publish a notice in the Wall Street Journal, notify the Trustee
thereof and give written notice of such Change of Control to each holder of
Notes, by first-class mail, postage prepaid, at the Noteholder's address
appearing in the Note register, stating, among other things, (i) that a Change
of Control has occurred, (ii) the Change of Control Purchase Price, (iii) the
Change of Control Purchase Date (which shall be a Business Day no earlier than
30 days nor later than 60 days from the date such notice is mailed, or such
later date as is necessary to comply with requirements under the Exchange Act),
(iv) that any Note not tendered shall continue to accrue interest and to have
all of the benefits of this Indenture, (v) that, unless the Company defaults in
the payment of the Change of Control Purchase Price, any Notes accepted for
payment pursuant to the Change of Control Offer shall cease to accrue interest
after the Change of Control Purchase Date and (vi) certain other procedures that
a holder of Notes must follow to accept a Change of Control Offer or to withdraw
such acceptance.
(c) The Company shall comply with the applicable tender offer
rules, including Rule 13e-4 under the Exchange Act, and any other applicable
securities laws or regulations in connection with a Change of Control Offer, and
any provisions of this Indenture that conflict with such laws shall be deemed to
be superseded by the provisions of such laws.
ARTICLE IV
PARTICULAR COVENANTS OF THE COMPANY
Section 4.1 Payment of Principal, Premium and Interest. The
Company covenants and agrees that it shall duly and punctually pay or cause to
be paid the principal of and premium, if any, and interest on each of the Notes
at the places, at the respective times and in the manner provided herein and in
the Notes. Each installment of interest on the Notes due on any
30
<PAGE> 37
semi-annual interest payment date may be paid by mailing checks for the interest
payable to or upon the written order of the holders of Notes entitled thereto as
they shall appear on the Note register; provided that, with respect to any
holder of Notes with an aggregate principal amount equal to or in excess of
$5,000,000, at the request (such request to include appropriate wire
instructions) of such holder in writing to the Trustee, interest on such
holder's Notes shall be paid by wire transfer in immediately available funds. An
installment of principal or interest shall be considered paid on the date due if
the Trustee or Paying Agent (other than the Company, a Subsidiary of the Company
or any Affiliate of any of them) holds on that date money designated for and
sufficient to pay the installment of principal or interest and is not prohibited
from paying such money to the holders of the Notes pursuant to the terms of this
Indenture.
Section 4.2 Maintenance of Office or Agency. The Company shall
maintain in the Borough of Manhattan, The City of New York, an office or agency
where the Notes may be surrendered for registration of transfer or exchange or
for presentation for payment or for conversion or redemption and where notices
and demands to or upon the Company in respect of the Notes and this Indenture
may be served. The Company shall give prompt written notice to the Trustee of
the location, and any change in the location, of such office or agency not
designated by the Trustee. If at any time the Company shall fail to maintain any
such office or agency or shall fail to furnish the Trustee with the address
thereof, such presentations, surrenders, notices and demands may be made or
served at the Corporate Trust Office of the Trustee.
The Company may also from time to time designate one or more
other offices or agencies where the Notes may be presented or surrendered for
any or all such purposes and may from time to time rescind such designations;
provided that no such designation or rescission shall in any manner relieve the
Company of its obligation to maintain an office or agency in the Borough of
Manhattan, The City of New York, for such purposes. The Company shall give
prompt written notice to the Trustee of any such designation or rescission and
of any change in the location of any such other office or agency.
The Company hereby initially designates the Trustee as paying
agent, Note registrar and conversion agent and each of the Corporate Trust
Office of the Trustee and the office of The Bank of New York in the Borough of
Manhattan, The City of New York, as one such office or agency of the Company for
the purposes set forth in the first paragraph of this Section 4.2.
So long as the Trustee is the Note registrar, the Trustee
agrees to mail, or cause to be mailed, the notices set forth in Section 7.11(a)
and the third paragraph of Section 7.12.
31
<PAGE> 38
Section 4.3 Appointments to Fill Vacancies in Trustee's
Office. The Company, whenever necessary to avoid or fill a vacancy in the office
of Trustee, shall appoint, in the manner provided in Section 7.11, a Trustee, so
that there shall at all times be a Trustee hereunder.
Section 4.4 Provisions as to Paying Agent.
(a) If the Company shall appoint a paying agent other than the
Trustee, or if the Trustee shall appoint such a paying agent, the Company or the
Trustee, as the case may be, shall cause such paying agent to execute and
deliver to the Trustee an instrument in which such agent shall agree with the
Trustee, subject to the provisions of this Section 4.4:
(1) that it shall hold all sums held by it as such agent for
the payment of the principal of, premium, if any, or interest on the
Notes (whether such sums have been paid to it by the Company or by any
other obligor on the Notes) in trust for the benefit of the holders of
the Notes;
(2) that it shall give the Trustee notice of any failure by
the Company (or by any other obligor on the Notes) to make any payment
of the principal of, premium, if any, or interest on the Notes when the
same shall be due and payable; and
(3) that at any time during the continuance of an Event of
Default, upon request of the Trustee, it shall forthwith pay to the
Trustee all sums so held in trust.
The Company shall, before each due date of the principal of,
premium, if any, or interest on the Notes, deposit with the paying agent a sum
sufficient to pay such principal, premium, if any, or interest, and (unless such
paying agent is the Trustee) the Company shall promptly notify the Trustee of
any failure to take such action.
(b) If the Company shall act as its own paying agent, it
shall, on or before each due date of the principal of, premium, if any, or
interest on the Notes, set aside, segregate and hold in trust for the benefit of
the holders of the Notes a sum sufficient to pay such principal, premium, if
any, or interest so becoming due and shall notify the Trustee of any failure to
take such action and of any failure by the Company (or any other obligor under
the Notes) to make any payment of the principal of, premium, if any, or interest
on the Notes when the same shall become due and payable.
(c) Anything in this Section 4.4 to the contrary
notwithstanding, the Company may, at any time, for the purpose of obtaining a
satisfaction and discharge of this Indenture, or for
32
<PAGE> 39
any other reason, pay or cause to be paid to the Trustee all sums held in trust
by the Company or any paying agent hereunder as required by this Section 4.4,
such sums to be held by the Trustee upon the trusts herein contained and upon
such payment by the Company or any paying agent to the Trustee, the Company or
such paying agent shall be released from all further liability with respect to
such sums.
(d) Anything in this Section 4.4 to the contrary
notwithstanding, the agreement to hold sums in trust as provided in this Section
4.4 is subject to Sections 12.3 and 12.4.
Section 4.5 Corporate Existence. Subject to Article XI, the
Company shall do or cause to be done all things necessary to preserve and keep
in full force and effect its corporate existence.
Section 4.6 Rule 144A Information Requirement. During the
three-year period following the original issuance date of any Note and during
the three-year period following the last date on which the Company or an
Affiliate of the Company was the owner of any Note (or shares of Common Stock
issued upon conversion of any Note), if the Company is subject neither to
Section 13 nor Section 15(d) of the Exchange Act, the Company shall at the
written request of any holder or beneficial holder of such Note (or shares of
Common Stock issued upon conversion of Notes) provide to such holder or
beneficial holder of such Note (or shares of Common Stock issued upon conversion
of Notes) and any prospective transferee designated by such holder or beneficial
holder of such Note (or shares of Common Stock issued upon conversion of Notes)
such information, if any, required by Rule 144A(d)(4) under the Securities Act
(so long as such information is required to permit such transfer under Rule
144A).
Section 4.7 Stay, Extension and Usury Laws. The Company
covenants (to the extent that it may lawfully do so) that it shall not at any
time insist upon, plead or in any manner whatsoever claim or take the benefit or
advantage of, any stay, extension or usury law or other law that would prohibit
or forgive the Company from paying all or any portion of the principal of or
interest on the Notes as contemplated herein, wherever enacted, now or at any
time hereafter in force, or that may affect the covenants or the performance of
this Indenture; and the Company (to the extent it may lawfully do so) hereby
expressly waives all benefit or advantage of any such law, and covenants that it
shall not, by resort to any such law, hinder, delay or impede the execution of
any power herein granted to the Trustee, but shall suffer and permit the
execution of every such power as though no such law has been enacted.
33
<PAGE> 40
Section 4.8 Compliance Statement; Notice of Defaults
(a) The Company will deliver to the Trustee annually,
commencing April 30, 1996, a certificate, from its principal executive officer,
principal financial officer or principal accounting officer, stating whether or
not to the best knowledge of the signer thereof the Company is in compliance
(without regard to periods of grace or notice requirements) with all conditions
and covenants under this Indenture, and if the Company shall not be in
compliance, specifying such non-compliance and the nature and status thereof of
which such signer may have knowledge.
(b) The Company shall file with the Trustee written notice of
the occurrence of any default or Event of Default within ten days of its
becoming aware of any such default or Event of Default.
ARTICLE V
NOTEHOLDERS' LISTS AND REPORTS BY
THE COMPANY
Section 5.1 Noteholders' Lists. The Trustee shall preserve in
as current a form as is reasonably practicable the most recent list available to
it of the names and addresses of holders of Notes and shall otherwise comply
with Trust Indenture Act Section 312(a). If the Trustee is not the Notes
registrar, the Company shall furnish to the Trustee on or before at least seven
Business Days preceding each interest payment date and at such other times as
the Trustee may request in writing a list in such form and as of such date as
the Trustee reasonably may require of the names and addresses of holders of
Notes, and the Company shall otherwise comply with Trust Indenture Act Section
312(a).
Section 5.2 Reports by Company. The Company shall deliver to
the Trustee within 15 days after it files the same with the Commission, copies
of all reports and information (or copies of such portions of any of the
foregoing as the Commission may by its rules and regulations prescribe), if any,
which the Company is required to file with the Commission pursuant to Section 13
or 15(d) of the Exchange Act or pursuant to the immediately following sentence.
So long as at least $5,000,000 aggregate principal amount of Notes remain
outstanding, the Company shall file with the Commission such reports as may be
required pursuant to Section 13 of the Exchange Act in respect of a security
registered pursuant to Section 12 of the Exchange Act, regardless of whether the
Company is otherwise required to file such reports. If the Company is not
subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act
(or otherwise required to file reports pursuant to the immediately
34
<PAGE> 41
preceding sentence), the Company shall deliver to the Trustee, within 15 days
after it would have been required to file such information with the Commission
were it required to do so, annual and quarterly financial statements, including
any notes thereto (and, in the case of a fiscal year end, an auditors' report by
an independent certified public accounting firm of established national
reputation), and a "Management's Discussion and Analysis of Financial Condition
and Results of Operations," in each case substantially equivalent to that which
it would have been required to include in such quarterly or annual reports,
information, documents or other reports if it had been subject to the
requirements of Section 13 or 15(d) of the Exchange Act. The Company shall
provide copies of the foregoing materials to the Noteholders to the extent
required by the Trust Indenture Act once this Indenture has been qualified. The
Company shall also comply with the other provisions of Section 314(a) of the
Trust Indenture Act.
Delivery of such reports, information and documents to the
Trustee is for informational purposes only and the Trustee's receipt of such
shall not constitute constructive notice of any information contained therein or
determinable from information contained therein, including the Company's
compliance with any of its covenants hereunder (as to which the Trustee is
entitled to rely exclusively on Officers' Certificates).
ARTICLE VI
DEFAULTS AND REMEDIES
Section 6.1 Events of Default. In case one or more of the
following Events of Default (whatever the reason for such Event of Default and
whether it shall be voluntary or involuntary or be effected by operation of law
or pursuant to any judgment, decree or order of any court or any order, rule or
regulation of any administrative or governmental body) shall have occurred and
be continuing:
(a) default in the payment of the principal of or premium, if
any, on the Notes when due at maturity, upon redemption or otherwise,
including failure by the Company to purchase the Notes when required
under Section 3.5 (whether or not such payment shall be prohibited by
the subordination provisions of this Indenture); or
(b) default in the payment of any installment of interest on
the Notes as and when the same shall become due and payable (whether or
not such payment shall be prohibited by the subordination provisions of
this Indenture), and continuance of such default for a period of 30
days; or
35
<PAGE> 42
(c) a failure on the part of the Company duly to observe or
perform any other covenants or agreements on the part of the Company in
this Indenture (other than a default in the performance or breach of a
covenant or agreement that is specifically dealt with elsewhere in this
Section 6.1) that continues for a period of 90 days after the date on
which written notice of such failure, requiring the Company to remedy
the same, shall have been given to the Company by the Trustee, or to
the Company and a Responsible Officer of the Trustee, by the holders of
at least 25% in aggregate principal amount of the Notes at the time
outstanding determined in accordance with Section 8.4; or
(d) the Company shall commence a voluntary case or other
proceeding seeking liquidation, reorganization or other relief with
respect to itself or its debts under any bankruptcy, insolvency or
other similar law now or hereafter in effect, or seeking the
appointment of a trustee, receiver, liquidator, custodian or other
similar official of it or any substantial part of its property, or
shall consent to any such relief or to the appointment of or taking
possession by any such official in an involuntary case or other
proceeding commenced against it or shall make a general assignment for
the benefit of creditors or shall fail generally to pay its debts as
they become due; or
(e) an involuntary case or other proceeding shall be commenced
against the Company seeking liquidation, reorganization or other relief
with respect to it or its debts under any bankruptcy, insolvency or
other similar law now or hereafter in effect or seeking the appointment
of a trustee, receiver, liquidator, custodian or other similar official
of it or any substantial part of its property, and such involuntary
case or other proceeding shall remain undismissed and unstayed for a
period of 90 consecutive days;
then, and in each and every such case (other than an Event of Default specified
in Section 6.1(d) or (e)), unless the principal of all of the Notes shall have
already become due and payable, either the Trustee or the holders of not less
than 25% in aggregate principal amount of the Notes then outstanding hereunder
determined in accordance with Section 8.4, by notice in writing to the Company
(and to the Trustee if given by Noteholders), may declare the principal of,
premium, if any, on the Notes and the interest accrued thereon to be due and
payable immediately, and upon any such declaration the same shall become and
shall be immediately due and payable, anything in this Indenture or in the Notes
contained to the contrary notwithstanding. If an Event of Default specified in
Section 6.1(d) or (e) occurs and is continuing, the principal of all the Notes
and the interest accrued thereon shall be immediately due and payable. The
foregoing provision is subject to the conditions that if, at any time after
36
<PAGE> 43
the principal of the Notes shall have been so declared due and payable, and
before any judgment or decree for the payment of the monies due shall have been
obtained or entered as hereinafter provided, the Company shall pay or shall
deposit with the Trustee a sum sufficient to pay all matured installments of
interest upon all Notes and the principal of and premium, if any, on any and all
Notes that shall have become due otherwise than by acceleration (with interest
on overdue installments of interest (to the extent that payment of such interest
is enforceable under applicable law) and on such principal and premium, if any,
at the rate borne by the Notes, to the date of such payment or deposit) and
amounts due to the Trustee pursuant to Section 7.7, and if any and all defaults
under this Indenture, other than the nonpayment of principal of, premium, if
any, and accrued interest on Notes that shall have become due by acceleration,
shall have been cured or waived pursuant to Section 6.7, then and in every such
case the holders of a majority in aggregate principal amount of the Notes then
outstanding, by written notice to the Company and to the Trustee, may waive all
defaults or Events of Default and rescind and annul such declaration and its
consequences; but no such waiver or rescission and annulment shall extend to or
shall affect any subsequent default or Event of Default, or shall impair any
right consequent thereto. The Company shall notify a Responsible Officer of the
Trustee, promptly upon becoming aware thereof, of any Event of Default.
In case the Trustee shall have proceeded to enforce any right
under this Indenture and such proceedings shall have been discontinued or
abandoned because of such waiver or rescission and annulment or for any other
reason or shall have been determined adversely to the Trustee, then and in every
such case the Company, the holders of Notes and the Trustee shall be restored
respectively to their several positions and rights hereunder, and all rights,
remedies and powers of the Company, the holders of Notes and the Trustee shall
continue as though no such proceeding had been taken.
Section 6.2 Payments of Notes on Default; Suit Therefor. The
Company covenants that (a) in case default shall be made in the payment of any
installment of interest upon any of the Notes as and when the same shall become
due and payable, and such default shall have continued for a period of 30 days,
or (b) in case default shall be made in the payment of the principal of or
premium, if any, on any of the Notes as and when the same shall have become due
and payable, whether at maturity of the Notes or in connection with any
redemption, by declaration or otherwise, then, upon demand of the Trustee, the
Company shall pay to the Trustee, for the benefit of the holders of the Notes,
the whole amount that then shall have become due and payable on all such Notes
for principal premium, if any, or interest, or both, as the case may be, with
interest upon the overdue principal, premium, if any, and (to the extent that
payment of such
37
<PAGE> 44
interest is enforceable under applicable law) upon the overdue installments of
interest at the rate borne by the Notes; and, in addition thereto, such further
amount as shall be sufficient to cover the costs and expenses of collection,
including reasonable compensation to the Trustee, its agents, attorneys and
counsel, and any expenses or liabilities incurred by the Trustee hereunder other
than through its negligence or bad faith. Until such demand by the Trustee, the
Company may pay the principal of and premium, if any, and interest on the Notes
to the registered holders, whether or not the Notes are overdue.
In case the Company shall fail forthwith to pay such amounts
upon such demand, the Trustee, in its own name and as trustee of an express
trust, shall be entitled and empowered to institute any actions or proceedings
at law or in equity for the collection of the sums so due and unpaid and may
prosecute any such action or proceeding to judgment or final decree, and may
enforce any such judgment or final decree against the Company or any other
obligor on the Notes and collect in the manner provided by law out of the
property of the Company or any other obligor on the Notes wherever situated the
monies adjudged or decreed to be payable.
In the case there shall be pending proceedings for the
bankruptcy or for the reorganization of the Company or any other obligor on the
Notes under Title 11 of the United States Code or any other applicable law, or
in case a receiver, assignee or trustee in bankruptcy or reorganization,
liquidator, sequestrator or similar official shall have been appointed for or
taken possession of the Company or such other obligor, the property of the
Company or such other obligor, or in the case of any other judicial proceedings
relative to the Company or such other obligor upon the Notes, or to the
creditors or property of the Company or such other obligor, the Trustee,
irrespective of whether the principal of the Notes shall then be due and payable
as therein expressed or by declaration or otherwise and irrespective of whether
the Trustee shall have made any demand pursuant to the provisions of this
Section 6.2, shall be entitled and empowered, by intervention in such
proceedings or otherwise, to file and prove a claim or claims for the whole
amount of principal, premium, if any, and interest owing and unpaid in respect
of the Notes and, in case of any judicial proceedings, to file such proofs of
claim and other papers or documents as may be necessary or advisable in order to
have the claims of the Trustee and of the Noteholders allowed in such judicial
proceedings relative to the Company or any other obligor on the Notes, its or
their creditors, or its or their property and to collect and receive any monies
or other property payable or deliverable on any such claims and to distribute
the same after the deduction of any amounts due the Trustee under Section 7.7;
and any receiver, assignee or trustee in bankruptcy or reorganization,
liquidator, custodian or similar official is hereby authorized by each of the
38
<PAGE> 45
Noteholders to make such payments to the Trustee and, in the event that the
Trustee shall consent to the making of such payments directly to the
Noteholders, to pay to the Trustee any amount due it for reasonable
compensation, expenses, advances and disbursements, including counsel fees
incurred by it up to the date of such distribution. To the extent that such
payment of reasonable compensation, expenses, advances and disbursements out of
the estate in any such proceedings shall be denied for any reason, payment of
the same shall be secured by a lien on, and shall be paid out of, any and all
distributions, dividends, monies, securities and other property that the holders
of the Notes may be entitled to receive in such proceedings, whether in
liquidation or under any plan of reorganization or arrangement or otherwise.
Nothing herein contained shall be deemed to authorize the
Trustee to authorize or consent to or adopt on behalf of any Noteholder any plan
of reorganization or arrangement affecting the Notes or the rights of any
Noteholder, or to authorize the Trustee to vote in respect of the claim of any
Noteholder in any such proceeding.
All rights of action and of asserting claims under this
Indenture, or under any of the Notes, may be enforced by the Trustee without the
possession of any of the Notes or the production thereof on any trial or other
proceeding relative thereto, and any such suit or proceeding instituted by the
Trustee shall be brought in its own name as trustee of an express trust, and any
recovery of judgment shall, after provision for the payment of the reasonable
compensation, expenses, disbursements and advances of the Trustee, its agents
and counsel, be for the ratable benefit of the holders of the Notes.
In any proceedings brought by the Trustee (and in any
proceedings involving the interpretation of any provision of this Indenture to
which the Trustee shall be a party), the Trustee shall be held to represent all
the holders of the Notes, and it shall not be necessary to make any holders of
the Notes parties to any such proceedings.
Section 6.3 Application of Monies Collected by Trustee. Any
monies collected by the Trustee pursuant to this Article VI shall be applied in
the order following, at the date or dates fixed by the Trustee for the
distribution of such monies, upon presentation of the several Notes and stamping
thereon the payment, if only partially paid, and upon surrender thereof, if
fully paid:
First: To the payment of all amounts due the Trustee under
Section 7.7;
39
<PAGE> 46
Second: Subject to the provisions of Article XV, in case the
principal of the outstanding Notes shall not have become due and be
unpaid, to the payment of interest on the Notes in default in the order
of the maturity of the installments of such interest, with interest (to
the extent that such interest has been collected by the Trustee) upon
the overdue installments of interest at the rate borne by the Notes,
such payments to be made ratably to the persons entitled thereto; and
Third: Subject to the provisions of Article XV, in case the
principal of the outstanding Notes shall have become due, by
declaration or otherwise, and be unpaid, to the payment of the whole
amount then holding and unpaid upon the Notes for principal, premium,
if any, and interest, with interest on the overdue principal and
premium, if any, and (to the extent that such interest has been
collected by the Trustee) upon overdue installments of interest at the
rate borne by the Notes; and in case such monies shall be insufficient
to pay in full the whole amounts so due and unpaid upon the Notes, then
to the payment of such principal, premium, if any, and interest without
preference or priority of principal and premium, if any, over interest,
or of interest over principal and premium, if any, or of any
installment of interest over any other installment of interest, or of
any Note over any other Note, ratably to the aggregate of such
principal and premium, if any, and accrued and unpaid interest.
Section 6.4 Proceedings by Noteholder. No holder of any Note
shall have any right by virtue of or by availing of any provision of this
Indenture to institute any suit, action or proceeding in equity or at law upon
or under or with respect to this Indenture, or for the appointment of a
receiver, trustee, liquidator, custodian or other similar official, or for any
other remedy hereunder, unless such holder previously shall have given to the
Trustee written notice of an Event of Default and of the continuance thereof, as
hereinbefore provided, and unless also the holders of not less than 25% in
aggregate principal amount of the Notes then outstanding shall have made written
request upon the Trustee to institute such action, suit or proceeding in its own
name as Trustee hereunder and shall have offered to the Trustee such reasonable
indemnity as it may require against the costs, expenses and liabilities to be
incurred therein or thereby, and the Trustee for 60 days after its receipt of
such notice, request and offer of indemnity, shall have neglected or refused to
institute any such action, suit or proceeding, and no direction inconsistent
with such written request shall have been given to the Trustee pursuant to
Section 6.7; it being understood and intended, and being expressly covenanted by
the taker and holder of every Note with every other taker and holder and the
Trustee, that no one or more holders of Notes shall have any right in any
40
<PAGE> 47
manner whatever by virtue of or by availing of any provision of this Indenture
to affect, disturb or prejudice the rights of any other holder of Notes, to
obtain or seek to obtain priority over or preference to any other such holder or
to enforce any right under this Indenture, except in the manner herein provided
and for the equal, ratable and common benefit of all holders of Notes (except as
otherwise provided herein). For the protection and enforcement of this Section
6.4, each and every Noteholder and the Trustee shall be entitled to such relief
as can be given either at law or in equity.
Notwithstanding any other provision of this Indenture and any
provision of any Note, the right of any holder of any Note to receive payment of
the principal of, premium, if any, and interest on such Note, on or after the
respective due dates expressed in such Note, or to institute suit for the
enforcement of any such payment on or after such respective dates against the
Company shall not be impaired or affected without the consent of such holder
except as otherwise set forth herein.
Anything in this Indenture or the Notes to the contrary
notwithstanding, the holder of any Note, without the consent of either the
Trustee or the holder of any other Note, in his own behalf and for his own
benefit, may enforce, and may institute and maintain any proceeding suitable to
enforce, his rights of conversion as provided herein.
Section 6.5 Proceedings by Trustee. In case of an Event of
Default, the Trustee may in its discretion proceed to protect and enforce the
rights vested in it by this Indenture by such appropriate judicial proceedings
as the Trustee shall deem most effectual to protect and enforce any of such
rights, either by suit in equity or by action at law or by proceeding in
bankruptcy or otherwise, whether for the specific enforcement of any covenant or
agreement contained in this Indenture or in aid of the exercise of any power
granted in this Indenture or to enforce any other legal or equitable right
vested in the Trustee by this Indenture or by law.
Section 6.6 Remedies Cumulative and Continuing. Except as
provided in Section 2.6, all powers and remedies given by this Article VI to the
Trustee or to the Noteholders shall, to the extent permitted by law, be deemed
cumulative and not exclusive of such powers and remedies or of any other powers
and remedies available to the Trustee or the holders of the Notes, by judicial
proceedings or otherwise, to enforce the performance or observance of the
covenants and agreements contained in this Indenture, and no delay or omission
of the Trustee or of any holder of any of the Notes to exercise any right or
power accruing upon any default or Event of Default occurring and continuing as
aforesaid shall impair any such right or power or shall be construed to be a
waiver of any such default or any acquiescence
41
<PAGE> 48
therein; and, subject to the provisions of Section 6.4, every power and remedy
given by this Article VI or by law to the Trustee or to the Noteholders may be
exercised from time to time, and as often as shall be deemed expedient, by the
Trustee or by the Noteholders.
Section 6.7 Direction of Proceedings and Waiver of Defaults by
Majority of Noteholders. The holders of a majority in aggregate principal amount
of the Notes at the time outstanding (determined in accordance with Section 8.4)
shall have the right to direct the time, method and place of conducting any
proceeding for any remedy available to the Trustee or exercising any trust or
power conferred on the Trustee; provided that (a) such direction shall not be in
conflict with any rule of law or with this Indenture and (b) the Trustee may
take any other action deemed proper by the Trustee that is not inconsistent with
such direction. The holders of a majority in aggregate principal amount of the
Notes at the time outstanding (determined in accordance with Section 8.4) may on
behalf of the holders of all of the Notes waive any past default or Event of
Default hereunder and its consequences except (i) a default in the payment of
interest or premium, if any, on, or the principal of, the Notes, (ii) a failure
by the Company to convert any Notes into Common Stock or (iii) a default in
respect of a covenant or provisions hereof that under Article X cannot be
modified or amended without the consent of the holders of all Notes then
outstanding. Upon any such waiver, the Company, the Trustee and the holders of
the Notes shall be restored to their former positions and rights hereunder; but
no such waiver shall extend to any subsequent or other default or Event of
Default or impair any right consequent thereon. Whenever any default or Event of
Default hereunder shall have been waived as permitted by this Section 6.7, said
default or Event of Default shall for all purposes of the Notes and this
Indenture be deemed to have been cured and to be not continuing; but no such
waiver shall extend to any subsequent or other default or Event of Default or
impair any right consequent thereon.
Section 6.8 Notice of Defaults. The Trustee shall, within 90
days after the occurrence of a default, mail to all Noteholders, as the names
and addresses of such holders appear upon the Note register, notice of all
defaults known to a Responsible Officer, unless such defaults shall have been
cured or waived before the giving of such notice; and provided that, except in
the case of default in the payment of the principal of, premium, if any, or
interest on any of the Notes, the Trustee shall be protected in withholding such
notice if and so long as a trust committee of directors and/or Responsible
Officers of the Trustee in good faith determine that the withholding of such
notice is in the interests of the Noteholders.
42
<PAGE> 49
Section 6.9 Undertaking to Pay Costs. All parties to this
Indenture agree, and each holder of any Note by his acceptance thereof shall be
deemed to have agreed, that any court may, in its discretion, require, in any
suit for the enforcement of any right or remedy under this Indenture, or in any
suit against the Trustee for any action taken or omitted by it as Trustee, the
filing by any party litigant in such suit of an undertaking to pay the costs of
such suit and that such court may in its discretion assess reasonable costs,
including reasonable attorneys' fees and expenses, against any party litigant in
such suit, having due regard to the merits and good faith of the claims or
defenses made by such party litigant; provided that the provisions of this
Section 6.9 shall not apply to any suit instituted by the Trustee, to any suit
instituted by any Noteholder or group of Noteholders holding in the aggregate
more than 10% in principal amount of the Notes at the time outstanding
determined in accordance with Section 8.4 or to any suit instituted by any
Noteholder for the enforcement of the payment of the principal of, premium, if
any, or interest on any Note on or after the due date expressed in such Note or
to any suit for the enforcement of the right to convert any Note in accordance
with the provisions of Article XIV.
ARTICLE VII
CONCERNING THE TRUSTEE
Section 7.1 Duties and Responsibilities of Trustee.
(a) If an Event of Default has occurred and is continuing, the
Trustee shall exercise the rights and powers vested in it by this Indenture and
use the same degree of care and skill in its exercise as a prudent person would
exercise or use under the circumstances in the conduct of such person's own
affairs.
(b) Except during the continuance of an Event of Default:
(1) the Trustee need perform only those duties that
are specifically set forth in this Indenture and no others;
and
(2) in the absence of bad faith on its part, the
Trustee may conclusively rely, as to the truth of the
statements and the correctness of the opinions expressed
therein, upon certificates or opinions furnished to the
Trustee and conforming to the requirements of this Indenture;
provided that in the case of any such certificates or opinions
which by any provision hereof are specifically required to be
furnished to the Trustee, the Trustee shall be under a duty to
43
<PAGE> 50
examine the same to determine whether or not they conform to
the requirements of this Indenture (but need not confirm or
investigate the accuracy of mathematical calculations or other
facts stated therein).
(c) The Trustee may not be relieved from liability for its own
negligent action, its own negligent failure to act or its own willful
misconduct, except that:
(1) this paragraph (c) does not limit the effect of
paragraph (b) of this Section 7.1;
(2) the Trustee shall not be liable for any error of
judgment made in good faith by an officer of the Trustee
unless it is proved that the Trustee was negligent in
ascertaining the pertinent facts; and
(3) the Trustee shall not be liable with respect to
any action it takes or omits to take in good faith in
accordance with a direction received by it pursuant to Section
6.7.
(d) Every provision of this Indenture that in any way relates
to the Trustee is subject to paragraphs (a), (b), (c) and (e) of this Section
7.1.
(e) The Trustee may refuse to perform any duty or exercise any
right or power or extend or risk its own funds or otherwise incur any financial
liability unless it receives indemnity satisfactory to it against any loss,
liability or expense.
Section 7.2 Reports by Trustee to Holders. Within 60 days
after each May 15 commencing with the May 15 following the date of this
Indenture, the Trustee shall, if required by the Trust Indenture Act, mail to
each Noteholder a brief report dated as of such May 15 that complies with
Section 313(a) of the Trust Indenture Act. The Trustee also shall comply with
Sections 313(b) and 313(c) of the Trust Indenture Act.
The Company shall promptly notify the Trustee in writing if
the Notes become listed or delisted on any stock exchange or automatic quotation
system.
A copy of each report at the time of its mailing to
Noteholders shall be mailed to the Company and, to the extent required by
Section 5.2 hereof and Section 313(d) of the Trust Indenture Act, filed with the
Commission and each stock exchange, if any, on which the Notes are listed.
Section 7.3 Reliance on Documents, Opinions, Etc. Except as
otherwise provided in Section 7.1:
44
<PAGE> 51
(a) The Trustee may rely and shall be protected in acting upon
any resolution, certificate, statement, instrument, opinion, report,
notice, request, consent, order, bond, debenture, coupon or other paper
or document believed by it in good faith to be genuine and to have been
signed or presented by the proper party or parties;
(b) Any request, direction, order or demand of the Company
mentioned herein shall be sufficiently evidenced by an Officers'
Certificate (unless other evidence in respect thereof be herein
specifically prescribed or required by the Trust Indenture Act); and
any resolution of the Board of Directors may be evidenced to the
Trustee by a copy thereof certified by the Secretary or an Assistant
Secretary of the Company;
(c) The Trustee may consult with counsel of its selection and
any advice or Opinion of Counsel shall be full and complete
authorization and protection in respect of any action taken or omitted
by it hereunder in good faith and in accordance with such advice or
Opinion of Counsel;
(d) The Trustee may execute any of the trusts or powers
hereunder or perform any duties hereunder either directly or by or
through agents or attorneys, and the Trustee shall not be responsible
for any misconduct or negligence on the part of any agent or attorney
appointed by it with due care hereunder; no Depositary, Custodian or
paying agent who is not the Trustee shall be deemed an agent of the
Trustee, and the Trustee (in its capacity as Trustee) shall not be
responsible for any act or omission by any such Depositary, Custodian
or paying agent;
(e) The Trustee shall be under no obligation to exercise any
of the rights or powers vested in it by the Indenture at the request or
direction of any of the holders pursuant to this Indenture unless such
holders have offered the Trustee reasonable security or indemnity
against the costs, expenses and liabilities that would be incurred by
it in compliance with such request or direction.
(f) Subject to the provisions of Section 7.1(c), the Trustee
shall not be liable for any action it takes or omits to take in good
faith that it believes to be authorized or within its rights or powers;
(g) In connection with any request to transfer or exchange any
Note, the Trustee may request a direction (in the form of an Officers'
Certificate) from the Company and an Opinion of Counsel with respect to
compliance with any restrictions on transfer or exchange imposed by
this Indenture, the Securities Act, other applicable law or the rules
45
<PAGE> 52
and regulations of any exchange on which the Notes or the capital stock
may be traded, and the Trustee may rely and shall be protected in
acting upon such direction and in accordance with such Officers'
Certificate and Opinion of counsel;
(h) The Trustee may rely and shall be fully protected in
acting upon the determination and notice by the Company of the
Conversion Price; and
(i) The Trustee shall not be deemed to have knowledge of any
Event of Default or other fact or event upon the occurrence of which it
may be required to take action hereunder unless one of its Responsible
Officers has actual knowledge thereof.
Section 7.4 No Responsibility for Recitals, Etc. The recitals
contained herein and in the Notes (except in the Trustee's certificate of
authentication) shall be taken as the statements of the Company, and the Trustee
assumes no responsibility for the correctness of the same. The Trustee makes no
representations as to the validity or sufficiency of this Indenture or of the
Notes. The Trustee shall not be accountable for the use or application by the
Company of any Notes or the proceeds of any Notes authenticated and delivered by
the Trustee in conformity with the provisions of this Indenture.
Section 7.5 Trustee, Paying Agents, Conversion Agents or
Registrar May Own Notes. The Trustee, any paying agent, any conversion agent or
any Note registrar, in its individual or any other capacity, may become the
owner or pledgee of Notes with the same rights it would have if it were not
Trustee, paying agent, conversion agent or Note registrar.
Section 7.6 Monies to Be Held in Trust. Subject to the
provisions of Section 12.4, all monies received by the Trustee shall, until used
or applied as herein provided, be held in trust for the purposes for which they
were received. Money held by the Trustee in trust hereunder need not be
segregated from other funds except to the extent required by law. The Trustee
shall be under no liability for interest on any money received by it hereunder
except as may be agreed to in writing from time to time by the Company and the
Trustee.
Section 7.7 Compensation and Expenses of Trustee. The Company
covenants and agrees to pay to the Trustee from time to time, and the Trustee
shall be entitled to, such compensation as the Company and the Trustee shall
from time to time agree in writing, for all services rendered by it hereunder in
any capacity (which shall not be limited by any provision of law in regard to
the compensation of a trustee of an express trust), and the Company shall pay or
reimburse the Trustee upon its request for
46
<PAGE> 53
all reasonable expenses, disbursements and advances incurred or made by the
Trustee in accordance with any of the provisions of this Indenture (including
the reasonable compensation and the expenses and disbursements of its counsel
and of all persons not regularly in its employ) except any such expense,
disbursement or advance as may arise from its negligence or bad faith. The
Company also covenants to indemnify each of the Trustee or any predecessor
Trustee in any capacity under this Indenture and its agents and any
authenticating agent for, and to hold them harmless against, any and all loss,
liability, damage, claim or expense, including taxes (other than taxes based on
the income of the Trustee) incurred without negligence or bad faith on the part
of the Trustee or such agent or authenticating agent, as the case may be, and
arising out of or in connection with the acceptance or administration of this
trust or in any other capacity hereunder, including the costs and expenses of
defending themselves against any claim of liability in the premises. The
obligations of the Company under this Section 7.7 to compensate or indemnify the
Trustee and to pay or reimburse the Trustee for expenses, disbursements and
advances shall be secured by a lien prior to that of the Notes upon all property
and funds held or collected by the Trustee as such, except funds held in trust
for the benefit of the holders of particular Notes. The obligation of the
Company under this Section shall survive the satisfaction and discharge of this
Indenture.
When the Trustee incurs expenses or renders services in
connection with an Event of Default specified in Section 6.1(d) hereof or
Section 6.1(e) hereof, the expenses (including the reasonable charges and
expenses of its counsel) and the compensation for the services are intended to
constitute expenses of administration under any applicable federal or state
bankruptcy, insolvency or other similar law.
Section 7.8 Officers' Certificate as Evidence. Except as
otherwise provided in Section 7.1, whenever in the administration of the
provisions of this Indenture the Trustee shall deem it necessary or desirable
that a matter be proved or established prior to taking or omitting any action
hereunder, such matter (unless other evidence in respect thereof be herein
specifically prescribed) may, in the absence of negligence or bad faith on the
part of the Trustee, be deemed to be conclusively proved and established by an
Officers' Certificate delivered to the Trustee, and such Officers' Certificate,
in the absence of negligence or bad faith on the part of the Trustee, shall be
full warrant to the Trustee for any action taken or omitted by it under the
provisions of this Indenture upon the faith thereof.
Section 7.9 Conflicting Interests of Trustee. In the event
that the Trust Indenture Act is applicable hereto, and if the Trustee has or
shall acquire a conflicting interest within the meaning of Section 310(b) of the
Trust Indenture Act and
47
<PAGE> 54
there exists an Event of Default hereunder (exclusive of any period of grace or
requirement of notice), the Trustee shall either eliminate such interest or
resign, to the extent and in the manner provided by, and subject to the
provisions of, the Trust Indenture Act and this Indenture.
Section 7.10 Eligibility of Trustee. There shall at all times
be a Trustee hereunder that shall be a person that satisfied the requirements of
Trust Indenture Act Section 310(a)(1) and Section 310(a)(5) and that has a
combined capital and surplus of at least $50,000,000. If such person publishes
reports of condition at least annually, pursuant to law or to the requirements
of any supervising or examining authority, then for the purposes of this
Section, the combined capital and surplus of such person shall be deemed to be
its combined capital and surplus as set forth in its most recent report of
condition so published. If at any time the Trustee shall cease to be eligible in
accordance with the provisions of this Section, it shall resign immediately in
the manner and with the effect hereinafter specified in this Article VII.
Section 7.11 Resignation or Removal of Trustee.
(a) The Trustee may at any time resign by giving written
notice of such resignation to the Company; and the Company shall mail, or cause
to be mailed, notice thereof to the holders of Notes at their addresses as they
shall appear on the Note register. Upon receiving such notice of resignation,
the Company shall promptly appoint a successor trustee by written instrument, in
duplicate, executed by order of the Board of Directors, one copy of which
instrument shall be delivered to the resigning Trustee and one copy to the
successor trustee.
(b) In case at any time any of the following shall occur:
(1) the Trustee shall fail to comply with Section 7.9 after
written request therefor by the Company or by any Noteholder who has
been a bona fide holder of a Note or Notes for at least six months; or
(2) the Trustee shall cease to be eligible in accordance with
the provisions of Section 7.10 and shall fail to resign after written
request therefor by the Company or by any such Noteholder; or
(3) the Trustee shall become incapable of acting, or shall be
adjudged a bankrupt or insolvent, or a receiver of the Trustee or of
its property shall be appointed, or any public officer shall take
charge or control of the Trustee or of its property or affairs for the
purpose of rehabilitation, conservation or liquidation,
48
<PAGE> 55
then, in any such case, the Company may remove the Trustee and appoint a
successor trustee by written instrument, in duplicate, executed by order of the
Board of Directors, one copy of which instrument shall be delivered to the
Trustee so removed and one copy to the successor trustee or any Noteholder who
has been a bona fide holder of a Note or Notes for at least six months may, on
behalf of himself and all others similarly situated, petition any court of
competent jurisdiction for the removal of the Trustee and the appointment of a
successor trustee. Such court may thereupon, after such notice, if any, as it
may deem proper and prescribe, remove the Trustee and appoint a successor
trustee.
(c) The holders of a majority in aggregate principal amount of
the Notes at the time outstanding may at any time remove the Trustee and
nominate a successor trustee, which shall be deemed appointed as successor
trustee unless within ten days after notice to the Company of such nomination
the Company objects thereto, in which case the Trustee so removed or any
Noteholder, upon the terms and conditions and otherwise as provided in the next
paragraph, may petition any court of competent jurisdiction for an appointment
of a successor trustee.
If no successor trustee shall have been so appointed and have
accepted appointment within 60 days after removal or the mailing of such notice
of resignation to the Noteholders, the Trustee resigning or being removed may
petition any court of competent jurisdiction for the appointment of a successor
trustee, or, in the case of either resignation or removal, any Noteholder who
has been a bona fide holder of a Note or Notes for at least six months may, on
behalf of himself and all others similarly situated, petition any such court for
the appointment of a successor trustee. Such court may thereupon, after such
notice, if any, as it may deem proper and prescribe, appoint a successor
trustee.
(d) Any resignation or removal of the Trustee and appointment
of a successor trustee pursuant to any of the provisions of this Section 7.11
shall become effective upon acceptance of appointment by the successor trustee
as provided in Section 7.12.
Section 7.12 Acceptance by Successor Trustee. Any successor
trustee appointed as provided in Section 7.11 shall execute, acknowledge and
deliver to the Company and to its predecessor trustee an instrument accepting
such appointment hereunder, and thereupon, the resignation or removal of the
predecessor trustee shall become effective and such successor trustee, without
any further act, deed or conveyance, shall become vested with all the rights,
powers, duties and obligations of its predecessor hereunder, with like effect as
if originally named as trustee herein; but on the written request of the Company
or of
49
<PAGE> 56
the successor trustee, the Trustee ceasing to act shall, upon payment of any
amounts then due it pursuant to the provisions of Section 7.7, execute and
deliver an instrument transferring to such successor trustee all the rights and
powers of the Trustee so ceasing to act. Upon request of any such successor
trustee, the Company shall execute any and all instruments in writing for more
fully and certainly vesting in and confirming to such successor trustee all such
rights and powers. Any Trustee ceasing to act shall, nevertheless, retain a lien
upon all property and funds held or collected by such trustee as such, except
for funds held in trust for the benefit of holders of particular Notes, to
secure any amounts then due it pursuant to the provisions of Section 7.7.
No successor trustee shall accept appointment as provided in
this Section 7.12 unless at the time of such acceptance such successor trustee
shall be qualified under the provisions of Section 7.9 and eligible under the
provisions of Section 7.10.
Upon acceptance of appointment by a successor trustee as
provided in this Section 7.12, the Company shall mail or cause to be mailed
notice of the succession of such Trustee hereunder to the holders of Notes at
their addresses as they shall appear on the Note register. If the Company fails
to mail such notice within ten days after acceptance of appointment by the
successor trustee, the successor trustee shall cause such notice to be mailed at
the expense of the Company.
Section 7.13 Successor, by Merger, Etc. Any corporation into
which the Trustee may be merged or converted or with which it may be
consolidated, or any corporation resulting from any merger, conversion or
consolidation to which the Trustee shall be a party, or any corporation
succeeding to all or substantially all of the corporate trust business of the
Trustee, shall be the successor to the Trustee hereunder, provided such
corporation shall be qualified under the provisions of Section 7.9 and eligible
under the provisions of Section 7.10 without the execution or filing of any
paper or any further act on the part of any of the parties hereto.
Section 7.14 Limitation on Rights of Trustee as Creditor. If
and when the Trustee shall be or become a creditor of the Company (or any other
obligor upon the Notes) and the Trust Indenture Act is applicable hereto, the
Trustee shall be subject to the provisions of Section 311(a) or, if applicable,
Section 311(b) of the Trust Indenture Act regarding the collection of the claims
against the Company (or any such other obligor).
50
<PAGE> 57
ARTICLE VIII
CONCERNING THE NOTEHOLDERS
Section 8.1 Action by Noteholders. Whenever in this Indenture
it is provided that the holders of a specified percentage in aggregate principal
amount of the Notes may take any action (including the making of any demand or
request, the giving of any notice, consent or waiver or the taking of any other
action), the fact that at the time of taking any such action, the holders of
such specified percentage have joined therein may be evidenced (a) by any
instrument or any number of instruments of similar tenor executed by Noteholders
in person or by agent or proxy appointed in writing, (b) by the record of the
holders of Notes voting in favor thereof at any meeting of Noteholders duly
called and held in accordance with the provisions of Article IX or (c) by a
combination of such instrument or instruments and any such record of such a
meeting of Noteholders. Whenever the Company or the Trustee solicits the taking
of any action by the holders of the Notes, the Company or the Trustee may fix in
advance of such solicitation, a date as the record date for determining holders
entitled to take such action. The record date shall be not more than 15 days
prior to the date of commencement of solicitation of such action.
Section 8.2 Proof of Execution by Noteholders. Subject to the
provisions of Sections 7.1, 7.2 and 9.5, proof of the execution of any
instrument by a Noteholder or his agent or proxy shall be sufficient if made in
accordance with such reasonable rules and regulations as may be prescribed by
the Trustee or in such manner as shall be satisfactory to the Trustee. The
holding of Notes shall be proved by the Note register or by a certificate of the
Note registrar.
The record of any Noteholders' meeting shall be proved in the
manner provided in Section 9.5.
Section 8.3 Who Are Deemed Absolute Owners. The Company, the
Trustee, any paying agent, any conversion agent and any Note registrar may deem
the person in whose name such Note shall be registered upon the books of the
Company to be, and may treat him as, the absolute owner of such Note (whether or
not such Note shall be overdue and notwithstanding any notation of ownership or
other writing thereon) for the purpose of receiving payment of or on account of
the principal of, premium, if any, and interest on such Note, for conversion of
such Note and for all other purposes; and neither the Company nor the Trustee
nor any paying agent nor any conversion agent nor any Note registrar shall be
affected by any notice to the contrary. All such payments so made to any holder
for the time being, or upon his order, shall be valid and, to the extent of the
sum or sums so
51
<PAGE> 58
paid, effectual to satisfy and discharge the liability for monies payable upon
any such Note.
The Depositary shall be deemed to be the owner of any global
Note for all purposes, including receipt of notices to Noteholders and payment
of principal of, premium, if any, and interest on the Notes. None of the
Company, the Trustee (in its capacity as Trustee), any paying agent or the Note
registrar (or co-registrar) shall have any responsibility for any aspect of the
records relating to or payments made on account of beneficial interests of a
global Note or for maintaining, supervising or reviewing any records relating to
such beneficial ownership interests; provided that the foregoing shall not apply
to the Trustee or any other person acting in its capacity as Custodian.
Section 8.4 Company-Owned Notes Disregarded. In determining
whether the holders of the requisite aggregate principal amount of Notes have
concurred in any direction, consent, waiver or other action under this
Indenture, Notes that are owned by the Company or any other obligor on the Notes
or by any person directly or indirectly controlling or controlled by or under
direct or indirect common control with the Company or any other obligor on the
Notes shall be disregarded and deemed not to be outstanding for the purpose of
any such determination; provided that for the purposes of determining whether
the Trustee shall be protected in relying on any such direction, consent, waiver
or other action, only Notes that a Responsible Officer actually knows are so
owned shall be so disregarded. Notes so owned that have been pledged in good
faith may be regarded as outstanding for the purposes of this Section 8.4 if the
pledgee shall establish to the satisfaction of the Trustee the pledger's right
to vote such Notes and that the pledgee is not the Company, any other obligor on
the Notes or a person directly or indirectly controlling or controlled by or
under direct or indirect common control with the Company or any such other
obligor. In the case of a dispute as to such right, any decision by the Trustee
taken upon the advice of counsel shall be full protection to the Trustee. Upon
request of the Trustee, the Company shall furnish to the Trustee promptly an
Officers' Certificate listing and identifying all Notes, if any, known by the
Company to be owned or held by or for the account of any of the above described
persons; and subject to Section 7.1, the Trustee shall be entitled to accept
such Officers' Certificate as conclusive evidence of the facts therein set forth
and of the fact that all Notes not listed therein are outstanding for the
purpose of any such determination.
Section 8.5 Revocation of Consents, Future Holders Bound. At
any time prior to (but not after) the evidencing to the Trustee, as provided in
Section 8.1, of the taking of any action by the holders of the percentage in
aggregate principal amount of the Notes specified in this Indenture in
connection
52
<PAGE> 59
with such action, any holder of a Note that is shown by the evidence to be
included in the Notes the holders of which have consented to such action may, by
filing written notice with the Trustee at its Corporate Trust Office and upon
proof of holding as provided in Section 8.2, revoke such action so far as
concerns such Note. Except as aforesaid, any such action taken by the holder of
any Note shall be conclusive and binding upon such holder and upon all future
holders and owners of such Note and of any Notes issued in exchange or
substitution therefor, irrespective of whether any notation in regard thereto is
made upon such Note or any Note issued in exchange or substitution therefor.
ARTICLE IX
NOTEHOLDERS' MEETINGS
Section 9.1 Purposes for Which Meetings May be Called. A
meeting of Noteholders may be called at any time and from time to time pursuant
to the provisions of this Article IX for any of the following purposes:
(i) to give any notice to the Company or to the Trustee, or to
give any directions to the Trustee, or to consent to the waiving of any
default hereunder and its consequences, or to take any other action
authorized to be taken by Noteholders pursuant to any of the provisions
of Article VI;
(ii) to remove the Trustee and appoint a successor trustee
pursuant to the provisions of Article VII;
(iii) to consent to the execution of an indenture or
indentures supplemental hereto pursuant to the provisions of Section
10.2; or
(iv) to take any other action authorized to be taken by or on
behalf of the holders of any specified aggregate principal amount of
the Notes under any other provisions of this Indenture or under
applicable law.
Section 9.2 Manner of Calling Meetings; Record Date. The
Trustee may at any time call a meeting of Noteholders to take any action
specified in Section 9.1, to be held at such time and at such place in the City
of New York, State of New York, as the Trustee shall determine. Notice of every
meeting of the Noteholders, setting forth the time and the place of such meeting
and in general terms the action proposed to be taken at such meeting, shall be
mailed not less than 30 nor more than 60 days prior to the date fixed for the
meeting to such Noteholders at their addresses as such addresses appear in the
Note register. For the purpose of determining Noteholders entitled to notice of
any meeting of Noteholders, the Trustee shall fix in advance a
53
<PAGE> 60
date as the record date for such determination, such date to be a business day
not more than ten days prior to the date of the mailing of such notice as
hereinabove provided. Only persons in whose name any Note shall be registered in
the Note register at the close of business on a record date fixed by the Trustee
as aforesaid, or by the Company or the Noteholders as provided in Section 9.3,
shall be entitled to notice of the meeting of Noteholders with respect to which
such record date was so fixed.
Section 9.3 Call of Meeting by Company or Noteholders. In case
at any time the Company, pursuant to a resolution of its Board of Directors or
the holders of at least 10% in aggregate principal amount of the Notes then
outstanding shall have requested the Trustee to call a meeting of Noteholders to
take any action authorized in Section 9.1 by written request setting forth in
reasonable detail the action proposed to be taken at the meeting, and the
Trustee shall not have mailed notice of such meeting within 20 days after
receipt of such request, then the Company or the holders of Notes in the amount
above specified, as the case may be, may fix the record date with respect to,
and determine the time and the place for, such meeting and may call such meeting
to take any action authorized in Section 9.1, by mailing notice thereof as
provided in Section 9.2. The record date fixed as provided in the preceding
sentence shall be set forth in a written notice to the Trustee and shall be a
business day not less than 15 nor more than 20 days after the date on which the
original request is sent to the Trustee.
Section 9.4 Who May Attend and Vote at Meetings. Only persons
entitled to receive notice of a meeting of Noteholders and their respective
proxies duly appointed by an instrument in writing shall be entitled to vote at
such meeting. The only persons who shall be entitled to be present or to speak
at any meeting of Noteholders shall be the persons entitled to vote at such
meeting and their counsel and any representatives of the Trustee and its counsel
and any representatives of the Company and its counsel. When a determination of
Noteholders entitled to vote at any meeting of Noteholders has been made as
provided in this Section, such determination shall apply to any adjournments
thereof.
Section 9.5 Manner of Voting at Meetings and Record to be
Kept. The vote upon any resolution submitted to any meeting of Noteholders shall
be by written ballots on each of which shall be subscribed the signature of the
Noteholder or proxy casting such ballot and the identifying number or numbers of
the Notes held or represented in respect of which such ballot is cast. The
chairman of the meeting shall appoint two inspectors of votes who shall count
all votes cast at the meeting for or against any resolution and who shall make
and file with the secretary of the meeting their verified written reports in
duplicate of all votes cast at the meeting. A record in duplicate of the
proceedings of
54
<PAGE> 61
each meeting of Noteholders shall be prepared by the secretary of the meeting
and there shall be attached to said record the original reports of the
inspectors of votes on any vote by ballot taken thereat and affidavits by one or
more persons having knowledge of the facts setting forth a copy of the notice of
the meeting and showing that said notice was mailed as provided in Section 9.2.
The record shall show the identifying numbers of the Notes voting in favor of or
against any resolution. Each counterpart of such record shall be signed and
verified by the affidavits of the chairman and secretary of the meeting and one
of the counterparts shall be delivered to the Company and the other to the
Trustee to be preserved by the Trustee.
Any counterpart record so signed and verified shall be
conclusive evidence of the matters therein stated and shall be the record
referred to in clause (b) of Section 8.1.
Section 9.6 Exercise of Rights of Trustee and Noteholders Not
To Be Hindered or Delayed. Nothing in this Article IX contained shall be deemed
or construed to authorize or permit, by reason of any call of a meeting of
Noteholders or any rights expressly or impliedly conferred hereunder to make
such call, any hinderance or delay in the exercise of any right or rights
conferred upon or reserved to the Trustee or to the Noteholders under any of the
provisions of this Indenture or of the Notes.
ARTICLE X
SUPPLEMENTAL INDENTURES
Section 10.1 Supplemental Indentures Without Consent of
Noteholders. The Company, when authorized by a Board Resolution, and the Trustee
may from time to time and at any time enter into an indenture or indentures
supplemental hereto for one or more of the following purposes:
(a) to make provision with respect to the conversion rights of
the holders of Notes pursuant to the requirements of Section 14.6;
(b) subject to Article XV, to convey, transfer, assign,
mortgage or pledge to the Trustee as security for the Notes, any
property or assets;
(c) to evidence the succession of another person to the
Company, or successive successions, and the assumption by the Successor
Company of the covenants, agreements and obligations of the Company
pursuant to Article XI;
55
<PAGE> 62
(d) to add to the covenants of the Company such further
covenants, restrictions or conditions as the Board of Directors and the
Trustee shall consider to be for the benefit of the holders of Notes
and to make the occurrence, or the occurrence and continuance, of a
default in any such additional covenants, restrictions or conditions a
default or an Event of Default permitting the enforcement of all or any
of the several remedies provided in this Indenture as herein set forth;
provided that in respect of any such additional covenant, restriction
or condition, such supplemental indenture may provide for a particular
period of grace after default (which period may be shorter or longer
than that allowed in the case of other defaults) or may provide for an
immediate enforcement upon such default or may limit the remedies
available to the Trustee upon such default;
(e) to provide for the issuance under this Indenture of Notes
in coupon form (including Notes registrable as to principal only) and
to provide for exchangeability of such Notes with the Notes issued
hereunder in fully registered form and to make all appropriate changes
for such purpose;
(f) to cure any ambiguity or to correct or supplement any
provision contained herein or in any supplemental indenture that may be
defective or inconsistent with any other provision contained herein or
in any supplemental indenture, or to make such other provisions in
regard to matters or questions arising under this Indenture that shall
not adversely affect the interests of the holders of the Notes;
(g) to evidence and provide for the acceptance of appointment
hereunder by a successor Trustee with respect to the Notes;
(h) to modify, eliminate or add to the provisions of this
Indenture to such extent necessary to effect the qualification of this
Indenture under the Trust Indenture Act (if applicable), or under any
similar federal statute hereafter enacted (if applicable); or
(i) to modify, eliminate or add to the provisions of this
Indenture to allow for the issuance of one or more Notes in global
form, in addition to the global Note provided for herein, representing
beneficial interests in Notes issued outside the United States in
reliance on Regulation S under the Securities Act, with such transfer
restrictions and legends as are consistent with such Regulation, and to
add provisions relating to the exchange and transfer of beneficial
interests in any Note or Notes represented by any such global Note or
Notes, any definitive Note and any global Note referred to in Section
2.5(b) hereof.
56
<PAGE> 63
The Trustee is hereby authorized to join with the Company in
the execution of any such supplemental indenture, to make any further
appropriate agreements and stipulations that may be therein contained and to
accept the conveyance, transfer and assignment of any property thereunder, but
the Trustee shall not be obligated to, but may in its discretion, enter into any
supplemental indenture that affects the Trustee's own rights, duties or
immunities under this Indenture or otherwise.
Any supplemental indenture authorized by the provisions of
this Section 10.1 may be executed by the Company and the Trustee without the
consent of the holders of any of the Notes at the time outstanding,
notwithstanding any of the provisions of Section 10.2.
Section 10.2 Supplemental Indentures With Consent of
Noteholders. With the consent (evidenced as provided in Article VIII) of the
holders of not less than a majority in aggregate principal amount of the Notes
at the time outstanding, the Company, when authorized by a Board Resolution and
the Trustee may from time to time and at any time enter into an indenture or
indentures supplemental hereto for the purpose of adding any provisions to or
changing in any manner or eliminating any of the provisions of this Indenture or
any supplemental indenture or of modifying in any manner the rights of the
holders of the Notes; provided that no such supplemental indenture shall (i)
extend the fixed maturity of any Note, or reduce the rate or extend the time of
payment of interest thereon, or reduce the principal amount thereof or premium,
if any, thereon or reduce any amount payable on redemption thereof, alter the
obligation of the Company to redeem the Notes at the option of the holder upon
the occurrence of a Change of Control or impair or affect the right of any
Noteholder to institute suit for the payment thereof or make the principal
thereof or interest or premium, if any, thereon payable in any coin or currency
other than that provided in the Notes, modify the subordination provisions in a
manner adverse to the holders of the Notes, or impair the right to convert the
Notes into Common Stock subject to the terms set forth herein without the
consent of the holder of each Note so affected or (ii) reduce the aforesaid
percentage of Notes, the holders of which are required to consent to any such
supplemental indenture, without the consent of the holders of all Notes then
outstanding.
Upon the request of the Company, accompanied by a copy of a
Board Resolution certified by its Secretary or Assistant Secretary authorizing
the execution of any such supplemental indenture, and upon the filing with the
Trustee of evidence of the consent of Noteholders as aforesaid, the Trustee
shall join with the Company in the execution of such supplemental indenture
unless such supplemental indenture affects the Trustee's own rights, duties or
immunities under this Indenture or otherwise,
57
<PAGE> 64
in which case the Trustee may in its discretion, but shall not be obligated to,
enter into such supplemental indenture.
It shall not be necessary for the consent of the Noteholders
under this Section 10.2 to approve the particular form of any proposed
supplemental indenture, but it shall be sufficient if such consent shall approve
the substance thereof.
Section 10.3 Effect of Supplemental Indentures. Any
supplemental indenture executed pursuant to the provisions of this Article X
shall comply with the Trust Indenture Act, as then in effect, if such
supplemental indenture is then required to so comply. Upon the execution of any
supplemental indenture pursuant to the provisions of this Article X, this
Indenture shall be and be deemed to be modified and amended in accordance
therewith and the respective rights, limitation of rights, obligations, duties
and immunities under this Indenture of the Trustee, the Company and the holders
of Notes shall thereafter be determined, exercised and enforced hereunder
subject in all respects to such modifications and amendments and all the terms
and conditions of any such supplemental indenture shall be and be deemed to be
part of the terms and conditions of this Indenture for any and all purposes.
Section 10.4 Notation on Notes. Notes authenticated and
delivered after the execution of any supplemental indenture pursuant to the
provisions of this Article X may bear a notation in form approved by the Trustee
as to any matter provided for in such supplemental indenture, but they need not
do so. If the Company or the Trustee shall determine to add such a notation, new
Notes so modified as to conform, in the opinion of the Trustee and the Board of
Directors, to any modification of this Indenture contained in any such
supplemental indenture may, at the Company's expense, be prepared and executed
by the Company, authenticated by the Trustee (or an authenticating agent duly
appointed by the Trustee pursuant to Section 16.14) and delivered in exchange
for the Notes then outstanding, upon surrender of such Notes then outstanding.
Section 10.5 Evidence of Compliance of Supplemental Indenture
to Be Furnished Trustee. The Trustee shall be furnished with and, subject to the
provisions of Sections 7.1 and 7.2, may rely upon an Officers' Certificate and
an Opinion of Counsel as conclusive evidence that any supplemental indenture
executed pursuant hereto complies with the requirements of this Article X.
58
<PAGE> 65
ARTICLE XI
CONSOLIDATION, MERGER, SALE, CONVEYANCE,
TRANSFER AND LEASE
Section 11.1 Company May Consolidate, Etc. on Certain Terms.
The Company shall not consolidate with or merge with or into, or convey,
transfer or lease all or substantially all of its assets to any person unless:
(i) either the Company is the resulting, surviving or transferee person (the
"Successor Company") or the Successor Company is a person organized and existing
under the laws of the United States or any State thereof or the District of
Columbia, and the Successor Company (if not the Company) expressly assumes by a
supplemental indenture, executed and delivered to the Trustee, in form
satisfactory to the Trustee, all the obligations of the Company under this
Indenture and the Notes, including the rights pursuant to Article XIV hereof;
(ii) immediately after giving effect to such transaction, no Event of Default
has happened and is continuing; and (iii) the Company delivers to the Trustee an
Officers' Certificate and an Opinion of Counsel, each stating that such
consolidation, merger or transfer and such supplemental indenture (if any)
comply with this Indenture.
Section 11.2 Successor Company To Be Substituted. In case of
any such consolidation, merger, sale, conveyance, transfer or lease and upon the
assumption by the Successor Company, by supplemental indenture, executed and
delivered to the Trustee and satisfactory in form to the Trustee, of the due and
punctual payment of the principal of, premium, if any, and interest on all of
the Notes and the due and punctual performance of all of the covenants and
conditions of this Indenture to be performed by the Company, such Successor
Company shall succeed to and be substituted for the Company, with the same
effect as if it had been named herein as the party hereto. Such Successor
Company thereupon may cause to be signed, and may issue either in its own name
or in the name of Healthsource, Inc. any or all of the Notes issuable hereunder
that theretofore shall not have been signed by the Company and delivered to the
Trustee; and, upon the order of such Successor Company instead of the Company
and subject to all the terms, conditions and limitations in this Indenture
prescribed, the Trustee shall authenticate and shall deliver, or cause to be
authenticated and delivered, any Notes that previously shall have been signed
and delivered by the officers of the Company to the Trustee for, authentication,
and any Notes that such Successor Company thereafter shall cause to be signed
and delivered to the Trustee for that purpose. All the Notes so issued shall in
all respects have the same legal rank and benefit under this Indenture as the
Notes theretofore or thereafter issued in accordance with the terms of this
Indenture as though all of such Notes had been issued at the date of the
execution hereof. In the event of any such consolidation, merger, sale,
59
<PAGE> 66
conveyance, transfer or lease, the person named as the "Company" in the first
paragraph of this Indenture or any successor that shall thereafter have become
such in the manner prescribed in this Article XI may be dissolved, wound up and
liquidated at any time thereafter and such person shall be released from its
liabilities as obligor and maker of the Notes and from its obligations under
this Indenture.
In case of any such consolidation, merger, sale, conveyance,
transfer or lease, such changes in phraseology and form (but not in substance)
may be made in the Notes thereafter to be issued as may be appropriate.
Section 11.3 Opinion of Counsel To Be Given to Trustee. The
Trustee subject to Sections 7.1 and 7.2, shall receive an Officers' Certificate
and an Opinion of Counsel as conclusive evidence that any such consolidation,
merger, sale, conveyance, transfer or lease and any such assumption complies
with the provisions of this Article XI.
ARTICLE XII
SATISFACTION AND DISCHARGE OF INDENTURE;
UNCLAIMED MONEYS
Section 12.1 Legal Defeasance and Covenant Defeasance of the
Notes.
(a) The Company may, at its option by Board Resolution, at any
time, with respect to the Notes, elect to have either paragraph (b) or paragraph
(c) below be applied to the outstanding Notes upon compliance with the
conditions set forth in paragraph (d).
(b) Upon the Company's exercise under paragraph (a) of the
option applicable to this paragraph (b), the Company shall be deemed to have
been released and discharged from its obligations with respect to the
outstanding Notes on the date the conditions set forth below are satisfied
(hereinafter, "legal defeasance"). For this purpose, such legal defeasance means
that the Company shall be deemed to have paid and discharged the entire
indebtedness represented by the outstanding Notes, which shall thereafter be
deemed to be "outstanding" only for the purposes of the Sections of and matters
under this Indenture referred to in clauses (i) and (ii) below and to have
satisfied all its other obligations under such Notes and this Indenture insofar
as such Notes are concerned, except for the following, which shall survive until
otherwise terminated or discharged hereunder: (i) the rights of holders of
outstanding Notes to receive solely from the trust fund described in paragraph
(d) below and as more fully set forth in such paragraph, payments in respect of
the principal
60
<PAGE> 67
of, premium, if any, and interest on such Notes when such payments are due and
(ii) obligations listed in Section 12.3.
(c) Upon the Company's exercise under paragraph (a) of the
option applicable to this paragraph (c), the Company shall be released and
discharged from its obligations under any covenant contained in Article XI and
in Section 3.5 with respect to the outstanding Notes on and after the date the
conditions set forth in paragraph (d) are satisfied (hereinafter, "covenant
defeasance"), and the Notes shall thereafter be deemed to be not "outstanding"
for the purpose of any direction, waiver, consent or declaration or act of
Holders (and the consequences of any thereof) in connection with such covenants,
but shall continue to be deemed "outstanding" for all other purposes hereunder.
For this purpose, such covenant defeasance means that, with respect to the
outstanding Notes, the Company may omit to comply with and shall have no
liability in respect of any term, condition or limitation set forth in any such
covenant, whether directly or indirectly, by reason of any reference elsewhere
herein to any such covenant or by reason of any reference in any such covenant
to any other provision herein or in any other document, and such omission to
comply shall not constitute a Default or an Event of Default under Section
6.1(c), but, except as specified above, the remainder of this Indenture and such
Notes shall be unaffected thereby.
(d) The following shall be the conditions to application of
either paragraph (b) or paragraph (c) above to the outstanding Notes:
(i) The Company shall have irrevocably deposited in trust with
the Trustee, pursuant to an irrevocable trust and security agreement in
form and substance satisfactory to the Trustee, cash or U.S. Government
Obligations maturing as to principal and interest at such times, or a
combination thereof, in such amounts as are sufficient, without
consideration of the reinvestment of such interest and after payment of
all federal, state and local taxes or other charges or assessments in
respect thereof payable by the Trustee, in the opinion of a nationally
recognized firm of independent public accountants expressed in a
written certification thereof (in form and substance reasonably
satisfactory to the Trustee) delivered to the Trustee, to pay the
principal of, premium, if any, and interest on the outstanding Notes on
the dates on which any such payments are due and payable in accordance
with the terms of this Indenture and of the Notes;
(ii) (A) No Event of Default shall have occurred or be
continuing on the date of such deposit, and (B) no Default or Event of
Default under Section 6.1(d) or 6.1(e)
61
<PAGE> 68
shall occur on or before the 123rd day after the date of such deposit;
(iii) Such deposit shall not result in a Default under this
Indenture or a breach or violation of, or constitute a default under,
any other instrument or agreement to which the Company is a party or by
which it or its property is bound;
(iv) In the case of a legal defeasance under paragraph (b)
above, the Company has delivered to the Trustee an Opinion of Counsel
stating that (A) the Company has received from, or there has been
published by, the Internal Revenue Service a ruling or (B) since the
date of this Indenture, there has been a change in the applicable
federal income tax law, in either case to the effect that, and based
thereon such opinion shall confirm that, the holders of the Notes shall
not recognize income, gain or loss for federal income tax purposes as a
result of such deposit, defeasance and discharge and shall be subject
to federal income tax on the same amounts and in the same manner and at
the same times as would have been the case if such deposit, defeasance
and discharge had not occurred; and, in the case of a covenant
defeasance under paragraph (c) above, the Company shall deliver to the
Trustee an Officers' Certificate and an Opinion of Counsel, in form and
substance reasonably satisfactory to the Trustee, to the effect that
holders of the Notes shall not recognize income, gain or loss for
federal income tax purposes as a result of such deposit and defeasance
and shall be subject to federal income tax on the same amounts, in the
same manner and at the same times as would have been the case if such
deposit and defeasance had not occurred;
(v) The holders shall have a perfected security interest under
applicable law in the cash or U.S. Government Obligations deposited
pursuant to Section 12(d)(i) above;
(vi) The Company shall have delivered to the Trustee an
Opinion of Counsel, in form and substance reasonably satisfactory to
the Trustee, to the effect that, after the passage of 123 days
following the deposit, the trust funds shall not be subject to any
applicable bankruptcy, insolvency, reorganization or similar law
affecting creditors' rights generally;
(vii) such defeasance shall not cause the Trustee to have a
conflicting interest with respect to any securities of the Company; and
(viii) The Company has delivered to the Trustee an Officers'
Certificate and an Opinion of Counsel, each stating that all conditions
precedent specified herein relating
62
<PAGE> 69
to the defeasance contemplated by this Section 12.1 have been complied
with;
provided, that no deposit under clause (d)(i) above shall be effective to
terminate the obligations of the Company under the Notes or this Indenture prior
to the passage of 123 days following such deposit.
Section 12.2 Termination of Obligations upon Cancellation of
the Notes. In addition to the Company's rights under Section 12.1, the Company
may terminate all of its obligations under this Indenture (subject to Section
12.3) when:
(a) (i) all Notes theretofore authenticated and delivered
(other than Notes that have been destroyed, lost or stolen and that
have been replaced or paid as provided in Section 2.6) have been
delivered to the Trustee for cancellation; and
(ii) the Company has paid or caused to be paid all other sums
payable hereunder and under the Notes by the Company; or
(b) (i) the Notes not previously delivered to the Trustee for
cancellation shall have become due and payable or are by their terms to
become due and payable within one year or are to be called for
redemption under arrangements satisfactory to the Trustee upon delivery
of notice; (ii) the Company shall have irrevocably deposited with the
Trustee, as trust funds, cash, in an amount sufficient to pay principal
of and interest on the outstanding Notes, to maturity or redemption, as
the case may be; (iii) such deposit shall not result in a breach or
violation of, or constitute a default under, any agreement or
instrument pursuant to which the Company is a party or by which it or
its property is bound; and (iv) the Company has delivered to the
Trustee an Officers' Certificate and an Opinion of Counsel, each
stating that all conditions related to such defeasance have been
complied with.
Section 12.3 Survival of Certain Obligations. Notwithstanding
the satisfaction and discharge of this Indenture and of the Notes referred to in
Section 12.1 or 12.2, the respective obligations of the Company and the Trustee
under Sections 2.3, 2.4, 2.5, 2.6, 3.1, 4.2, 5.1, 6.4, 6.9, 7.6, 7.11, 12.5,
12.6, 12.7, Articles XIV and XV shall survive until the Notes are no longer
outstanding, and thereafter, the obligations of the Company and the Trustee
under Sections 6.9, 7.6, 12.5, 12.6 and 12.7 shall survive. Nothing contained in
this Article XII shall abrogate any of the rights, obligations or duties of the
Trustee under this Indenture.
63
<PAGE> 70
Section 12.4 Acknowledgment of Discharge by Trustee. Subject
to Section 12.7, after (i) the conditions of Section 12.1 or 12.2 have been
satisfied, (ii) the Company has paid or caused to be paid all other sums payable
hereunder by the Company and (iii) the Company has delivered to the Trustee an
Officers' Certificate and an Opinion of Counsel, each stating that all
conditions precedent referred to in clause (i) above relating to the
satisfaction and discharge of this Indenture have been complied with, the
Trustee upon written request shall acknowledge in writing the discharge of the
Company's obligations under this Indenture except for those surviving
obligations specified in Section 12.3.
Section 12.5 Application of Trust Assets. The Trustee shall
hold any cash or U.S. Government Obligations deposited with it in the
irrevocable trust established pursuant to Section 12.1 or 12.2, as the case may
be. The Trustee shall apply the deposited cash or the U.S. Government
Obligations, together with earnings thereon in accordance with this Indenture
and the terms of the irrevocable trust agreement established pursuant to Section
12.1 or 12.2, as the case may be, to the payment of principal of, premium, if
any, and interest on the Notes. The cash or U.S. Government Obligations so held
in trust and deposited with the Trustee in compliance with Section 12.1 or 12.2,
as the case may be, shall not be part of the trust estate under this Indenture,
but shall constitute a separate trust fund for the benefit of all holders
entitled thereto. Except as specifically provided herein, the Trustee shall not
be requested to invest any amounts held by it for the benefit of the holders or
pay interest on uninvested amounts to any holder.
The Company shall pay and indemnify the Trustee against any
tax, fee or other charge imposed on or assessed against the U.S. Government
Obligations deposited pursuant to Section 12.1 hereof or Section 12.2 hereof or
the principal and interest received in respect thereof other than any such tax,
fee or other charge which by law is for the account of the holders of
outstanding Notes.
Section 12.6 Repayment to the Company; Unclaimed Money.
Subject to applicable laws governing escheat of such property, and upon
termination of the trust established pursuant to Section 12.1 hereof or 12.2
hereof, as the case may be, the Trustee shall promptly pay to the Company upon
written request any excess cash or U.S. Government Obligations held by them.
Additionally, if amounts for the payment of principal, premium, if any, or
interest remains unclaimed for two years, the Trustee shall, upon written
request, pay such amounts back to the Company forthwith. Thereafter, all
liability of the Trustee with respect to such amounts shall cease. After payment
to the Company, holders entitled to such payment must look to the Company for
64
<PAGE> 71
such payment as general creditors unless an applicable abandoned property law
designates another person.
Section 12.7 Reinstatement. If the Trustee is unable to apply
any cash or U.S. Government Obligations in accordance with Section 12.1 or 12.2
by reason of any legal proceeding or by reason of any order or judgment of any
court or governmental authority enjoining, restraining or otherwise prohibiting
such application, the Company's obligations under this Indenture and the Notes
shall be revived and reinstated as though no deposit had occurred pursuant to
Section 12.1 or 12.2 until such time as the Trustee is permitted to apply all
such cash or U.S. Government Obligations in accordance with Section 12.1 or
12.2, as the case may be; provided that if the Company makes any payment of
principal of, premium, if any, or interest on any Notes following the
reinstatement of its obligations, the Company shall be subrogated to the rights
of the holders of such Notes to receive such payment from the amounts held by
the Trustee.
ARTICLE XIII
IMMUNITY OF INCORPORATORS, STOCKHOLDERS,
OFFICERS AND DIRECTORS
Section 13.1 Indenture and Notes Solely Corporate Obligations.
No recourse for the payment of the principal of, or premium, if any, or interest
on any Note, or for any claim based thereon or otherwise in respect thereof, and
no recourse under or upon any obligation, covenant or agreement of the Company
in this Indenture or in any supplemental indenture or in any Note, or because of
the creation of any indebtedness represented thereby, shall be had against any
incorporator, stockholder, officer or director, as such, past, present or
future, of the Company or of any successor entity, either directly or through
the Company or any successor entity, whether by virtue of any constitution,
statute or rule of law, or by the enforcement of any assessment or penalty or
otherwise; it being expressly understood that all such liability is hereby
expressly waived and released as a condition of, and as a consideration for, the
execution of this Indenture and the issue of the Notes.
ARTICLE XIV
CONVERSION OF NOTES
Section 14.1 Right to Convert. Subject to and upon compliance
with the provisions of this Indenture, the holder of any Note shall have the
right, at his option, at any time after 60 days following the latest date of
original issuance of the Notes and prior to the close of business on March 1,
2003 (except
65
<PAGE> 72
that, with respect to any Note or portion of a Note that shall be called for
redemption or delivered for repurchase, such right shall terminate, except as
provided in the fourth paragraph of Section 14.2, at the close of business on
the last Trading Day prior to the date fixed for redemption of such Note or
portion of a Note unless the Company shall default in payment due upon
redemption thereof) to convert the principal amount of any such Note, or any
portion of such principal amount that is $1,000 or an integral multiple thereof,
into that number of fully paid and nonassessable shares of Common Stock (as such
shares shall then be constituted) obtained by dividing the aggregate principal
amount of the Notes or portion thereof surrendered for conversion by the
Conversion Price in effect at such time rounded to three digits, by surrender of
the Note so to be converted in whole or in part in the manner provided in
Section 14.2. A holder of Notes is not entitled to any rights of a holder of
Common Stock until such holder has converted his Notes to Common Stock and only
to the extent such Notes are deemed to have been converted to Common Stock under
this Article XIV.
Section 14.2 Exercise of Conversion Privilege; Issuance of
Common Stock on Conversion; No Adjustment for Interest or Dividends. In order to
exercise the conversion privilege with respect to any Note in definitive form,
the holder of any such Note to be converted in whole or in part shall surrender
such Note, duly endorsed, at an office or agency maintained by the Company
pursuant to Section 4.2, accompanied by the funds, if any, required by the
penultimate paragraph of this Section 14.2, and shall give written notice of
conversion in the form provided on the form of Note (or such other notice that
is acceptable to the Company) to the office or agency that the holder elects to
convert such Note or the portion thereof specified in said notice. Such notice
shall also state the name or names (with address) in which the certificate or
certificates for shares of Common Stock that shall be issuable on such
conversion shall be issued and shall be accompanied by transfer taxes, if
required pursuant to Section 14.7. Each such Note surrendered for conversion
shall, unless the shares issuable on conversion are to be issued in the name of
the holder of such Note as it appears on the Note register, be duly endorsed by,
or be accompanied by instruments of transfer in form satisfactory to the Company
duly executed by, the holder or his duly authorized attorney.
In order to exercise the conversion privilege with respect to
any interest in a global Note, the beneficial holder must complete the
appropriate instruction form for conversion pursuant to the Depositary's
book-entry conversion program and follow the other procedures set forth in such
program.
As promptly as practicable after satisfaction of the
requirements for conversion set forth above, subject to compliance with any
restrictions on transfer if shares issuable on
66
<PAGE> 73
conversion are to be issued in a name other than that of the Noteholder (as if
such transfer were a transfer of the Note or Notes (or portion thereof) so
converted), the Company shall issue and shall deliver to such holder at the
office or agency maintained by the Company for such purpose pursuant to Section
4.2, a certificate or certificates for the number of full shares issuable upon
the conversion of such Note or portion thereof in accordance with the provisions
of this Article XIV and a check or cash in respect of any fractional interest in
respect of a share of Common Stock arising upon such conversion, as provided in
Section 14.3. In case any Note of a denomination greater than $1,000 shall be
surrendered for partial conversion, and subject to Section 2.3, the Company
shall execute and the Trustee shall authenticate and make available for delivery
to the holder of the Note so surrendered, without charge to him, a new Note or
Notes in authorized denominations in an aggregate principal amount equal to the
unconverted portion of the surrendered Note.
Each conversion shall be deemed to have been effected as to
any such Note (or portion thereof) on the date on which the requirements set
forth above in this Section 14.2 have been satisfied as to such Note (or portion
thereof), and the person in whose name any certificate or certificates for
shares of Common Stock shall be issuable upon such conversion shall be deemed to
have become on said date the holder of record of the shares represented thereby;
provided that any such surrender on any date when the stock transfer books of
the Company shall be closed shall constitute the person in whose name the
certificates are to be issued as the record holder thereof for all purposes on
the next succeeding day on which such stock transfer books are open, but such
conversion shall be at the Conversion Price in effect on the date upon which
such Note shall have been surrendered.
Any Note or portion thereof surrendered for conversion during
the period from the close of business on the record date for any interest
payment date through the close of business on the next succeeding interest
payment date shall (unless such Note or portion thereof being converted shall
have been called for redemption on a date in such period) be accompanied by
payment, in funds acceptable to the Company, of an amount equal to the interest
otherwise payable on such interest payment date on the principal amount being
converted; provided, however, that no such payment need be made if there shall
exist at the time of conversion a default in the payment of interest on the
Notes. An amount equal to such payment shall be paid by the Company on such
interest payment date to the holder of such Note at the close of business on
such record date; provided that if the Company shall default in the payment of
interest on such interest payment date, such amount shall be paid to the person
who made such required payment. The interest payment with respect to a Note
called for redemption on a date during the period from the close of business on
or after any record date to the opening of business on the
67
<PAGE> 74
business day following the corresponding payment date will be payable on the
corresponding interest payment date to the registered Holder at the close of
business on that record date (notwithstanding the conversion of such Note before
the corresponding interest payment date) and a Holder who elects to convert need
not include funds equal to the interest paid. Except as provided above in this
Section 14.2, no adjustment shall be made for interest accrued on any Note
converted or for dividends on any shares issued upon the conversion of such Note
as provided in this Article XIV.
Upon the conversion of an interest in a global Note, the
Trustee, or the Custodian at the direction of the Trustee, shall make a notation
on such global Note as to the reduction in the principal amount represented
thereby.
Section 14.3 Cash Payments in Lieu of Fractional Shares. No
fractional shares of Common Stock or scrip representing fractional shares shall
be issued upon conversion of Notes. If more than one Note shall be surrendered
for conversion at one time by the same holder, the number of full shares that
shall be issuable upon conversion shall be computed on the basis of the
aggregate principal amount of the Notes (or specified portions thereof to the
extent permitted hereby) so surrendered. If any fractional share of stock would
be issuable upon the conversion of any Note or Notes, the Company shall make an
adjustment therefor in cash at the current market value thereof. The current
market value of a share of Common Stock shall be the Closing Price on the first
Trading Day immediately preceding the day on which the Notes (or specified
portions thereof) are deemed to have been converted and such Closing Price shall
be determined as provided in Section 14.5(g).
Section 14.4 Conversion Price. The Conversion Price shall be
as specified in the forms of Notes (herein called the "Conversion Price")
attached as Exhibits A, B and C hereto, subject to adjustment as provided in
this Article XIV.
Section 14.5 Adjustment of Conversion Price. The Conversion
Price shall be adjusted from time to time by the Company as follows:
(a) In case the Company shall hereafter pay a dividend or make
a distribution to all holders of the outstanding Common Stock in shares
of Common Stock, the Conversion Price in effect at the opening of
business on the date following the date fixed for the determination of
stockholders entitled to receive such dividend or other distribution
shall be reduced by multiplying such Conversion Price by a fraction the
numerator of which shall be the number of shares of Common Stock
outstanding at the close of business on the Record Date (as defined in
Section 14.5(g)) fixed for such
68
<PAGE> 75
determination and the denominator of which shall be the sum of such
number of shares and the total number of shares constituting such
dividend or other distribution, such reduction to become effective
immediately after the opening of business on the day following the
Record Date. The Company shall not pay any dividend or make any
distribution on shares of Common Stock held in the treasury of the
Company nor shall any shares be deemed outstanding.
(b) In case the Company shall issue rights or warrants to all
holders of its outstanding shares of Common Stock entitling them (for a
period expiring within 45 days after the date fixed for determination
of stockholders entitled to receive such rights or warrants) to
subscribe for or purchase shares of Common Stock at a price per share
less than the Current Market Price (as defined in Section 14.5(g)) on
the Record Date fixed for determination of stockholders entitled to
receive such rights or warrants, the Conversion Price shall be adjusted
so that the same shall equal the price determined by multiplying the
Conversion Price in effect at the opening of business on the date after
the Record Date by a fraction the numerator of which shall be the
number of shares of Common Stock outstanding at the close of business
on the Record Date plus the number of shares that the aggregate
offering price of the total number of shares so offered would purchase
at such Current Market Price, and the denominator of which shall be the
number of shares of Common Stock outstanding on the close of business
on the Record Date plus the total number of additional shares of Common
Stock so offered for subscription or purchase. Such adjustment shall
become effective immediately after the opening of business on the day
following the Record Date fixed for determination of stockholders
entitled to receive such rights or warrants. To the extent that shares
of Common Stock are not delivered after the expiration or termination
of such rights or warrants, the Conversion Price shall be readjusted to
the Conversion Price that would then be in effect had the adjustments
made upon the issuance of such rights or warrants been made on the
basis of delivery of only the number of shares of Common Stock actually
delivered. In the event that such rights or warrants are not so issued,
the Conversion Price shall again be adjusted to be the Conversion Price
that would then be in effect if such date fixed for the determination
of stockholders entitled to receive such rights or warrants had not
been fixed. In determining whether any rights or warrants entitle the
holders to subscribe for or purchase shares of Common Stock at less
than such Current Market Price, and in determining the aggregate
offering price of such shares of Common Stock, there shall be taken
into account any consideration received for such rights or warrants,
the value of
69
<PAGE> 76
such consideration, if other than cash, to be determined by the Board
of Directors.
(c) In case outstanding shares of Common Stock shall be
subdivided into a greater number of shares of Common Stock, the
Conversion Price in effect at the opening of business on the day
following the day upon which such subdivision becomes effective shall
be proportionately reduced, and conversely, in case outstanding shares
of Common Stock shall be combined into a smaller number of shares of
Common Stock, the Conversion Price in effect at the opening of business
on the day following the day upon which such combination becomes
effective shall be proportionately increased, such reduction or
increase, as the case may be, to become effective immediately after the
opening of business on the day following the day upon which such
subdivision or combination becomes effective.
(d) In case the Company shall, by dividend or otherwise,
distribute to all holders of its Common Stock shares of any class of
capital stock of the Company (other than any dividends or distributions
to which Section 14.5(a) applies) or evidences of its indebtedness or
assets (including securities, but excluding any rights or warrants
referred to in Section 14.5(b), and excluding any dividend or
distribution (x) in connection with the liquidation, dissolution or
winding-up of the Company, whether voluntary or involuntary, (y)
exclusively in cash or (z) referred to in Section 14.5(a) (any of the
foregoing hereinafter in this Section 14.5(d) called the
"Securities")), then, in each such case, the Conversion Price shall be
reduced so that the same shall be equal to the price determined by
multiplying the Conversion Price in effect immediately prior to the
close of business on the Record Date (as defined in Section 14.5(g))
with respect to such distribution by a fraction of which the numerator
shall be the Current Market Price (determined as provided in Section
14.5(g)) on such date less the fair market value (as determined by the
Board of Directors, whose determination shall be conclusive and
described in a Board Resolution) on such date of the portion of the
Securities so distributed applicable to one share of Common Stock and
the denominator shall be such Current Market Price, such reduction to
become effective immediately prior to the opening of business on the
day following the Record Date; provided, however, that in the event the
then fair market value (as so determined) of the portion of the
Securities so distributed applicable to one share of Common Stock is
equal to or greater than the Current Market Price on the Record Date,
in lieu of the foregoing adjustment, adequate provision shall be made
so that each Noteholder shall have the right to receive upon conversion
the amount of Securities such holder would have received had such
holder converted each Note on
70
<PAGE> 77
such date. In the event that such dividend or distribution is not so
paid or made, the Conversion Price shall again be adjusted to be the
Conversion Price that would then be in effect if such dividend or
distribution had not been declared. If the Board of Directors
determines the fair market value of any distribution for purposes of
this Section 14.5(d) by reference to the actual or when issued trading
market for any securities comprising all or part of such distribution,
it must in doing so consider the prices in such market over the same
period used in computing the Current Market Price pursuant to Section
14.5(g) to the extent possible.
Notwithstanding the foregoing provisions of this Section
14.5(d), no adjustment shall be made hereunder for any distribution of
Securities if the Company makes proper provision so that each
Noteholder who converts such Note (or any portion thereof) after the
date fixed for determination of stockholders entitled to receive such
distribution shall be entitled to receive upon such conversion, in
addition to the shares of Common Stock issuable upon such conversion,
the amount and kind of Securities that such holder would have been
entitled to receive if such holder had, immediately prior to such
determination date, converted such Note into Common Stock; provided
that, with respect to any Securities that are convertible, exchangeable
or exercisable, the foregoing provision shall only apply to the extent
(and so long as) the Securities receivable upon conversion of such Note
would be convertible, exchangeable or exercisable, as applicable,
without any loss of rights or privileges for a period of at least 60
days following conversion of such Note.
Rights or warrants distributed by the Company to all holders
of Common Stock entitling the holders thereof to subscribe for or
purchase shares of the Company's capital stock (either initially or
under certain circumstances), which rights or warrants, until the
occurrence of a specified event or events (the "Trigger Event") (i) are
deemed to be transferred with such shares of Common Stock, (ii) are not
exercisable and (iii) are also issued in respect of future issuances of
Common Stock, shall not be deemed distributed for purposes of this
Section 14.5(d) (and no adjustment to the Conversion Price under
Section 14.5(d) shall be required) until the occurrence of the earliest
Trigger Event. In addition, in the event of any distribution of rights
or warrants, or any Trigger Event with respect thereto, that shall have
resulted in an adjustment to the Conversion Price under this Section
14.5(d), (1) in the case of any such rights or warrants that shall all
have been redeemed or repurchased without exercise by any holders
thereof, the Conversion Price shall be readjusted upon such final
71
<PAGE> 78
redemption or repurchase to give effect to such distribution or Trigger
Event, as the case may be, as though it were a cash distribution, equal
to the per share redemption or repurchase price received by a holder of
Common Stock with respect to such rights or warrants (assuming such
holder had retained such rights or warrants), made to all holders of
Common Stock as of the date of such redemption or repurchase, and (2)
in the case of such rights or warrants all of which shall have expired
or been terminated without exercise by any holder thereof, the
Conversion Price shall be readjusted as if such issuance had not
occurred.
For purposes of this Section 14.5(d) and Sections 14.5(a) and
(b), any dividend or distribution to which this Section 14.5(d) is
applicable that also includes shares of Common Stock, or rights or
warrants to subscribe for or purchase shares of Common Stock (or both),
shall be deemed instead to be (1) a dividend or distribution of the
evidences of indebtedness, assets or shares of capital stock other than
such shares of Common Stock or rights or warrants (and any Conversion
Price reduction required by this Section 14.5(d) with respect to such
dividend or distribution shall then be made) immediately followed by
(2) a dividend or distribution of such shares of Common Stock or such
rights or warrants (and any further Conversion Price reduction required
by Sections 14.5(a) and (b) with respect to such dividend or
distribution shall then be made, except (A) the Record Date of such
dividend or distribution shall be substituted as "the date fixed for
the determination of stockholders entitled to receive such dividend or
other distribution" and "the date fixed for such determination" within
the meaning of Sections 14.5(a) and (b) and (B) any shares of Common
Stock included in such dividend or distribution shall not be deemed
"outstanding at the close of business on the date fixed for such
determination" within the meaning of Section 14.5(a).
(e) In case the Company shall, by dividend or otherwise,
distribute to all holders of its Common Stock cash (excluding any cash
that is distributed upon a merger or consolidation to which Section
14.6 applies or as part of a distribution referred to in Section
14.5(d) for which an adjustment to the Conversion Price is provided
therein) in an aggregate amount that, combined together with (1) the
aggregate amount of any other such distributions to all holders of its
Common Stock made exclusively in cash within the 12 months preceding
the date of payment of such distribution, and in respect of which no
adjustment pursuant to this Section 14.5(e) has been made, and (2) the
aggregate of any cash plus the fair market value (as determined by the
Board of Directors, whose determination shall be conclusive and
described in a Board Resolution) of consideration pay-
72
<PAGE> 79
able in respect of any tender offer, by the Company or any of its
subsidiaries for all or any portion of the Common Stock concluded
within the 12 months preceding the date of payment of such
distribution, and in respect of which no adjustment pursuant to Section
14.5(f) has been made, exceeds 20.0% of the product of the Current
Market Price (determined as provided in Section 14.5(g)) on the Record
Date with respect to such distribution times the number of shares of
Common Stock outstanding on such date, then, and in each such case,
immediately after the close of business on such date, unless the
Company elects to reserve such cash for distribution to the holders of
the Notes upon the conversion of the Notes so that any such holder
converting Notes shall receive upon such conversion, in addition to the
shares of Common Stock to that such holder is entitled, the amount of
cash which such holder would have received if such holder had,
immediately prior to the Record Date for such distribution of cash,
converted its Notes into Common Stock, the Conversion Price shall be
reduced so that the same shall equal the price determined by
multiplying the Conversion Price in effect immediately prior to the
close of business on such date by a fraction (i) the numerator of which
shall be equal to the Current Market Price on the Record Date less an
amount equal to the quotient of (x) the excess of such combined amount
over such 20.0% and (y) the number of shares of Common Stock
outstanding on the Record Date and (ii) the denominator of which shall
be equal to the Current Market Price on such date; provided, however,
that in the event the portion of the cash so distributed applicable to
one share of Common Stock is equal to or greater than the Current
Market Price of the Common Stock on the Record Date, in lieu of the
foregoing adjustment, adequate provision shall be made so that each
Noteholder shall have the right to receive upon conversion the amount
of cash such holder would have received had such holder converted each
Note on the Record Date. In the event that such dividend or
distribution is not so paid or made, the Conversion Price shall again
be adjusted to be the Conversion Price that would then be in effect if
such dividend or distribution had not been declared.
(f) In case a tender offer made by the Company or any of its
subsidiaries for all or any portion of the Common Stock shall expire
and such tender offer (as amended upon the expiration thereof) shall
require the payment to stockholders (based on the acceptance (up to any
maximum specified in the terms of the tender offer) of Purchased Shares
(as defined below)) of an aggregate consideration having a fair market
value (as determined by the Board of Directors, whose determination
shall be conclusive and described in a Board Resolution) that combined
together with (1) the aggregate of the cash plus the fair market value
(as determined
73
<PAGE> 80
by the Board of Directors, whose determination shall be conclusive and
described in a Board Resolution), as of the expiration of such tender
offer, of consideration payable in respect of any other tender offer,
by the Company or any of its subsidiaries for all or any portion of the
Common Stock expiring within the 12 months preceding the expiration of
such tender offer, and in respect of which no adjustment pursuant to
this paragraph (f) has been made, and (2) the aggregate amount of any
distributions to all holders of the Company's Common Stock made
exclusively in cash within 12 months preceding the expiration of such
tender offer, and in respect of which no adjustment pursuant to
paragraph (e) of this Section has been made, exceeds 20.0% of the
product of the Current Market Price (determined as provided in
paragraph (g) of this Section) as of the last time (the "Expiration
Time") tenders could have been made pursuant to such tender offer (as
it may be amended) times the number of shares of Common Stock
outstanding (including any tendered shares) on the Expiration Time,
then, and in each such case, immediately prior to the opening of
business on the day after the date of the Expiration Time, the
Conversion Price shall be adjusted so that the same shall equal the
price determined by multiplying the Conversion Price in effect
immediately prior to close of business on the date of the Expiration
Time by a fraction of which the numerator shall be the number of shares
of Common Stock outstanding (including any tendered shares) on the
Expiration Time multiplied by the Current Market Price of the Common
Stock on the Trading Day next succeeding the Expiration Time and the
denominator shall be the sum of (x) the fair market value (determined
as aforesaid) of the aggregate consideration payable to stockholders
based on the acceptance (up to any maximum specified in the terms of
the tender offer) of all shares validly tendered and not withdrawn as
of the Expiration Time (the shares deemed so accepted, up to any such
maximum, being referred to as the "Purchased Shares") and (y) the
product of the number of shares of Common Stock outstanding (less any
Purchased Shares) on the Expiration Time and the Current Market Price
of the Common Stock on the Trading Day next succeeding the Expiration
Time, such reduction to become effective immediately prior to the
opening of business on the day following the Expiration Time. In the
event that the Company is obligated to purchase shares pursuant to any
such tender offer, but the Company is permanently prevented by
applicable law from effecting any such purchases or all such purchases
are rescinded, the Conversion Price shall again be adjusted to be the
Conversion Price that would then be in effect if such tender offer had
not been made.
(g) For purposes of this Section 14.5, the following terms
shall have the meaning indicated:
74
<PAGE> 81
(1) "Closing Price" with respect to any securities on
any day shall mean the closing sale price regular way on such
day or, in case no such sale takes place on such day, the
average of the reported closing bid and asked prices, regular
way, in each case on the New York Stock Exchange, or, if such
security is not listed or admitted to trading on such
Exchange, on the principal national security exchange or
quotation system on which such security is quoted or listed or
admitted to trading, or, if not quoted or listed or admitted
to trading on any national securities exchange or quotation
system, the average of the closing bid and asked prices of
such security on the over-the-counter market on the day in
question as reported by the National Quotation Bureau
Incorporated, or a similar generally accepted reporting
service, or if not so available, in such manner as furnished
by any New York Stock Exchange member firm selected from time
to time by the Board of Directors for that purpose, or a price
determined in good faith by the Board of Directors, whose
determination shall be conclusive and described in a Board
Resolution.
(2) "Current Market Price" shall mean the average of
the daily Closing Prices per share of Common Stock for the ten
consecutive Trading Days immediately prior to the date in
question; provided that (1) if the "ex" date (as hereinafter
defined) for any event (other than the issuance or
distribution or Change of Control requiring such computation)
that requires an adjustment to the Conversion Price pursuant
to Section 14.5(a), (b), (c), (d), (e) or (f) occurs during
such ten consecutive Trading Days, the Closing Price for each
Trading Day prior to the "ex" date for such other event shall
be adjusted by multiplying such Closing Price by the same
fraction by which the Conversion Price is so required to be
adjusted as.a result of such other event, (2) if the "ex" date
for any event (other than the issuance, distribution or Change
of Control requiring such computation) that requires an
adjustment to the Conversion Price pursuant to Section
14.5(a), (b), (c), (d), (e) or (f) occurs on or after the "ex"
date for the issuance or distribution requiring such
computation and prior to the day in question, the Closing
Price for each Trading Day on and after the "ex" date for such
other event shall be adjusted by multiplying such Closing
Price by the reciprocal of the fraction by which the
Conversion Price is so required to be adjusted as a result of
such other event and (3) if the "ex" date for the issuance,
distribution or Change of Control requiring such computation
is prior to the day in question, after taking into account any
adjustment re-
75
<PAGE> 82
quired pursuant to clause (1) or (2) of this proviso, the
Closing Price for each Trading Day on or after such "ex" date
shall be adjusted by adding thereto the amount of any cash and
the fair market value (as determined by the Board of Directors
in a manner consistent with any determination of such value
for purposes of Section 14.5(d) or (f), whose determination
shall be conclusive and described in a Board Resolution) of
the evidences of indebtedness, shares of capital stock or
assets being distributed applicable to one share of Common
Stock as of the close of business on the day before such "ex"
date. For purposes of any computation under Section 14.5(f),
the Current Market Price of the Common Stock on any date shall
be deemed to be the average of the daily Closing Prices per
share of Common Stock for such day and the next two succeeding
Trading Days; provided, however, that if the "ex" date for any
event (other than the tender or exchange offer requiring such
computation) that requires an adjustment to the Conversion
Price pursuant to Section 14.5(a), (b), (c), (d), (e) or (f)
occurs on or after the Expiration Time for the tender or
exchange offer requiring such computation and prior to the day
in question, the Closing Price for each Trading Day on and
after the "ex" date for such other event shall be adjusted by
multiplying such Closing Price by the reciprocal of the
fraction by which the Conversion Price is so required to be
adjusted as a result of such other event. For purposes of this
paragraph, the term "ex" date, (1) when used with respect to
any issuance or distribution, means the first date on which
the Common Stock trades regular way on the relevant exchange
or in the relevant market from which the Closing Price was
obtained without the right to receive such issuance or
distribution, (2) when used with respect to any subdivision or
combination of shares of Common Stock, means the first date on
which the Common Stock trades regular way on such exchange or
in such market after the time at which such subdivision or
combination becomes effective and (3) when used with respect
to any tender or exchange offer means the first date on which
the Common Stock trades regular way on such exchange or in
such market after the expiration of such offer.
Notwithstanding the foregoing, whenever successive adjustments
to the Conversion Price are called for pursuant to this
Section 14.5, such adjustments shall be made to the Current
Market Price as may be necessary or appropriate to effectuate
the intent of this Section 14.5 and to avoid unjust or
inequitable results as determined in good faith by the Board
of Directors.
76
<PAGE> 83
(3) "fair market value" shall mean the amount that a
willing buyer would pay a willing seller in an arm's-length
transaction.
(4) "Record Date" shall mean, with respect to any
dividend, distribution or other transaction or event in which
the holders of Common Stock have the right to receive any
cash, securities or other property or in which the Common
Stock (or other applicable security) is exchanged for or
converted into any combination of cash, securities or other
property, the date fixed for determination of stockholders
entitled to receive such cash, securities or other property
(whether such date is fixed by the Board of Directors or by
statute, contract or otherwise).
(5) "Trading Day" shall mean (x) if the applicable
security is listed or admitted for trading on the New York
Stock Exchange or another national security exchange, a day on
which the New York Stock Exchange or that other national
security exchange is open for business or (y) if the
applicable security is quoted on the Nasdaq National Market, a
day on which trades may be made thereon or (z) if the
applicable security is not so listed, admitted for trading or
quoted, any day other than a Saturday or Sunday or a day on
which banking institutions in the State of New York are
authorized or obligated by law or executive order to close.
(h) The Company may make such reductions in the Conversion
Price, in addition to those required by Sections 14.5(a), (b), (c),
(d), (e) and (f), as the Board of Directors considers to be advisable
to avoid or diminish any income tax to holders of Common Stock or
rights to purchase Common Stock resulting from any dividend or
distribution of stock (or rights to acquire stock) or from any event
treated as such for income tax purposes. To the extent permitted by
applicable law, the Company from time to time may reduce the Conversion
Price by any amount for any period of time if the period is at least 20
days, the reduction is irrevocable during the period and the Board of
Directors shall have made a determination that such reduction would be
in the best interests of the Company, which determination shall be
conclusive and described in a Board Resolution. Whenever the Conversion
Price is reduced pursuant to the preceding sentence, the Company shall
mail to all holders of record of the Notes a notice of the reduction at
least 15 days prior to the date the reduced Conversion Price takes
effect, and such notice shall state the reduced Conversion Price and
the period it shall be in effect.
77
<PAGE> 84
(i) No adjustment in the Conversion Price shall be required
unless such adjustment would require an increase or decrease of at
least 1% in such price; provided, that any adjustments that by reason
of this Section 14.5(i) are not required to be made shall be carried
forward and taken into account in any subsequent adjustment. All
calculations under this Article XIV shall be made by the Company and
shall be made to the nearest cent or to the nearest one-hundredth of a
share, as the case may be.
No adjustment need be made for rights to purchase Common Stock
pursuant to a Company plan for reinvestment of dividends or interest.
No adjustment need be made for a change in the par value, or
to or from no par value, of the Common Stock.
To the extent the Notes become convertible into cash, assets,
property or securities (other than Common Stock of the Company), no
adjustment need be made thereafter as to the cash, assets, property or
such securities (except as such securities may otherwise by their terms
provide), and interest shall not accrue on such cash.
(j) Whenever the Conversion Price is adjusted as herein
provided, the Company shall promptly file with the Trustee and any
conversion agent other than the Trustee an Officers' Certificate
setting forth the Conversion Price after such adjustment and setting
forth a brief statement of the facts requiring such adjustment.
Promptly after delivery of such certificate, the Company shall prepare
a notice of such adjustment of the Conversion Price setting forth the
adjusted Conversion Price and the date on which each adjustment becomes
effective and shall mail such notice of such adjustment of the
Conversion Price to the holder of each Note at his last address
appearing on the Note register provided for in Section 2.5, within 20
days after execution thereof. Failure to deliver such notice shall not
effect the legality or validity of any such supplemental indenture.
(k) In any case in which this Section 14.5 provides that an
adjustment shall become effective immediately after a Record Date for
an event, the Company may defer until the occurrence of such event (i)
issuing to the holder of any Note converted after such Record Date and
before the occurrence of such event the additional shares of Common
Stock issuable upon such conversion by reason of the adjustment
required by such event over and above the Common Stock issuable upon
such conversion before giving effect to such adjustment and (ii) paying
to such holder any amount in cash in lieu of any fraction pursuant to
Section 14.3.
78
<PAGE> 85
Section 14.6 Effect of Reclassification, Consolidation, Merger
or Sale. If any of the following events occur, namely (i) any reclassification
or change of outstanding shares of Common Stock (other than a change in par
value, or to or from no par value, as a result of a subdivision or combination),
(ii) any consolidation, merger or combination of the Company with another
corporation as a result of which holders of Common Stock shall be entitled to
receive stock, securities or other property or assets (including cash) with
respect to or in exchange for such Common Stock or (iii) any sale or conveyance
of the properties and assets of the Company as, or substantially as, an entirety
to any other corporation as a result of which holders of Common Stock shall be
entitled to receive stock, securities or other property or assets (including
cash) with respect to or in exchange for such Common Stock, then the Company or
the successor or purchasing corporation, as the case may be, shall execute with
the Trustee a supplemental indenture (which shall comply with the Trust
Indenture Act as in force at the date of execution of such supplemental
indenture if such supplemental indenture is then required to so comply)
providing that such Note shall be convertible into the kind and amount of shares
of stock and other securities or property or assets (including cash) receivable
upon such reclassification, change, consolidation, merger, combination, sale or
conveyance by a holder of a number of shares of Common Stock issuable upon
conversion of such Notes (assuming, for such purposes, a sufficient number of
authorized shares of Common Stock available to convert all such Notes)
immediately prior to such reclassification, change, consolidation, merger,
combination, sale or conveyance, assuming such holder of Common Stock did not
exercise his rights of election, if any, as to the kind or amount of securities,
cash or other property receivable upon such reclassification, change,
consolidation, merger, combination, sale or conveyance (provided that, if the
kind or amount of securities, cash or other property receivable upon such
reclassification, change, consolidation, merger, combination, sale or conveyance
is not the same for each share of Common Stock in respect of which such rights
of election shall not have been exercised ("non-electing share"), then for the
purposes of this Section 14.6 the kind and amount of securities, cash or other
property receivable upon such reclassification, change, consolidation, merger,
combination, sale or conveyance for each non-electing share shall be deemed to
be the kind and amount so receivable per share by a plurality of the
non-electing shares). Such supplemental indenture shall provide for adjustments
that shall be as nearly equivalent as may be practicable to the adjustments
provided for in this Article XIV.
The Company shall cause notice of the execution of such
supplemental indenture to be mailed to each holder of Notes, at his address
appearing on the Note register provided for in Section 2.5, within 20 days after
execution thereof. Failure to
79
<PAGE> 86
deliver such notice shall not affect the legality or validity of such
supplemental indenture.
The above provisions of this Section 14.6 shall similarly
apply to successive reclassifications, changes, consolidations, mergers,
combinations, sales and conveyances.
If this Section 14.6 applies to any event or occurrence,
Section 14.5 shall not apply.
Section 14.7 Taxes on Shares Issued. The issue of stock
certificates on conversions of Notes shall be made without charge to the
converting Noteholder for any transfer or similar tax in respect of the issue
thereof. The Company shall not, however, be required to pay any tax that may be
payable in respect of any transfer involved in the issue and delivery of stock
in any name other than that of the holder of any Note converted, and the Company
shall not be required to issue or deliver any such stock certificate unless and
until the person or persons requesting the issue thereof shall have paid to the
Company the amount of such tax or shall have established to the satisfaction of
the Company that such tax has been paid.
Section 14.8 Reservation of Shares; Shares to Be Fully Paid;
Listing of Common Stock. The Company shall provide, free from preemptive rights,
out of its authorized but unissued shares or shares held in treasury, sufficient
shares to provide for the conversion of the Notes from time to time as such
Notes are presented for conversion.
Before taking any action that would cause an adjustment
reducing the Conversion Price below the then par value, if any, of the shares of
Common Stock issuable upon conversion of the Notes, the Company shall take all
corporate action that may, in the opinion of its counsel, be necessary in order
that the Company may validly and legally issue shares of such Common Stock at
such adjusted Conversion Price.
The Company covenants that all shares of Common Stock that may
be issued upon conversion of Notes shall, upon issue, be fully paid and
nonassessable by the Company and free from all taxes, liens and charges with
respect to the issue thereof.
The Company further covenants that it shall, if permitted by
the rules of the New York Stock Exchange, list and keep listed, so long as the
Common Stock shall be so listed on such exchange, all Common Stock issuable upon
conversion of the Notes.
Section 14.9 Responsibility of Trustee. The Trustee and any
other conversion agent shall not at any time be under any duty or responsibility
to any holder of Notes to determine whether any facts exist that may require any
adjustment of the
80
<PAGE> 87
Conversion Price, or with respect to the nature or extent or calculation of any
such adjustment when made, or with respect to the method employed, or herein or
in any supplemental indenture provided to be employed, in making the same. The
Trustee and any other conversion agent shall not be accountable with respect to
the validity or value (or the kind or amount) of any shares of Common Stock, or
of any securities or property, that may at any time be issued or delivered upon
the conversion of any Note; and the Trustee and any other conversion agent make
no representations with respect thereto. Subject to the provisions of Section
7.1, neither the Trustee nor any conversion agent shall be responsible for any
failure of the Company to issue, transfer or deliver any shares of Common Stock
or stock certificates or other securities or property or cash upon the surrender
of any debenture for the purpose of conversion or to comply with any of the
duties, responsibilities or covenants of the Company contained in this Article
XIV. Without limiting the generality of the foregoing, neither the Trustee nor
any conversion agent shall be under any responsibility to determine whether a
supplemental indenture under Section 14.6 hereof need to be entered into or the
correctness of any provisions contained in any supplemental indenture entered
into pursuant to Section 14.6 relating either to the kind or amount of shares of
stock or securities or property (including cash) receivable by Noteholders upon
the conversion of their Notes after any event referred to in such Section 14.6
or to any adjustment to be made with respect thereto, but, subject to the
provisions of Section 7.1, may accept as conclusive evidence of the correctness
of any such provisions, and shall be protected in relying upon, the Officers'
Certificate (which the Company shall be obligated to file with the Trustee prior
to the execution of any such supplemental indenture) with respect thereto.
Section 14.10 Notice to Holders Prior to Certain Actions. In
case:
(a) the Company makes any distribution or dividend that would
require an adjustment in the Conversion Price pursuant to Section 14.5;
or
(b) the Company takes any action that would require a
supplemental indenture pursuant to Section 14.6; or
(c) of the voluntary or involuntary dissolution, liquidation
or winding-up of the Company,
the Company shall cause to be filed with the Trustee and to be mailed to each
holder of Notes at his address appearing on the Note register, as promptly as
possible but in any event at least 15 days prior to the applicable date
hereinafter specified, a notice stating (x) the date on which a record date is
to be taken for the purpose of such dividend, distribution, rights or warrants,
or, if a record is not to be taken, the date as of which
81
<PAGE> 88
the holders of Common Stock of record to be entitled to such dividend,
distribution, rights or warrants are to be determined or (y) the date on which
such reclassification, change, consolidation, merger, sale, conveyance,
transfer, dissolution, liquidation or winding-up is expected to become effective
or occur and the date as of which it is expected that holders of record of
Common Stock shall be entitled to exchange their Common Stock for securities or
other property deliverable upon such reclassification, change, consolidation,
merger, sale, conveyance, transfer, dissolution, liquidation or winding-up.
Failure to give such notice, or any defect therein, shall not affect the
legality or validity of such dividend, distribution, reclassification, change,
consolidation, merger, sale, conveyance, transfer, dissolution, liquidation or
winding-up. Neither the failure to give such notice nor any defect therein shall
affect the legality or validity of the proceedings referenced in clauses (a)
through (c) of this Section 14.10.
ARTICLE XV
SUBORDINATION
Section 15.1 Agreement to Subordinate. The Company agrees, and
each Noteholder by accepting a Note agrees, that the indebtedness evidenced by
the Note is subordinated in right of payment, to the extent and in the manner
provided in this Article XV, to the prior payment in full of all Senior
Indebtedness and that the subordination is for the benefit of the holders of
Senior Indebtedness.
Section 15.2 Certain Definitions. For purposes of this Article
XV, the following terms shall have the meaning indicated:
(1) "Representative" shall mean the indenture trustee or other
trustee, agent or representative for any Senior Indebtedness.
(2) "Senior Indebtedness" with respect to the Notes means the
principal of, premium, if any, and interest on, and any fees, costs,
expenses and any other amounts (including indemnity payments) related
to the following, whether outstanding on the date hereof or hereafter
incurred or created: (a) indebtedness, matured or unmatured, whether or
not contingent, of the Company for money borrowed evidenced by notes or
other written obligations, (b) any interest rate contract, interest
rate swap agreement or other similar agreement or arrangement designed
to protect the Company or any of its subsidiaries against fluctuations
in interest rates, (c) indebtedness, matured or unmatured, whether or
not contingent, of the Company evidenced by notes, deben-
82
<PAGE> 89
tures, bonds or similar instruments or letters of credit (or
reimbursement agreements in respect thereof), (d) obligations of the
Company as lessee under capitalized leases and under leases of property
made as part of any sale and lease-back transactions, (e) indebtedness
of others of any of the kinds described in the preceding clauses (a)
through (d) assumed or guaranteed by the Company and (f) renewals,
extensions, modifications, amendments, and refundings of, and
indebtedness and obligations of a successor person issued in exchange
for or in replacement of, indebtedness or obligations of the kinds
described in the preceding clauses (a) through (f), unless the
agreement pursuant to which any such indebtedness described in clauses
(a) through (f) is created, issued, assumed or guaranteed expressly
provides that such indebtedness is not senior or superior in right of
payment to the Notes; provided, however, that the following shall not
constitute Senior Indebtedness: (i) any indebtedness or obligation of
the Company in respect of the Notes, (ii) any indebtedness of the
Company to any of its subsidiaries or other Affiliates; (iii) any
indebtedness that is subordinated or junior in any respect to any other
indebtedness of the Company other than Senior Indebtedness; and (iv)
any indebtedness incurred for the purchase of goods or materials in the
ordinary course of business.
For the purposes of this Indenture, Senior Indebtedness shall
not be deemed to have been paid in full until the holders of the Senior
Indebtedness shall have indefeasibly received payment in full in cash of all
Senior Indebtedness; provided that if any holder of Senior Indebtedness agrees
to accept payment in full of such Senior Indebtedness for consideration other
than cash, such holder shall be deemed to have indefeasibly received payment in
full of such Senior Indebtedness. The provisions of this Article XV shall
continue to be effective or be reinstated, as the case may be, if at any time
any payment of any of the Senior Indebtedness is rescinded or must otherwise be
returned by any holder of Senior Indebtedness upon the insolvency, bankruptcy or
organization of the Company or otherwise, all as though such payment had not
been made.
A distribution may consist of cash, securities or other
property, by set-off or otherwise.
Section 15.3 Liquidation; Dissolution; Bankruptcy. Upon any
distribution to creditors of the Company in a liquidation or dissolution of the
Company or in a bankruptcy, reorganization, insolvency, receivership or similar
proceeding relating to the Company or its property, in an assignment for the
benefit of creditors or any marshalling of the Company's assets and liabilities,
holders of Senior Indebtedness shall be entitled to receive payment in full of
all amounts due or to become due thereon before Noteholders shall be entitled to
receive any
83
<PAGE> 90
payment with respect to the principal of, premium, if any, or interest on the
Notes (except that Noteholders may receive securities that are subordinated to
at least the same extent as the Notes to Senior Indebtedness and any securities
issued in exchange for Senior Indebtedness).
Section 15.4 Default on Senior Indebtedness. The Company may
not make any payment upon or in respect of the Notes (except in such
subordinated securities) if:
(a) a default in the payment of the principal of, premium, if
any, or interest on Senior Indebtedness occurs and is continuing beyond
any applicable period of grace; or
(b) a default, other than a default referred to in subsection
(i) above, on Senior Indebtedness occurs and is continuing that permits
holders of the Senior Indebtedness as to which such default relates to
accelerate its maturity and the Trustee receives a notice of the
default (a "Payment Blockage Notice") from the representative or
representatives of holders of at least a majority in principal amount
of Senior Indebtedness then outstanding. No nonpayment default that
existed or was continuing on the date of delivery of any such Payment
Blockage Notice to the Trustee shall be, or be made, the basis for a
subsequent Payment Blockage Notice unless such default shall have been
cured or waived for a period of not less than 180 days.
The Company may and shall resume payments on and distributions
in respect of the Notes and may acquire them upon the earlier of:
(a) in the case of a payment default, upon the date on which
the default is cured or waived, or
(b) in the case of a default referred to in Section 15.4(b)
hereof, 179 days after the date on which the applicable Payment
Blockage Notice is received, unless the maturity of such Senior
Indebtedness has been accelerated. No new period of payment blockage
may be commenced within 360 days after the receipt by the Trustee of
any prior Payment Blockage Notice. No default referred to in Section
15.4(b) hereof that existed or was continuing on the date of delivery
of any Payment Blockage Notice to the Trustee shall be, or be made, the
basis for a subsequent Payment Blockage Notice unless such default
shall have been cured or waived for a period of not less than 180 days,
if this Article XV otherwise permits the payment, distribution or acquisition at
the time of such payment or acquisition.
84
<PAGE> 91
Section 15.5 When Distribution Must Be Paid Over. In the event
that the Trustee (or Paying Agent if other than the Trustee) or any Noteholder
receives any payment of principal or interest with respect to the Notes at a
time when such payment is prohibited by Section 15.3 or 15.4 hereof, such
payment shall be held by the Trustee (or Paying Agent if other than the Trustee)
or such Noteholder, in trust for the benefit of, and immediately shall be paid
over and delivered, upon written request, to, the holders of Senior Indebtedness
as their interests may appear or their Representative under the indenture or
other agreement (if any) pursuant to which Senior Indebtedness may have been
issued, as their respective interests may appear, for application to the payment
of all Senior Indebtedness remaining unpaid to the extent necessary to pay all
Senior Indebtedness in full in accordance with its terms, after giving effect to
any concurrent payment or distribution to or for the holders of Senior
Indebtedness.
With respect to the holders of Senior Indebtedness, the
Trustee undertakes to perform only such obligations on the part of the Trustee
as are specifically set forth in this Article XV, and no implied covenants or
obligations with respect to the holders of Senior Indebtedness shall be read
into this Indenture against the Trustee. The Trustee shall not be deemed to owe
any fiduciary duty to the holders of Senior Indebtedness, and shall not be
liable to any such holders if the Trustee shall pay over or distribute to or on
behalf of Noteholders or the Company or any other person money or assets to
which any holders of Senior Indebtedness shall be entitled by virtue of this
Article XV, except if such payment is made as a result of the willful misconduct
or gross negligence of the Trustee.
Section 15.6 Notice by Company. The Company shall promptly
notify the Trustee and the Paying Agent of any facts known to the Company that
would cause a payment of any principal or interest with respect to the Notes to
violate this Article XV, but failure to give such notice shall not affect the
subordination of the Notes to the Senior Indebtedness as provided in this
Article XV.
Section 15.7 Subrogation. After all Senior Indebtedness is
paid in full and until the Notes are paid in full, Noteholders shall be
subrogated (equally and ratably with all other Indebtedness pari passu with the
Notes) to the rights of holders of Senior Indebtedness to receive distributions
applicable to Senior Indebtedness to the extent that distributions otherwise
payable to the Noteholders have been applied to the payment of Senior
Indebtedness. A distribution made under this Article XV to holders of Senior
Indebtedness that otherwise would have been made to Noteholders is not, as
between the Company and Noteholders, a payment by the Company on the Notes.
85
<PAGE> 92
Section 15.8 Relative Rights. This Article XV defines the
relative rights of Noteholders and holders of Senior Indebtedness. Nothing in
this Indenture shall:
(a) impair, as between the Company and the Noteholders, the
obligation of the Company, which is absolute and unconditional, to pay
principal of and interest on the Notes in accordance with their terms;
(b) affect the relative rights of Noteholders and creditors of
the Company other than their rights in relation to holders of Senior
Indebtedness; or
(c) prevent the Trustee or any Noteholder from exercising its
available remedies upon a default or Event of Default, subject to the
rights of holders and owners of Senior Indebtedness to receive
distributions and payments otherwise payable to Noteholders.
If the Company fails because of this Article XV to pay
principal of or interest on a Note on the due date, the failure is still a
default or Event of Default.
Section 15.9 Subordination May Not Be Impaired by Company. No
right of any holder of Senior Indebtedness to enforce the subordination of the
indebtedness evidenced by the Notes shall be impaired by any act or failure to
act by the Company or any holder of Notes or by the failure of the Company or
any holder of Notes to comply with this Indenture.
Section 15.10 Distribution or Notice to Representative.
Whenever a distribution is to be made or a notice given to holders of Senior
Indebtedness, the distribution may be made and the notice given to their
Representative.
Upon any payment or distribution of assets of the Company
referred to in this Article XV, the Trustee and the Noteholders shall be
entitled to rely upon any order or decree made by any court of competent
jurisdiction or upon any certificate of such Representative or of the
liquidating trustee or agent or other person making any distribution to the
Trustee or to the Noteholders for the purpose of ascertaining the persons
entitled to participate in such distribution, the holders of the Senior
Indebtedness and other indebtedness of the Company, the amount thereof or
payable thereon, the amount or amounts paid or distributed thereon and all other
facts pertinent thereto or to this Article XV.
Section 15.11 Rights of Trustee and Paying Agent.
Notwithstanding the provisions of this Article XV or any other provision of this
Indenture, the Trustee shall not be charged with knowledge of the existence of
any facts that would prohibit
86
<PAGE> 93
the making of any payment or distribution by the Trustee, and the Trustee and
the Paying Agent may continue to make payments on the Notes, unless the Trustee
shall have received at its Corporate Trust Office at least three Business Days
prior to the date of such payment written notice of facts that would cause the
payment of any principal and interest with respect to the Notes to violate this
Article XV. Only the Company or a Representative may give the notice. Nothing in
this Article XV shall impair the claims of, or payments to, the Trustee under or
pursuant to Section 7.6 hereof.
The Trustee shall be entitled to rely on the delivery to it of
a written notice by a person representing himself to be a holder of Senior
Indebtedness (or a trustee or agent on behalf of such holder) to establish that
such notice has been given by a holder of Senior Indebtedness (or a trustee or
agent on behalf of any such holder). In the event that the Trustee determines in
good faith that further evidence is required with respect to the right of any
person as a holder of Senior Indebtedness to participate in any payment or
distribution pursuant to this Article XV, the Trustee may request such person to
furnish evidence to the reasonable satisfaction of the Trustee as to the amount
of Senior Indebtedness held by such person, the extent to which such person is
entitled to participate in such payment or distribution and any other facts
pertinent to the rights of such person under this Article XV, and if such
evidence is not furnished, the Trustee may defer any payment which it may be
required to make for the benefit of such person pursuant to the terms of this
Indenture pending judicial determination as to the rights of such person to
receive such payment.
The Trustee in its individual or any other capacity may hold
Senior Indebtedness with the same rights it would have if it were not Trustee.
Any Agent may do the same with like rights.
Section 15.12 Authorization to Effect Subordination. Each
holder of a Note by the holder's acceptance thereof authorizes and directs the
Trustee on the holder's behalf to take such action as may be necessary or
appropriate to effectuate the subordination as provided in this Article XV, and
appoints the Trustee to act as the holder's attorney-in-fact for any and all
such purposes. Without limiting the foregoing, each Representative is hereby
irrevocably authorized and empowered (in its own name or in the name of the
Noteholders or the Trustee or otherwise), but shall have no obligation, to
demand, sue for, collect and receive every payment or distribution referred to
in Section 15.3 above and give acquittance therefor and to file claims and
proofs of claim and take such other action as it may deem necessary or advisable
for the exercise or enforcement of any of the rights or interests of the holders
or owners of the Senior Indebtedness hereunder; provided that for purposes of
this
87
<PAGE> 94
Section 15.12 holders or owners of Senior Indebtedness may act only through such
Representative.
Section 15.13 Conversions Not Deemed Payment. For the purposes
of this Article XV only, the issuance and delivery of Common Stock upon
conversion of the Notes in accordance with Article XIV shall not be deemed to
constitute a payment or distribution on account of the principal of or interest
on the Notes or on account of the purchase or other acquisition of Notes.
Nothing contained in this Article or elsewhere in this Indenture or in the Notes
is intended to or shall impair, as among the Company, its creditors other than
holders of Senior Indebtedness and the holders, the right, which is absolute and
unconditional, of the holder of any Note to convert such Note in accordance with
Article XIV.
Section 15.14 Amendments. The provisions of this Article XV
shall not be amended or modified without the written consent of the holders of
Senior Indebtedness.
ARTICLE XVI
MISCELLANEOUS PROVISIONS
Section 16.1 Pooling of Interests. The Company desires to
preserve its ability to account for acquisition and other business combination
transactions using the pooling-of-interests method where appropriate, and the
provisions of this Indenture shall be interpreted accordingly.
Section 16.2 Provisions Binding on Company's Successors. All
the covenants, stipulations, promises and agreements in this Indenture made by
the Company shall bind its successors and assigns whether so expressed or not.
Section 16.3 Official Acts by Successor Company. Any act or
proceeding by any provision of this Indenture authorized or required to be done
or performed by any board (including the Board of Directors), committee or
officer of the Company shall and may be done and performed with like force and
effect by the like board, committee or officer of any corporation that shall at
the time be the lawful sole successor of the Company.
Section 16.4 Addresses for Notices, Etc. Any notice or demand
that by any provision of this Indenture is required or permitted to be given or
served by the Trustee or by the holders of Notes on the Company shall be deemed
to have been sufficiently given or made, for all purposes if given or served by
being sent by prepaid overnight delivery or being deposited postage prepaid by
registered or certified mail in a post office letter box addressed (until
another address is filed by the Company with the
88
<PAGE> 95
Trustee) to Healthsource, Inc., Two College Park Drive, Hooksett, New Hampshire
03106, Attention: Chief Financial Officer with a copy to Sheehan, Phinney, Bass
+ Green, Professional Association. Any notice, direction, request or demand
hereunder to or upon the Trustee shall be deemed to have been sufficiently given
or made, for all purposes, if given or served by being sent by prepaid overnight
delivery or being deposited postage prepaid by registered or certified mail in a
post office letter box addressed to the Corporate Trust Office of the Trustee,
which office is, at the date as of which this Indenture is dated, located at 101
Barclay Street, Floor 21 West, New York, New York 10286, Attention: Corporate
Trust Trustee Administration.
The Trustee, by notice to the Company, may designate
additional or different addresses for subsequent notices or communications.
Any notice or communication mailed to a Noteholder shall be
mailed to him by first class mail, postage prepaid, at his address as it appears
on the Note register and shall be sufficiently given to him if so mailed within
the time prescribed.
Failure to mail a notice or communication to a Noteholder or
any defect in it shall not affect its sufficiency with respect to other
Noteholders. If a notice or communication is mailed in the manner provided
above, it is duly given, whether or not the addressee receives it.
Section 16.5 Communications by Holders with Other Holders.
Noteholders may communicate pursuant to Section 312(b) of the Trust Indenture
Act with other Noteholders with respect to their rights under this Indenture or
the Notes. The Company, the Trustee, the Note registrar and any other person
shall have the protection of Section 312(c) of the Trust Indenture Act.
Section 16.6 Governing Law. This Indenture and each Note shall
be deemed to be a contract made under the substantive laws of New York and for
all purposes shall be construed in accordance with the substantive laws of New
York without regard to conflicts of laws principles thereof.
Section 16.7 Evidence of Compliance with Conditions Precedent;
Certificates to Trustee. Upon any application or demand by the Company to the
Trustee to take any action under any of the provisions of this Indenture,
including those actions set forth in Trust Indenture Act Section 314(c), the
Company shall furnish to the Trustee an Officers' Certificate stating that all
conditions precedent, if any, provided for in this Indenture relating to the
proposed action have been complied with, and an Opinion of Counsel stating that,
in the Opinion of such Counsel, all such conditions precedent have been complied
with.
89
<PAGE> 96
Each certificate or opinion provided for in this Indenture and
delivered to the Trustee with respect to compliance with a condition or covenant
provided for in this Indenture shall include: (1) a statement that the person
making such certificate or opinion has read such covenant or condition; (2) a
brief statement as to the nature and scope of the examination or investigation
upon which the statement or opinion contained in such certificate or opinion is
based; (3) a statement that, in the opinion of such person, he has made such
examination or investigation as is necessary to enable him to express an
informed opinion as to whether or not such covenant or condition has been
complied with; and (4) a statement as to whether or not, in the opinion of such
person, such condition or covenant has been complied with.
Section 16.8 Legal Holidays. In any case where the date of
maturity of interest on or principal of the Notes or the date fixed for
redemption of any Note shall not be a Business Day, then payment of such
interest on or principal of the Notes need not be made on such date, but may be
made on the next succeeding Business Day with the same force and effect as if
made on the date of maturity or the date fixed for redemption, and no interest
shall accrue for the period from and after such date.
Section 16.9 No Security Interest Created. Nothing in this
Indenture or in the Notes, expressed or implied, shall be construed to
constitute a security interest under the Uniform Commercial Code or similar
legislation, as now or hereafter enacted and in effect, in any jurisdiction
where property of the Company or its subsidiaries is located.
Section 16.10 Trust Indenture Act. This Indenture is hereby
made subject to, and shall be governed by, the provisions of the Trust Indenture
Act required to be part of and to govern indentures qualified under the Trust
Indenture Act.
Section 16.11 Trust Indenture Act Controls. If any provision
of this Indenture limits, qualifies, or conflicts with the duties imposed by
operation of the Trust Indenture Act, the imposed duties, upon qualification of
this Indenture under the Trust Indenture Act, shall control.
Section 16.12 Benefits of Indenture. Nothing in this Indenture
or in the Notes, expressed or implied, shall give to any person, other than the
parties hereto, any paying agent, any authenticating agent, any Note registrar
and their successors hereunder and the holders of Notes, any benefit or any
legal or equitable right, remedy or claim under this Indenture.
Section 16.13 Table of Contents, Headings Etc. The table of
contents and the titles and headings of the articles and sections of this
Indenture have been inserted for convenience of
90
<PAGE> 97
reference only, are not to be considered a part hereof, and shall in no way
modify or restrict any of the terms or provisions hereof.
Section 16.14 Authenticating Agent. The Trustee may appoint an
authenticating agent that shall be authorized to act on its behalf and subject
to its direction in the authentication and delivery of Notes in connection with
the original issuance thereof and transfers and exchanges of Notes hereunder,
including under Sections 2.4, 2.5, 2.6, 2.7 and 3.3, as fully to all intents and
purposes as though the authenticating agent had been expressly authorized by
this Indenture and those Sections to authenticate and deliver Notes. For all
purposes of this Indenture, the authentication and delivery of Notes by the
authenticating agent shall be deemed to be authentication and delivery of such
Notes "by the Trustee" and a certificate of authentication executed on behalf of
the Trustee by an authenticating agent shall be deemed to satisfy any
requirement hereunder or in the Notes for the Trustee's certificate of
authentication. Such authenticating agent shall at all times be a person
eligible to serve as Trustee hereunder pursuant to Section 7.10.
Any corporation into which any authenticating agent may be
merged or converted or with which it may be consolidated, or any corporation
resulting from any merger, consolidation or conversion to which any
authenticating agent shall be a party, or any corporation succeeding to the
corporate trust business of any authenticating agent, shall be the successor of
the authenticating agent hereunder, if such successor company is otherwise
eligible under this Section, without the execution or filing of any paper or any
further act on the part of the parties hereto or the authenticating agent or
such successor company.
Any authenticating agent may at any time resign by giving
written notice of resignation to the Trustee and to the Company. The Trustee may
at any time terminate the agency of any authenticating agent by giving written
notice of termination to such authenticating agent and to the Company. Upon
receiving such a notice of resignation or upon such a termination, or in case at
any time any authenticating agent shall cease to be eligible under this Section,
the Trustee shall promptly appoint a successor authenticating agent (which may
be the Trustee), shall give written notice of such appointment to the Company
and shall mail notice of such appointment to all holders of Notes as the names
and addresses of such holders appear on the Note register.
The Company agrees to pay to the authenticating agent from
time to time reasonable compensation for its services.
The provisions of Sections 7.3, 7.4, 7.5, 8.3 and this Section
16.14 shall be applicable to any authenticating agent.
91
<PAGE> 98
Section 16.15 Execution in Counterparts. This Indenture may be
executed in any number of counterparts, each of which shall be an original, but
such counterparts shall together constitute but one and the same instrument.
[This space is intentionally left blank.]
92
<PAGE> 99
The Bank of New York hereby accepts the trusts in this
Indenture declared and provided, upon the terms and conditions hereinabove set
forth.
IN WITNESS WHEREOF, the parties hereto have caused this
Indenture to be duly signed and attested, all as of the date first written
above.
HEALTHSOURCE, INC.
By: /s/ Norman C. Payson, M.D.
-------------------------------------
Name: Norman C. Payson, M.D.
Title: President and Chief Executive
Officer
Attest:
/s/ Jon S. Richardson
- -------------------------------------
Jon S. Richardson, Secretary
THE BANK OF NEW YORK, as Trustee
By: /s/ Mary Jane Morrissey
-------------------------------------
Name: Mary Jane Morrissey
Title: Vice President
Attest:
/s/
- -------------------------------------
<PAGE> 100
EXHIBIT A - FORM OF DEFINITIVE NOTE
[FORM OF FACE OF NOTE]
No. A-1
$_________________
CUSIP 42221EAB0
HEALTHSOURCE, INC.
5% Convertible Subordinated Notes Due 2003
THE NOTE EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED
STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS
SET FORTH IN THE FOLLOWING SENTENCE. BY ACQUISITION HEREOF, THE HOLDER
(1) REPRESENTS THAT (A) IT IS A "QUALIFIED INSTITUTIONAL BUYER" (AS
DEFINED IN RULE 144A UNDER THE SECURITIES ACT) OR (B) IT IS AN
INSTITUTIONAL "ACCREDITED INVESTOR" (AS DEFINED IN RULE 501(A) (1),
(2), (3) OR (7) UNDER THE SECURITIES ACT) ("INSTITUTIONAL ACCREDITED
INVESTOR") OR (C) IT IS NOT A U.S. PERSON AND IS ACQUIRING THE NOTE
EVIDENCED HEREBY IN AN OFFSHORE TRANSACTION; (2) AGREES THAT IT WILL
NOT PRIOR TO THE DATE THAT IS THREE YEARS AFTER THE LATER OF THE
ORIGINAL ISSUANCE OF THE NOTE EVIDENCED HEREBY AND THE LAST DATE ON
WHICH HEALTHSOURCE, INC. (THE "COMPANY") OR ANY "AFFILIATE" (AS DEFINED
IN RULE 144 UNDER THE SECURITIES ACT) OF THE COMPANY WAS THE OWNER OF
THE NOTE (THE "RESTRICTION TERMINATION DATE") RESELL OR OTHERWISE
TRANSFER THE NOTE EVIDENCED HEREBY OR THE COMMON STOCK ISSUABLE UPON
CONVERSION OF SUCH NOTE EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY
THEREOF, (B) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE
144A UNDER THE SECURITIES ACT, (C) TO AN INSTITUTIONAL ACCREDITED
INVESTOR THAT, PRIOR TO SUCH TRANSFER, FURNISHES TO THE BANK OF NEW
YORK, AS TRUSTEE, A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS
AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THE NOTE
EVIDENCED HEREBY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM SUCH
TRUSTEE), (D) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904
UNDER THE SECURITIES ACT, (E) PURSUANT TO THE EXEMPTION FROM
REGISTRATION PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF
AVAILABLE) OR (F) PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BEEN
DECLARED EFFECTIVE UNDER THE SECURITIES ACT; AND (3) AGREES THAT IT
WILL DELIVER TO EACH PERSON TO WHOM THE NOTE EVIDENCED HEREBY IS
TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN
CONNECTION WITH ANY TRANSFER OF THE NOTE EVIDENCED HEREBY BEFORE THE
RESTRICTION TERMINATION DATE, THE HOLDER MUST CHECK THE APPROPRIATE BOX
SET FORTH ON THE REVERSE HEREOF RELATING TO THE MANNER OF SUCH TRANSFER
AND SUBMIT THIS
A-1
<PAGE> 101
CERTIFICATE TO THE BANK OF NEW YORK, AS TRUSTEE. IF THE PROPOSED
TRANSFER IS PURSUANT TO CLAUSE (C), (D) OR (E) ABOVE, THE HOLDER MUST,
PRIOR TO SUCH TRANSFER, FURNISH TO THE BANK OF NEW YORK, AS TRUSTEE,
SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS THE COMPANY
MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE
PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THIS LEGEND WILL BE
REMOVED UPON THE RESTRICTION TERMINATION DATE. AS USED HEREIN, THE
TERMS "OFFSHORE TRANSACTION," "UNITED STATES" AND "U.S. PERSON" HAVE
THE MEANINGS GIVEN TO THEM BY REGULATION S UNDER THE SECURITIES ACT.
HEALTHSOURCE, INC., a corporation duly organized and validly existing
under the laws of the State of New Hampshire (the "Company"), which term
includes any Successor Company under the Indenture referred to on the reverse
hereof, for value received hereby promises to pay to ___________________________
________________, or registered assigns, the principal sum of __________________
______________________________________ Dollars on March 1, 2003, at the office
or agency of the Company maintained for that purpose in the Borough of
Manhattan, The City of New York, or, at the option of the holder of this Note,
at the Corporate Trust Office of the Trustee, in such coin or currency of the
United States of America as at the time of payment shall be legal tender for the
payment of public and private debts, and to pay interest, semi-annually on March
1 and September 1 of each year, commencing September 1, 1996, on said principal
sum at said office or agency, in like coin or currency, at the rate per annum
specified in the title of this Note, from the March 1 or September 1 as the case
may be, next preceding the date of this Note to which interest has been paid or
duly provided for, unless the date hereof is a date to which interest has been
paid or duly provided for, in which case from the date of this Note, or unless
no interest has been paid or duly provided for on the Notes, in which case from
March 1, 1996, until payment of said principal sum has been made or duly
provided for; provided that if the Company shall default in the payment of
interest due on such March 1 or September 1, then this Note shall bear interest
from the next preceding March 1 or September 1 to which interest has been paid
or duly provided for or, if no interest has been paid or duly provided for on
such Note, from March 1, 1996. The interest so payable on any March 1 or
September 1 will be paid to the person in whose name this Note (or one or more
Predecessor Notes) is registered at the close of business on the record date,
which shall be the February 15 or August 15 (whether or not a Business Day) next
preceding such March 1 or September 1, respectively; provided that any such
interest not punctually paid or duly provided for shall be payable as provided
in the Indenture. Interest shall be paid by check mailed to the registered
holder at the registered address of such person unless other arrangements are
made in accordance with the provisions of the Indenture.
A-2
<PAGE> 102
Reference is made to the further provisions of this Note set forth on
the reverse hereof, including, without limitation, provisions giving the holder
of this Note the right to convert this Note into Common Stock of the Company on
the terms and subject to the limitations referred to on the reverse hereof and
as more fully specified in the Indenture. Such further provisions shall for all
purposes have the same effect as though fully set forth at this place.
This Note shall be deemed to be a contract made under the laws of the
State of New York, and for all purposes shall be construed in accordance with
and governed by the laws of said State, without regard to conflicts of laws
principles thereof.
This Note shall not be valid or become obligatory for any purpose until
the certificate of authentication hereon shall have been manually signed by the
Trustee, or a duly authorized authenticating agent under the Indenture.
A-3
<PAGE> 103
IN WITNESS WHEREOF, the Company has caused this Note to be duly
executed under its corporate seal.
HEALTHSOURCE, INC.
By:________________________
Name:
Title:
Attest:
__________________________
Secretary
A-4
<PAGE> 104
[FORM OF CERTIFICATE OF AUTHENTICATION]
CERTIFICATE OF AUTHENTICATION
Dated: March 6, 1996
This is one of the Notes described in the within-named indenture.
THE BANK OF NEW YORK, as Trustee
By:_________________________________
Authorized Signatory
By:_________________________________
Authorized Signatory
[FORM OF REVERSE OF NOTE]
HEALTHSOURCE, INC.
5% Convertible Subordinated Notes Due 2003
This Note is one of a duly authorized issue of Notes of the Company,
designated as its 5% Convertible Subordinated Notes due 2003 (herein called the
"Notes"), limited to the aggregate principal amount of $247,250,000 all issued
or to be issued under and pursuant to an Indenture dated as of March 6, 1996
(the "Indenture"), between the Company and The Bank of New York, as trustee (the
"Trustee"), to which Indenture and all indentures supplemental thereto reference
is hereby made for a complete description of the rights, limitations of rights,
obligations, duties and immunities thereunder of the Trustee, the Company and
the holders of the Notes. Each Note is subject to, and qualified by, all such
terms as set forth in the Indenture certain of which are summarized hereon and
each holder of a Note is referred to the corresponding provisions of the
Indenture for a complete statement of such terms. To the extent that there is
any inconsistency between the summary provisions set forth in the Notes and the
Indenture, the provisions of the Indenture shall govern. Capitalized terms used
but not defined in this Note shall have the meanings ascribed to them in the
Indenture.
In case an Event of Default, as defined in the Indenture, shall have
occurred and be continuing, the principal of, premium, if any, and accrued
interest on all Notes may be declared, and upon said declaration shall become,
due and payable, in the manner, with
A-5
<PAGE> 105
the effect and subject to the conditions provided in the Indenture.
The Indenture contains provisions permitting the Company and the
Trustee, with the consent of the holders of not less than a majority in
aggregate principal amount of the Notes at the time outstanding, evidenced as in
the Indenture provided, to execute supplemental indentures adding any provisions
to or changing in any manner or eliminating any of the provisions of the
Indenture or of any supplemental indenture or modifying in any manner the rights
of the holders of the Notes; provided that no such supplemental indenture shall
(i) extend the fixed maturity of any Note, or reduce the rate or extend the time
of payment of interest thereon, or reduce the principal amount thereof or
premium, if any, thereon, or reduce any amount payable on redemption thereof,
alter the obligation of the Company to redeem the Notes at the option of the
holders upon the occurrence of a Change of Control or impair or affect the right
of any Noteholder to institute suit for the payment thereof, or make the
principal thereof or interest or premium, if any, thereon payable in any coin or
currency other than that provided in the Notes, modify the subordination
provisions in a manner adverse to the holders of the Notes, or impair the right
to convert the Notes into Common Stock subject to the terms set forth in the
Indenture without the consent of the holder of each Note so affected or (ii)
reduce the aforesaid percentage of Notes, the holders of which are required to
consent to any such supplemental indenture, without the consent of the holders
of all Notes then outstanding. It is also provided in the Indenture that, prior
to any declaration accelerating the maturity of the Notes, the holders of a
majority in aggregate principal amount of the Notes at the time outstanding may
on behalf of the holders of all of the Notes waive any past default or Event of
Default under the Indenture and its consequences except a default in the payment
of interest or any premium on or the principal of any of the Notes, a failure by
the Company to convert any Notes into Common Stock of the Company or a default
in respect of a covenant or provision of the Indenture that under Article X
thereof cannot be modified or amended without the consent of the holders of all
Notes then outstanding. Any such consent or waiver by the holder of this Note
(unless revoked as provided in the Indenture) shall be conclusive and binding
upon such holder and upon all future holders and owners of this Note and any
Notes that may be issued in exchange or substitution hereof, irrespective of
whether or not any notation thereof is made upon this Note or such other Notes.
No reference herein to the Indenture and no provision of this Note or
of the Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and any premium and interest
on this Note at the place, at the respective times, at the rate and in the coin
or currency herein prescribed.
A-6
<PAGE> 106
Interest on the Notes shall be computed on the basis of a 360-day year
composed of twelve 30-day months.
The Notes are issuable in registered form without coupons in
denominations of $1,000 principal amount and integral multiples thereof. At the
office or agency of the Company referred to on the face hereof, and in the
manner and subject to the limitations provided in the Indenture, without payment
of any service charge but with payment of a sum sufficient to cover any tax or
other governmental charge that may be imposed in connection with any
registration or exchange of Notes, Notes may be exchanged for a like aggregate
principal amount of Notes of other authorized denominations.
The Notes are not redeemable at the option of the Company prior to
March 1, 1999. At any time on or after that date, the Notes may be redeemed at
the Company's option, upon notice as set forth in the Indenture, in whole at any
time or in part from time to time, at the optional redemption prices set forth
below, together with accrued interest to the date fixed for redemption.
If redeemed during the 12-month period beginning:
<TABLE>
<CAPTION>
Date Percentage
---- ----------
<S> <C>
March 1, 1999 102.5%
March 1, 2000 101.7%
March 1, 2001 100.8%
</TABLE>
and 100% on or after March 1, 2002; provided that if the date fixed for
redemption is a date on or after the record date and on or before the next
following interest payment date, then the interest payable on such date shall be
paid to the holder of record on the next preceding February 15 or August 15,
respectively.
If a Change of Control (as defined in the Indenture) shall occur at any
time, then each holder of Notes shall have the right to require that the Company
purchase such holder's Notes in whole or in part in integral multiples of
$1,000, at a purchase price in cash in an amount equal to 101% of the principal
amount of such Notes, plus accrued and unpaid interest, if any, to the
repurchase date pursuant to an offer to be made by the Company and in accordance
with the procedures set forth in the Indenture.
Subject to the provisions of the Indenture, the holder hereof has the
right, at its option, at any time after 60 days following the latest date of
original issuance of the Notes and prior to the close of business on March 1,
2003, or, as to all or any portion hereof called for redemption, prior to the
close of business on the Trading Day next preceding the date fixed for
redemption (unless the Company shall default in payment due upon redemption
thereof), to convert the principal hereof or any portion
A-7
<PAGE> 107
of such principal that is $1,000 or an integral multiple thereof, into that
number of fully paid and non-assessable shares of Company's Common Stock, as
said shares shall be constituted at the date of conversion, obtained by dividing
the principal amount of this Note or portion thereof to be converted by the
conversion price of $46.965 or such conversion price as adjusted from time to
time as provided in the Indenture, upon surrender of this Note, together with a
conversion notice as provided in the Indenture, to the Company at the office or
agency of the Company maintained for that purpose in the Borough of Manhattan,
The City of New York, or at the option of such holder, the Corporate Trust
Office of the Trustee, and, unless the shares issuable on conversion are to be
issued in the same name as this Note, duly endorsed by, or accompanied by
instruments of transfer in form satisfactory to the Company duly executed by,
the holder or by his duly authorized attorney. No adjustment in respect of
interest or dividends will be made upon any conversion; provided that if this
Note shall be surrendered for conversion during the period from the close of
business on any record date for the payment of interest through the close of
business on the Business Day next preceding the following interest payment date,
this Note (unless it or the portion being converted shall have been called for
redemption on a date in such period) must be accompanied by an amount, in funds
acceptable to the Company, equal to the interest payable on such interest
payment date on the principal amount being converted. The interest payment with
respect to a Note called for redemption on a date during the period from the
close of business on or after any record date to the opening of business on the
business day following the corresponding payment date will be payable on the
corresponding interest payment date to the registered Holder at the close of
business on that record date (notwithstanding the conversion of such Note before
the corresponding interest payment date) and a Holder who elects to convert need
not to include funds equal to the interest paid. No fractional shares will be
issued upon any conversion, but an adjustment in cash will be made, as provided
in the Indenture, in respect of any fraction of a share that would otherwise be
issuable upon the surrender of any Note or Notes for conversion.
Any Notes called for redemption, unless surrendered for conversion on
or before the close of business on the Business Day before the date fixed for
redemption, may be deemed to be purchased from the holder of such Notes at an
amount equal to the applicable redemption price, together with accrued interest
to the date fixed for redemption, by one or more investment bankers or other
purchasers who may agree with the Company to purchase such Notes from the
holders thereof and convert them into Common Stock of the Company and to make
payment for such Notes as aforesaid to the Trustee in trust for such holders.
Upon due presentment for registration of transfer of this Note at the
office or agency of the Company in the Borough of Manhattan, The City of New
York, or at the option of the holder of
A-8
<PAGE> 108
this Note, at the Corporate Trust Office of the Trustee, a new Note or Notes of
authorized denominations for an equal aggregate principal amount will be issued
to the transferee in exchange thereof, subject to the conditions and limitations
provided in the Indenture, without charge except for any tax or other
governmental charge imposed in connection therewith.
The Company, the Trustee, any authenticating agent, any paying agent,
any conversion agent and any Note registrar may deem and treat the registered
holder hereof as the absolute owner of this Note (whether or not this Note shall
be overdue and notwithstanding any notation of ownership or other writing hereon
made by anyone other than the Company or any Note registrar), for the purpose of
receiving payment hereof, or on account hereof, for the conversion hereof and
for all other purposes, and neither the Company nor the Trustee nor any other
authenticating agent nor any paying agent nor any other conversion agent nor any
Note registrar shall be affected by any notice to the contrary. All payments
made to or upon the order of such registered holder shall, to the extent of the
sum or sums paid, satisfy and discharge liability for monies payable on this
Note.
No recourse for the payment of the principal of or any premium or
interest on this Note, or for any claim based hereon or otherwise in respect
hereof, and no recourse under or upon any obligation, covenant or agreement of
the Company in the Indenture or any indenture supplemental thereto or in any
Note, or because of the creation of any indebtedness represented thereby, shall
be had against any incorporator, stockholder, officer or director, as such,
past, present or future, of the Company or of any Successor Company, either
directly or through the Company or any Successor Company, whether by virtue of
any constitution, statute or rule of law or by the enforcement of any assessment
or penalty or otherwise, all such liability being, by the acceptance hereof and
as part of the consideration for the issue hereof, expressly waived and
released.
A-9
<PAGE> 109
ABBREVIATIONS
The following abbreviations, when used in the inscription of the face
of this Note, shall be construed as though they were written out in full
according to applicable laws or regulations:
TEN COM - as tenants in common UNIF GIFT MIN ACT -
TEN ENT - as tenants by the __________________ Custodian
entireties (Cust)
JT TEN - as joint tenants with __________________ under
right of survivorship (Minor)
and not as tenants in
common Uniform Gifts to
Minors Act ___________________
(State)
Additional abbreviations may also be used though
not in the above list.
A-10
<PAGE> 110
[FORM OF CONVERSION NOTICE]
CONVERSION NOTICE
To: Healthsource, Inc.
The undersigned registered owner of this Note hereby irrevocably
exercises the option to convert this Note, or the portion hereof (which is
$1,000 principal amount or an integral multiple thereof) below designated, into
shares of Common Stock, par value $.10 per share, of the Company in accordance
with the terms of the Indenture referred to in this Note, and directs that the
shares issuable and deliverable upon such conversion, together with any check in
payment for fractional shares and any Notes representing any unconverted
principal amount hereof, be issued and delivered to the registered holder hereof
unless a different name has been indicated below. If shares or any portion of
this Note not converted are to be issued in the name of a person other than the
undersigned, the undersigned will check the appropriate box below and pay all
transfer taxes payable with respect thereto. Any amount required to be paid to
the undersigned on account of interest accompanies this Note.
Dated: __________________________
______________________________
______________________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks,
stock brokers, savings and loan associations
and credit unions) with membership in an
approved signature guarantee medallion
program pursuant to Securities and Exchange
Commission Rule 17Ad-15 if shares of Common
Stock are to be issued, or Notes to be
delivered, other than to and in the name
of the registered holder.
____________________________________________
Signature Guarantee
Fill in for registration of shares if to
A-11
<PAGE> 111
be issued, and Notes if to be delivered,
other than to and in the name of the
registered holder:
____________________________________________
(Name)
____________________________________________
(Street Address)
____________________________________________
(City, State and Zip Code)
Please print name and address
Principal amount to be converted (if
less than all) $____________________
____________________________________
Social Security or other Taxpayer
Identification Number
A-12
<PAGE> 112
[FORM OF OPTION TO ELECT REPAYMENT
UPON A CHANGE OF CONTROL]
To: Healthsource, Inc.
The undersigned registered owner of this Note hereby irrevocably
acknowledges receipt of a notice from Healthsource, Inc. (the "Company") as to
the occurrence of a Change of Control with respect to the Company and requests
and instructs the Company to repay the entire principal amount of this Note, or
the portion thereof (which is $1,000 principal amount or an integral multiple
thereof) below designated, in accordance with the terms of the Indenture
referred to in this Note, together with accrued interest to such date, to the
registered holder hereof.
Dated:________________________
____________________________________
____________________________________
Signature(s)
____________________________________
Social Security or Other Taxpayer
Identification Number
Principal amount to be repaid (if
less than all): $__________________
A-13
<PAGE> 113
[FORM OF ASSIGNMENT]
For value received _____________________________ hereby sell(s),
assign(s) and transfer(s) unto _________________________ (Please insert social
security or other identifying number of assignee) the within Note, and hereby
irrevocably constitutes and appoints ________________________________ attorney
to transfer the said Note on the books of the Company, with full power of
substitution in the premises.
In connection with any transfer of the within Note (or any issuance of
shares of Common Stock, par value $.10 per share, of Healthsource, Inc. upon
conversion of the within Note) occurring prior to the third anniversary of the
date of original issuance of such Note, the undersigned confirms that such Note
(or shares of Common Stock, as the case may be) are being transferred:
[ ] To Healthsource, Inc. or a subsidiary thereof; or
[ ] Pursuant to and in compliance with Rule 144A under the Securities Act of
1933, as amended; or
[ ] To an Institutional Accredited Investor pursuant to and in compliance with
the Securities Act of 1933, as amended; or
[ ] Pursuant to and in compliance with Regulation S under the Securities Act of
1933, as amended; or
[ ] Pursuant to and in compliance with Rule 144 under the Securities Act of
1933, as amended.
Unless one of the boxes above is checked, the Trustee will refuse to
register any of the within Notes (or such shares of Common Stock, as the case
may be) in the name of any person other than the registered holder thereof (or
hereof); provided, however, that the Trustee may, in its sole discretion,
register the transfer of such Notes (or such shares of Common Stock, as the case
may be) if it has received such certifications, legal opinions and/or other
information as the Company has reasonably requested to confirm that such
transfer is being made pursuant to an exemption from, or in a transaction not
subject to, the registration requirements of the Securities Act of 1933, as
amended.
In addition, if the transferee is an institutional accredited investor
or a purchaser who is not a U.S. person, the holder must furnish to the Trustee
(i) in the case of an
A-14
<PAGE> 114
institutional accredited investor, a signed letter containing certain
representations and agreements relating to the restrictions on
transfer of the security evidenced hereby and (ii) such other
certifications, legal opinions or other information as it may
reasonably require to confirm that such transfer is being made
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act of 1933, as amended.
Dated:_____________________________
___________________________________
___________________________________
Signature(s)
Signature(s) must be guaranteed by
an eligible Guarantor Institution (banks,
stock brokers, savings and loan associations
and credit unions) with membership in an
approved signature guarantee medallion
program pursuant to Securities and
Exchange Commission Rule 17Ad-15.
Signature Guarantee
___________________________________
NOTICE: The signature on the conversion notice, the option to elect
payment upon a Change of Control or the assignment must correspond
with the name as written upon the face of the Note in every particular
without alteration or enlargement or any change whatever.
A-15
<PAGE> 115
EXHIBIT B - FORM OF RESTRICTED GLOBAL NOTE
[FORM OF FACE OF NOTE]
No. B-1 $_______________
CUSIP 42221EAA2
HEALTHSOURCE, INC.
5% Convertible Subordinated Notes Due 2003
UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN
DEFINITIVE FORM, THIS RESTRICTED GLOBAL NOTE MAY NOT BE TRANSFERRED EXCEPT
AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE
OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR
BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A
NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS CERTIFICATE IS PRESENTED
BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK
CORPORATION (THE "DEPOSITARY"), TO THE ISSUER OR ITS AGENT FOR REGISTRATION
OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED
IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED
REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR SUCH OTHER
ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY
PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS
AN INTEREST HEREIN.
THE NOTE EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES
LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR
THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS SET FORTH IN THE
FOLLOWING SENTENCE. BY ACQUISITION HEREOF, THE HOLDER (1) REPRESENTS THAT
(A) IT IS A "QUALIFIED INSTITUTIONAL BUYER" (AS DEFINED IN RULE 144A UNDER
THE SECURITIES ACT) OR (B) IT IS AN INSTITUTIONAL "ACCREDITED INVESTOR" (AS
DEFINED IN RULE 501(A)(1), (2), (3) OR (7) UNDER THE SECURITIES ACT)
("INSTITUTIONAL ACCREDITED INVESTOR") OR (C) IT IS NOT A U.S. PERSON AND IS
ACQUIRING THE NOTE EVIDENCED HEREBY IN AN OFFSHORE TRANSACTION; (2) AGREES
THAT IT WILL NOT PRIOR TO THE DATE THAT IS THREE YEARS AFTER THE LATER OF
THE ORIGINAL ISSUANCE OF THE NOTE EVIDENCED HEREBY AND
B-1
<PAGE> 116
THE LAST DATE ON WHICH HEALTHSOURCE, INC. (THE "COMPANY") OR ANY
"AFFILIATE" (AS DEFINED IN RULE 144 UNDER THE SECURITIES ACT) OF THE
COMPANY WAS THE OWNER OF THE NOTE (THE "RESTRICTION TERMINATION DATE")
RESELL OR OTHERWISE TRANSFER THE NOTE EVIDENCED HEREBY OR THE COMMON STOCK
ISSUABLE UPON CONVERSION OF SUCH NOTE EXCEPT (A) TO THE COMPANY OR ANY
SUBSIDIARY THEREOF, (B) TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE
WITH RULE 144A UNDER THE SECURITIES ACT, (C) TO AN INSTITUTIONAL ACCREDITED
INVESTOR THAT, PRIOR TO SUCH TRANSFER, FURNISHES TO THE BANK OF NEW YORK,
AS TRUSTEE, A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND
AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THE NOTE EVIDENCED
HEREBY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM SUCH TRUSTEE), (D)
OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 UNDER THE SECURITIES
ACT, (E) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144
UNDER THE SECURITIES ACT (IF AVAILABLE) OR (F) PURSUANT TO A REGISTRATION
STATEMENT WHICH HAS BEEN DECLARED EFFECTIVE UNDER THE SECURITIES ACT; AND
(3) AGREES THAT IT WILL DELIVER TO EACH PERSON TO WHOM THE NOTE EVIDENCED
HEREBY IS TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND.
IN CONNECTION WITH ANY TRANSFER OF THE NOTE EVIDENCED HEREBY BEFORE THE
RESTRICTION TERMINATION DATE, THE HOLDER MUST CHECK THE APPROPRIATE BOX SET
FORTH ON THE REVERSE HEREOF RELATING TO THE MANNER OF SUCH TRANSFER AND
SUBMIT THIS CERTIFICATE TO THE BANK OF NEW YORK, AS TRUSTEE. IF THE
PROPOSED TRANSFER IS PURSUANT TO CLAUSE (C), (D) OR (E) ABOVE, THE HOLDER
MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE BANK OF NEW YORK, AS TRUSTEE,
SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS THE COMPANY MAY
REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO
AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT. THIS LEGEND WILL BE REMOVED UPON THE
RESTRICTION TERMINATION DATE. AS USED HEREIN, THE TERMS "OFFSHORE
TRANSACTION," "UNITED STATES" AND "U.S. PERSON" HAVE THE MEANINGS GIVEN TO
THEM BY REGULATION S UNDER THE SECURITIES ACT.
HEALTHSOURCE, INC., a corporation duly organized and validly existing
under the laws of the State of New Hampshire (the "Company"), which term
includes any Successor Company under the Indenture referred to on the reverse
hereof, for value received hereby promises to pay to ___________________________
________________________________________________________________________________
________________________________________________________________________________
____________________, or registered assigns, the principal sum of
B-2
<PAGE> 117
________________________________________________________________________________
________________________________________________________________________________
_____________________________ Dollars (subject to adjustment as set forth in the
next paragraph hereof) on March 1, 2003, at the office or agency of the Company
maintained for that purpose in the Borough of Manhattan, The City of New York,
or, at the option of the holder of this Restricted Global Note, at the Corporate
Trust Office of the Trustee, in such coin or currency of the United States of
America as at the time of payment shall be legal tender for the payment of
public and private debts, and to pay interest, semi-annually on March 1 and
September 1 of each year, commencing September 1, 1996, on said principal sum at
said office or agency, in like coin or currency, at the rate per annum specified
in the title of this Restricted Global Note, from the March 1 or September 1, as
the case may be, next preceding the date of this Restricted Global Note to which
interest has been paid or duly provided for, unless the date hereof is a date to
which interest has been paid or duly provided for, in which case from the date
of this Restricted Global Note, or unless no interest has been paid or duly
provided for on the Notes, in which case from March 1, 1996, until payment of
said principal sum has been made or duly provided for; provided that if the
Company shall default in the payment of interest due on such March 1 or
September 1, then this Restricted Global Note shall bear interest from the next
preceding March 1 or September 1, to which interest has been paid or duly
provided for or, if no interest has been paid or duly provided for on such Note,
from March 1, 1996. The interest so payable on any March 1 or September 1 will
be paid to the person in whose name this Restricted Global Note (or one or more
Predecessor Notes) is registered at the close of business on the record date,
which shall be the February 15 or August 15 (whether or not a Business Day) next
preceding such March 1 or September 1, respectively; provided that any such
interest not punctually paid or duly provided for shall be payable as provided
in the Indenture. Interest shall be paid by check mailed to the registered
holder at the registered address of such person unless other arrangements are
made in accordance with the provisions of the Indenture.
The aggregate principal amount of this Restricted Global Note
represented hereby may from time to time be reduced or increased to reflect
exchanges of a part of this Restricted Global Note for interests in the
Regulation S Global Note or definitive Notes or exchanges of interests in the
Regulation S Global Note or definitive Notes for a part of this Restricted
Global Note or conversions or redemptions of a part of this Restricted Global
Note or cancellations of a part of this Restricted Global
B-3
<PAGE> 118
Note or transfers of interests in the Regulation S Global Note or definitive
Notes in return for a part of this Restricted Global Note or transfers of a part
of this Restricted Global Note effected by delivery of interests in the
Regulation S Global Note or definitive Notes, in each case, and in any such
case, by means of notations on the Schedule of Exchanges, Conversions,
Redemptions, Cancellations and Transfers on the last page hereof.
Notwithstanding any provision of this Restricted Global Note to the contrary,
(i) exchanges of a part of this Restricted Global Note for interests in the
Regulation S Global Note or definitive Notes, (ii) exchanges of interests in the
Regulation S Global Note or definitive Notes for a part of this Restricted
Global Note, (iii) conversions or redemptions of a part of this Restricted
Global Note, (iv) cancellations of a part of this Restricted Global Note, (v)
transfers of interests in the Regulation S Global Note or definitive Notes in
return for a part of this Restricted Global Note and (vi) transfers of a part of
this Restricted Global Note effected by delivery of interests in the Regulation
S Global Note or definitive Notes may be effected without the surrendering of
this Restricted Global Note, provided that appropriate notations on the Schedule
of Exchanges, Conversions, Redemptions, Cancellations and Transfers are made by
the Trustee, or the Custodian at the direction of the Trustee, to reflect the
appropriate reduction or increase, as the case may be, in the aggregate
principal amount of this Restricted Global Note resulting therefrom or as a
consequence thereof.
Reference is made to the further provisions of this Restricted Global
Note set forth on the reverse hereof, including, without limitation, provisions
giving the holder of this Restricted Global Note the right to convert this
Restricted Global Note into Common Stock of the Company on the terms and subject
to the limitations referred to on the reverse hereof and as more fully specified
in the Indenture. Such further provisions shall for all purposes have the same
effect as though fully set forth at this place.
This Restricted Global Note shall be deemed to be a contract made under
the laws of the State of New York, and for all purposes shall be construed in
accordance with and governed by the laws of said State, without regard to
conflicts of laws principles thereof.
This Restricted Global Note shall not be valid or become obligatory for
any purpose until the certificate of authentication hereon shall have been
manually signed by the Trustee or a duly authorized authenticating agent
B-4
<PAGE> 119
under the Indenture.
IN WITNESS WHEREOF, the Company has caused this Restricted Global Note
to be duly executed under its corporate seal.
HEALTHSOURCE, INC.
By:________________________
Name:
Title:
Attest:
________________________
Secretary
B-5
<PAGE> 120
[FORM OF CERTIFICATE OF AUTHENTICATION]
CERTIFICATE OF AUTHENTICATION
Dated: March 6, 1996
This is one of the Notes described in the within-named indenture.
THE BANK OF NEW YORK, as Trustee
By:______________________________
Authorized Signatory
By:______________________________
Authorized Signatory
[FORM OF REVERSE OF RESTRICTED GLOBAL NOTE]
HEALTHSOURCE, INC.
5% Convertible Subordinated Notes Due 2003
This Restricted Global Note is one of a duly authorized issue of Notes
of the Company, designated as its 5% Convertible Subordinated Notes Due 2003
(herein called the "Notes"), limited to the aggregate principal amount of
$247,250,000 all issued or to be issued under and pursuant to an Indenture dated
as of March 6, 1996 (the "Indenture"), between the Company and The Bank of New
York, as trustee (the "Trustee"), to which Indenture and all indentures
supplemental thereto reference is hereby made for a complete description of the
rights, limitations of rights, obligations, duties and immunities thereunder of
the Trustee, the Company and the holders of the Notes. Each Note is subject to,
and qualified by, all such terms as set forth in the Indenture certain of which
are summarized hereon and each holder of a Note is referred to the corresponding
provisions of the Indenture for a complete statement of such terms. To the
extent that there is any inconsistency between the summary provisions set forth
in the Notes and the Indenture, the provisions of the Indenture shall govern.
Capitalized terms used but not defined in this Note shall have the meanings
ascribed to them in the Indenture.
B-6
<PAGE> 121
In case an Event of Default, as defined in the Indenture, shall have
occurred and be continuing, the principal of, premium, if any, and accrued
interest on all Notes may be declared, and upon said declaration shall become,
due and payable, in the manner, with the effect and subject to the conditions
provided in the Indenture.
The Indenture contains provisions permitting the Company and the
Trustee, with the consent of the holders of not less than a majority in
aggregate principal amount of the Notes at the time outstanding, evidenced as in
the Indenture provided, to execute supplemental indentures adding any provisions
to or changing in any manner or eliminating any of the provisions of the
Indenture or of any supplemental indenture or modifying in any manner the rights
of the holders of the Notes; provided that no such supplemental indenture shall
(i) extend the fixed maturity of any Note, or reduce the rate or extend the time
of payment of interest thereon, or reduce the principal amount thereof or
premium, if any, thereon, or reduce any amount payable on redemption thereof,
alter the obligation of the Company to redeem the Notes at the option of the
holders upon the occurrence of a Change of Control or impair or affect the right
of any Noteholder to institute suit for the payment thereof, or make the
principal thereof or interest or premium, if any, thereon payable in any coin or
currency other than that provided in the Notes, modify the subordination
provisions in a manner adverse to the holders of the Notes, or impair the right
to convert the Notes into Common Stock subject to the terms set forth in the
Indenture without the consent of the holder of each Note so affected or (ii)
reduce the aforesaid percentage of Notes, the holders of which are required to
consent to any such supplemental indenture, without the consent of the holders
of all Notes then outstanding. It is also provided in the Indenture that, prior
to any declaration accelerating the maturity of the Notes, the holders of a
majority in aggregate principal amount of the Notes at the time outstanding may
on behalf of the holders of all of the Notes waive any past default or Event of
Default under the Indenture and its consequences except a default in the payment
of interest or any premium on or the principal of any of the Notes, a failure by
the Company to convert any Notes into Common Stock of the Company or a default
in respect of a covenant or provision of the Indenture that under Article X
thereof cannot be modified or amended without the consent of the holders of all
Notes then outstanding. Any such consent or waiver by the holder of this
Restricted Global Note (unless revoked as provided in the Indenture) shall be
conclusive and
B-7
<PAGE> 122
binding upon such holder and upon all future holders and owners of this
Restricted Global Note and any Notes that may be issued in exchange or
substitution hereof, irrespective of whether or not any notation thereof is made
upon this Restricted Global Note or such other Notes.
No reference herein to the Indenture and no provision of this
Restricted Global Note or of the Indenture shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay the principal of and
any premium and interest on this Restricted Global Note at the place, at the
respective times, at the rate and in the coin or currency herein prescribed.
Interest on the Notes shall be computed on the basis of a 360-day year
composed of twelve 30-day months.
The Notes are issuable in registered form without coupons in
denominations of $1,000 principal amount and integral multiples thereof. At the
office or agency of the Company referred to on the face hereof, and in the
manner and subject to the limitations provided in the Indenture, without payment
of any service charge but with payment of a sum sufficient to cover any tax or
other governmental charge that may be imposed in connection with any
registration or exchange of Notes, Notes may be exchanged for a like aggregate
principal amount of Notes of other authorized denominations.
The Notes are not redeemable at the option of the Company prior to
March 1, 1999. At any time on or after that date, the Notes may be redeemed at
the Company's option, upon notice as set forth in the Indenture, in whole at any
time or in part from time to time, at the optional redemption prices set forth
below together with accrued interest to the date fixed for redemption.
If redeemed during the 12-month period beginning:
<TABLE>
<CAPTION>
Date Percentage
---- ----------
<S> <C>
March 1, 1999 102.5%
March 1, 2000 101.7%
March 1, 2001 100.8%
</TABLE>
and 100% on or after March 1, 2002; provided that if the date fixed for
redemption is on a date or after the record date and on or before the next
following interest payment date, then the interest payable on such date
B-8
<PAGE> 123
shall be paid to the holder of record on the next preceding February 15 or
September 15, respectively.
If a Change of Control shall occur at any time, then each holder of
Notes shall have the right to require that the Company purchase such holder's
Notes in whole or in part in integral multiples of $1,000, at a purchase price
in cash in an amount equal to 101% of the principal amount of such Notes, plus
accrued and unpaid interest, if any, to the repurchase date pursuant to an offer
to be made by the Company and in accordance with the procedures set forth in the
Indenture.
Subject to the provisions of the Indenture, the holder hereof has the
right, at its option, at any time after 60 days following the latest date of
original issuance of the Notes and prior to the close of business on March 1,
2003, or, as to all or any portion hereof called for redemption, prior to the
close of business on the Trading Day next preceding the date fixed for
redemption (unless the Company shall default in payment due upon redemption
thereof), to convert the principal hereof or any portion of such principal that
is $1,000 or an integral multiple thereof, into that number of fully paid and
non-assessable shares of Company's Common Stock, as said shares shall be
constituted at the date of conversion, obtained by dividing the principal amount
of this Restricted Global Note or portion thereof to be converted by the
conversion price of $46.965 or such conversion price as adjusted from time to
time as provided in the Indenture, upon surrender of this Restricted Global
Note, together with a conversion notice as provided in the Indenture, to the
Company at the office or agency of the Company maintained for that purpose in
the Borough of Manhattan, The City of New York, or at the option of such holder,
the Corporate Trust Office of the Trustee, and, unless the shares issuable on
conversion are to be issued in the same name as this Restricted Global Note,
duly endorsed by, or accompanied by instruments of transfer in form satisfactory
to the Company duly executed by, the holder or by his duly authorized attorney.
No adjustment in respect of interest or dividends will be made upon any
conversion; provided that if this Restricted Global Note shall be surrendered
for conversion during the period from the close of business on any record date
for the payment of interest through the close of business on the Business Day
next preceding the following interest payment date, this Restricted Global Note
(unless it or the portion being converted shall have been called for redemption
on a date in such period) must be accompanied by an amount, in funds acceptable
to the Company, equal to the interest payable on such interest payment date on
the
B-9
<PAGE> 124
principal amount being converted. The interest payment with respect to a Note
called for redemption on a date during the period from the close of business on
or after any record date to the opening of business on the business day
following the corresponding payment date will be payable on the corresponding
interest payment date to the registered Holder at the close of business on that
record date (notwithstanding the conversion of such Note before the
corresponding interest payment date) and a Holder who elects to convert need not
to include funds equal to the interest paid. No fractional shares will be issued
upon any conversion, but an adjustment in cash will be made, as provided in the
Indenture, in respect of any fraction of a share that would otherwise be
issuable upon the surrender of any Note or Notes for conversion.
Upon due presentment for registration of transfer of this Restricted
Global Note at the office or agency of the Company in the Borough of Manhattan,
The City of New York, or at the option of the holder of this Restricted Global
Note, at the Corporate Trust Office of the Trustee, a new Note or Notes of
authorized denominations for an equal aggregate principal amount will be issued
to the transferee in exchange thereof, subject to the conditions and limitations
provided in the Indenture, without charge except for any tax or other
governmental charge imposed in connection therewith.
The Company, the Trustee, any authenticating agent, any paying agent,
any conversion agent and any Note registrar may deem and treat the registered
holder hereof as the absolute owner of this Restricted Global Note (whether or
not this Restricted Global Note shall be overdue and notwithstanding any
notation of ownership or other writing hereon made by anyone other than the
Company or any Note registrar), for the purpose of receiving payment hereof, or
on account hereof, for the conversion hereof and for all other purposes, and
neither the Company nor the Trustee nor any other authenticating agent nor any
paying agent nor any other conversion agent nor any Note registrar shall be
affected by any notice to the contrary. All payments made to or upon the order
of such registered holder shall, to the extent of the sum or sums paid, satisfy
and discharge liability for monies payable on this Restricted Global Note.
No recourse for the payment of the principal of or any premium or
interest on this Restricted Global Note, or for any claim based hereon or
otherwise in respect hereof, and no recourse under or upon any obligation,
covenant or agreement of the Company in the Indenture or any indenture
supplemental thereto or in any
B-10
<PAGE> 125
Note, or because of the creation of any indebtedness represented thereby, shall
be had against any incorporator, stockholder, officer or director, as such,
past, present or future, of the Company or of any Successor Company, either
directly or through the Company or any Successor Company, whether by virtue of
any constitution, statute or rule of law or by the enforcement of any assessment
or penalty or otherwise, all such liability being, by the acceptance hereof and
as part of the consideration for the issue hereof, expressly waived and
released.
B-11
<PAGE> 126
ABBREVIATIONS
The following abbreviations, when used in the inscription of the face
of this Restricted Global Note, shall be construed as though they were written
out in full according to applicable laws or regulations:
TEN COM - as tenants in common UNIF GIFT MIN ACT -
___________________ Custodian
(Cust)
TEN ENT - as tenants by the ___________________ under
entireties (Minor)
JT TEN - as joint tenants with
right of survivorship Uniform Gifts to
and not as tenants in Minors Act ________________
common (State)
Additional abbreviations may also be used though
not in the above list.
B-12
<PAGE> 127
[FORM OF CONVERSION NOTICE]
CONVERSION NOTICE
To: Healthsource, Inc.
The undersigned registered owner of this Restricted Global Note hereby
irrevocably exercises the option to convert this Restricted Global Note, or the
portion hereof (which is $1,000 principal amount or an integral multiple
thereof) below designated, into shares of Common Stock in accordance with the
terms of the Indenture referred to in this Restricted Global Note, and directs
that the shares issuable and deliverable upon such conversion, together with any
check in payment for fractional shares and any Notes representing any
unconverted principal amount hereof, be issued and delivered to the registered
holder hereof unless a different name has been indicated below. If shares or any
portion of this Restricted Global Note not converted are to be issued in the
name of a person other than the undersigned, the undersigned will check the
appropriate box below and pay all transfer taxes payable with respect thereto.
Any amount required to be paid to the undersigned on account of interest
accompanies this Restricted Global Note.
Dated:___________________
___________________________
___________________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks,
stock brokers, savings and loan
associations and credit unions) with
membership in an approved signature
guarantee medallion program pursuant
to Securities and Exchange Commission
Rule 17Ad-15 if shares of Common Stock
are to be issued, or Notes to be
delivered, other than to and in the name
of the registered holder.
_________________________________________
Signature Guarantee
B-13
<PAGE> 128
Fill in for registration of shares if to be issued, and Notes if to be
delivered, other than to and in the name of the registered holder:
_________________________________________
(Name)
_________________________________________
(Street Address)
_________________________________________
(City, State and Zip Code)
Please print name and address
Principal amount to be converted (if less than all)
$____________
_________________________________________
B-14
<PAGE> 129
[FORM OF OPTION TO ELECT REPAYMENT
UPON A CHANGE OF CONTROL]
To: Healthsource, Inc.
The undersigned registered owner of this Restricted Global Note hereby
irrevocably acknowledges receipt of a notice from Healthsource, Inc. (the
"Company") as to the occurrence of a Change of Control with respect to the
Company and requests and instructs the Company to repay the entire principal
amount of this Restricted Global Note, or the portion thereof (which is $1,000
principal amount or an integral multiple thereof) below designated, in
accordance with the terms of the Indenture referred to in this Restricted Global
Note, together with accrued interest to such date, to the registered holder
hereof.
Dated:____________________
___________________________
___________________________
Signature(s)
___________________________
Social Security or Other
Taxpayer Identification
Number
Principal amount to be
repaid (if less than all):
$__________________________
B-15
<PAGE> 130
[FORM OF ASSIGNMENT]
For value received ____________________________________ hereby sell(s),
assign(s) and transfer(s) unto ____________________ (please insert social
security or other identifying number of assignee) the within Note, and hereby
irrevocably constitutes and appoints ____________________________________
attorney to transfer the said Note on the books of the Company, with full power
of substitution in the premises.
In connection with any transfer of the within Note (or any issuance of
shares of Common Stock upon conversion of the within Note) occurring prior to
the third anniversary of the date of original issuance of such Note, the
undersigned confirms that such Note (or shares of Common Stock, as the case may
be) are being transferred:
[ ] To Healthsource, Inc. or a subsidiary thereof; or
[ ] Pursuant to and in compliance with Rule 144A under the Securities Act
of 1933, as amended; or
[ ] To an Institutional Accredited Investor pursuant to and in compliance
with the Securities Act of 1933, as amended; or
[ ] Pursuant to and in compliance with Regulation S under the Securities
Act of 1933, as amended; or
[ ] Pursuant to and in compliance with Rule 144 under the Securities Act of
1933, as amended.
Unless one of the boxes above is checked, the Trustee will refuse to
register any of the within Notes (or such shares of Common Stock, as the case
may be) in the name of any person other than the registered holder thereof (or
hereof); provided, however, that the Trustee may, in its sole discretion,
register the transfer of such Notes (or such shares of Common Stock, as the case
may be) if it has received such certifications, legal opinions and/or other
information as the Company has
B-16
<PAGE> 131
reasonably requested to confirm that such transfer is being made pursuant to an
exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act of 1933, as amended.
In addition, if the transferee is an institutional accredited investor
or a purchaser who is not a U.S. person, the holder must furnish to the Trustee
(i) in the case of an institutional accredited investor, a signed letter
containing certain representations and agreements relating to the restrictions
on transfer of the security evidenced hereby, and (ii) such other
certifications, legal opinions or other information as it may reasonably require
to confirm that such transfer is being made pursuant to an exemption from, or in
a transaction not subject to, the registration requirements of the Securities
Act of 1933, as amended.
Dated: _______________________
______________________________
______________________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks,
stock brokers, savings and loan
associations and credit unions) with
membership in an approved signature
guarantee medallion program pursuant
to Securities and Exchange Commission
Rule 17Ad-15.
________________________________________
Signature Guarantee
NOTICE: The signature on the conversion notice, the option to elect payment upon
a Change of Control or the assignment must correspond with the name as written
upon the face of the Note in every particular without alteration or enlargement
or any change whatever.
B-17
<PAGE> 132
SCHEDULE A
SCHEDULE OF EXCHANGES
The initial principal amount of this Restricted Global Note is U.S.
$_____________. The following additions to principal, redemptions, exchanges of
a part of this Restricted Global Note for an interest in the Regulation S Global
Note or definitive Note and conversions into Common Shares have been made:
<TABLE>
<CAPTION>
=================================================================================================================
Principal
Amount Re-
Principal deemed,
Amount Added Exchanged for
on Interest in
Exchange of the Regula- Remaining
Date of Addi- Interest in tion S Principal
tion to Prin- the Regula- Global Note Amount Out-
cipal, Re- tion S Global or Definitive standing Notation
demption, Note or De- Notes or Con- Following Made by or
Exchange or finitive verted into such Transac- on behalf of
Conversion Notes Common Shares tion the Trustee
<S> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------
=================================================================================================================
</TABLE>
B-18
<PAGE> 133
EXHIBIT C - FORM OF REGULATION S GLOBAL NOTE
[FORM OF FACE OF NOTE]
No. C-1 $_________________
CUSIP U42262AA0
HEALTHSOURCE, INC.
5% Convertible Subordinated Notes Due 2003
UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR NOTES IN
DEFINITIVE FORM, THIS REGULATION S GLOBAL NOTE MAY NOT BE TRANSFERRED
EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR
BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF
THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A
SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS
THIS REGULATION S GLOBAL NOTE IS PRESENTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(THE "DEPOSITARY"), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF
TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED
IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO.
OR SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE
BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.
THE NOTE EVIDENCED HEREBY HAS NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE
SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED
STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS EXCEPT AS
SET FORTH IN THE FOLLOWING SENTENCE. BY ACQUISITION HEREOF, THE HOLDER
(1) REPRESENTS THAT (A) IT IS A "QUALIFIED INSTITUTIONAL BUYER" (AS
DEFINED IN RULE 144A UNDER THE SECURITIES ACT) OR (B) IT IS AN
INSTITUTIONAL "ACCREDITED INVESTOR" (AS DEFINED IN RULE 501(A) (1),
(2), (3)
C-1
<PAGE> 134
OR (7) UNDER THE SECURITIES ACT) ("INSTITUTIONAL ACCREDITED INVESTOR")
OR (C) IT IS NOT A U.S. PERSON AND IS ACQUIRING THE NOTE EVIDENCED
HEREBY IN AN OFFSHORE TRANSACTION; (2) AGREES THAT IT WILL NOT PRIOR TO
THE DATE THAT IS THREE YEARS AFTER THE LATER OF THE ORIGINAL ISSUANCE
OF THE NOTE EVIDENCED HEREBY AND THE LAST DATE ON WHICH HEALTHSOURCE,
INC. (THE "COMPANY") OR ANY "AFFILIATE" (AS DEFINED IN RULE 144 UNDER
THE SECURITIES ACT) OF THE COMPANY WAS THE OWNER OF THE NOTE (THE
"RESTRICTION TERMINATION DATE") RESELL OR OTHERWISE TRANSFER THE NOTE
EVIDENCED HEREBY OR THE COMMON STOCK ISSUABLE UPON CONVERSION OF SUCH
NOTE EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) TO A
QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE
SECURITIES ACT, (C) TO AN INSTITUTIONAL ACCREDITED INVESTOR THAT, PRIOR
TO SUCH TRANSFER, FURNISHES TO THE BANK OF NEW YORK, AS TRUSTEE, A
SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS
RELATING TO THE RESTRICTIONS ON TRANSFER OF THE NOTE EVIDENCED HEREBY
(THE FORM OF WHICH LETTER CAN BE OBTAINED FROM SUCH TRUSTEE), (D)
OUTSIDE THE UNITED STATES IN COMPLIANCE WITH RULE 904 UNDER THE
SECURITIES ACT, (E) PURSUANT TO THE EXEMPTION FROM REGISTRATION
PROVIDED BY RULE 144 UNDER THE SECURITIES ACT (IF AVAILABLE) OR (F)
PURSUANT TO A REGISTRATION STATEMENT WHICH HAS BEEN DECLARED EFFECTIVE
UNDER THE SECURITIES ACT; AND (3) AGREES THAT IT WILL DELIVER TO EACH
PERSON TO WHOM THE NOTE EVIDENCED HEREBY IS TRANSFERRED A NOTICE
SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN CONNECTION WITH ANY
TRANSFER OF THE NOTE EVIDENCED HEREBY BEFORE THE RESTRICTION
TERMINATION DATE, THE HOLDER MUST CHECK THE APPROPRIATE BOX SET FORTH
ON THE REVERSE HEREOF RELATING TO THE MANNER OF SUCH TRANSFER AND
SUBMIT THIS CERTIFICATE TO THE BANK OF NEW YORK, AS TRUSTEE. IF THE
PROPOSED TRANSFER IS PURSUANT TO CLAUSE (C), (D) OR (E) ABOVE, THE
HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE BANK OF NEW YORK,
AS TRUSTEE, SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS
THE COMPANY MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS
BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. THIS
LEGEND WILL BE REMOVED UPON THE RESTRICTION TERMINATION DATE. AS USED
HEREIN, THE TERMS "OFFSHORE TRANSACTION," "UNITED STATES"
C-2
<PAGE> 135
AND "U.S. PERSON" HAVE THE MEANINGS GIVEN TO THEM BY
REGULATION S UNDER THE SECURITIES ACT.
HEALTHSOURCE, INC., a corporation duly organized and validly existing
under the laws of the State of New Hampshire (the "Company"), which term
includes any Successor Company under the Indenture referred to on the reverse
hereof, for value received hereby promises to pay to ___________________________
________________________________________________________________________________
________________________________________________________________________________
______________, or registered assigns, the principal sum of ____________________
________________________________________________________________________________
______________________________________________________________________ Dollars
(subject to adjustment as set forth in the next paragraph hereof) on March 1,
2003, at the office or agency of the Company maintained for that purpose in the
Borough of Manhattan, The City of New York, or, at the option of the holder of
this Regulation S Global Note, at the Corporate Trust Office of the Trustee, in
such coin or currency of the United States of America as at the time of payment
shall be legal tender for the payment of public and private debts, and to pay
interest, semi-annually on March 1 and September 1 of each year, commencing
September 1, 1996, on said principal sum at said office or agency, in like coin
or currency, at the rate per annum specified in the title of this Regulation S
Global Note, from the March 1 or September 1, as the case may be, next preceding
the date of this Regulation S Global Note to which interest has been paid or
duly provided for, unless the date hereof is a date to which interest has been
paid or duly provided for, in which case from the date of this Regulation S
Global Note, or unless no interest has been paid or duly provided for on the
Notes, in which case from March 1, 1996, until payment of said principal sum has
been made or duly provided for; provided that if the Company shall default in
the payment of interest due on such March 1 or September 1, then this Regulation
S Global Note shall bear interest from the next preceding March 1 or September
1, to which interest has been paid or duly provided for or, if no interest has
been paid or duly provided for on such Note, from March 1, 1996. The interest so
payable on any March 1 or September 1 will be paid to the person in whose name
this Regulation S Global Note (or one or more Predecessor Notes) is registered
at
C-3
<PAGE> 136
the close of business on the record date, which shall be the February 15 or
August 15 (whether or not a Business Day) next preceding such March 1 or
September 1, respectively; provided that any such interest not punctually paid
or duly provided for shall be payable as provided in the Indenture. Interest
shall be paid by check mailed to the registered holder at the registered address
of such person unless other arrangements are made in accordance with the
provisions of the Indenture.
The aggregate principal amount of this Regulation S Global Note
represented hereby may from time to time be reduced or increased to reflect
exchanges of a part of this Regulation S Global Note for interests in the
Restricted Global Note or definitive Notes or exchanges of interests in the
Restricted Global Note or definitive Notes for a part of this Regulation S
Global Note or conversions or redemptions of a part of this Regulation S Global
Note or cancellations of a part of this Regulation S Global Note or transfers of
interests in the Restricted Global Note or definitive Notes in return for a part
of this Regulation S Global Note or transfers of a part of this Regulation S
Global Note effected by delivery of interests in the Restricted Global Note or
definitive Notes, in each case, and in any such case, by means of notations on
the Schedule of Exchanges, Conversions, Redemptions, Cancellations and Transfers
on the last page hereof. Notwithstanding any provision of this Regulation S
Global Note to the contrary, (i) exchanges of a part of this Regulation S Global
Note for interests in the Restricted Global Note or definitive Notes, (ii)
exchanges of interests in the Restricted Global Note or definitive Notes for a
part of this Regulation S Global Note, (iii) conversions or redemptions of a
part of this Regulation S Global Note, (iv) cancellations of a part of this
Regulation S Global Note, (v) transfers of interests in the Restricted Global
Note or definitive Notes in return for a part of this Regulation S Global Note
and (vi) transfers of a part of this Regulation S Global Note effected by
delivery of interests in the Restricted Global Note or definitive Notes may be
effected without the surrendering of this Regulation S Global Note, provided
that appropriate notations on the Schedule of Exchanges, Conversions,
Redemptions, Cancellations and Transfers are made by the Trustee, or the
Custodian at the direction of the Trustee, to reflect the appropriate reduction
or increase, as
C-4
<PAGE> 137
the case may be, in the aggregate principal amount of this Regulation S Global
Note resulting therefrom or as a consequence thereof.
Reference is made to the further provisions of this Regulation S Global
Note set forth on the reverse hereof, including, without limitation, provisions
giving the holder of this Regulation S Global Note the right to convert this
Regulation S Global Note into Common Stock of the Company on the terms and
subject to the limitations referred to on the reverse hereof and as more fully
specified in the Indenture. Such further provisions shall for all purposes have
the same effect as though fully set forth at this place.
This Regulation S Global Note shall be deemed to be a contract made
under the laws of the State of New York, and for all purposes shall be construed
in accordance with and governed by the laws of said State, without regard to
conflicts of laws principles thereof.
This Regulation S Global Note shall not be valid or become obligatory
for any purpose until the certificate of authentication hereon shall have been
manually signed by the Trustee or a duly authorized authenticating agent under
the Indenture.
C-5
<PAGE> 138
IN WITNESS WHEREOF, the Company has caused this Regulation S Global
Note to be duly executed under its corporate seal.
HEALTHSOURCE, INC.
By:_____________________________
Name:
Title:
Attest:
_________________________
Secretary
C-6
<PAGE> 139
[FORM OF CERTIFICATE OF AUTHENTICATION]
CERTIFICATE OF AUTHENTICATION
Dated:
This is one of the Notes described in the within-named indenture.
THE BANK OF NEW YORK, as Trustee
By:_____________________________
Authorized Signatory
As Authenticating Agent
(if different from Trustee)
By:_____________________________
Authorized Signatory
[FORM OF REVERSE OF REGULATION S GLOBAL NOTE]
HEALTHSOURCE, INC.
5% Convertible Subordinated Notes Due 2003
This Regulation S Global Note is one of a duly authorized issue of
Notes of the Company, designated as its 5% Convertible Subordinated Notes Due
2003 (herein called the "Notes"), limited to the aggregate principal amount of
$247,250,000 all issued or to be issued under and pursuant to an Indenture dated
as of March 6, 1996 (the "Indenture"), between the Company and The Bank of New
York, the trustee (the "Trustee"), to which Indenture and all indentures
supplemental thereto reference is hereby made for a complete description of the
rights, limitations of rights, obligations, duties and immunities thereunder of
the Trustee, the Company and the holders of the Notes. Each Note is subject to,
and qualified by, all such terms as set forth in the Indenture certain of which
are summarized hereon and each holder of a Note is referred to the corresponding
provisions of the Indenture for a complete statement of such terms. To the
extent that there is any inconsistency between the summary provisions set forth
in the Notes and the Indenture, the
C-7
<PAGE> 140
provisions of the Indenture shall govern. Capitalized terms used but not defined
in this Note shall have the meanings ascribed to them in the Indenture.
In case an Event of Default, as defined in the Indenture, shall have
occurred and be continuing, the principal of, premium, if any, and accrued
interest on all Notes may be declared, and upon said declaration shall become,
due and payable, in the manner, with the effect and subject to the conditions
provided in the Indenture.
The Indenture contains provisions permitting the Company and the
Trustee, with the consent of the holders of not less than a majority in
aggregate principal amount of the Notes at the time outstanding, evidenced as in
the Indenture provided, to execute supplemental indentures adding any provisions
to or changing in any manner or eliminating any of the provisions of the
Indenture or of any supplemental indenture or modifying in any manner the rights
of the holders of the Notes; provided that no such supplemental indenture shall
(i) extend the fixed maturity of any Note, or reduce the rate or extend the time
of payment of interest thereon, or reduce the principal amount thereof or
premium, if any, thereon, or reduce any amount payable on redemption thereof,
alter the obligation of the Company to redeem the Notes at the option of the
holders upon the occurrence of a Change of Control or impair or affect the right
of any Noteholder to institute suit for the payment thereof, or make the
principal thereof or interest or premium, if any, thereon payable in any coin or
currency other than that provided in the Notes, modify the subordination
provisions in a manner adverse to the holders of the Notes, or impair the right
to convert the Notes into Common Stock subject to the terms set forth in the
Indenture without the consent of the holder of each Note so affected or (ii)
reduce the aforesaid percentage of Notes, the holders of which are required to
consent to any such supplemental indenture, without the consent of the holders
of all Notes then outstanding. It is also provided in the Indenture that, prior
to any declaration accelerating the maturity of the Notes, the holders of a
majority in aggregate principal amount of the Notes at the time outstanding may
on behalf of the holders of all of the Notes waive any past default or Event of
Default under the Indenture and its consequences except a default
C-8
<PAGE> 141
in the payment of interest or any premium on or the principal of any of the
Notes, a failure by the Company to convert any Notes into Common Stock of the
Company or a default in respect of a covenant or provision of the Indenture that
under Article X thereof cannot be modified or amended without the consent of the
holders of all Notes then outstanding. Any such consent or waiver by the holder
of this Regulation S Global Note (unless revoked as provided in the Indenture)
shall be conclusive and binding upon such holder and upon all future holders and
owners of this Regulation S Global Note and any Notes that may be issued in
exchange or substitution hereof, irrespective of whether or not any notation
thereof is made upon this Regulation S Global Note or such other Notes.
No reference herein to the Indenture and no provision of this
Regulation S Global Note or of the Indenture shall alter or impair the
obligation of the Company, which is absolute and unconditional, to pay the
principal of and any premium and interest on this Regulation S Global Note at
the place, at the respective times, at the rate and in the coin or currency
herein prescribed.
Interest on the Notes shall be computed on the basis of a 360-day year
composed of twelve 30-day months.
The Notes are issuable in registered form without coupons in
denominations of $1,000 principal amount and integral multiples thereof. At the
office or agency of the Company referred to on the face hereof, and in the
manner and subject to the limitations provided in the Indenture, without payment
of any service charge but with payment of a sum sufficient to cover any tax or
other governmental charge that may be imposed in connection with any
registration or exchange of Notes, Notes may be exchanged for a like aggregate
principal amount of Notes of other authorized denominations.
The Notes are not redeemable at the option of the Company prior to
March 1, 1999. At any time on or after that date, the Notes may be redeemed at
the Company's option, upon notice as set forth in Section 3.2, in whole at any
time or in part from time to time, at the optional redemption prices set forth
below, together with accrued interest to the date fixed for
C-9
<PAGE> 142
redemption.
If redeemed during the 12-month period beginning:
<TABLE>
<CAPTION>
Date Percentage
---- ----------
<S> <C>
March 1, 1999 102.5%
March 1, 2000 101.7%
March 1, 2001 100.8%
</TABLE>
and 100% on or after March 1, 2002; provided that if the date fixed for
redemption is on a date or after the record date and on or before the next
following interest payment date, then the interest payable on such date shall be
paid to the holder of record on the next preceding February 15 or April 15,
respectively.
If a Change of Control (as defined in the Indenture) shall occur at any
time, then each holder of Notes shall have the right to require that the Company
purchase such holder's Notes in whole or in part in integral multiples of
$1,000, at a purchase price in cash in an amount equal to 101% of the principal
amount of such Notes, plus accrued and unpaid interest, if any, to the
repurchase date pursuant to an offer to be made by the Company and in accordance
with the procedures set forth in the Indenture.
Subject to the provisions of the Indenture, the holder hereof has the
right, at its option, at any time after 60 days following the latest date of
original issuance of the Notes and prior to the close of business on March 1,
2003, or, as to all or any portion hereof called for redemption, prior to the
close of business on the Trading Day next preceding the date fixed for
redemption (unless the Company shall default in payment due upon redemption
thereof), to convert the principal hereof or any portion of such principal that
is $1,000 or an integral multiple thereof, into that number of fully paid and
non-assessable shares of Company's Common Stock, as said shares shall be
constituted at the date of conversion, obtained by dividing the principal amount
of this Regulation S Global Note or portion thereof to be converted by the
conversion price of $46.965 or such conversion price as adjusted from time to
time as provided in the Indenture, upon surrender of this Regulation S Global
Note, together with a conversion notice as provided in
C-10
<PAGE> 143
the Indenture, to the Company at the office or agency of the Company maintained
for that purpose in the Borough of Manhattan, The City of New York, or at the
option of such holder, the Corporate Trust Office of the Trustee, and, unless
the shares issuable on conversion are to be issued in the same name as this
Regulation S Global Note, duly endorsed by, or accompanied by instruments of
transfer in form satisfactory to the Company duly executed by, the holder or by
his duly authorized attorney. No adjustment in respect of interest or dividends
will be made upon any conversion; provided that if this Regulation S Global Note
shall be surrendered for conversion during the period from the close of business
on any record date for the payment of interest through the close of business on
the Business Day next preceding the following interest payment date, this
Regulation S Global Note (unless it or the portion being converted shall have
been called for redemption on a date in such period) must be accompanied by an
amount, in funds acceptable to the Company, equal to the interest payable on
such interest payment date on the principal amount being converted. The interest
payment with respect to a Note called for redemption on a date during the period
from the close of business on or after any record date to the opening of
business on the business day following the corresponding payment date will be
payable on the corresponding interest payment date to the registered Holder at
the close of business on that record date (notwithstanding the conversion of
such Note before the corresponding interest payment date) and a Holder who
elects to convert need not to include funds equal to the interest paid. No
fractional shares will be issued upon any conversion, but an adjustment in cash
will be made, as provided in the Indenture, in respect of any fraction of a
share that would otherwise be issuable upon the surrender of any Note or Notes
for conversion.
Upon due presentment for registration of transfer of this Regulation S
Global Note at the office or agency of the Company in the Borough of Manhattan,
The City of New York, or at the option of the holder of this Regulation S Global
Note, at the Corporate Trust Office of the Trustee, a new Note or Notes of
authorized denominations for an equal aggregate principal amount will be issued
to the transferee in exchange thereof, subject to the conditions and limitations
provided in the Indenture, without charge except for any tax or other
governmental charge imposed in connection therewith.
C-11
<PAGE> 144
The Company, the Trustee, any authenticating agent, any paying agent,
any conversion agent and any Note registrar may deem and treat the registered
holder hereof as the absolute owner of this Regulation S Global Note (whether or
not this Regulation S Global Note shall be overdue and notwithstanding any
notation of ownership or other writing hereon made by anyone other than the
Company or any Note registrar), for the purpose of receiving payment hereof, or
on account hereof, for the conversion hereof and for all other purposes, and
neither the Company nor the Trustee nor any other authenticating agent nor any
paying agent nor any other conversion agent nor any Note registrar shall be
affected by any notice to the contrary. All payments made to or upon the order
of such registered holder shall, to the extent of the sum or sums paid, satisfy
and discharge liability for monies payable on this Regulation S Global Note.
No recourse for the payment of the principal of or any premium or
interest on this Regulation S Global Note, or for any claim based hereon or
otherwise in respect hereof, and no recourse under or upon any obligation,
covenant or agreement of the Company in the Indenture or any indenture
supplemental thereto or in any Note, or because of the creation of any
indebtedness represented thereby, shall be had against any incorporator,
stockholder, officer or director, as such, past, present or future, of the
Company or of any Successor Company, either directly or through the Company or
any Successor Company, whether by virtue of any constitution, statute or rule of
law or by the enforcement of any assessment or penalty or otherwise, all such
liability being, by the acceptance hereof and as part of the consideration for
the issue hereof, expressly waived and released.
C-12
<PAGE> 145
ABBREVIATIONS
The following abbreviations, when used in the inscription of the face
of this Regulation S Global Note, shall be construed as though they were written
out in full according to applicable laws or regulations:
TEN COM - as tenants in common UNIF GIFT MIN ACT - _____________
Custodian (Cust)
TEN ENT - as tenants by the __________________ under
entireties (Minor)
JT TEN - as joint tenants with
right of survivorship Uniform Gifts to
and not as tenants in Minors Act _______________________
common (State)
Additional abbreviations may also be
used though not in the above list.
C-13
<PAGE> 146
[FORM OF CONVERSION NOTICE]
CONVERSION NOTICE
To: Healthsource, Inc.
The undersigned registered owner of this Regulation S Global Note
hereby irrevocably exercises the option to convert this Regulation S Global
Note, or the portion hereof (which is $1,000 principal amount or an integral
multiple thereof) below designated, into shares of Common Stock in accordance
with the terms of the Indenture referred to in this Regulation S Global Note,
and directs that the shares issuable and deliverable upon such conversion,
together with any check in payment for fractional shares and any Notes
representing any unconverted principal amount hereof, be issued and delivered to
the registered holder hereof unless a different name has been indicated below.
If shares or any portion of this Regulation S Global Note not converted are to
be issued in the name of a person other than the undersigned, the undersigned
will check the appropriate box below and pay all transfer taxes payable with
respect thereto. Any amount required to be paid to the undersigned on account of
interest accompanies this Regulation S Global Note.
Dated:_____________________
__________________________________
__________________________________
Signature(s)
Signature(s) must be guaranteed by an eligible Guarantor Institution (banks,
stock brokers, savings and loan associations and credit unions) with membership
in an approved signature guarantee medallion program pursuant to Securities and
Exchange Commission Rule 17Ad-15 if shares of Common Stock are to be issued, or
Notes to be delivered, other than to and in the name of the registered holder.
__________________________________
Signature Guarantee
C-14
<PAGE> 147
Fill in for registration of shares if to be issued, and Notes if to be
delivered, other than to and in the name of the registered holder:
__________________________________
(Name)
__________________________________
(Street Address)
__________________________________
(City, State and Zip Code)
Please print name and address
Principal amount to be converted
(if less than all) $____________
________________________________
C-15
<PAGE> 148
[FORM OF OPTION TO ELECT REPAYMENT
UPON A CHANGE OF CONTROL]
To: Healthsource, Inc.
The undersigned registered owner of this Regulation S Global Note
hereby irrevocably acknowledges receipt of a notice from Healthsource, Inc. (the
"Company") as to the occurrence of a Change of Control with respect to the
Company and requests and instructs the Company to repay the entire principal
amount of this Regulation S Global Note, or the portion thereof (which is $1,000
principal amount or an integral multiple thereof) below designated, in
accordance with the terms of the Indenture referred to in this Regulation S
Global Note, together with accrued interest to such date, to the registered
holder hereof.
Dated:_______________
__________________________________
__________________________________
Signature(s)
__________________________________
Social Security or Other Taxpayer
Identification Number
Principal amount to be repaid (if
less than all): $__________________
C-16
<PAGE> 149
[FORM OF ASSIGNMENT]
For value received ______________________________ hereby sell(s),
assign(s) and transfer(s) unto ___________________________ (please insert social
security or other identifying number of assignee) the within Note, and hereby
irrevocably constitutes and appoints ______________________________ attorney to
transfer the said Note on the books of the Company, with full power of
substitution in the premises.
In connection with any transfer of the within Note (or any issuance of
shares of Common Stock upon conversion of the within Note) occurring prior to
the third anniversary of the date of original issuance of such Note, the
undersigned confirms that such Note (or shares of Common Stock, as the case may
be) are being transferred:
[ ] To Healthsource, Inc. or a subsidiary thereof;
or
[ ] Pursuant to and in compliance with Rule 144A under the Securities Act
of 1933, as amended; or
[ ] To an Institutional Accredited Investor pursuant to and in compliance
with the Securities Act of 1933, as amended; or
[ ] Pursuant to and in compliance with Regulation S under the Securities
Act of 1933, as amended; or
[ ] Pursuant to and in compliance with Rule 144 under the Securities Act
of 1933, as amended.
Unless one of the boxes above is checked, the Trustee will refuse to
register any of the within Notes (or such shares of Common Stock, as the case
may be) in the name of any person other than the registered holder thereof (or
hereof); provided, however, that the Trustee may, in its sole discretion,
register the transfer of such Notes (or such shares of Common Stock, as the case
may be) if it has received such certifications, legal opinions and/or other
information as the Company has
C-17
<PAGE> 150
reasonably requested to confirm that such transfer is being made pursuant to an
exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act of 1933, as amended.
In addition, if the transferee is an institutional accredited investor
or a purchaser who is not a U.S. person, the holder must furnish to the Trustee
(i) in the case of an institutional accredited investor, a signed letter
containing certain representations and agreements relating to the restrictions
on transfer of the security evidenced hereby, and (ii) such other
certifications, legal opinions or other information as it may reasonably require
to confirm that such transfer is being made pursuant to an exemption from, or in
a transaction not subject to, the registration requirements of the Securities
Act of 1933, as amended.
Dated:_______________________________
_____________________________________
Signature(s)
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks,
stock brokers, savings and loan
associations and credit unions) with mem
bership in an approved signature
guarantee medallion program pursuant to
Securities and Exchange Commission Rule
17Ad-15.
_____________________________________
Signature Guarantee
NOTICE: The signature on the conversion notice, the option to elect payment upon
a Change of Control or the assignment must correspond with the name as written
upon the face of the Note in every particular without alteration or enlargement
or any change whatever.
C-18
<PAGE> 151
SCHEDULE A
SCHEDULE OF EXCHANGES
The initial principal amount of this Regulation S Global Note is U.S.$
_____________. The following additions to principal, redemptions, exchanges of a
part of this Regulation S Global Note for an interest in the Restricted Global
Note, definitive Note and conversions into Common Shares have been made:
<TABLE>
<CAPTION>
======================================================================================================================
Principal
Amount Re-
deemed,
Principal Exchanged for
Amount Added Interest in
on the Restrict- Remaining
Date of Addi- Exchange of ed Principal
tion to Prin- Interest in Global Note Amount Out-
cipal, Re- the Restrict- or Definitive standing Notation
demption, ed Global Notes or Con- Following Made by or
Exchange or Note or De- verted into such Transac- on behalf of
Conversion finitive Note Common Shares tion the Trustee
<S> <C> <C> <C> <C>
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------
======================================================================================================================
</TABLE>
C-19
<PAGE> 1
Exhibit 4.2
================================================================================
NOTE RESALE REGISTRATION RIGHTS AGREEMENT
Dated as of March 6, 1996
by and among
HEALTHSOURCE, INC.
and
THE PURCHASERS NAMED HEREIN
================================================================================
<PAGE> 2
This Note Resale Registration Rights Agreement (this
"Agreement") is made and entered into as of March 6, 1996 by and among
Healthsource, Inc., a New Hampshire corporation (the "Company"), and Bear,
Stearns & Co. Inc., Goldman, Sachs & Co., Merrill Lynch & Co., Morgan Stanley &
Co. Incorporated, Robertson, Stephens & Company and Smith Barney Inc.
(collectively, the "Purchasers"), which Purchasers have agreed to purchase from
the Company up to $215,000,000 principal amount of 5% Convertible Subordinated
Notes due 2003 (the "Notes") pursuant to the Purchase Agreement (as defined
below).
This Agreement is made pursuant to the Purchase Agreement,
dated March 1, 1996 (the "Purchase Agreement"), by and among the Company
and the Purchasers. In order to induce the Purchasers to purchase the Notes, the
Company has agreed to provide the registration rights set forth in this
Agreement. The execution and delivery of this Agreement is provided for in the
Purchase Agreement.
The parties hereby agree as follows:
1. DEFINITIONS
As used in this Agreement, the following capitalized terms
shall have the following meanings:
Act: Securities Act of 1933, as amended.
Agreement: As defined in the preamble hereto.
Broker-Dealer: Any broker or dealer registered under the
Exchange Act.
Business Day: A day, other than a Saturday, a Sunday or
a day on which the banking institutions in the State of New York are authorized
or obligated by law or executive order to close on a day which is declared a
national or New York state holiday.
Closing Date: The date of this Agreement.
Commission: Securities and Exchange Commission.
<PAGE> 3
Common Stock: Common Stock of the Company, par value $.10 per
share, issuable upon conversion of the Notes.
Company: As defined in the preamble hereto.
Consummate: An Exchange Offer shall be deemed "Consummated" for
purposes of this Agreement upon (i) the filing and effectiveness under the Act
of the Exchange Offer Registration Statement relating to the New Notes to be
issued in the Exchange Offer, (ii) the maintenance of such Exchange Offer
Registration Statement continuously effective and the keeping of the Exchange
Offer open for a period of not less than the minimum period required under
applicable federal and state securities laws to consummate the Exchange Offer,
provided, however, that in no event shall such period be less than 20 Business
Days, and (iii) the delivery by the Company to the registrar under the Indenture
of New Notes in the same aggregate principal amount as the aggregate principal
amount of Notes that were tendered by Holders thereof pursuant to the Exchange
Offer.
Effectiveness Target Date: As defined in Section 3 hereof.
Exchange Act: Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated thereunder.
Exchange Offer: The registration by the Company under
the Act of the New Notes pursuant to the Exchange Offer Registration Statement
through which the Company offers the Holders of all outstanding Transfer
Restricted Securities the opportunity to exchange all such outstanding Transfer
Restricted Securities held by such Holders for New Notes in an aggregate
principal amount equal to the aggregate principal amount of the Transfer
Restricted Securities tendered in such exchange offer by such Holders.
Exchange Offer Registration Statement: As defined in Section
3(c).
Exempt Resales: The transactions in which the Purchasers
propose to sell the Notes (i) to certain "qualified institutional buyers," as
such term is defined
2
<PAGE> 4
in Rule 144A under the Act ("QIBs"), (ii) to certain institutional "accredited
investors," as such term is defined in Rule 501(a)(1), (2), (3) or (7) of
Regulation D under the Act ("Accredited Institutions") and (iii) outside the
United States, to certain persons in offshore transactions in reliance on
Regulation S under the Act.
Holder: As defined in Section 2(b) hereof.
Indemnified Holder: As defined in Section 6(a) hereof.
Indenture: The Indenture, dated as of March 6, 1996, by and
between the Company and The Bank of New York, as trustee (the "Trustee"),
pursuant to which the Notes are to be issued, as such Indenture is amended,
modified or supplemented from time to time in accordance with the terms thereof.
Interest Payment Date: As defined in the Indenture and the
Notes.
NASD: National Association of Securities Dealers, Inc.
New Notes: As defined in Section 3(c) hereof.
Notes: As defined in the preamble hereto.
Person: An individual, partnership, corporation, trust,
unincorporated organization or a government, agency or political subdivision
thereof.
Prospectus: The prospectus included in any Registration
Statement, as amended or supplemented including without limitation by any
post-effective amendments thereto, and all material incorporated by reference
into such prospectus.
Purchase Agreement: As defined in the preamble hereto.
Purchasers: As defined in the preamble hereto.
Registration Statement: The Shelf Registration Statement or the
Exchange Offer Registration Statement of the Company which is filed pursuant to
the provisions of
3
<PAGE> 5
Section 3 hereof, including the Prospectus included therein, all amendments and
supplements thereto (including any post-effective amendments) and all exhibits
and material incorporated by reference therein.
Shelf Filing Deadline: As defined in Section 3 hereof.
Shelf Registration Statement: As defined in Section 3 hereof.
TIA: The Trust Indenture Act of 1939 (15 U.S.C. Section
77aaa-77bbbb), as amended and in effect on the date of the Indenture.
Transfer Restricted Securities: Each Note, and any Common Stock
issued upon conversion of any Note, until the earliest to occur of (i) the date
on which such Note or Common Stock, as the case may be, has been effectively
registered under the Act and disposed of in accordance with an effective Shelf
Registration Statement, (ii) the date on which such Note is exchanged for a New
Note in the Exchange Offer and entitled to be resold to the public by the Holder
thereof without complying with the prospectus delivery requirements of the Act,
(iii) the date on which such Note or Common Stock, as the case may be, is
distributed to the public pursuant to Rule 144 under the Act or by a
Broker-Dealer pursuant to the "Plan of Distribution" contemplated by the
Exchange Offer Registration Statement (including delivery of the Prospectus
contained therein), and (iv) the date on which such Note is converted into
Common Stock in accordance with the terms and provisions of the Notes and the
Indenture.
Underwritten Registration or Underwritten Offering: A
registration in which securities of the Company are sold to an underwriter for
reoffering to the public.
2. SECURITIES SUBJECT TO THIS AGREEMENT
(a) Transfer Restricted Securities. The securities entitled to
the benefits of this Agreement are the Transfer Restricted Securities.
4
<PAGE> 6
(b) Holders of Transfer Restricted Securities. A Person is
deemed to be a holder of Transfer Restricted Securities (each, a "Holder")
whenever such Person owns Transfer Restricted Securities of record.
3. REGISTRATION
(a) Shelf Registration. The Company hereby agrees to:
(i) use its best efforts to file or cause to be filed a
continuous registration statement pursuant to Rule 415 under the Act
(together with the Prospectus included therein, all amendments and
supplements thereto (including post-effective amendments) and all
exhibits and materials incorporated by reference therein, the "Shelf
Registration Statement") on or prior to the 90th day after the Closing
Date (the "Shelf Filing Deadline"), which Shelf Registration Statement
shall provide for resales of all Transfer Restricted Securities,
provided that the Holders thereof shall have provided the information
required pursuant to Section 3(b) hereof; and
(ii) use all reasonable efforts to cause the Shelf Registration
Statement to be declared effective by the Commission as promptly as
practicable after the Closing Date (the "Effectiveness Target Date").
Subject to any notice by the Company in accordance with Section 4(b) hereof of
the existence of any fact or event of the kind described in Section 4(b)(iii)(D)
hereof, the Company shall use all reasonable efforts to keep the Shelf
Registration Statement continuously effective, supplemented and amended as
required by the provisions of Sections 4(a) and (b) hereof to the extent
necessary to ensure that it is available for resales of Transfer Restricted
Securities by the Holders of Transfer Restricted Securities entitled to the
benefit of this Section 3(a) and to ensure that the Shelf Registration Statement
conforms to the requirements of this Agreement, the Act and the policies, rules
and regulations of the Commission as announced from time to time thereunder for
a period of at least three years following the Closing Date, provided, however,
that the Company shall not be obligated to keep the Shelf Registration Statement
effec-
5
<PAGE> 7
tive, if it has received an opinion from its outside counsel, Sheehan, Phinney,
Bass + Green, Professional Association, or other counsel reasonably acceptable
to the Purchasers, to the effect that the Restricted Transfer Securities can be
freely tradable without the continued effectiveness of the Shelf Registration
Statement.
(b) Certificated Securities; Provision by Holders of Certain
Information in Connection with the Shelf Registration Statement. No Holder of
Transfer Restricted Securities may include any of its Transfer Restricted
Securities in any Shelf Registration Statement pursuant to this Agreement unless
(i) such Holder holds such Transfer Restricted Securities in the form of
definitive Notes or shares of Common Stock (as provided in the Indenture) which
are evidenced by physical certificates and (ii) until such Holder furnishes to
the Company in writing, within 20 Business Days after receipt of a request
therefor, such information as the Company may reasonably request for use in
connection with the Shelf Registration Statement or any Prospectus or
preliminary Prospectus included therein. In connection with all such requests
for information from Holders of Transfer Restricted Securities, the Company
shall notify such Holders of the requirements set forth in the preceding
sentence. Each Holder as to which any Shelf Registration Statement is being
effected agrees to furnish promptly to the Company all information required to
be disclosed in order to make the information previously furnished to the
Company by such Holder not materially misleading.
(c) Registered Exchange Offer. If, based upon a written opinion
of counsel (other than in-house counsel) to the Company addressed and delivered
to the Holders, the Company determines that it is permissible under applicable
law and Commission policy to Consummate an Exchange Offer, the Company may at
its election Consummate an Exchange Offer in lieu of filing and maintaining the
Shelf Registration Statement described herein. If the Company elects to
Consummate an Exchange Offer in accordance with the provisions hereof, the
Company shall (i) cause to be filed with the Commission no later than the Shelf
Filing Deadline (or later if the Company has filed and maintained a Shelf
Registration Statement pursuant to this Agreement), a Registration Statement
(the "Exchange Offer Registration Statement") under the Act relating to (A) a
new issue of notes identical in all
6
<PAGE> 8
material respects to the Notes except as to transfer restrictions (the "New
Notes") and (B) the shares of Common Stock issuable upon conversion of such New
Notes, (ii) use all reasonable efforts to cause such Registration Statement to
become effective no later than the Effectiveness Target Date, (iii) in
connection with the foregoing, file (A) all pre-effective amendments to such
Registration Statement as may be necessary in order to cause such Registration
Statement to become effective, (B) if applicable, a post-effective amendment to
such Registration Statement pursuant to Rule 430A under the Act and (C) cause
all necessary filings in connection with the registration and qualification of
the New Notes to be made under the Blue Sky laws of such jurisdictions as are
necessary to permit Consummation of the Exchange Offer and (iv) upon the
effectiveness of the Registration Statement, commence the Exchange Offer. The
Company shall cause the Exchange Offer to comply with all applicable federal and
state securities laws. No securities other than the New Notes (and the shares of
Common Stock issuable upon conversion of such New Notes) shall be included in
the Exchange Offer Registration Statement. The Company shall use all reasonable
efforts to cause the Exchange Offer to be Consummated on the earliest
practicable date after the Exchange Offer Registration Statement has become
effective, but in no event later than 30 Business Days after such effectiveness.
The Exchange Offer shall be on the appropriate form permitting registration of
the New Notes to be offered in exchange for the Notes and to permit resales of
New Notes and shares of Common Stock received by Broker-Dealers in the Exchange
Offer by delivering the Prospectus contained in the Exchange Offer Registration
Statement. The "Plan of Distribution" section in the Prospectus contained in the
Exchange Offer Registration Statement shall not name any such Broker-Dealer or
disclose the amount of Notes held by any such Broker-Dealer except to the extent
required by Commission policy. The Company shall use its best efforts to keep
the Exchange Offer Registration Statement continuously effective, supplemented
and amended to the extent necessary to ensure that it is available for resales
of New Notes acquired by Broker-Dealers for their own accounts as a result of
market-making activities or other trading activities, and to ensure that it
conforms with the requirements of this Agreement, the Act and the policies,
rules and regulations of the Commission as announced from time to time, for a
period of one year
7
<PAGE> 9
from the date on which the Exchange Offer Registration Statement is declared
effective. The Company shall provide sufficient copies of the latest version of
such Prospectus to Broker-Dealers promptly upon request at any time during such
one-year period in order to facilitate such resales. Notwithstanding anything
herein to the contrary, despite the Consummation of an Exchange Offer, the
Company shall be required to file the Shelf Registration Statement in accordance
with Section 3(a) hereof if any Holder of Transfer Restricted Securities shall
notify the Company within 20 Business Days of the Consummation of the Exchange
Offer (x) that such Holder is prohibited by applicable law or Commission policy
from participating in the Exchange Offer, (y) that such Holder may not resell
the New Notes acquired by it in the Exchange Offer to the public without
delivering a prospectus and that the Prospectus contained in the Exchange Offer
Registration Statement is not appropriate or available for such resales by such
Holder or (z) that such Holder is a Broker-Dealer and holds Notes acquired
directly from the Company or one of its affiliates.
4. REGISTRATION PROCEDURES
(a) In connection with any Shelf Registration Statement, the
Company shall comply with all the provisions of Section 4(b) below and shall use
all reasonable efforts to effect such registration to permit the resale of the
Transfer Restricted Securities being sold in accordance with the intended method
or methods of distribution thereof. The parties hereto agree that the Transfer
Restricted Securities shall not be sold in any Underwritten Offering and the
Company shall in no event be required to cooperate with or pay for any
Underwritten Offering.
(b) In connection with any Registration Statement and any
Prospectus required by this Agreement, the Company shall:
(i) subject to any notice by the Company in
accordance with this Section 4(b) of the existence of any fact
or event of the kind described in Section 4(b)(iii)(D) hereof,
use all reasonable efforts to keep such Registration Statement
continuously effective and provide all requisite financial
statements for the
8
<PAGE> 10
period specified in Section 3 of this Agreement; upon the
occurrence of any event that would cause such Registration
Statement or the Prospectus contained therein (A) to contain a
material misstatement or omission or (B) not to be effective
and usable for resales of Transfer Restricted Securities during
the period required by this Agreement, the Company shall file
promptly an appropriate amendment to such Registration
Statement correcting any such misstatement or omission, and, in
the case of either clause (A) or (B), except as set forth in
Section 4(b)(xv) below, use all reasonable efforts to cause
such amendment to be declared effective and such Registration
Statement and the related Prospectus to become usable for their
intended purpose(s) as soon as practicable thereafter;
(ii) prepare and file with the Commission such
amendments and post-effective amendments to such Registration
Statement as may be necessary to keep such Registration
Statement effective for the applicable period set forth in
Section 3 hereof, or such shorter period as will terminate when
all Transfer Restricted Securities covered by such Registration
Statement have been sold; cause the Prospectus to be
supplemented by any required Prospectus supplement, and as so
supplemented, cause the Prospectus to be filed pursuant to Rule
424 under the Act and to comply fully with the applicable
provisions of Rules 424 and 430A under the Act in a timely
manner; and comply with the provisions of the Act with respect
to the disposition of all securities covered by such
Registration Statement during the applicable period in
accordance with the intended method or methods of distribution
by the sellers thereof set forth in such Registration Statement
or supplement to the Prospectus;
(iii) advise the selling Holders promptly and,
if requested by such Persons, to confirm such advice in
writing, (A) when the Prospectus or any Prospectus supplement
or post-effective amendment to any Registration
9
<PAGE> 11
Statement has been filed, and, with respect to any Registration
Statement or any post-effective amendment thereto, when the
same has become effective, (B) of any request by the Commission
for amendments to the Registration Statement or amendments or
supplements to the Prospectus or for additional information
relating thereto, (C) of the issuance by the Commission of any
stop order suspending the effectiveness of the Registration
Statement under the Act or of the suspension by any state
securities commission of the qualification of the Transfer
Restricted Securities for offering or sale in any jurisdiction
or of the initiation of any proceeding for any of the preceding
purposes, (D) of the existence of any fact or the happening of
any event (including without limitation pending negotiations
relating to, or the consummation of, a transaction or the
occurrence of any event which would require additional
disclosure of material, non-public information by the Company
in the Registration Statement as to which the Company has a
bona fide business purpose for preserving confidentiality or
which renders the Company unable to comply with Commission
requirements) that makes untrue any statement of a material
fact made in the Registration Statement, the Prospectus, any
amendment or supplement thereto or any document incorporated by
reference therein, or that requires the making of any additions
to or changes in the Registration Statement or the Prospectus
in order to make the statements therein not misleading. If at
any time the Commission shall issue any stop order suspending
the effectiveness of the Registration Statement, or any state
securities commission or other regulatory authority shall issue
an order suspending the qualification or exemption from
qualification of the Transfer Restricted Securities under state
securities or Blue Sky laws, the Company shall use its best
efforts to obtain the withdrawal or lifting of such order at
the earliest possible time;
(iv) furnish to each of the selling Holders,
upon request, before filing with the
10
<PAGE> 12
Commission, copies of any Registration Statement or any
Prospectus included therein and any amendments or supplements
thereto (including all documents incorporated by reference
prior to the effectiveness of such Registration Statement),
which documents, other than documents incorporated by
reference, will be subject to the review of such Holders for a
period of at least 5 Business Days, and the Company shall not
file any such Registration Statement or Prospectus or any
amendment or supplement to any such Registration Statement or
Prospectus to which a selling Holder of Transfer Restricted
Securities covered by such Registration Statement shall
reasonably object within 5 Business Days after the receipt
thereof; a selling Holder shall be deemed to have reasonably
objected to such filing only if such Registration Statement,
amendment, Prospectus or supplement, as applicable, as proposed
to be filed, contains a material misstatement or omission;
(v) if practicable, promptly prior to the
filing of any document that is to be incorporated by reference
into a Registration Statement or Prospectus subsequent to the
effectiveness thereof, and in any event no later than the date
such document is filed with the Commission, provide copies of
such document to the selling Holders, if requested, make
representatives of the Company available in New Hampshire or by
conference call for discussion of such document and other
customary due diligence matters, and include such information
in such document prior to the filing thereof as such selling
Holders reasonably may request;
(vi) subject to having received reasonable
confidentiality assurance from any such selling Holders, make
available at reasonable times for inspection by the selling
Holders, participating in any disposition pursuant to such
Registration Statement and any attorney or accountant retained
by such selling Holder all financial and other records,
pertinent corporate documents and properties of the Com-
11
<PAGE> 13
pany and cause the officers, directors and employees of the
Company to supply all information reasonably requested by any
such selling Holder, attorney or accountant in connection with
such Registration Statement subsequent to the filing thereof
and prior to its effectiveness;
(vii) if requested by any selling Holder,
promptly incorporate in any Registration Statement or
Prospectus, pursuant to a supplement or post-effective
amendment if necessary, such information as such selling
Holders may reasonably request to have included therein, the
purchase price being paid therefor and any other terms of the
offering of the Transfer Restricted Securities or New Notes to
be sold in such offering; and make all required filings of any
such Prospectus supplement or post-effective amendment as soon
as practicable after the Company is notified of the matters to
be incorporated in such Prospectus supplement or post-effective
amendment;
(viii) cause the Transfer Restricted
Securities covered by the Registration Statement to be rated
with the appropriate rating agencies, if so requested by the
Holders of a majority in aggregate principal amount of Notes or
New Notes covered thereby;
(ix) deliver to each selling Holder, without
charge, as many copies of the Prospectus (including each
preliminary prospectus intended for public distribution) and
any amendment or supplement thereto as such selling Holder
reasonably may request; subject to any notice by the Company in
accordance with this Section 4(b) of the existence of any fact
or event of the kind described in Section 4(b)(iii) hereof, the
Company hereby consents to the use of the Prospectus and any
amendment or supplement thereto by each of the selling Holders
in connection with the offering and the sale of the Transfer
Restricted Securities or New Notes covered by the Prospectus or
any amendment or supplement thereto;
12
<PAGE> 14
(x) subject to any notice by the Company in
accordance with this Section 4(b) of the existence of any fact
or event of the kinds described in Section 4(b)(iii)(D) hereof,
take all such other customary actions in connection therewith
in order to expedite or facilitate the disposition of the
Transfer Restricted Securities or New Notes pursuant to any
Registration Statement contemplated by this Agreement, all to
such extent as may be requested by any Purchaser or by any
Holder of Transfer Restricted Securities in connection with any
sale or resale pursuant to any Registration Statement
contemplated by this Agreement, the Company shall:
(A) furnish to each Purchaser and each selling
Holder, upon the date of the effectiveness of the
Shelf Registration Statement, and, to the extent
applicable, upon the Consummation of the Exchange
Offer copies of the following:
(1) a certificate, dated the date of
effectiveness of the Shelf Registration
Statement (or, to the extent applicable, dated
the date of Consummation of the Exchange
Offer) signed by (y) the president or chief
executive officer of the Company and (z) the
chief financial officer or the principal
financial or accounting officer or the
Company, confirming, as of the date thereof,
the matters set forth in Section 6(c)(i) and
(iii) of the Purchase Agreement and such other
matters as such parties reasonably requested
at the time of Effectiveness of the Shelf
Registration Statement;
(2) opinions, dated the date of
effectiveness of the Shelf Registration
Statement (or, to the extent applicable, dated
the date of Consummation of the Exchange
Offer) of outside counsel for the Company,
13
<PAGE> 15
covering the matters set forth in Sections
6(a) of the Purchase Agreement and addressed
to all Purchasers and selling Holders; and
(3) a customary comfort letter, dated
as of the date of Effectiveness of the Shelf
Registration Statement (and, to the extent
applicable, as of the date of Consummation of
the Exchange Offer) from the independent
certified public accountants of the Company,
in the customary form, addressed to all
Purchasers and selling Holders, and addressing
the matters set forth in the comfort letters
delivered pursuant to Section 6(d) of the
Purchase Agreement, without exception;
(B) deliver such other documents and
certificates as were reasonably requested at the time
of Effectiveness of the Shelf Registration Statement
by such parties to evidence compliance with clause (A)
above.
If at any time the representations and warranties of
the Company indirectly referenced in clause (A)(1) above cease
to be true and correct, the Company shall so advise the
Purchasers and each selling Holder promptly and, if requested
by such Persons, shall confirm such advice in writing;
(xi) prior to any public offering of Transfer
Restricted Securities, cooperate with the selling Holders, and
their respective counsel in connection with the registration
and qualification of the Transfer Restricted Securities under
the securities or Blue Sky laws of such domestic jurisdictions
as the selling Holders may request; and do any and all other
acts or things reasonably necessary or advisable to enable the
disposition in such jurisdictions of the Transfer Restricted
Securities covered by the Shelf Registration Statement;
14
<PAGE> 16
provided, however, that the Company shall not be required to
register or qualify as a foreign corporation where it is not
now so qualified or to take any action that would subject it to
service of process in suits or to taxation, other than as to
matters and transactions relating to the Registration
Statement, in any domestic jurisdiction where it is not now so
subject;
(xii) cooperate with the selling Holders to
facilitate the timely preparation and delivery of certificates
representing Transfer Restricted Securities to be sold and not
bearing any restrictive legends; and enable such Transfer
Restricted Securities to be in such denominations and
registered in such names as the selling Holders may request at
least two Business Days prior to any sale of Transfer
Restricted Securities;
(xiii) use all reasonable efforts to cause the
Transfer Restricted Securities covered by the Registration
Statement to be registered with or approved by such other
domestic governmental agencies or authorities as may be
necessary to enable the selling Holder(s) thereof to consummate
the disposition of such Transfer Restricted Securities, subject
to the proviso contained in clause (xi) above;
(xiv) as soon as reasonably practicable after
the occurrence of any fact or event of the kind described in
clause (b)(iii)(D) above, prepare a supplement or
post-effective amendment to the Registration Statement or
related Prospectus or any document incorporated therein by
reference or file any other required document so that, as
thereafter delivered to the purchasers of Transfer Restricted
Securities, the Prospectus will not contain an untrue statement
of a material fact or omit to state any material fact
necessary, in light of the circumstances in which it was made,
to make the statements therein not misleading, provided,
however, that notwithstanding anything to the contrary herein,
the Company shall not be re-
15
<PAGE> 17
quired to prepare and file such a supplement or post-effective
amendment or document if the fact no longer exists; and
provided further, however, that, in the event of a material
business transaction (including without limitation pending
negotiations relating to such a transaction) which, based upon
the advice of the Company's outside counsel, Sheehan, Phinney,
Bass + Green, Professional Association, or other counsel
reasonably acceptable to the Purchasers, would require
disclosure by the Company in the Registration Statement of
material, nonpublic information which the Company has a bona
fide business purpose for not disclosing, then for so long as
such circumstances and such business purpose continue to exist,
the Company shall not be required to prepare and file a
supplement or post-effective amendment hereunder;
(xv) provide a CUSIP number for all Transfer
Restricted Securities not later than the effective date of the
Registration Statement and provide the Trustee under the
Indenture with printed certificates for the Notes or New Notes,
as the case may be, which are in a form eligible for deposit
with The Depository Trust Company;
(xvi) use all reasonable efforts to cause such
Registration Statement to become effective;
(xvii) otherwise use its best efforts to
comply with all applicable rules and regulations of the
Commission, and make generally available to its security
holders, in a regular filing on Form 10Q or Form 10K, a
consolidated earnings statement meeting the requirements of
Rule 158 (which need not be audited) for the twelve-month
period commencing after the effective date of the Registration
Statement;
(xviii) cause the Indenture to be qualified
under the TIA not later than the effective date of the first
Registration Statement required to be filed by this Agreement,
16
<PAGE> 18
and, in connection therewith: cooperate with the Trustee and
the Holders of Notes to effect such changes to the Indenture as
may be required for such Indenture to be so qualified in
accordance with the terms of the TIA; and execute and use all
reasonable efforts to cause the Trustee to execute, all
documents that may be required to effect such changes and all
other forms and documents required to be filed with the
Commission to enable such Indenture to be so qualified in a
timely manner;
(xix) cause all Transfer Restricted Securities
covered by the Registration Statement to be listed on each
securities exchange on which similar securities issued by the
Company are then listed if requested by the Holders of a
majority in aggregate principal amount of Transfer Restricted
Securities; and
(xx) provide promptly to each Holder upon
request any document filed with the Commission pursuant to the
requirements of Section 13 and Section 15 of the Exchange Act.
Each Holder agrees by acquisition of a Transfer Restricted
Security that, upon receipt of any notice from the Company of the existence of
any fact or event of the kind described in Section 4(b)(iii)(D) hereof, such
Holder shall: (i) keep the fact of such notice confidential and (ii) forthwith
discontinue disposition of Transfer Restricted Securities pursuant to the
applicable Registration Statement until such Holder's receipt of the copies of a
supplemented or amended Prospectus as contemplated by Section 4(b)(xiii) hereof,
or until it is advised in writing (the "Advice") by the Company that the
use of the Prospectus may be resumed, and has received copies of any additional
or supplemental filings that are incorporated by reference in the Prospectus. If
so directed by the Company, each Holder will deliver to the Company (at the
expense of the Company) all copies, other than permanent file copies then in
such Holder's possession, of the Prospectus covering such Transfer Restricted
Securities that was current at the time of receipt of such notice. In the event
the Company shall give any such notice, the time period regarding the
effectiveness of such Registration Statement set forth in Section 3
17
<PAGE> 19
hereof shall be extended by the number of days during the period from and
including the date of the giving of such notice pursuant to Section 4(b)(iii)(D)
hereof to and including the date when each selling Holder covered by such
Registration Statement shall have received the copies of the supplemented or
amended prospectus contemplated by Section 4(b)(xiv) hereof or shall have
received the Advice, provided, however, that the time period regarding the
effectiveness of such Registration Statement set forth in Section 3 hereof shall
not be extended, if the Company has received an opinion from its outside
counsel, Sheehan, Phinney, Bass + Green, Professional Association, or other
counsel reasonably acceptable to the Purchasers, to the effect that the
Restricted Transfer Securities can be freely tradable without the continued
effectiveness of the Shelf Registration Statement.
(c) In connection with the Exchange Offer, the Company shall
comply with all of the provisions of Section 4(b) (other than those which are
not applicable) and shall use its best efforts to effect such exchange to permit
the sale of Transfer Restricted Securities being sold in accordance with the
intended method or methods of distribution thereof. In addition, prior to
effectiveness of the Exchange Offer Registration Statement, the Company shall
provide a supplemental letter to the Commission (i) stating that they are
registering the Exchange Offer in reliance on the position of the Commission
enunciated in Exxon Capital Holdings Corporation (available May 13,
1988), Morgan Stanley and Co., Inc. (available June 5, 1991) and, if
applicable, any no-action letter obtained by the Company and (ii) including a
representation that the Company has not entered into any arrangement or
understanding with any Person to distribute the New Notes to be received in the
Exchange Offer and that, to the best of the Company's information and belief,
each Holder participating in the Exchange Offer is acquiring the New Notes in
its ordinary course of business and has no arrangement or understanding with any
Person to participate in the distribution of the New Notes received in the
Exchange Offer. As a condition to its participation in the Exchange Offer
pursuant to the terms of this Agreement, each Holder of Transfer Restricted
Securities shall furnish, upon the request of the Company, prior to the
Consummation thereof, a written representation to the Company (which may be
contained in the letter of transmittal contemplated by
18
<PAGE> 20
the Exchange Offer Registration Statement) to the effect that (A) it is not an
affiliate of the Company, (B) it is not engaged in and does not intend to engage
in and has no arrangement or understanding with any person to participate in, a
distribution of the New Notes to be issued in the Exchange Offer and (C) it is
acquiring the New Notes in its ordinary course of business. In addition, all
such Holders of Transfer Restricted Securities shall otherwise cooperate in the
Company's preparations for the Exchange Offer. Each Holder hereby acknowledges
and agrees that any Broker-Dealer and any such Holder using the Exchange Offer
to participate in a distribution of the securities to be acquired in the
Exchange Offer (1) could not under Commission policy as in effect on the date of
this Agreement rely on the position of the Commission enunciated in Morgan
Stanley and Co., Inc. (available June 5, 1991) and Exxon Capital Holdings
Corporation (available May 13, 1988), as interpreted in the Commission's letter
to Shearman & Sterling dated July 2, 1993, and similar no-action letters and (2)
must comply with the registration and prospectus delivery requirements of the
Act in connection with a secondary resale transaction and that such a secondary
resale transaction should be covered by an effective registration statement
containing the selling security holder information required by Item 507 or 508,
as applicable, of Regulation S-K if the resales are of New Notes obtained by
such Holder in exchange for Notes acquired by such Holder directly from the
Company.
5. REGISTRATION EXPENSES
(a) The following expenses incident to the Company's
performance of or compliance with this Agreement will be borne by the Company
regardless of whether a Registration Statement becomes effective, including: (i)
all registration and filing fees and expenses (including filings made by any
Purchaser or Holder with the NASD); (ii) all fees and expenses associated with
compliance with federal securities and state Blue Sky or securities laws
including the legal fees of Skadden, Arps, Slate, Meagher & Flom relating solely
to legal counsel on Blue Sky matters, such fees not to exceed $15,000; (iii) all
expenses of printing or copying (including printing of any certificates
evidencing the Notes and printing or copying of Prospectuses), messenger and
delivery services and telephone; (iv) all fees and
19
<PAGE> 21
disbursements of counsel for the Company; (v) all application and filing fees in
connection with listing any securities on a national securities exchange or
automated quotation system pursuant to the requirements hereof; and (vi) all
fees and disbursements of independent certified public accountants of the
Company (including the expenses of any special audit and comfort letters
required by or incident to such performance).
The Company will, in any event, bear its own internal expenses
(including, without limitation, all salaries and expenses of its officers and
employees performing legal or accounting duties), the expenses of any annual
audit and the fees and expenses of any Person, including special experts,
retained by the Company.
(b) In connection with any Registration Statement required by
this Agreement, the Purchasers agree to pay for the reasonable fees and
disbursements of not more than one counsel to the Purchasers and Holders, who
shall be Skadden, Arps, Slate, Meagher & Flom or such other counsel as may be
chosen by the Holders of a majority in principal amount of the Transfer
Restricted Securities for whose benefit such Registration Statement is being
prepared.
6. INDEMNIFICATION
(a) The Company agrees to indemnify and hold harmless (i) each
Holder and (ii) each person, if any, who controls (within the meaning of Section
15 of the Act or Section 20 of the Exchange Act) any Holder (any of the persons
referred to in this clause (ii) being hereinafter referred to as a "controlling
person") and (iii) the respective officers, directors, partners, employees,
representatives and agents of any Holder or any controlling person (any person
referred to in clause (i), (ii) or (iii) may hereinafter be referred to as an
"Indemnified Holder"), to the fullest extent lawful, from and against
any and all losses, claims, damages, liabilities, judgments, costs and expenses
("Losses") (including, without limitation and as incurred, reimbursement
of all costs of investigating, preparing, pursuing or defending any claim or
action, or any investigation or proceeding by any governmental agency or body,
commenced or threatened, including the reasonable fees and expenses of counsel
to any Indemnified Holder) directly or indirectly
20
<PAGE> 22
caused by, related to, based upon, arising out of or in connection with any
untrue statement or alleged untrue statement of a material fact contained in any
Registration Statement or Prospectus (or any amendment or supplement thereto) or
any omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading, except insofar as such
Losses are caused by an untrue statement or omission or alleged untrue statement
or omission that is made in reliance upon and in conformity with information
relating to any of the Holders furnished in writing to the Company by any of the
Holders for use therein provided also, that the Company does not indemnify and
hold harmless (and shall not be liable to) any Indemnified Holder, or any other
person pursuant to this Section 6 with respect to any preliminary Prospectus or
final Prospectus, as amended or supplemented, as the case may be, to the extent
that any such loss, claim, damage or liability of such Indemnified Holder, or
other person results from the fact that such Indemnified Holder, or other person
sold Transfer Restricted Securities to a person to whom there was not sent or
given, at or prior to the written confirmation of such sale, a copy of the final
Prospectus, as then amended or supplemented, if the Company has previously
furnished copies thereof to such Indemnified Holder, or person and such final
Prospectus, as then amended or supplemented, had corrected any untrue statement
or misstatement of a material fact, or omission of a material fact. The Company
shall notify the Holders promptly of the institution, threat or assertion of any
claim, proceeding (including any governmental investigation) or litigation in
connection with the matters addressed by this Agreement which involves the
Company or any Indemnified Holder.
(b) In case any action or proceeding (including, without
limitation, any governmental or regulatory investigation or proceeding) shall be
brought or asserted against any of the Indemnified Holders with respect to which
indemnity may be sought against the Company, such Indemnified Holder (or the
Indemnified Holder controlled by such controlling person) shall promptly notify
the Company in writing (provided that the failure to give such notice shall not
relieve the Company of its obligations pursuant to this Agreement). Any
21
<PAGE> 23
Indemnified Holder shall have the right to employ separate counsel in any such
action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Indemnified Holder, provided, however,
that the fees and expenses of such counsel shall be at the expense of the
Company if (i) the Company has failed to assume the defense and employ counsel
reasonably satisfactory to the Holders or (ii) the named parties to any such
action (including any impleaded parties) include such indemnified Holder and the
Company and such Indemnified Holder shall have reasonably concluded that there
may be one or more legal defenses available to it that are different from or in
addition to those available to the Company; provided, further that the Company
shall not in such event be responsible hereunder for the fees and expenses of
more than one firm of separate counsel, which firm shall be designated by the
Holders and shall be subject to the Company's approval, not to be unreasonably
withheld, in connection with any action in the same jurisdiction, in addition to
any local counsel. The Company shall not be liable for any settlement of any
such action or proceeding effected without its prior written consent, which
consent shall not be unreasonably withheld or delayed, and the Company agrees to
indemnify and hold harmless any Indemnified Holder from and against any Loss by
reason of any settlement of any action effected with its written consent. The
Company shall not, without the prior written consent of each Indemnified Holder,
settle or compromise or consent to the entry of a judgment in or otherwise seek
to terminate any pending or threatened action, claim, litigation or proceeding
in respect of which indemnification or contribution may be sought hereunder
(whether or not any Indemnified Holder is a party thereto), unless such
settlement, compromise, consent or termination includes an unconditional release
of each Indemnified Holder from all liability arising out of such action, claim,
litigation or proceeding.
(c) Each Holder of Transfer Restricted Securities agrees,
severally and not jointly, to indemnify and hold harmless the Company, its
directors, its officers, and any person controlling (within the meaning of
Section 15 of the Act or Section 20 of the Exchange Act) the Company, and the
respective officers, directors, partners, employees, representatives and agents
of each such person, to the same extent as the foregoing indemni-
22
<PAGE> 24
ty from the Company to each of the Indemnified Holders, but only with respect to
claims and actions based on information relating to such Holder furnished in
writing by such Holder for use in any Registration Statement or Prospectus. In
case any action or proceeding shall be brought against any of Company or its
directors or officers or any such controlling person in respect of which
indemnity may be sought against a Holder of Transfer Restricted Securities, such
Holder shall have the rights and duties given the Company, and each of the
Company or its directors or officers of such controlling person shall have the
rights and duties given to each Holder by the proceeding paragraph. In no event
shall the liability of any selling Holder hereunder be greater in amount than
the dollar amount of the proceeds received by such Holder upon the sale of the
securities registered pursuant to provisions hereof giving rise to such
indemnification obligation.
(d) If the indemnification provided for in this Section 6 is
unavailable to a party entitled to indemnification in respect of any Losses
referred to herein, then each indemnifying party, in lieu of indemnifying such
indemnified party, shall contribute to the amount paid or payable by such
indemnified party as a result of such Losses (i) in such proportion as is
appropriate to reflect the relative benefits received by the Company on the one
hand and the Holders on the other hand from their sale of Transfer Restricted
Securities or (ii) if such allocation is not permitted by applicable law, the
relative fault of the Company on the one hand and of the Indemnified Holder on
the other in connection with the statements or omissions which resulted in such
Losses as well as any other relevant equitable considerations. The relative
fault of the Company on the one hand and of the Indemnified Holder on the other
shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company or by
the Indemnified Holder and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
The indemnity and contribution obligations of each indemnifying party set forth
herein shall be in addition to any liability or obligation such indemnifying
party may
23
<PAGE> 25
otherwise have to any indemnified party, including under this Agreement.
The Company and each Holder of Transfer Restricted Securities
agree that it would not be just and equitable if contribution pursuant to this
Section 6(d) were determined by pro rata allocation (even if the Holders were
treated as one entity for such purpose) or by any other method of allocation
which does not take account of the equitable considerations referred to in the
immediately preceding paragraph. The amount paid or payable by an indemnified
party as a result of the Losses referred to in the immediately preceding
paragraph shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses reasonably incurred by such indemnified party
in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 6, none of the Holders (and their
related Indemnified Holders) shall be required to contribute, in the aggregate,
any amount in excess of the amount by which the total proceeds received by such
Holder with respect to the Notes exceeds the amount of any damages which such
Holder has otherwise been required to pay by reason of such untrue or alleged
untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The Holders' obligations to contribute pursuant to this
Section 6(d) are several in proportion to the respective principal amount of
Notes held by each of the Holders hereunder and not joint.
7. RULE 144A
The Company hereby agrees with each Holder, for so long as any
Transfer Restricted Securities remain outstanding, to make available to any
Holder or beneficial owner of Transfer Restricted Securities in connection with
any sale thereof and any prospective purchase of such Transfer Restricted
Securities from such Holder or beneficial owner, any information required to be
supplied to a Holder by Rule 144A(d)(4) under the Act in order to permit offers
and sales of such Transfer Restricted Securities pursuant to Rule 144A.
24
<PAGE> 26
8. PARTICIPATION IN UNDERWRITTEN REGISTRATIONS
No Holder may participate in any Underwritten Registration
hereunder of Transfer Restricted Securities.
9. MISCELLANEOUS
(a) Remedies. Each party agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by such
party of the provisions of this Agreement and hereby agrees to waive the defense
in any action for specific performance that a remedy at law would be adequate.
(b) No Inconsistent Agreements. The Company will not, on or
after the date of this Agreement, enter into any agreement with respect to its
securities that is inconsistent with the rights granted to the Holders in this
Agreement or otherwise conflicts with the provisions hereof. The rights granted
to the Holders hereunder are not inconsistent with the rights granted to the
holders of the Company's securities under any agreement in effect on the date
hereof.
(c) Amendments and Waivers. The provisions of this Agreement
may not be amended, modified or supplemented, and waivers or consents to or
departures from the provisions hereof may not be given, unless the Company has
obtained the written consent of Holders of a majority of the outstanding
principal amount of Transfer Restricted Securities.
(d) Notices. All notices and other communications provided for
or permitted hereunder shall be made in writing by hand-delivery, first-class
mail (registered or certified, return- receipt requested), or courier
guaranteeing over- night delivery;
(i) if to a Holder, at the address set forth
on the records of the Registrar under the Indenture, with a
copy to the Registrar under the Indenture; and
25
<PAGE> 27
(ii) if to the Company:
Healthsource, Inc.
Two College Park Drive
Hooksett, N.H. 03106
Attention: Norman C. Payson, M.D.,
President
with a copy to:
Healthsource, Inc.
Two College Park Drive
Hooksett, N.H. 03106
Attention: Robert J. Moses
General Counsel
All such notices and communications shall be deemed to have
been duly given when delivered.
Copies of all such notices, demands or other communications
shall be concurrently delivered by the Person giving the same to the Trustee at
the address specified in the Indenture.
(e) Successors and Assigns. This Agreement shall inure to the
benefit of and be binding upon the successors and assigns of each of the
parties, including without limitation and without the need for an express
assignment, subsequent Holders of Transfer Restricted Securities; provided,
however, that this Agreement shall not inure to the benefit of or be binding
upon a successor or assign of a Holder unless and to the extent such successor
or assign acquired Transfer Restricted Securities from such Holder.
(f) Counterparts. This Agreement may be executed in any number
of counterparts and by the parties hereto in separate counterparts, each of
which when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same agreement.
(g) Headings. The headings in this Agreement are for
convenience of reference only and shall not limit or otherwise affect the
meaning hereof.
26
<PAGE> 28
(h) Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD
TO THE CONFLICT OF LAW RULES THEREOF.
(i) Severability. In the event that any one or more of the
provisions contained herein, or the application thereof in any circumstance, is
held invalid, illegal or unenforceable, the validity, legality and
enforceability of any such provision in every other respect and the remaining
provisions contained herein shall not be affected or impaired thereby.
(j) Entire Agreement. This Agreement, together with the other
Transaction Documents (as defined in the Purchase Agreement), is intended by the
parties as a final expression of their agreement and intended to be a complete
and exclusive statement of the agreement and understanding of the parties hereto
in respect of the subject matter contained herein. There are no restrictions,
promises, warranties or undertakings, other than those set forth or referred to
herein with respect to the registration rights granted by the Company with
respect to the Transfer Restricted Securities. This Agreement supersedes all
prior agreements and understandings between the parties with respect to such
subject matter.
27
<PAGE> 29
IN WITNESS WHEREOF, the parties have executed this Agreement as
of the date first written above.
HEALTHSOURCE, INC.
By: /s/ Thomas M. Cougoran
-----------------------
Name: Thomas M. Cougoran
Title: Chief Financial Office
BEAR, STEARNS & CO. INC.
As representative for the
Purchasers named above
By: /s/ Curtis S. Lane
----------------------
Name: Curtis S. Lane
Title: Senior Managing Director
28
<PAGE> 1
Exhibit 10.1
$215,000,000 of 5% Convertible Subordinated
Notes Due 2003
HEALTHSOURCE, INC.
PURCHASE AGREEMENT
March 1, 1996
BEAR, STEARNS & CO. INC.
as Representative of the Several
Initial Purchasers named in
Schedule 1 attached hereto
c/o Bear, Stearns & Co. Inc.
245 Park Avenue
New York, New York 10167
Ladies and Gentlemen:
Healthsource, Inc., a corporation organized and existing under the laws
of New Hampshire (the "Company"), proposes, subject to the terms and conditions
stated herein, to issue and sell to Bear, Stearns & Co. Inc. and the several
initial purchasers listed on Schedule 1 hereto (the "Initial Purchasers") an
aggregate of $215,000,000 of its 5% Convertible Subordinated Notes due 2003.
Said aggregate of $215,000,000 of Notes are herein called the "Firm Notes." In
addition, the Company proposes to grant to the Initial Purchasers an option to
purchase up to $32,250,000 of additional notes (the "Optional Notes"), as
provided in Section 2 hereof. The Firm Notes and, to the extent such option is
exercised, the Optional Notes are hereinafter collectively referred to as the
"Notes."
The Notes will be issued pursuant to an indenture to be dated as of
March 6, 1996 (the "Indenture") between the Company and The Bank of New York, as
trustee. The holders of the Notes will be entitled to certain registration
rights provided under a Note Resale Registration Rights Agreement to be dated as
of March 6, 1996 (the "Registration Rights Agreement") between the Company and
the Initial Purchasers.
<PAGE> 2
The Company has prepared a preliminary offering circular dated February
22, 1996 (the "Preliminary Offering Circular") and a final offering circular
dated March 1, 1996, as may be supplemented by mutual written agreement of the
parties, (the "Offering Circular") relating to and summarizing the terms of the
Notes to be sold pursuant hereto as agreed upon by the parties.
None of the Notes have been registered under the Securities Act of
1933, as amended (the "Securities Act"), and such securities are being sold in
reliance on exemptions from or in transactions not subject to the registration
requirements of the Securities Act, including sales (i) to institutional
"accredited investors" (as defined in Rule 501 (a)(1), (2), (3) or (7) under the
Securities Act); (ii) to "qualified institutional buyers" (as defined in Rule
144A under the Securities Act) or (iii) to non-U.S. persons outside the United
States in reliance upon Regulation S under the Securities Act.
1. Representations and Warranties of the Company.
The Company represents and warrants to, and agrees with, the Initial
Purchasers that:
(a) The Offering Circular, as of the date hereof, and as of the Closing
Date (as defined herein) and as of any Additional Closing Date (as defined
herein), if any, is and will be accurate in all material respects and does not
and will not contain an untrue statement of a material fact and does not or will
not omit to state any material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. No representation and warranty is made in
this subsection (a) with respect to any information contained in or omitted from
the Offering Circular or any amendment thereof or supplement thereto furnished
in writing to the Company by the Initial Purchasers expressly for use in the
Offering Circular.
(b) Deloitte & Touche LLP, who have expressed their respective opinions
with respect to the financial statements of the Company and schedules included
in the Offering Circular, are independent accountants as re-
2
<PAGE> 3
quired by the Securities Act and the rules and regulations thereunder (the
"Rules and Regulations").
(c) The annual audited financial statements of the Company included in
the Offering Circular present fairly the financial position of the Company, as
of the respective dates of such financial statements, and the results of
operations and changes in financial position of the Company for the respective
periods covered thereby. Such statements and related notes have been prepared in
accordance with generally accepted accounting principles applied on a consistent
basis, in each case, as certified by one or more of the independent accountants
named in subsection 1(b). The selected financial data set forth in the Offering
Circular under the captions "Summary," "Capitalization," "Selected Historical
Consolidated Financial Data" and "Selected Pro Forma Consolidated Financial
Data" fairly present the information set forth therein on the basis stated in
the Offering Circular.
(d) The pro forma condensed consolidated balance sheet and condensed
consolidated statements of operations and the related notes thereto included in
the Offering Circular have been prepared in accordance with the applicable
requirements of Rule 11-02 of Regulation S-X promulgated under the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and have been compiled on
the pro forma basis described therein, and the assumptions used in the
preparation thereof were reasonable at the time made and the adjustments used
therein are based upon good faith estimates and assumptions believed by the
Company to be reasonable at the time made.
(e) As of the date hereof, the Company does not have any assets or
liabilities or conduct any business or operations that are material either
individually or in the aggregate to the business, prospects, properties,
operations, condition (financial or other) or results of operations of the
Company and its Subsidiaries taken as a whole, other than assets, liabilities,
businesses and operations of the Company and its Principal Subsidiaries (as
defined herein).
(f) Subsequent to the dates as of which information is given in the
Offering Circular, there has been
3
<PAGE> 4
no material adverse change or any development involving a prospective material
adverse change in the business, prospects, properties, operations, condition
(financial or other) or results of operations of the Company and its
Subsidiaries (as defined herein) taken as a whole, whether or not arising from
transactions in the ordinary course of business, and since the date of the
latest balance sheet presented in the Offering Circular, neither the Company nor
any of its Subsidiaries has incurred or undertaken any liabilities or
obligations, direct or contingent, which in the aggregate are material to the
Company and its Subsidiaries taken as a whole, except for liabilities or
obligations which are disclosed in the Offering Circular.
(g) The Company has the corporate power and authority to enter into
this Agreement and the other agreements, documents and instruments to be
executed by the Company in furtherance of the transactions contemplated hereby,
including without limitation, the Indenture, the Notes and the Registration
Rights Agreement (collectively, the "Transaction Documents"), and to consummate
the transactions contemplated hereby and thereby.
(h) The execution, delivery, and performance of this Agreement by the
Company and the consummation of the transactions contemplated hereby do not and
will not (i) conflict with or result in a breach of any of the terms and
provisions of, or constitute a default (or an event which with notice or lapse
of time, or both, would constitute a default) under, or result in the creation
or imposition of any lien, charge or encumbrance upon any property or assets of
the Company or any of its Principal Subsidiaries (as defined herein) pursuant to
any agreement, instrument, franchise, license or permit to which the Company or
any of its Principal Subsidiaries is a party or by which any of such
corporations or their respective properties or assets may be bound or (ii)(a)
violate or conflict with any provision of the certificate of incorporation or
the by-laws of the Company or any of its Principal Subsidiaries or (b) any
judgment, decree, order, statute, rule or regulation of any court or any public,
governmental or regulatory agency or body having jurisdiction over or applicable
to the Company or any of its Principal Subsidiaries or any of their respective
properties or assets, except with respect to clauses (i)
4
<PAGE> 5
and (ii)(b) hereof (A) as disclosed in the Offering Circular, (B) the lien of
the Trustee under the Indenture, or (C) any breach, default, violation or state
of facts of the types referenced in this paragraph which would not have a
material adverse effect on the business, prospects, properties, operations,
condition (financial or other) or results of operations of the Company and its
Subsidiaries taken as a whole. No consent, approval, authorization, order,
registration, filing, qualification, license or permit of or with any court or
any public, governmental or regulatory agency or body having jurisdiction over
or applicable to the Company or any of its Principal Subsidiaries or any of
their respective properties or assets is required for the execution, delivery
and performance of this Agreement or the consummation of the transactions
contemplated hereby, including the issuance, sale and delivery of the Notes to
be issued, sold and delivered by the Company hereunder except (i) such consents,
approvals, authorizations, orders, registrations, filings, qualifications,
licenses and permits as have been obtained or made or as may be required under
applicable foreign securities and state securities or Blue Sky laws in
connection with the purchase and distribution of the Notes by the Initial
Purchasers or (ii) where the failure to have such consents, approvals,
authorizations, orders, registrations, filings, qualifications, licenses and
permits will not in the aggregate have a material adverse effect on the
business, prospects, properties, operations, condition (financial or other) or
results of operations of the Company and its Subsidiaries taken as a whole or
result in any material adverse change or any development involving a material
adverse change in the business, prospects, properties, operations, condition
(financial or other) or results of operations of the Company and its
Subsidiaries taken as a whole.
(i) The Company had, as of December 31, 1995, an authorized and
outstanding capitalization as set forth in the Offering Circular and the capital
stock of the Company conforms in all material respects to the description
thereof contained in the Offering Circular.
(j) Each of the Company and its Principal Subsidiaries has been duly
organized and is validly existing as a corporation in good standing under the
laws of its jurisdiction of incorporation. Each of the Compa-
5
<PAGE> 6
ny and its Principal Subsidiaries is duly qualified to do business and in good
standing as a foreign corporation in each jurisdiction in which the character or
location of its properties (owned, leased or licensed) or the nature or conduct
of its business makes such qualification necessary, except for those failures to
be so qualified or in good standing that will not in the aggregate have a
material adverse effect on the business, prospects, properties, operations,
condition (financial or other) or results of operations of the Company and its
Subsidiaries taken as a whole or result in any material adverse change or any
development involving a material adverse change in the business, prospects,
properties, operations, condition (financial or other) or results of operations
of the Company and its Subsidiaries taken as a whole. Each of the Company and
its Principal Subsidiaries has all requisite power and authority, and, each of
the Company and its Principal Subsidiaries, has all necessary consents,
approvals, authorizations, orders, registrations, qualifications, licenses,
franchises, and permits of and from all public, regulatory or governmental
agencies and bodies, to own, lease and operate its properties and conduct its
business as now being conducted as described in the Offering Circular except
where the failure to have such consents, approvals, authorizations, orders,
registrations, qualifications, licenses, franchises, and permits will not in the
aggregate have a material adverse effect on the business, prospects, properties,
operations, condition (financial or other) or results of operations of the
Company and its Subsidiaries taken as a whole or result in any material adverse
change or any development involving a material adverse change in the business,
prospects, properties, operations, condition (financial or other) or results of
operations of the Company and its Subsidiaries taken as a whole. No such
consent, approval, authorization, order, registration, qualification, license or
permit contains a materially burdensome restriction not adequately disclosed in
the Offering Circular. For the purpose of this Agreement, "Subsidiary" means
each corporation, partnership, joint venture, limited liability company,
business fund or other entity in which the Company, directly or indirectly
through Subsidiaries, owns 50 percent or more of the equity therein with the
power to elect members of the Board of Directors or other body performing a
comparable management function. Except as disclosed in Schedule 2, the Company
owns, directly or indirectly, all of the out-
6
<PAGE> 7
standing capital stock of each of its Principal Subsidiaries, free and clear of
all claims, liens, charges and encumbrances, except for the rights, if any, of
any state insurance or regulatory agency as contemplated in the Offering
Circular. The Company's "Principal Subsidiaries" or each "Principal Subsidiary"
of the Company are defined as those Subsidiaries listed on Schedule 2 to this
Agreement.
(k) Except as described in the Offering Circular, there is no
litigation or governmental proceeding to which the Company or any of its
Subsidiaries is a party or to which any property of the Company or any of its
Subsidiaries is subject or which is pending or, to the knowledge of the Company,
contemplated against the Company or any of its Subsidiaries which might
reasonably be expected to result in any material adverse change or any
development involving a material adverse change in the business, prospects,
properties, operations, condition (financial or other) or results of operations
of the Company and its Subsidiaries taken as a whole.
(l) The Company has not taken and will not take, directly or
indirectly, any action designed to cause or result in, or which constitutes or
which might reasonably be expected to constitute, the stabilization or
manipulation of the price of the Notes to facilitate the sale or resale of the
Notes.
(m) Neither the Company nor any of its Subsidiaries is (i) an
"investment company" or a company "controlled" by an investment company within
the meaning of the Investment Company Act of 1940, as amended, (ii) a "holding
company" or a "subsidiary company" of a holding company or an "affiliate"
thereof within the meaning of the Public Utility Holding Company Act of 1935, as
amended, or (iii) subject to regulation under the Federal Power Act, the
Interstate Commerce Act and the Company is not subject to any federal or state
statute or regulation limiting its ability to incur indebtedness for borrowed
money.
(n) None of the Company, any of its affiliates or any person acting on
its behalf (excluding the Initial Purchasers and their respective affiliates, as
to which no representation is made) has engaged in any "directed selling
efforts" (as such term is defined in Regulation S
7
<PAGE> 8
of the Securities Act) in the United States with respect to the Notes and (ii)
each of the Company and any of its affiliates and any person acting on behalf of
any of them (other than the Initial Purchasers and their respective affiliates,
as to whom the Company makes no representation) has complied with the offering
restrictions requirement of Regulation S.
(o) None of the Company, any of its affiliates or any person authorized
to act on its behalf (excluding the Initial Purchasers and their respective
affiliates, as to which no representation is made) has engaged in any form of
general solicitation or general advertising (as such terms are defined in Rule
502(c) under the Securities Act).
(p) None of the Company, any of its affiliates (as defined in Rule
501(b) under the Securities Act) or any person authorized to act on its behalf
(excluding the Initial Purchasers and their respective affiliates, as to which
no representation is made) has sold, offered for sale, solicited offers to buy
or otherwise negotiated in respect of any security (as such term is defined in
the Securities Act) of the Company in a manner which would require registration
under the Securities Act during the six (6) month period ending as of the date
of this Agreement, other than issuance of options to purchase Common Stock to
employees or directors of the Company and sale of Common Stock pursuant to stock
options issued under the Company's existing or proposed stock option plans.
(q) The Notes are eligible for resale pursuant to Rule 144A and, when
issued, will not be of the same class as securities listed on a national
securities exchange registered under Section 6 of the Exchange Act or quoted in
a U.S. automated inter-dealer quotation system.
(r) The Company is subject to Section 13 of the Exchange Act and is in
compliance with the provisions of such section.
(s) Subject to compliance by the Initial Purchasers with the
representations and warranties set forth in Section 2 hereof and the procedures
set forth in Section 3 hereof, it is not necessary in connection with the offer,
sale and delivery of the Notes to the Initial
8
<PAGE> 9
Purchasers in the manner contemplated by this Agreement and the Offering
Circular to register the Notes under the Securities Act or to qualify the
Indenture under the Trust Indenture Act of 1939, as amended.
(t) Neither the Company nor its Principal Subsidiaries has any material
liabilities or obligations (direct or indirect, contingent or absolute matured
or unmatured) of any nature whatsoever, whether arising out of contract, tort,
statute or otherwise (the "Liabilities"), except (i) as reflected or reserved
against in the balance sheet of the Company included in its annual financial
statements for the year ended December 31, 1995 and not heretofore discharged,
(ii) as specifically disclosed in the Offering Circular or (iii) Liabilities
incurred in the ordinary course of business since December 31, 1995.
(u) Neither the Company nor any of its Principal Subsidiaries is (i) in
violation or default of any provision of its certificate of incorporation,
by-laws or other organizational documents, or (ii) is in breach of or default
with respect to any provision of any judgment, decree, order, or (iii) is in
breach or default with respect to any provision of any agreement, mortgage, deed
of trust, lease, franchise, license, indenture, permit or other instrument to
which it is a party or by which it or any of its properties are bound; and there
does not exist any state of facts which constitutes an event of default on the
part of the Company or any such subsidiary as defined in such documents or
which, with notice or lapse of time or both, would constitute such an event of
default, except with respect to clauses (ii) and (iii) hereof for any breach,
default, violation or state of facts of the types referred to in this paragraph
which would not have a material adverse effect on the business, prospects,
properties, operations, condition (financial or other) or results of operations
of the Company or its Subsidiaries taken as a whole.
(v) The Company and its Principal Subsidiaries are in compliance, and
have complied at all times during the past five (5) years, and all transactions
involving the issuance, offer, placement and sale, pursuant to the terms of the
Transaction Documents and the Notes comply with all applicable federal, state
and local statutes, codes, ordinances, rules and regulations of the United
9
<PAGE> 10
States and all other countries and subdivisions thereof (the "Laws") to the
extent applicable, except (i) with respect to any applicable foreign securities
and state Blue Sky laws in connection with transactions involving the issuance,
offer, placement and sale pursuant to the terms of the Transaction Documents and
the Notes or (ii) where the failure to comply with the Laws would not have a
material adverse effect on the business, prospects, properties, operations,
condition (financial or other) or results of operations of the Company or its
Subsidiaries taken as a whole. Neither the Company nor any of its Subsidiaries
has received notice within the past five (5) years of any violations of any Laws
which would have had a material adverse effect on the business, prospects,
properties, operations, condition (financial or other) or results of operations
of the Company and its Subsidiaries taken as a whole.
(w) This Agreement has been duly and validly authorized, executed and
delivered by the Company and is a valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as such
enforcement may be subject to or limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or hereafter in effect
relating to creditors' rights and remedies generally and (ii) general principles
of equity (regardless of whether such enforcement may be sought in a proceeding
in equity or at law).
(x) The Notes have been duly and validly authorized by the Company, and
the Notes, when authenticated by the Trustee and issued, sold and delivered in
accordance with this Agreement and the Indenture, will have been duly and
validly executed, authenticated, issued and delivered and will constitute valid
and binding obligations of the Company, enforceable against the Company in
accordance with their terms and entitled to the benefits provided by the
Indenture except as such enforcement may be subject to or limited by (i)
bankruptcy, insolvency, reorganization, moratorium or other similar laws now or
hereafter in effect relating to creditors' rights and remedies generally and
(ii) general principles of equity (regardless of whether such enforcement may be
sought in a proceeding in equity or at law). The Notes conform in all material
respects to the description thereof contained in the Offering Circular.
10
<PAGE> 11
(y) The Indenture has been duly and validly authorized by the Company,
and the Indenture when executed and delivered by the Company and the Trustee,
will constitute a valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms, except as such enforcement may
be subject to or limited by (i) bankruptcy, insolvency, reorganization,
moratorium or other similar laws now or hereafter in effect relating to
creditors' rights and remedies generally and (ii) general principles of equity
(regardless of whether such enforcement may be sought in a proceeding in equity
or at law). The Indenture conforms in all material respects to the description
thereof contained in the Offering Circular.
(z) The Registration Rights Agreement has been duly and validly
authorized by the Company, and the Registration Rights Agreement when executed
and delivered by the Company and the Initial Purchasers, will constitute a valid
and binding obligation of the Company, enforceable against the Company in
accordance with its terms, except as such enforcement may be subject to or
limited by (i) bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or hereafter in effect relating to creditors' rights and
remedies generally and (ii) general principles of equity (regardless of whether
such enforcement may be sought in a proceeding in equity or at law). The
Registration Rights Agreement conforms in all material respects to the
description thereof contained in the Offering Circular.
(aa) All of the outstanding shares of Common Stock are duly and validly
authorized and issued, fully paid and nonassessable, have been issued in
compliance with all federal and state securities laws, and were not issued and
are not now in violation of or subject to any preemptive rights. All issued and
outstanding shares of capital stock of each Principal Subsidiary of the Company
have been duly authorized and validly issued and are fully paid and
nonassessable. Except as disclosed in or contemplated by the Offering Circular
and on Schedule 3 hereto, or in the financial statements of the Company, and the
related notes thereto, included in the Offering Circular, neither the Company
nor any Principal Subsidiary has outstanding any options to purchase, or any
preemptive rights or other rights to subscribe for or to purchase, any
securities or obligations convertible into,
11
<PAGE> 12
or any contracts or commitments to issue or sell, shares of its capital stock or
any such options, rights, convertible securities or obligations.
(bb) The shares of Common Stock issuable upon conversion of the Notes
have been duly authorized and, when issued in accordance with the terms of the
Notes and the Indenture, will be validly issued, fully paid and nonassessable
and will conform in all material respects to the description thereof contained
in the Offering Circular. No preemptive rights or other rights to subscribe for
or purchase securities exist with respect to the issuance and sale of the Notes
by the Company pursuant to this Agreement or the issuance of Common Stock on
conversion of the Notes. No security holder or other party (other than as
disclosed in Schedule 3 hereto and except Provident Life and Accident Insurance
Company, the holder of preferred shares of the Company which will be redeemed
with the proceeds of the offering contemplated by this Agreement) of the Company
has any right that has not been satisfied or waived to require the Company to
register the sale of any securities owned by such security holder or other party
under the Securities Act in the Shelf Registration Statement or the New Notes
Registration Statement (as such terms are defined in the Offering Circular),
except as contemplated by the Registration Rights Agreement (as defined in the
Offering Circular). The shares of Common Stock issuable on conversion of the
Notes at the initial conversion price have been reserved for issuance and no
further approval or authority of the stockholders or the Board of Directors of
the Company will be required for such issuance of Common Stock.
(cc) The Company or the applicable Principal Subsidiary has good and
marketable title to all the properties and assets reflected as owned in the
financial statements hereinabove described (or elsewhere in the Offering
Circular), not subject to any lien, mortgage, pledge, charge or encumbrance of
any kind except (i) those, if any, reflected in such financial statements (or
elsewhere in the Offering Circular) or (ii) those that are materially
significant in amount in relation to the business, prospects, properties,
operations, condition (financial or other) or results of operations of the
Company and its Subsidiaries taken as a whole, and do not materially adversely
affect the use made and proposed to be made of such property by the Company and
its Subsid-
12
<PAGE> 13
iaries. The Company or the applicable Principal Subsidiary holds its leased
properties under valid and binding leases, with such exceptions as are not
materially significant in relation to the business, prospects, properties,
operations, condition (financial or other) or results of operations of the
Company and its Subsidiaries taken as a whole. Except as disclosed in the
Offering Circular, the Company or the applicable Principal Subsidiary owns or
leases all such properties as are necessary to its operations as now conducted.
(dd) Except as disclosed in or specifically contemplated by the
Offering Circular, the Company and its Principal Subsidiaries have sufficient
trademarks, trade names, patent rights, copyrights, and licenses, or similar
rights to intellectual property to conduct their businesses as now conducted,
except where the failure to have such trademarks, trade names, patent rights,
copyrights, and licenses, or similar rights to intellectual property would not
have a material adverse effect on the business, prospects, properties,
operations, condition (financial and other) or results of operations of the
Company and its Subsidiaries taken as a whole; the expiration of any trademarks,
trade names, patent rights, copyrights, and licenses, or similar rights to
intellectual property would not have a material adverse effect on the business,
prospects, properties, operations, condition (financial or other) or results of
operations of the Company and its Subsidiaries taken as a whole; and the Company
has no knowledge of any material infringement by it or its Subsidiaries of
trademarks, trade names, patents, copyrights, and licenses, or other similar
rights to intellectual property, trade secrets or other similar rights of
others, and there is no claim being made against the Company or its Principal
Subsidiaries regarding trademarks, trade names, patents, copyrights, and
licenses, or similar rights to intellectual property, trade secrets or other
infringement that would have a material adverse effect on the business,
prospects, properties, operations, condition (financial or other) or results of
operations of the Company and its Subsidiaries taken as a whole.
(ee) The Company and its Principal Subsidiaries have filed all
necessary federal, state and foreign income and franchise tax returns and have
paid all taxes shown as due thereon; and the Company has no knowledge of
13
<PAGE> 14
any tax deficiency which has been asserted or threatened against the Company or
its Principal Subsidiaries that could have a material and adverse effect on the
business, prospects, properties, operations, condition (financial or other) or
results of operations of the Company and its Subsidiaries taken as a whole.
(ff) The Company or its Principal Subsidiaries maintain insurance of
the types and in the amounts generally deemed adequate for its business and that
of its Principal Subsidiaries against theft, damage, destruction, acts of
vandalism and all other risks customarily insured against, all of which
insurance is in full force and effect.
(gg) To the knowledge of the Company, neither the Company nor any of
its Principal Subsidiaries has (i) made any unlawful contribution to any
candidate for foreign office, or failed to disclose fully any contribution in
violation of law or (ii) made any payment to any federal or state governmental
officer of official, or other person charged with similar public or quasi-public
duties, other than payments required or permitted by the laws of the United
States of any jurisdiction thereof.
(hh) The Company has not received notice of an action that has been
taken and no law, statute, rule or regulation or order has been enacted, adopted
or issued by any governmental agency or body that prevents the issuance of the
Notes, prevents or suspends the use of any Preliminary Offering Circular or the
Offering Circular, or suspends the sale of the Notes in any jurisdiction
referred to in Section 4(c) hereof; no injunction, restraining order or other
order or relief of any nature by a federal or state court or other tribunal of
competent jurisdiction has been issued with respect to and served upon the
Company or any of its Principal Subsidiaries that would prevent or suspend the
issuance or sale of the Notes or the use of any Preliminary Offering Circular or
the Offering Circular in any jurisdiction referred to in Section 4(c) hereof; no
action, suit or proceeding is pending or, to the Company's knowledge, threatened
against or affecting the Company or any of its Principal Subsidiaries before any
court or arbitrator or any governmental body, agency or official, domestic or
foreign, which, if adversely determined, would materially interfere with or
adversely affect the issuance of the
14
<PAGE> 15
Notes or in any manner draw into question the validity of the Transaction
Documents or the Notes; and every request to the Company of any securities
authority or agency of any jurisdiction for additional information (to be
included in the Offering Circular or otherwise) has been complied with.
2. Purchase, Sale and Delivery of the Notes. (a) On the
basis of the representations, warranties, covenants and agreements herein
contained, but subject to the terms and conditions herein set forth, the Company
agrees to sell to the Initial Purchasers and the Initial Purchasers, acting
severally and not jointly, agree to purchase from the Company $215,000,000
principal amount of Notes in the respective amounts set forth on Schedule 1
hereto at a purchase price equal to 97.75% of their principal amount
plus accrued interest, if any. At the Closing, the Company hereby agrees
to pay to the Initial Purchasers for their services rendered in connection with
the transaction contemplated herein in an amount equal to 2.25% of the aggregate
principal amount of the Notes sold by the Company.
(b) Payment of the purchase price for, and delivery of, the
Notes shall be made at the offices of Skadden, Arps, Slate, Meagher & Flom, 919
Third Avenue, New York, New York 10022 at 9:00 a.m. (New York City time), unless
postponed in accordance with Section 9 hereof, on March 6, 1996 or such other
time and date as shall be mutually agreed between the Company and the Initial
Purchasers (such time and date of such payment and delivery being herein called
the "Closing Date"). At or prior to the Closing Date, the Company shall execute
and deliver for authentication one or more certificates in global or definitive
form for the Notes in such denominations and registered in such names as the
Initial Purchasers request upon notice to the Company at least two business days
prior to the Closing Date. Against such delivery of the Notes, the Initial
Purchasers shall pay or cause to be paid to the Company the purchase price for
the Notes. Payment shall be made to the Company by wire transfer of immediately
available funds to an account or accounts designated by the Company. The Initial
Purchasers shall have the right to deduct from the purchase price payable to the
Company hereunder the selling concession and the combined management and
commission referred to in subsection (a) hereof.
15
<PAGE> 16
(c) In addition, on the basis of the representations and
warranties herein contained, but subject to the terms and conditions herein set
forth, the Company hereby grants to the Initial Purchasers the option to
purchase up to $32,250,000 principal amount of Optional Notes at the same
purchase price to be paid by the Initial Purchasers to the Company for the Firm
Notes as set forth in this Section 2, for the sole purpose of covering
over-allotments in the sale of Firm Notes by the Initial Purchasers. This option
may be exercised at any time, in whole or in part, on or before the 30th day
following the date of the Offering Circular, by written notice by the Initial
Purchasers to the Company. Such notice shall set forth the aggregate principal
amount of Optional Notes as to which the option is being exercised and the date
and time, as reasonably determined by the Initial Purchasers, when the Optional
Notes are to be delivered (such date and time being herein sometimes referred to
as the "Additional Closing Date"); provided, however, that the Additional
Closing Date shall not be earlier than the Closing Date or earlier than the
second full business day after the date on which the option shall have been
exercised nor later than the eighth full business day after the date on which
the option shall have been exercised (unless such date and time are postponed in
accordance with the provisions of Section 9 hereof). Certificates evidencing the
Optional Notes shall be in such denominations and registered in such names as
the Initial Purchasers request at least 48 hours prior to the Additional Closing
Date.
Payment for the Optional Notes shall be made by wire transfer
of immediately available funds to an account or accounts as designated by the
Company, upon delivery of the Optional Notes to the Initial Purchasers.
(d) Each Initial Purchaser hereby represents and warrants to,
and agrees with, the Company that it (i) is a "qualified institutional buyer"
within the meaning of Rule 144A under the Securities Act or an "accredited
investor" as defined in Rule 501(a)(1), (2), (3), or (7) under the Securities
Act; (ii) has not and will not solicit offers for, or offer or sell, Notes by
means of any general solicitation or general advertising within the meaning of
Rule 502(c) under Regulation D under the Securities Act; and (iii) will
otherwise act in accordance with the terms and conditions set forth in this
16
<PAGE> 17
Agreement and in the Offering Circular in connection with the placement of the
Notes contemplated hereby.
3. Subsequent Offers and Resales of the Notes.
The Initial Purchasers and the Company hereby establish and
agree to observe the following procedures in connection with the offer and
resale by the Initial Purchasers of the Notes:
(a) Offers and sales of the Notes will be made by the Initial
Purchasers only (i) to institutional investors that are reasonably believed to
qualify as accredited investors (as defined in Rule 501(a)(1), (2), (3) or (7)
under the Securities Act) (each such institutional investor being hereinafter
referred to as an "institutional accredited investor") or, (ii) in the case of
Notes resold or otherwise transferred pursuant to Rule 144A under the Securities
Act, to institutional investors that are reasonably believed to qualify as
"qualified institutional buyers" (as therein defined) (each such institutional
investor being hereinafter referred to as a "qualified institutional buyer") or
(iii) to non-U.S. persons outside the United States in reliance upon Regulation
S under the Securities Act, in transactions meeting the requirements of
Regulation S.
(b) The Notes will be offered by the Initial Purchasers only by
approaching prospective purchasers on an individual basis. No general
solicitation or general advertising (as such terms are used in Regulation D
under the Securities Act) will be used in connection with the offering of the
Notes.
(c) In the case of a non-bank purchaser of a Note acting as a
fiduciary for one or more third parties, in connection with an offer and sale to
such purchaser pursuant to clause (a) above, each third party shall, in the
judgment of the applicable Initial Purchasers, be an institutional accredited
investor or a non-U.S. person outside the United States.
(d) In connection with sales outside the United States, each
Initial Purchaser agrees that it will not offer, sell or deliver Notes (i) as
part of its distribution at any time or (ii) otherwise until 40 days after the
later of the commencement of the offering or
17
<PAGE> 18
last closing date with respect to the Notes, to, or for the account or benefit
of, U.S. persons. Accordingly, each Initial Purchaser represents and agrees that
neither it, its affiliates nor any person acting on its behalf has engaged or
will engage in any directed selling efforts with respect to the Notes, and
further that each such person has complied and will comply with the offering
restrictions requirement of Regulation S under the Securities Act. Each Initial
Purchaser also agrees that, at or prior to confirmation of sale of the Notes, it
will send to each dealer to which it sells Notes during the restricted period a
confirmation or other notice setting forth the restrictions on offers, sales and
deliveries of the Notes within the United States or to, or for the account or
benefit of U.S. persons.
(e) Each Initial Purchaser agrees that (i) it has not offered
or sold (and will not, for so long as Part III of the Companies Act 1985 remains
in force in relation to Notes which are not listed on the London Stock Exchange,
offer or sell) any Notes, other than to persons whose ordinary business it is to
buy or sell shares or debentures, whether as principal or agent, or in
circumstances which do not constitute an offer to the public within the meaning
of the Companies Act 1985; (ii) it has complied and will comply with all
applicable provisions of the Financial Services Act 1986 with respect to
anything done by it in relation to the Notes in, from or otherwise involving the
United Kingdom; and (iii) it has only issued or passed on, and will only issue
or pass on, in the United Kingdom any document received by it in connection with
the issue of the Notes to a person who is of a kind described in Article 9(3) of
the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order
1988 (as amended).
(f) Each Initial Purchaser agrees that it has not, directly or
indirectly, offered or sold and will not, directly or indirectly, offer or sell
any Notes in Japan, except pursuant to an exemption from the registration
requirements of, and otherwise in compliance with, the Securities and Exchange
Law and in compliance with other applicable requirements of the laws of Japan.
(g) Each Initial Purchaser agrees that it will not offer or
sell any Notes directly or indirectly in any
18
<PAGE> 19
province of Canada except in compliance with all requirements of applicable
securities laws.
(h) No sale of the Notes to any one purchaser will be for less
than $250,000 principal amount, and no Note will be issued in a smaller
principal amount. If the purchaser is a non-bank fiduciary acting on behalf of
others, each person for whom it is acting must purchase at least $250,000
principal amount of the Notes.
(i) The transfer restrictions and the other provisions set
forth in Article II of the Indenture, including the legend required thereby,
shall apply to the Notes except as otherwise agreed by the Company and the
Initial Purchasers. Following the sale of the Notes by the Initial Purchasers to
their respective Purchasers (the "Subsequent Purchasers") pursuant to the terms
hereof, the Initial Purchasers shall not be liable or responsible to the Company
for any losses, damages or liabilities suffered or incurred by the Company,
including any losses, damages or liabilities under the Securities Act, arising
from or relating to any subsequent resale or transfer of any Notes.
(j) Each Initial Purchaser will deliver to each purchaser of
the Notes from the Initial Purchaser, in connection with its original
distribution of the Notes, a copy of the Offering Circular, as amended and
supplemented at the date of such delivery.
(k) In connection with its original distribution of the Notes,
the Company agrees that, prior to any offer or resale of the Notes by the
Initial Purchasers, the Initial Purchasers and the Initial Purchasers' Counsel
(as defined herein) shall have the right to make reasonable due diligence
inquiries into the business of the Company and its Principal Subsidiaries. The
Company also agrees to provide answers to questions from each prospective
Subsequent Purchaser concerning the Company and its Principal Subsidiaries (to
the extent that such information is available to prospective Subsequent
Purchasers without unreasonable effort or expense and to the extent the
provision thereof is not prohibited by applicable law) and the terms and
conditions of the offering of the Notes, as provided in the Offering Circular.
19
<PAGE> 20
4. Covenants of the Company. The Company covenants and agrees
with the Initial Purchasers that:
(a) If at any time prior to the Closing Date or the Additional
Closing Date any event shall have occurred as a result of which the Offering
Circular as then amended or supplemented would in the judgment of the Initial
Purchasers or the Company include an untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were
made, not misleading, the Company will notify the Representative on behalf of
the Initial Purchasers promptly and prepare and deliver to the Representative on
behalf of the Initial Purchasers an amendment or supplement (in form and
substance satisfactory to you) which will correct such statement or omission.
(b) The Company will promptly deliver to the Representative on
behalf of the Initial Purchasers such number of copies of the Offering Circular
and all amendments of and supplements thereto as the Representative on behalf of
the Initial Purchasers may reasonably request.
(c) The Company will endeavor in good faith, in cooperation
with the Representative on behalf of the Initial Purchasers, to qualify the
Notes for offering and sale under the securities laws relating to the offering
or sale of the Notes of such domestic jurisdictions as the Initial Purchasers
may designate and to maintain such qualification in effect for so long as
required for the distribution thereof, except that in no event shall the Company
be obligated in connection therewith to qualify as a foreign corporation or to
execute a general consent to service of process.
(d) The Company will apply the proceeds from the sale of the
Notes as set forth under "Use of Proceeds" in the Offering Circular.
(e) The Company will use its best efforts to cause the Notes to
be designated Private Offerings, Resales and Trading through Automated Linkages
("PORTAL") market securities in accordance with the rules and regulations
adopted by the National Association of Securities Dealers, Inc., relating to
trading in the PORTAL market.
20
<PAGE> 21
(f) Except for (i) the offer, issuance, sale of any Common
Stock or grant of any option to purchase with regard thereto in connection with
investments in, acquisitions of, or mergers or combinations with other entities
by the Company or (ii) grants of stock options (and issuance of Common Stock
pursuant to stock option exercises) to employees or directors of the Company
pursuant to existing stock option plans of the Company and the proposed 1996
Directors Stock Option Plan of the Company, during the period of ninety (90)
days from the date hereof, the Company will not, without prior written consent
of the Representative, issue, sell, offer or contract to sell, grant any option
for the sale of, or otherwise dispose of, directly or indirectly, any Common
Stock (or any securities convertible into, exercisable for or exchangeable for
Common Stock or any rights to acquire Common Stock) in any such case for cash,
other than the Company's sale of Notes hereunder and the Company's issuance of
Common Stock upon the exercise of presently outstanding stock options and
conversion of Notes. The Company will obtain a written undertaking from each
person who is an executive officer of the Company as listed on Schedule 4 to the
effect that such person will not, directly or indirectly, offer, sell, offer or
contract to sell, grant any option for the sale of, or otherwise dispose of any
shares of Common Stock (or any securities convertible into, exercisable for or
exchangeable for shares of Common Stock or any rights to acquire Common Stock)
for a period of sixty (60) days after the date hereof without the prior written
consent of the Initial Purchasers.
(g) None of the Company, its affiliates (as defined in Rule
501(b) of the Securities Act) or any person acting on their behalf (other than
the Initial Purchasers and their respective affiliates) will solicit any offer
to buy or offer or sell the Notes by means of any form of general solicitation
or general advertising (as those terms are used in Regulation D under the
Securities Act) or in any manner involving a public offering within the meaning
of Section 4(2) of the Securities Act.
(h) Except for the transactions contemplated herein, none of
the Company, its affiliates (as defined in Rule 501(b) of the Securities Act) or
any person acting on their behalf (other than the Initial Purchasers and their
respective affiliates) will offer, sell or
21
<PAGE> 22
solicit offers to buy or otherwise negotiate in respect of any security (as
defined in the Securities Act) of the Company in a manner that would require the
registration of the Notes under the Securities Act.
(i) During the period from the Closing Date to three years
after the Closing Date, the Company and its Subsidiaries will not, and will not
permit any of their "affiliates" (as defined in Rule 144 under the Securities
Act) to, resell any of the Notes that have been reacquired by them, except for
Notes purchased by the Company and its Subsidiaries or any of their affiliates
and resold in a transaction registered under the Securities Act.
(j) None of the Company, its affiliates and any person acting
on their behalf (other than the Initial Purchasers) will engage in any directed
selling efforts (as that term is defined in Regulation S) with respect to the
Notes sold pursuant to Regulation S, and the Company and its affiliates and each
person acting on their behalf (other than the Initial Purchasers) will comply
with the offering restrictions of Regulation S with respect to those Notes sold
pursuant thereto.
(k) The Company will, so long as the Notes are outstanding and
are "restricted securities" within the meaning of Rule 144(a)(3) under the
Securities Act, either (i) file reports and other information with the
Commission under Section 13 or 15(d) of the Exchange Act, or (ii) in the event
it is not subject to Section 13 or 15(d) of the Exchange Act, make available to
holders of the Notes and prospective purchasers of the Notes designated by such
holders, upon request of such prospective purchasers, the information required
to be delivered pursuant to Rule 144A(d)(4) under the Securities Act to permit
compliance with Rule 144A in connection with resales of the Notes.
(l) The Company will, if requested by the Initial Purchasers,
use its best efforts in cooperation with the Initial Purchasers to permit the
Notes to be eligible for clearance and settlement through The Depository Trust
Company ("DTC").
(m) Each of the Notes will bear the legend contained in
"Transfer Restrictions" in the Offering
22
<PAGE> 23
Circular for the time period and upon the other terms stated therein, except
after such Note is resold pursuant to a registration statement effective under
the Securities Act.
5. Payment of Expenses. Whether or not the transactions
contemplated in this Agreement are consummated or this Agreement is terminated,
the Company hereby agrees to pay all costs and expenses incident to the
performance of the obligations of the Company hereunder, including those in
connection with (i) preparing, printing, duplicating, filing and distributing
the Offering Circular and any amendments or supplements thereto (including fees
and expenses of the Company's accountants and counsel), the Transaction
Documents (including this Agreement) and all other documents related to the
offering of the Notes (including those supplied to the Initial Purchasers in
quantities as hereinabove stated), (ii) the issuance, transfer and delivery of
the Notes to the Initial Purchasers, including any transfer or other taxes
payable thereon, (iii) the qualification of the Notes under state or foreign
securities or Blue Sky laws, including the costs of printing and mailing a
preliminary and final "Blue Sky Survey" but not including the fees of counsel
for the Initial Purchasers and such counsel's disbursements in relation thereto,
(iv) the cost of printing the Notes, (v) the cost and charges of any transfer
agent, registrar, trustee or fiscal paying agent and (vi) the cost and charges
of DTC, Euroclear and CEDEL. The Initial Purchasers shall be responsible for
payment of their own out-of-pocket expenses including without limitation the
fees and expenses of their legal counsel.
6. Conditions of Initial Purchasers' Obligations. The
obligations of the Initial Purchasers to purchase and pay for the Notes and the
Optional Notes as provided herein, shall be subject to the accuracy of the
representations and warranties of the Company herein contained, as of the date
hereof and as of the Closing Date (for purposes of this Section 6 the "Closing
Date" shall refer to the Closing Date for the Notes and any Additional Closing
Date, if different, for the Optional Notes), to the absence from any
certificates, opinions, written statements or letters furnished to you or to
Skadden, Arps, Slate, Meagher & Flom (the "Initial Purchasers' Counsel")
pursuant to this Section 6 of any
23
<PAGE> 24
misstatement or omission, to the performance by the Company of its obligations
hereunder, and to the following additional conditions:
(a) At the Closing Date you shall have received the
opinion of Sheehan, Phinney, Bass + Green, Professional Association,
counsel for the Company, addressed to the Initial Purchasers and dated
the Closing Date or the Additional Closing Date, as the case may be, to
the effect that:
(1) The Company has the requisite corporate power and
corporate authority to enter into this Agreement and to sell
and deliver the Notes to the Initial Purchasers; this Agreement
has been duly authorized, executed and delivered by or on
behalf of the Company; and no approval, authorization, order or
consent of any court or governmental authority or agency is
required under the laws of the State of New Hampshire or the
United States of America in connection with the transactions
contemplated by this Agreement, except (i) such as have been
obtained or made or as may be required under applicable foreign
securities laws or state securities or Blue Sky laws in
connection with the purchase and distribution of the Notes by
the Initial Purchasers as to which such counsel expresses no
opinion or (ii) where the failure to obtain any such approval,
authorization, order or consent would not have a material
adverse effect on the business, properties, operations,
condition (financial or other) or results of operations of the
Company and its Subsidiaries taken as a whole.
(2) The execution, delivery and performance of this
Agreement by the Company and the consummation of the
transactions contemplated hereby by the Company do not and will
not (i) conflict with or result in a breach of any of the terms
and provisions of, or constitute a default (or an event which
with notice or lapse of time, or both, would constitute a
default) under, or result in the creation or imposition of any
lien, charge or encumbrance upon any property or assets of the
Company or any of its
24
<PAGE> 25
Principal Subsidiaries pursuant to, any agreement, instrument,
franchise, license or permit known to such counsel to which the
Company or any of its Principal Subsidiaries is a party or by
which any of such corporations or their respective properties
or assets may be bound or (ii) violate or conflict with any
provision of the certificate of incorporation or bylaws of the
Company or any of its Principal Subsidiaries, or, (iii) to the
best knowledge of such counsel, any judgment, decree, order,
statute, rule or regulation of any court or any public,
governmental or regulatory agency or body having jurisdiction
over the Company or any of its Principal Subsidiaries or any of
their respective properties or assets, except (a) as disclosed
in the Offering Circular, (b) the lien of the Trustee under the
Indenture, or (c) with respect to clauses (i) and (iii) hereof,
any breach, default, violation or state of facts of the types
references in this paragraph which would not have a material
adverse effect on the business, properties, operations,
condition (financial or other) or results of operations of the
Company and its Subsidiaries taken as a whole. No consent,
approval, authorization, order, registration, filing,
qualification, license or permit of or with any court or any
public, governmental or regulatory agency or body having
jurisdiction over the Company or any of its Principal
Subsidiaries or any of their respective properties or assets is
required for the execution, delivery and performance of this
Agreement or the consummation of the transactions contemplated
hereby, including the issuance, sale and delivery of the Notes
to be issued, sold and delivered by the Company except (i) such
consents, approvals, authorizations, orders, registrations,
filings, qualifications, licenses and permits as have been
obtained or made or as may be required under applicable foreign
securities and state securities or Blue Sky laws in connection
with the purchase and distribution of the Notes by the Initial
Purchasers or (ii) where the failure to have such consents,
approvals, authorizations, orders, registrations, filings,
qualifications,
25
<PAGE> 26
licenses and permits would not have a material adverse effect
on the business, properties, operations, condition (financial
or other) or results of operations of the Company and its
Subsidiaries taken as a whole;
(3) The Notes have been duly authorized by requisite
corporate action on the part of the Company, executed, issued
and delivered by the Company and (assuming due authorization,
execution, authentication and delivery thereof by the Trustee)
constitute valid and binding obligations of the Company,
enforceable against the Company in accordance with their terms
and entitled to the benefits of the Indenture, except that
enforcement may be subject to or limited by (i) bankruptcy,
insolvency, reorganization, moratorium or other similar laws
now or hereafter in effect relating to creditors' rights and
remedies generally and (ii) general principles of equity
(regardless of whether such enforcement may be sought in a
proceeding in equity or at law);
(4) The Indenture has been duly authorized, executed
and delivered by the Company and (assuming the due
authorization, execution and delivery thereof by the Trustee)
constitutes a valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms,
except that enforcement may be subject to or limited by (i)
bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or hereafter in effect relating to creditors'
rights and remedies generally and (ii) general principles of
equity (regardless of whether such enforcement may be sought in
a proceeding in equity or at law);
(5) The Registration Rights Agreement has been duly
authorized, executed and delivered by the Company and (assuming
the due authorization, execution and delivery thereof by the
Initial Purchasers) constitutes a valid and binding obligation
of the Company enforceable against the Company in accordance
with its terms, except that (a) enforcement may be sub-
26
<PAGE> 27
ject to or limited by (i) bankruptcy, insolvency,
reorganization, moratorium or other similar laws now or
hereafter in effect relating to creditors' rights and remedies
generally and (ii) general principles of equity (regardless of
whether such enforcement may be sought in a proceeding in
equity or at law) and (b) the indemnification and contribution
provisions contained in the Registration Rights Agreement may
be limited by federal or state securities laws or the public
policy underlying such laws;
(6) The information in the Offering Circular under the
heading "Description of the Notes," to the extent that it
constitutes matters of law, summaries of legal matters,
documents or proceedings, or legal conclusions, has been
reviewed by such counsel and is correct in all material
respects;
(7) The information in the Offering Circular under the
heading "Certain Tax Considerations--U.S. Federal Income Tax
Considerations," to the extent that it constitutes a matter of
law and summaries of matters of law, is correct in all material
respects;
(8) The statements in the Offering Memorandum under
the heading "Transfer Restrictions," insofar as they purport to
summarize matters of United States federal law, is correct in
all material respects;
(9) It is not necessary in connection with (a) the
offer, sale and delivery of the Notes to the Initial Purchasers
in the manner contemplated by the Purchase Agreement and the
Offering Circular or (b) the initial resale of the Notes by the
Initial Purchasers in the manner contemplated in the Purchase
Agreement and the Offering Circular to (i) register the Notes
under the Securities Act, it being understood that no opinion
need be expressed as to any subsequent resale of any Note, or
(ii) qualify the Indenture under the Trust Indenture Act of
1939, as amended. In rendering the opinion set forth in this
paragraph, such coun-
27
<PAGE> 28
sel may assume without independent investigation (1) the
accuracy of the representations and warranties of the Company
set forth in Section 1 of the Purchase Agreement and of the
Initial Purchasers in Section 2 of the Purchase Agreement, (2)
the compliance of the Initial Purchasers with the offering and
transfer procedures and restrictions described in the offering
Circular and in Section 3 of the Purchase Agreement, (3) the
due performance by the Company of the covenants and agreements
set forth in Sections 4(g), 4(h) and 4(j) of the Purchase
Agreement, (4) the accuracy of the representations and
warranties made in accordance with the Purchase Agreement and
the Offering Circular by purchasers to whom the Initial
Purchasers initially resell Notes and (5) that purchasers to
whom the Initial Purchasers initially resell Notes receive a
copy of the Offering Circular prior to such sale;
(10) The shares of Common Stock issuable upon
conversion of the Notes have been duly authorized by the
Company and, when issued and delivered upon such conversion in
accordance with the terms and provisions of the Notes and the
Indenture (assuming payment for and delivery of the Notes in
accordance with the Purchase Agreement), will be validly
issued, fully paid and nonassessable;
(11) The capital stock of the Company conforms in all
material respects to the description thereof contained in the
Offering Circular under the caption "Description of Capital
Stock"; all outstanding shares of Common Stock have been duly
and validly authorized and issued, are fully paid and
non-assessable, and were not issued in violation of or subject
to any preemptive right, no holder of currently outstanding
shares of Common Stock has any preemptive or, to such counsel's
knowledge and except as disclosed by the Offering Circular and
this Agreement, other similar rights to subscribe for or
purchase any shares of Common Stock (or any security
exchangeable for or convertible into Common Stock); the Common
28
<PAGE> 29
Stock currently outstanding is listed on the New York Stock
Exchange;
(12) Each of the Company and its Principal
Subsidiaries has been duly incorporated and is existing as a
corporation in good standing under the laws of its jurisdiction
of incorporation and is duly qualified to do business as a
foreign corporation and is in good standing in all other
jurisdictions where the ownership or leasing of properties or
the conduct of its business requires such qualification, except
for jurisdictions in which the failure to so qualify or be in
good standing would not have a material adverse effect on the
business, properties, operations, condition (financial or
other) or results of operations of the Company and its
Principal Subsidiaries, taken as a whole. Each of the Company
and its Principal Subsidiaries has all requisite corporate
power and corporate authority to own, lease and license its
respective properties and conduct its business as described in
the Offering Circular;
(13) All of the issued and outstanding shares of
capital stock of the Principal Subsidiaries has been duly and
validly issued and is fully paid and non-assessable and, except
as shown on Schedule 2 hereto, is owned, directly or indirectly
by the Company, are free and clear of all liens, encumbrances,
equities, claims, security interests, voting trusts or other
defects of title whatsoever, except for the rights, if any, of
any state insurance or other regulatory entity;
(14) To such counsel's knowledge, no holders of
securities (other than as disclosed in Schedule 3 and except
Provident Life and Accident Insurance Company, the holder of
preferred shares of the Company which will be redeemed with the
proceeds of the offering contemplated by this Agreement) of the
Company have rights which have not been satisfied or waived to
the registration of shares of Common Stock or other securities
of the Company because of the filing of the Shelf Registration
29
<PAGE> 30
Statement or the New Notes Registration Statement (as such
terms are defined in the Offering Circular) by the Company or
the respective offerings contemplated thereby; and
(15) Except as disclosed in or specifically
contemplated by the Offering Circular and this Agreement, to
such counsel's knowledge, except for stock options outstanding
pursuant to the Company's existing and proposed stock option
plans, there are no outstanding options, warrants or other
rights calling for the issuance of, and no commitments, plans
or arrangements to issue, any shares of capital stock of the
Company or any security convertible into or exchangeable for
capital stock of the Company;
(16) Based solely upon review of records of the
Company, including responses to requests for information from
the Company's independent public accountants and discussion
with in-house legal counsel to the Company, to the best of such
counsel's knowledge there is no litigation or governmental or
other action, suit, proceeding or investigation before any
court or before or by any public, regulatory or governmental
agency or body pending or threatened against, or involving the
properties or business of, the Company or any of its Principal
Subsidiaries, which is of a character required to be disclosed
in the Offering Circular which has not been properly disclosed
in the Offering Circular;
(17) Such counsel has participated in conferences with
officers and other representatives of the Company, in-house
attorneys of the Company, representatives of the independent
accountants of the Company, representatives of the Initial
Purchasers and representatives of the Initial Purchasers'
Counsel at which the contents of the Offering Circular and
related matters were discussed and, although such counsel is
not passing upon, and does not assume any responsibility for,
the accuracy, completeness or fairness of the statements
contained in the Offering Circular and has made no
30
<PAGE> 31
independent check or verification thereof (other than to the
extent specified in paragraphs 6, 7, 8 and 10 above), on the
basis of the foregoing, no facts have come to the attention of
such counsel which would lead such counsel to believe that the
Offering Circular, as of its date and as of the Closing Date,
contained or contains an untrue statement of a material fact or
omitted or omits to state any material fact required to be
stated therein or necessary to make the statements therein not
misleading (it being understood that such counsel need express
no belief or opinion with respect to the financial statements
and schedules and other financial data included therein or
excluded therefrom).
In rendering such opinion, such counsel may rely (i) as to
matters involving the application of laws other than the laws of the United
States and jurisdictions in which they are admitted, to the extent such counsel
deems proper and to the extent specified in such opinion, if at all, upon an
opinion or opinions (in form and substance reasonably satisfactory to Initial
Purchasers' counsel) of other counsel reasonably acceptable to Initial
Purchasers' Counsel, familiar with the applicable laws; and (ii) as to matters
of fact, to the extent such counsel deems proper, on certificates of responsible
officers of the Company, certificates or other written statements from the
Company's independent public accountants, Deloitte & Touche LLP, and
certificates or other written statements of officers of departments of various
jurisdictions having custody of documents respecting the corporate existence or
good standing or licensing of the Company and its Principal Subsidiaries,
provided that copies of any such statements or certificates shall be delivered
to Initial Purchasers' Counsel. The opinion of such counsel for the Company
shall state that the opinion of any such other counsel is in form satisfactory
to such counsel and, in its opinion, you and the Initial Purchasers' Counsel are
justified in relying thereon. In rendering the opinions set forth in paragraph
(1) above, such counsel need not express any opinion as to (i) the securities
laws of any jurisdiction, (ii) laws other than those which, in the experience of
such counsel, are normally applicable to transactions of the type provided for
by this Agreement and (iii) any
31
<PAGE> 32
consent, approval, authorization, validation or filing that may have become
applicable to the Company as a result of the involvement of the Initial
Purchasers in this Agreement because of the legal or regulatory status of the
Initial Purchasers or because of any other facts specifically pertaining to the
Initial Purchasers. In rendering the opinions set forth in paragraph (2) above,
such counsel (i) may reference a list of material agreements, mortgages, deeds
of trust, leases, franchises, licenses, indentures, permits and other
instruments, which list shall be taken from the list of material contracts
included as an exhibit to the Company's Form 10-K for the fiscal year ended
December 31, 1995 and shall be attached by such counsel to its opinion and (ii)
need not express any opinion as to (a) the securities laws of any jurisdiction,
(b) laws other than those which, in the experience of such counsel, are normally
applicable to transactions of the type provided for by this Agreement and (c)
any consent, approval, authorization, validation or filing that may have become
applicable to the Company as a result of the involvement of the Initial
Purchasers in this Agreement because of the legal or regulatory status of the
Initial Purchasers or because of any other facts specifically pertaining to the
Initial Purchasers.
(b) All proceedings taken in connection with the sale of the
Notes as herein contemplated shall be satisfactory in form and substance to you
and to Initial Purchasers' Counsel, and the Initial Purchasers shall have
received from said Initial Purchasers' Counsel a favorable opinion, dated the
Closing Date with respect to the issuance and sale of the Notes, the Offering
Circular and such other related matters as you may reasonably require, and the
Company shall have furnished to Initial Purchasers' Counsel such documents as
they request for the purpose of enabling them to pass upon such matters.
(c) At the Closing Date you shall have received a certificate
of the Chief Executive Officer and Chief Financial Officer of the Company, dated
the Closing Date, to the effect that (i) as of the date hereof and as of the
Closing Date, the representations and warranties of the Company set forth in
Section 1 hereof are accurate, (ii) as of the Closing Date, the obligations of
the Company to be performed hereunder on or prior thereto have been duly
performed and (iii) subsequent to the respective dates as of which information
is given in the
32
<PAGE> 33
Offering Circular, the Company and its Principal Subsidiaries have not sustained
any material loss or interference with their respective businesses or properties
from fire, flood, hurricane, accident or other calamity, whether or not covered
by insurance, or from any labor dispute or any legal or governmental proceeding,
and there has not been any material adverse change, or any development involving
a material adverse change, in the business, prospects, properties, operations,
condition (financial or otherwise), or results of operations of the Company and
its Subsidiaries taken as a whole, except in each case as described in or
contemplated by the Offering Circular.
(d) At the time this Agreement is executed and at the Closing
Date, you shall have received a letter from Deloitte & Touche, LLP, independent
accountants for the Company, dated, respectively, as of the date of this
Agreement and as of the Closing Date addressed to the Initial Purchasers in form
and substance satisfactory to the Initial Purchasers.
(e) Prior to the Closing Date the Company shall have furnished
to the Initial Purchasers such further information, certificates and documents
as the Initial Purchasers may reasonably request.
(f) You shall have received from each person who is an
executive officer of the Company as listed on Schedule 4 hereto an agreement to
the effect that such person will not, directly or indirectly, offer, sell, offer
or contract to sell, grant any option for the sale of, or otherwise dispose of
any shares of Common Stock (or any securities convertible into, exercisable for
or exchangeable for shares of Common Stock or any rights to acquire Common
Stock) for a period of sixty (60) days after the date hereof without the prior
written consent of the Initial Purchasers.
(g) At the Closing Date, the Notes shall have been approved for
quotation in the PORTAL market.
If any of the conditions specified in this Section 6 shall not
have been fulfilled when and as required by this Agreement, or if any of the
certificates, opinions, written statements or letters furnished to you or to the
Initial Purchasers' Counsel pursuant to
33
<PAGE> 34
this Section 6 shall not be in all material respects reasonably satisfactory in
form and substance to the Initial Purchasers and to the Initial Purchasers'
Counsel, all obligations of the Initial Purchasers hereunder may be cancelled by
you at, or at any time prior to, the Closing Date and the obligations of the
Initial Purchaser to purchase the Optional Notes may be cancelled by you at, or
at any time prior to, the Additional Closing Date. Notice of such cancellation
shall be given to the Company in writing, or by telephone, telex or telegraph,
confirmed in writing.
7. Indemnification.
(a) The Company agrees to indemnify and hold harmless each
Initial Purchaser and each person, if any, who controls any Initial Purchaser
within the meaning of Section 15 of the Securities Act or Section 20(a) of the
Exchange Act, against any and all losses, liabilities, claims, damages and
expenses whatsoever as incurred (including but not limited to attorneys' fees
and any and all expenses whatsoever incurred in investigating, preparing or
defending against any litigation, commenced or threatened, or any claim
whatsoever, and any and all amounts paid in settlement of any claim or
litigation), joint or several, to which they or any of them may become subject
under the Securities Act, the Exchange Act or otherwise, insofar as such losses,
liabilities, claims, damages or expenses (or actions in respect thereof) arise
out of or are based upon any untrue statement or alleged untrue statement of a
material fact contained in the Offering Circular or the Preliminary Offering
Circular or arise out of or are based upon the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading or arise out of or are based upon any
inaccuracy in the representations and warranties of the Company contained herein
or any failure of the Company to perform its obligations hereunder or under
applicable law; and will reimburse the Initial Purchasers and each such
controlling person for any legal and other expenses as such expenses are
reasonably incurred by the Initial Purchasers or such controlling person in
connection with investigating, defending, settling, compromising or paying any
such loss, claim, damage, liability, expense or action; provided,
however, that the Company will not be liable in any such case to the
extent but only to the
34
<PAGE> 35
extent that any such loss, liability, claim, damage or expense arises out of or
is based upon any such untrue statement or alleged untrue statement or omission
or alleged omission made therein in reliance upon and in conformity with written
information furnished to the Company by or on behalf of the Initial Purchasers
expressly for use therein; and provided, further, that this
indemnity agreement with respect to the Preliminary Offering Circular shall not
inure to the benefit of any Initial Purchaser from whom the person asserting any
such losses, liabilities, claims, damages or expenses purchased Notes, or any
person controlling such Initial Purchaser, if a copy of the Offering Circular
(as then amended or supplemented if the Company shall have furnished any such
amendments or supplements thereto) was not sent or given by or on behalf of such
Initial Purchaser to such person, if such is required by law, at or prior to the
written confirmation of the sale of such Notes to such person and if the
Offering Circular (as so amended or supplemented) would have corrected the
defect giving rise to such loss, liability, claim, damage or expense. This
indemnity agreement will be in addition to any liability which the Company may
otherwise have including under this Agreement.
(b) Each Initial Purchaser severally, and not jointly, agrees
to indemnify and hold harmless the Company, each of the directors of the
Company, each of the officers of the Company and each other person, if any, who
controls the Company within the meaning of Section 15 of the Securities Act or
Section 20(a) of the Exchange Act, against any losses, liabilities, claims,
damages and expenses whatsoever as incurred (including but not limited to
attorneys' fees and any and all expenses whatsoever incurred in investigating,
preparing or defending against any litigation, commenced or threatened, or any
claim whatsoever, and any and all amounts paid in settlement of any claim or
litigation), jointly or severally, to which they or any of them may become
subject under the Securities Act, the Exchange Act or otherwise, insofar as such
losses, liabilities, claims, damages or expenses (or actions in respect thereof)
arise out of or are based upon any untrue statement or alleged untrue statement
of a material fact contained in the Offering Circular, or the Preliminary
Offering Circular, or in any amendment thereof or supplement thereto, or arise
out of or are based upon the omission or alleged omission to state
35
<PAGE> 36
therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, in each case to the extent, but only to the
extent, that any such loss, liability, claim, damage or expense arises out of or
is based upon any such untrue statement or alleged untrue statement or omission
or alleged omission made therein in reliance upon and in conformity with written
information furnished to the Company by or on behalf of the Initial Purchasers
expressly for use therein and will reimburse the Company, or any such director,
officer, or controlling person for any legal and other expense reasonably
incurred by the Company, or any such director, officer or controlling person in
connection with investigating, defending, settling, compromising or paying any
such loss, claim, damage, liability, expense or action; provided,
however, that in no case shall any Initial Purchaser be liable or
responsible for any amount in excess of the discount applicable to the Notes
purchased by such Initial Purchaser hereunder. This indemnity will be in
addition to any liability which any Initial Purchaser may otherwise have
including under this Agreement. The Company acknowledges that the statements set
forth in the last paragraph of the cover page and in the seventh paragraph and
the second and third sentences in the twelfth paragraph under the caption "Plan
of Distribution" in the Offering Circular constitute the only information
furnished in writing by or on behalf of the Initial Purchasers expressly for use
in the Offering Circular or in any amendment thereof or supplement thereto, as
the case may be.
(c) Promptly after receipt by an indemnified party under
subsection (a) or (b) above of notice of the commencement of any action, such
indemnified party shall, if a claim in respect thereof is to be made against the
indemnifying party under such subsection, notify each party against whom
indemnification is to be sought in writing of the commencement thereof (but the
failure so to notify an indemnifying party shall not relieve it from any
liability which it may have under this Section 7). In case any such action is
brought against any indemnified party, and it notifies an indemnifying party of
the commencement thereof, the indemnifying party will be entitled to participate
therein, and to the extent it may elect by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such
indemnified party, to assume the defense thereof
36
<PAGE> 37
with counsel reasonably satisfactory to such indemnified party. Notwithstanding
the foregoing, the indemnified party or parties shall have the right to employ
its or their own counsel in any such case, but the fees and expenses of such
counsel shall be at the expense of such indemnified party or parties unless (i)
the employment of such counsel shall have been authorized in writing by one of
the indemnifying parties in connection with the defense of such action, (ii) the
indemnifying parties shall not have employed counsel to take charge of the
defense of such action within a reasonable time after notice of commencement of
the action, or (iii) such indemnified party or parties shall have reasonably
concluded that there may be defenses available to it or them which are different
from or additional to those available to one or all of the indemnifying parties
(in which case the indemnifying parties shall not have the right to direct the
defense of such action on behalf of the indemnified party or parties), in any of
which events such fees and expenses shall be borne by the indemnifying parties;
provided, however, that the indemnifying party under subsection (a) or (b) above
shall only be liable for the legal expenses of one counsel (and any local
counsel) for all indemnified parties and that all such fees and expenses of
counsel shall be reimbursed as they are incurred. Anything in this subsection to
the contrary notwithstanding, an indemnifying party shall not be liable for any
settlement of any claim or action effected without its written consent;
provided, however, that such consent was not unreasonably
withheld.
8. Contribution. In order to provide for contribution
in circumstances in which the indemnification provided for in Section 7 hereof
is for any reason held to be unavailable from any indemnifying party or is
insufficient to hold harmless a party indemnified thereunder, the Company and
the Initial Purchaser shall contribute to the aggregate losses, claims, damages,
liabilities and expenses of the nature contemplated by such indemnification
provision (including any investigation, legal and other expenses incurred in
connection with, and any amount paid in settlement of, any action, suit or
proceeding or any claims asserted, but after deducting in the case of losses,
claims, damages, liabilities and expenses suffered by the Company any
contribution received by the Company from persons, other than the Initial
Purchasers, who may also be liable for contribution,
37
<PAGE> 38
including persons who control the Company within the meaning of Section 15 of
the Act or Section 20(a) of the Exchange Act, officers and directors of the
Company) as incurred to which the Company and one or more of the Initial
Purchasers may be subject, in such proportions as is appropriate to reflect the
relative benefits received by the Company and the Initial Purchaser from the
offering of the Notes or, if such allocation is not permitted by applicable law
or indemnification is not available as a result of the indemnifying party not
having received notice as provided in Section 7 hereof, in such proportion as is
appropriate to reflect not only the relative benefits referred to above but also
the relative fault of the Company and the Initial Purchasers in connection with
the statements or omissions or inaccuracies in the representations and
warranties herein which resulted in such losses, claims, damages, liabilities or
expenses, as well as any other relevant equitable considerations. The relative
benefits received by the Company and the Initial Purchasers shall be deemed to
be in the same proportion as (x) the total proceeds from the offering (net of
underwriting discounts and commissions but before deducting expenses) received
by the Company and (y) the underwriting discounts and commissions received by
the Initial Purchasers respectively. The relative fault of the Company and of
the Initial Purchasers shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact or the inaccurate or the
alleged inaccurate representation or warranty relates to information supplied by
the Company or the Initial Purchasers and the parties' relative intent,
knowledge, access to information and opportunity to correct or prevent such
statement or omission. The Company and the Initial Purchasers agree that it
would not be just and equitable if contribution pursuant to this Section 8 were
determined by pro rata allocation (even if the Initial Purchasers were treated
as one entity for such purpose) or by any other method of allocation which does
not take account of the equitable considerations referred to above.
Notwithstanding the provisions of this Section 8, (i) in no case shall any
Initial Purchaser be liable or responsible for any amount in excess of the
underwriting discount applicable to the Notes purchased by such Initial
Purchaser hereunder and (ii) no person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities
38
<PAGE> 39
Act) shall be entitled to contribution from any person who was not guilty of
such fraudulent misrepresentation. Notwithstanding the provisions of this
Section 8, no Initial Purchaser shall be required to contribute any amount in
excess of the amount by which the total price at which the Notes underwritten by
it and distributed to the public were offered to the public exceeds the amount
of any damages that such Initial Purchaser has otherwise been required to pay by
reason of such untrue or alleged untrue statement or omission or alleged
omission. For purposes of this Section 8, each person, if any, who controls an
Initial Purchaser within the meaning of Section 15 of the Securities Act or
Section 20(a) of the Exchange Act shall have the same rights to contribution as
such Initial Purchaser, and each person, if any, who controls the Company within
the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act, each
officer and each director of the Company shall have the same rights to
contribution as the Company, subject in each case to clauses (i) and (ii) of
this Section 8. Any party entitled to contribution will, promptly after receipt
of notice of commencement of any action, suit or proceeding against such party
in respect of which a claim for contribution may be made against another party
or parties, notify each party or parties from whom contribution may be sought,
but the omission to so notify such party or parties shall not relieve the party
or parties from whom contribution may be sought from any obligation it or they
may have under this Section 8 or otherwise. No party shall be liable for
contribution with respect to any action or claim settled without its consent;
provided, however, that such consent was not unreasonably
withheld.
9. Default by an Initial Purchaser. If one of the Initial
Purchasers shall fail at Closing Date or the Additional Closing Date to purchase
the Firm Notes or Optional Notes which it is obligated to purchase under this
Agreement (the "Defaulted Notes"), the non-defaulting Initial Purchasers may in
their discretion, within five calendar days thereafter, make arrangements to
purchase all, but not less than all, of the Defaulted Notes upon the terms
herein set forth; if, however, the non-defaulting Initial Purchasers shall not
have completed such arrangements within such five calendar day period, then this
Agreement shall terminate without liability on the part of the non-defaulting
Initial Purchasers.
39
<PAGE> 40
Nothing in this Section shall relieve any defaulting Initial
Purchaser from its liability, if any, to the Company or the non-defaulting
Initial Purchasers for damages occasioned by its default.
In the event of any such default which does not result in a
termination of this Agreement, either the non-defaulting Initial Purchasers or
the Company shall have the right to postpone the Closing Date for a period not
exceeding seven days in order to effect any required changes in the Offering
Circular or in any other documents or arrangements.
10. Survival of Representations and Agreements. All
representations and warranties, covenants and agreements of the Initial
Purchasers and the Company contained in this Agreement, including the agreements
contained in Section 5, the indemnity agreements contained in Section 7 and the
contribution agreements contained in Section 8, shall remain operative and in
full force and effect regardless of any investigation made by or on behalf of
the Initial Purchasers or any controlling person thereof or by or on behalf of
the Company, any of its officers and directors or any controlling person
thereof, and shall survive delivery of and payment for the Notes to and by the
Initial Purchasers. The representations contained in Section 1 and the
agreements contained in Sections 5, 7, 8 and 11(c) hereof shall survive the
termination of this Agreement, including termination pursuant to Section 9 or 11
hereof.
11. Termination.
(a) The Initial Purchasers shall have the right to terminate
this Agreement at any time prior to the Closing Date or the obligations of the
Initial Purchasers to purchase the Optional Notes at any time prior to the
Additional Closing Date, as the case may be, if (A) any domestic or
international event or act or occurrence has materially disrupted, or in your
opinion will in the immediate future materially disrupt, the United States or
international securities markets; or (B) if trading on the New York Stock
Exchange or the Nasdaq National Market shall have been suspended or materially
limited; or (C) if a banking moratorium has been declared by any United States
federal or New York State authority or if any new restriction materially
adversely affecting
40
<PAGE> 41
the distribution of the Notes or the Optional Notes, as the case may be, shall
have become effective; or (D) if any downgrading in the rating of the Company's
debt securities by any "nationally recognized statistical rating organization"
(as defined for purposes of Rule 436(g) under the Securities Act); or (E)(i) if
the United States becomes engaged in hostilities or there is an escalation of
hostilities involving the United States or there is a declaration of a national
emergency or war by the United States or (ii) if there shall have been such
change in political, financial or economic conditions if the effect of any such
event in (i) or (ii) in your judgment makes it impracticable or inadvisable to
proceed with the offering, sale and delivery of the Notes or the Optional Notes,
as the case may be, on the terms contemplated by the Offering Circular.
(b) Any notice of termination pursuant to this Section 11 shall
be by telephone, telex, or telegraph, confirmed in writing by letter.
(c) If this Agreement shall be terminated pursuant to any of
the provisions hereof (otherwise than pursuant to Section 9 or 11(a) hereof), or
if the sale of the Notes provided for herein is not consummated because any
condition to the obligations of the Initial Purchasers set forth herein is not
satisfied or because of any refusal, inability or failure on the part of the
Company to perform any agreement herein or comply with any provision hereof, the
Company will, subject to demand by you, reimburse the Initial Purchasers for all
out-of-pocket expenses (including the fees and expenses of their counsel),
incurred by the Initial Purchasers in connection herewith.
12. Notice. All communications hereunder, except as may
be otherwise specifically provided herein, shall be in writing and, if sent to
the Initial Purchasers, shall be made in writing by hand-delivery, first-class
mail (registered or certified, return-receipt requested), or courier
guaranteeing overnight delivery to Bear, Stearns & Co. Inc., 245 Park Avenue,
3rd floor, New York, New York 10167, Attention: Curtis S. Lane; if sent to the
Company, shall be made in writing by hand-delivery, first-class mail (registered
or certified, return-receipt requested), or courier guaranteeing overnight
delivery to the Company, Healthsource, Inc., Two College
41
<PAGE> 42
Park Drive, Hooksett, New Hampshire 03106, Attention: Norman C. Payson, M.D.
with a copy to Sheehan, Phinney, Bass + Green, Professional Association,
Attention: Daniel N. Gregoire, Esq.
13. Parties. This Agreement shall inure solely to the
benefit of, and shall be binding upon, the Initial Purchasers and the Company
and the controlling persons, directors, officers, employees and agents referred
to in Section 7 and 8, and their respective successors and assigns, and no other
person shall have or be construed to have any legal or equitable right, remedy
or claim under or in respect of or by virtue of this Agreement or any provision
herein contained. The term "successors and assigns" shall not include a
purchaser, in its capacity as such, of Notes from any of the Initial Purchasers.
14. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, BUT WITHOUT
REGARD TO PRINCIPLES OF CONFLICTS OF LAW.
42
<PAGE> 43
If the foregoing correctly sets forth the understanding between
you and the Company, please so indicate in the space provided below for that
purpose, whereupon this letter shall constitute a binding agreement among us.
Very truly yours,
HEALTHSOURCE, INC.
By /s/ Norman C. Payson
----------------------------
Norman C. Payson, M.D.
President
Accepted as of the date first above written
BEAR, STEARNS & CO. INC.
By /s/ Curtis S. Lane
-------------------------
Name: Curtis S. Lane
Title: Senior Managing Director
On behalf of itself and the
other Initial Purchasers named
in Schedule 1 hereto.
43
<PAGE> 44
SCHEDULE 1
<TABLE>
<CAPTION>
Initial Purchaser Principal Amount
- ----------------- ----------------
<S> <C>
Bear, Stearns & Co. Inc. $107,500,000
Goldman, Sachs & Co. 21,500,000
Merrill Lynch & Co. 21,500,000
Morgan Stanley & Co. Incorporated 21,500,000
Robertson, Stephens & Company 21,500,000
Smith Barney Inc. 21,500,000
Total $215,000,000
</TABLE>
44
<PAGE> 1
<TABLE>
HEALTHSOURCE, INC. EXHIBIT 11
COMPUTATION OF NET INCOME PER SHARE
(UNAUDITED)
<CAPTION>
Three Months Ended
March 31,
---------------------------------
1996 1995
-------- -------
(in thousands
except per share data)
<S> <C> <C>
NET INCOME . . . . . . . . . . . . . . . . $15,562 $11,771
======= =======
Preferred dividend . . . . . . . . . . . . (1,128) -
------- -------
Net income available to
common stockholders . . . . . . . . . . . $14,434 $11,771
======= =======
COMPUTATION OF SHARES OUTSTANDING:
- ----------------------------------
Average weighted common shares
outstanding . . . . . . . . . . . . . 63,615 62,606
Dilutive effect of stock options issued . 2,338 1,456
------- -------
Average weighted common shares and share
equivalents outstanding . . . . . . . $65,953 64,062
======= =======
NET INCOME PER SHARE: $ 0.22 $ 0.18
- --------------------
</TABLE>
20
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> MAR-31-1996
<EXCHANGE-RATE> 1
<CASH> 132,153
<SECURITIES> 143,457
<RECEIVABLES> 115,204
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 434,019
<PP&E> 114,747
<DEPRECIATION> 0
<TOTAL-ASSETS> 990,236
<CURRENT-LIABILITIES> 325,698
<BONDS> 247,250
<COMMON> 6,368
0
0
<OTHER-SE> 394,683
<TOTAL-LIABILITY-AND-EQUITY> 990,236
<SALES> 419,092
<TOTAL-REVENUES> 425,553
<CGS> 285,561
<TOTAL-COSTS> 399,196
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 2,373
<INCOME-PRETAX> 23,984
<INCOME-TAX> 8,422
<INCOME-CONTINUING> 15,562
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 15,562
<EPS-PRIMARY> .22
<EPS-DILUTED> 0
</TABLE>
